dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Sissetulev kiriAvalik

Pöördumine

Sotsiaalministeerium · 24. september 2019
Viit
1.4-2/2349-1
Registreeritud
24. september 2019
Dokumendi liik
Sissetulev kiri
Adressaat
World Health Organization
Saabumis/saatmisviis
e-post
Funktsioon
1.4 EL otsustusprotsess ja rahvusvaheline koostöö
Sari
1.4-2 Rahvusvahelise koostöö korraldamisega seotud kirjavahetus (Arhiiviväärtuslik)
Toimik
1.4-2/2019
Vastutaja
Eda Lopato (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Terviseala asekantsleri vastutusvaldkond, Ravimiosakond)
Lahendamise tähtaeg
21. detsember 2019

Failid

  • 📎C.L.42.2019 (proposed INN list 121).pdf3872 KB
  • 📎E-kiri.pdf67 KB
  • 📎WHO C.L.41.2019 (recommended INN list 81).msg2948 KB

Sisu (failidest)

Saatja: [email protected] <[email protected]> Teema: WHO: C.L.41.2019 (recommended INN list 81) Dear Member States of the World Health Organization, Please find attached, in the six official languages, C.L.41.2019 regarding the list of recommended international nonproprietary names for pharmaceutical substances which has been published by the World Health Organization in WHO Drug Information, Vol. 33, N°1, 2019. The annex is the same in all languages and is attached to the English version. Best regards, Department of Governing Bodies World Health Organization Saatja: <[email protected]> Saadetud: 23.09.2019 17:12 Teema: WHO: C.L.42.2019 (proposed INN list 121) Dear Member States of the World Health Organization,Please find attached, in the six official languages, C.L.42.2019 regarding the list of proposed international nonproprietary names for pharmaceutical substances which has been published by the World Health Organization in WHO Drug Information, vol. 33, n°2, 2019.The list is similar in the six languages and is attached to the English version.Best regards,Department of Governing BodiesWorld Health Organization 20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT Ref.: C.L.42.2019 The World Health Organization presents its compliments and has the honour to transmit, in accordance with Article 3 of the “Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances”, 1 a list of proposed international nonproprietary names (prop. INN) which has been published by the World Health Organization in WHO Drug Information, Vol. 33, No. 2, 2019. It would be appreciated if this communication could be forwarded to the appropriate patent and trade-mark office and to any other organization dealing with the introduction of nonproprietary names for pharmaceutical substances. Any comments that may be made, or notifications of a conflict between proposed names and existing proprietary rights, should be addressed to the INN Programme, World Health Organization, 1211 Geneva 27, within four months following the publication of the above-mentioned journal, i.e. no later than 21 December 2019. The selection of international nonproprietary names by the World Health Organization for use in all Member States presents many difficulties. It would therefore be appreciated if this were borne in mind when it is contemplated to exercise the right to raise objections. Furthermore, the World Health Organization would be grateful if, in the interest of public health and pursuant to the procedure referred to in the first paragraph of this communication, the ... enclosed list of names* could be granted protection in Member States during the period they are under consideration by the World Health Organization as international nonproprietary names. GENEVA, 19 September 2019 1 Annex to resolution EB15.R7, Off. Rec. Wld Hlth Org., No. 60, pp. 3 and 55. This text was amended by resolution EB43.R9, Off. Rec.Wld Hlth Org., No. 173, p. 10 and resolution EB115.R4, Executive Board, 115th Session, Resolutions and Decisions (EB115/2005/REC/1), p. 2. ... ENCL.: (1) * Prop. INN: List 121 published in WHO Drug Information, Vol. 33, No. 2, 2019. WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121 International Nonproprietary Names for Pharmaceutical Substances (INN) Notice is hereby given that, in accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances, the names given in the list on the following pages are under consideration by the World Health Organization as Proposed International Nonproprietary Names. The inclusion of a name in the lists of Proposed International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy. Lists of Proposed (1–117) and Recommended (1–78) International Nonproprietary Names can be found in Cumulative List No. 17, 2017 (available in CD-ROM only). The statements indicating action and use are based largely on information supplied by the manufacturer. This information is merely meant to provide an indication of the potential use of new substances at the time they are accorded Proposed International Nonproprietary Names. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature, these descriptors will neither be revised nor included in the Cumulative Lists of INNs. Dénominations communes internationales des Substances pharmaceutiques (DCI) Il est notifié que, conformément aux dispositions de l'article 3 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques les dénominations ci-dessous sont mises à l'étude par l'Organisation mondiale de la Santé en tant que dénominations communes internationales proposées. L'inclusion d'une dénomination dans les listes de DCI proposées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie. On trouvera d'autres listes de Dénominations communes internationales proposées (1–117) et recommandées (1–78) dans la Liste récapitulative No. 17, 2017 (disponible sur CD-ROM seulement). Les mentions indiquant les propriétés et les indications des substances sont fondées sur les renseignements communiqués par le fabricant. Elles ne visent qu'à donner une idée de l'utilisation potentielle des nouvelles substances au moment où elles sont l'objet de propositions de DCI. L'OMS n'est pas en mesure de confirmer ces déclarations ni de faire de commentaires sur l'efficacité du mode d'action ainsi décrit. En raison de leur caractère provisoire, ces informations ne figureront pas dans les listes récapitulatives de DCI. Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI) De conformidad con lo que dispone el párrafo 3 del "Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas", se comunica por el presente anuncio que las denominaciones detalladas en las páginas siguientes están sometidas a estudio por la Organización Mundial de La Salud 233 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019 como Denominaciones Comunes Internacionales Propuestas. La inclusión de una denominación en las listas de las DCI Propuestas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia. Las listas de Denominaciones Comunes Internacionales Propuestas (1–117) y Recomendadas (1–78) se encuentran reunidas en Cumulative List No. 17, 2017 (disponible sólo en CD-ROM). Las indicaciones sobre acción y uso que aparecen se basan principalmente en la información facilitada por los fabricantes. Esta información tiene por objeto dar una idea únicamente de las posibilidades de aplicación de las nuevas sustancias a las que se asigna una DCI Propuesta. La OMS no está facultada para respaldar esas indicaciones ni para formular comentarios sobre la eficacia de la acción que se atribuye al producto. Debido a su carácter provisional, esos datos descriptivos no deben incluirse en las listas recapitulativas de DCI. Proposed International Nonproprietary Names: List 121 Comments on, or formal objections to, the proposed names may be forwarded by any person to the INN Programme of the World Health Organization within four months of the date of their publication in WHO Drug Information, i.e., for List 121 Proposed INN not later than 21 December 2019. Publication date: 21/08/2019 Dénominations communes internationales proposées: Liste 121 Des observations ou des objections formelles à l'égard des dénominations proposées peuvent être adressées par toute personne au Programme des Dénominations communes internationales de l'Organisation mondiale de la Santé dans un délai de quatre mois à compter de la date de leur publication dans WHO Drug Information, c'est à dire pour la Liste 121 de DCI Proposées le 21 décembre 2019 au plus tard. Date de publication : 21/08/2019 Denominaciones Comunes Internacionales Propuestas: Lista 121 Cualquier persona puede dirigir observaciones u objeciones respecto de las denominaciones propuestas, al Programa de Denominaciones Comunes Internacionales de la Organización Mundial de la Salud, en un plazo de cuatro meses, contados desde la fecha de su publicación en WHO Drug Information, es decir, para la Lista 121 de DCI Propuestas el 21 diciembre de 2019 a más tardar. Fecha de publicación: 21/08/2019 234 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121 Proposed INN Chemical name or description: Action and use: Molecular formula (Latin, English, French, Chemical Abstracts Service (CAS) registry number: Graphic Spanish) formula DCI Proposée Nom chimique ou description: Propriétés et indications: Formule brute : Numéro dans le registre du CAS: Formule développée DCI Propuesta Nombre químico o descripción: Acción y uso: Fórmula molecular Número de registro del CAS: Fórmula desarrollada  DFLGXPDUOLSRLFXP  DUOLSRLFDFLG > R GLWKLRODQ\O@SHQWDQRLFDFLG antioxidant  DFLGHDUOLSRwTXH DFLGH> R GLWKLRODQ\O@SHQWDQRwTXH antioxydant  iFLGRDUOLSyLFR iFLGR> R GLWLRODQLO@SHQWDQRLFR antioxidante    &+26         DFWLQLXP $F OLQWX]XPDEXPVDWHWUD[HWDQXP  DFWLQLXP $F OLQWX]XPDEVDWHWUD[HWDQ   LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens &' VLDOLFDFLGELQGLQJ,JOLNHOHFWLQ6,*/(& 6,*/(&JSS @KXPDQL]HGPRQRFORQDO DQWLERG\FRQMXJDWHGWRVDWHWUD[HWDQ '27$ GHULYDWLYH DQGUDGLRODEHOOHGZLWKDFWLQLXP JDPPDKHDY\FKDLQKXPDQL]HG  >9+ Homo sapiens ,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*   *P &+.    KLQJH   &+  &+'  /    &+6    @   GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG    >9.$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens ,*.&   .P$  9     @GLPHU    ELVGLVXOILGHSURGXFHGLQ63$JPXULQH P\HORPDFHOOOLQHJO\FRIRUPDOIDDFWLQLXP $F  UDGLRODEHOOHGVDWHWUD[HWDQ '27$GHULYDWLYH  FRQMXJDWHRQDQDYHUDJHRIRUO\V\O )RUWKHsatetraxetanSDUWSOHDVHUHIHUWRWKHGRFXPHQWINN for pharmaceutical substances: Names for radicals, groups & others  antineoplastic   235 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019      DFWLQLXP $F OLQWX]XPDEVDWpWUD[pWDQ  LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens &' OHFWLQHGHW\SH,JOLNHOLDQWO DFLGHVLDOLTXH6,*/(& 6,*/(&JSS @DQWLFRUSVPRQRFORQDO KXPDQLVpFRQMXJXpDXVDWpWUD[pWDQ GpULYp'27$ HW UDGLRPDUTXpjO DFWLQLXP $F  FKDvQHORXUGHJDPPDKXPDQLVpH  >9+ Homo sapiens ,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*   *P &+.     FKDUQLqUH  &+  &+'  /    &+6    @  GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD KXPDQLVpH   >9.$33$ Homo sapiens,*.9    ,*.-   >@    Homo sapiens ,*.&   .P$   9     @GLPqUH    ELVGLVXOIXUHSURGXLWHGDQVODOLJQpHFHOOXODLUHGH P\pORPHPXULQ63$JJO\FRIRUPHDOIDFRQMXJXp DXVDWpWUD[pWDQ GpULYp'27$ VXUjO\V\OHQ PR\HQQHHWUDGLRPDUTXpjO DFWLQLXP $F  3RXUODSDUWLHsatétraxétanYHXLOOH]YRXVUpIpUHUDXGRFXPHQW INN for pharmaceutical substances: Names for radicals, groups & others  antinéoplasique  DFWLQLR $F OLQWX]XPDEVDWHWUD[HWiQ   LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens &' OHFWLQDGHWLSR,JOLNHTXHVHXQHDOiFLGRVLiOLFR 6,*/(&6,*/(&JSS @DQWLFXHUSR PRQRFORQDOKXPDQL]DGRFRQMXJDGRFRQVDWHWUD[HWiQ GHULYDGR'27$ \UDGLRPDUFDGRFRQDFWLQLR $F   FDGHQDSHVDGDJDPPDKXPDQL]DGD  >9+ Homo sapiens ,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*   *P &+.     ELVDJUD  &+  &+'  /    &+6    @  GLVXOIXURFRQODFDGHQDOLJHUDNDSSD KXPDQL]DGD   >9.$33$ Homo sapiens ,*.9   ,*.-   >@    Homo sapiens ,*.&   .P$  9     @ GtPHUR   ELVGLVXOIXURSURGXFLGRHQ ODOtQHDFHOXODUGHPLHORPDPXULQR63$J JOLFRIRUPDDOIDFRQMXJDGRFRQVDWHWUD[HWiQ GHULYDGR '27$ HQRUHVWRVOLVLOSRUWpUPLQRPHGLR\ UDGLRPDUFDGRFRQDFWLQLR $F  3DUDODIUDFFLyQsatetraxetánVHSXHGHUHIHULUDOGRFXPHQWR INN for pharmaceutical substances: Names for radicals, groups & others  antineoplásico      236 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121     +HDY\ FKDLQ  &KDvQH ORXUGH  &DGHQD SHVDGD QVQLVQSGAE VKKPGSSVKV SCKASGYTFT DYNMHWVRQA PGQGLEWIGY 50 IYPYNGGTGY NQKFKSKATI TADESTNTAY MELSSLRSED TAVYYCARGR 100 PAMDYWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150 EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200 VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL 250 MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300 VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350 PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400 GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK 446 /LJKW FKDLQ  &KDvQH OpJqUH  &DGHQD OLJHUD DIQMTQSPSS LSASVGDRVT ITCRASESVD NYGISFMNWF QQKPGKAPKL 50 LIYAASNQGS GVPSRFSGSG SGTDFTLTIS SLQPDDFATY YCQQSKEVPW 100 TFGQGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150 QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200 THQGLSSPVT KSFNRGEC 218 3RVWWUDQVODWLRQDO PRGLILFDWLRQV 'LVXOILGH EULGJHV ORFDWLRQ  3RVLWLRQ GHV SRQWV GLVXOIXUH  3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR ,QWUD+ &&             ,QWUD/ &&         ,QWHU+/ K &/     ,QWHU++ K  K    1JO\FRV\ODWLRQ VLWHV  6LWHV GH 1JO\FRV\ODWLRQ  3RVLFLRQHV GH 1JOLFRVLODFLyQ + &+ 1   )XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ 63$JW\SH JO\FDQV  JO\FDQHV GH W\SH 63$J ELDQWHQQDLUHV FRPSOH[HV IXFRV\OpV  JOLFDQRV GH WLSR 63$J ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV &WHUPLQDO O\VLQH FOLSSLQJ + &+6 .   0RGLILHG UHVLGXHV  5pVLGXV PRGLILpV  5HVWRV PRGLILFDGRV rac 2& 5 . $Q DYHUDJH RI  WR  DUH NVXEVWLWXWHG E\ 5 2& (QYLURQ  j  VRQW NVXEVWLWXpV SDU 5 1 1 8QD PHGLGD GH  D  HVWiQ NVXVWLWXLGRV SRU 5 + 6 $F + & 1 1 1 + 2& &2     DPLYDQWDPDEXP  DPLYDQWDPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens(*)5 HSLGHUPDOJURZWK IDFWRUUHFHSWRUUHFHSWRUW\URVLQHSURWHLQNLQDVHHUE%(5%%+(5 +(5(5%% @DQGDQWL>Homo sapiens0(7 PHWSURWRRQFRJHQH KHSDWRF\WHJURZWKIDFWRU +*) UHFHSWRU+*)5VFDWWHUIDFWRU 6)  UHFHSWRU+*)6)UHFHSWRUUHFHSWRUW\URVLQHSURWHLQNLQDVHFPHWSDSLOODU\ UHQDOFHOOFDUFLQRPD5&&3 @Homo sapiensPRQRFORQDODQWLERG\ ELVSHFLILF JDPPDKHDY\FKDLQHomo sapiensDQWL(*)5  >9+ Homo sapiens ,*+9    ,*+' ,*+-   >@  Homo sapiens,*+* *PQ*P &+5    KLQJH  &+  &+(  0  )!/     &+6    @  GLVXOILGHZLWKNDSSDOLJKWFKDLQ Homo sapiensDQWL(*)5   >9.$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens,*.&    .P$  9     @ JDPPDKHDY\FKDLQHomo sapiensDQWL0(7   >9+ Homo sapiens ,*+9    ,*+' ,*+-   >@   Homo sapiens,*+* *PQ*P &+5    KLQJH  &+  &+(  0  .!5     &+6     @   GLVXOILGHZLWKNDSSDOLJKW FKDLQHomo sapiensDQWL0(7   >9.$33$ Homo sapiens,*.9    ,*.-   >@   Homo sapiens,*.&   .P$  9     @     237 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019   GLPHU   ELVGLVXOILGHSURGXFHGLQ&KLQHVH +DPVWHU2YDU\ &+2 FHOOVJO\FRIRUPDOID immunomodulator, antineoplastic  DPLYDQWDPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens(*)5 UpFHSWHXU GXIDFWHXUGHFURLVVDQFHpSLGHUPLTXHUpFHSWHXUW\URVLQHSURWpLQH NLQDVHHUE(5%%+(5+(5(5%% @HWDQWL>Homo sapiens 0(7 SURWRRQFRJqQHPHWUpFHSWHXUGXIDFWHXUGHFURLVVDQFH KpSDWRF\WDLUH+*)5UpFHSWHXUGXIDFWHXUGHGLVSHUVLRQUpFHSWHXU GHO +*)6)UpFHSWHXUSURWpLQHW\URVLQHNLQDVHF0HWFDUFLQRPH SDSLOODLUHjFHOOXOHVUpQDOHV5&&3 @DQWLFRUSVPRQRFORQDOHomo sapiensELVSpFLILTXH FKDvQHORXUGHJDPPDHomo sapiensDQWL(*)5  >9+ Homo sapiens,*+9    ,*+' ,*+-    >@  Homo sapiens,*+* *PQ*P &+ 5    FKDUQLqUH  &+   &+(  0  )!/    &+6     @  GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD Homo sapiensDQWL(*)5   >9.$33$ Homo sapiens ,*.9   ,*.-   >@   Homo sapiens,*.&   .P$  9     @ FKDvQHORXUGHJDPPDHomo sapiensDQWL0(7   >9+ Homo sapiens ,*+9    ,*+' ,*+-    >@   Homo sapiens,*+* *PQ*P &+ 5    FKDUQLqUH  &+   &+(  0  .!5    &+6     @   GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD Homo sapiensDQWL0(7   >9.$33$ Homo sapiens,*.9    ,*.-   >@   Homo sapiens ,*.&   .P$  9     @ GLPqUH   ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHV RYDULHQQHVGHKDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID immunomodulateur, antinéoplasique  DPLYDQWDPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens(*)5 UHFHSWRUGHO IDFWRUGHFUHFLPLHQWRHSLGpUPLFRUHFHSWRUWLURVLQDSURWHtQDNLQDVD HUE(5%%+(5+(5(5%% @\DQWL>Homo sapiens 0(7 SURWRRQFRJpQPHWUHFHSWRUGHOIDFWRUGHFUHFLPLHQWRKHSDWRFLWDULR +*)5UHFHSWRUGHOIDFWRUGHGLVSHUVLyQUHFHSWRUGHO +*)6) UHFHSWRUSURWHtQDWLURVLQDNLQDVDF0HWFDUFLQRPDSDSLODUGHFpOXODV UHQDOHV5&&3 @DQWLFXHUSRPRQRFORQDOHomo sapiens ELHVSHFtILFR FDGHQDSHVDGDJDPPDHomo sapiensDQWL(*)5  >9+ Homo sapiens,*+9    ,*+' ,*+-    >@  Homo sapiens,*+* *PQ*P &+ 5    ELVDJUD  &+  &+ (  0  )!/    &+6    @  GLVXOIXURFRQODFDGHQDOLJHUDNDSSDHomo sapiensDQWL(*)5   >9.$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens,*.&   .P$  9     @ FDGHQDSHVDGDJDPPDHomo sapiensDQWL0(7   >9+ Homo sapiens ,*+9    ,*+' ,*+-    >@   Homo sapiens,*+* *PQ*P &+ 5    ELVDJUD  &+  &+ (  0  .!5    &+6     @   GLVXOIXURFRQOD   238 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121  FDGHQDOLJHUDNDSSDHomo sapiensDQWL0(7   >9 .$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens,*.&   .P $  9     @ GtPHUR   ELVGLVXOIXURSURGXFLGRHQODV FpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID inmunomodulador, antineoplásico        +HDY\ FKDLQ  &KDvQH ORXUGH  &DGHQD SHVDGD DQWL(*)5 QVQLVESGGG VVQPGRSLRL SCAASGFTFS TYGMHWVRQA PGKGLEWVAV 50 IWDDGSYKYY GDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDG 100 ITMVRGVMKD YFDYWGQGTL VTVSSASTKG PSVFPLAPSS KSTSGGTAAL 150 GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS 200 LGTQTYICNV NHKPSNTKVD KRVEPKSCDK THTCPPCPAP ELLGGPSVFL 250 FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR 300 EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ 350 PREPQVYTLP PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK 400 TTPPVLDSDG SFLLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS 450 LSPGK 455 /LJKW FKDLQ  &KDvQH OpJqUH  &DGHQD OLJHUD DQWL(*)5 AIQLTQSPSS LSASVGDRVT ITCRASQDIS SALVWYQQKP GKAPKLLIYD 50 ASSLESGVPS RFSGSESGTD FTLTISSLQP EDFATYYCQQ FNSYPLTFGG 100 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150 DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200 LSSPVTKSFN RGEC 214 +HDY\ FKDLQ  &KDvQH ORXUGH  &DGHQD SHVDGD DQWL0(7 QVQLVQSGAE VKKPGASVKV SCETSGYTFT SYGISWVRQA PGHGLEWMGW 50 ISAYNGYTNY AQKLQGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARDL 100 RGTNYFDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150 YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200 ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250 DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300 TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350 YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400 DSDGSFFLYS RLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK 449 /LJKW FKDLQ  &KDvQH OpJqUH  &DGHQD OLJHUD DQWL0(7 DIQMTQSPSS VSASVGDRVT ITCRASQGIS NWLAWFQHKP GKAPKLLIYA 50 ASSLLSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ ANSFPITFGQ 100 GTRLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150 DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200 LSSPVTKSFN RGEC 214 3RVWWUDQVODWLRQDO PRGLILFDWLRQV 'LVXOILGH EULGJHV ORFDWLRQ  3RVLWLRQ GHV SRQWV GLVXOIXUH  3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR ,QWUD+ &&             ,QWUD/ &&         ,QWHU+/ K &/     ,QWHU++ K  K    1JO\FRV\ODWLRQ VLWHV  6LWHV GH 1JO\FRV\ODWLRQ  3RVLFLRQHV GH 1JOLFRVLODFLyQ + &+ 1   /RZ IXFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV  JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV  FRPSOH[HV IDLEOHPHQW IXFRV\OpV  JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV EDMRV IXFRVLODGRV   DQHWXPDEXPFRUL[HWDQXP  DQHWXPDEFRUL[HWDQ LPPXQRJOREXOLQ*ODPEGDDQWL>Homo sapiens 06/1 PHVRWKHOLQSUHSURPHJDNDU\RF\WHSRWHQWLDWLQJIDFWRU PHJDNDU\RF\WHSRWHQWLDWLQJIDFWRU03)&$. @Homo sapiens PRQRFORQDODQWLERG\FRQMXJDWHGWRFKHODWRUFRUL[HWDQ JDPPDKHDY\FKDLQ Homo sapiens  >9+ Homo sapiens ,*+9    ,*+' ,*+-   >@   Homo sapiens,*+*   *P &+.    KLQJH  &+  &+'  /    &+6    @   GLVXOILGHZLWKODPEGDOLJKWFKDLQHomo sapiens   >9 /$0%'$ Homo sapiens,*/9   ,*.-   >@   Homo sapiens ,*/&    $!*     @GLPHU    ELVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 6FHOO OLQHJO\FRIRUPDOIDFRQMXJDWHGWRFKHODWRUFRUL[HWDQZLWKDQ DYHUDJHRIFKHODWRUSHUDQWLERG\ antineoplastic    239 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019 DQpWXPDEFRUL[pWDQ FKDvQHORXUGHJDPPDHomo sapiens  >9+ Homo sapiens ,*+9    ,*+' ,*+-   >@   Homo sapiens,*+*   *P &+.     FKDUQLqUH  &+  &+'  /    &+6    @  GLVXOIXUHDYHFOD FKDvQHOpJqUHODPEGDHomo sapiens   >9/$0%'$ Homo sapiens,*/9   ,*.-   >@    Homo sapiens ,*/&   $!*     @GLPqUH   ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHV GHKDPVWHUVFKLQRLV &+2 OLJQpHFHOOXODLUH&+26JO\FRIRUPHDOID FRQMXJXpDXFKpODWHXUFRUL[pWDQDYHFXQHPR\HQQHGHFKpODWHXU SDUDQWLFRUSV antinéoplasique  DQHWXPDEFRUL[HWiQ LQPXQRJOREXOLQD*ODPEGDDQWL>Homo sapiens 06/1 PHVRWHOLQD IDFWRUSRWHQFLDGRUGHSUHSURPHJDFDULRFLWRIDFWRUSRWHQFLDGRUGHORV PHJDFDULRFLWRV03)&$. @DQWLFXHUSRPRQRFORQDOHomo sapiens FRQMXJDGRFRQHOTXHODQWHFRUL[HWiQ FDGHQDSHVDGDJDPPDHomo sapiens  >9+ Homo sapiens ,*+9    ,*+' ,*+-   >@   Homo sapiens,*+*   *P &+.     ELVDJUD  &+  &+'  /     &+6    @  GLVXOIXURFRQODFDGHQD OLJHUDODPEGDHomo sapiens   >9/$0%'$ Homo sapiens ,*/9   ,*.-   >@   Homo sapiens ,*/&   $!*     @GtPHUR    ELVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDVGH KDPVWHUVFKLQRV &+2 OtQHDFHOXODU&+26JOLFRIRUPDDOIDFRQMXJDGR FRQHOTXHODQWHFRUL[HWiQFRQXPDPHGLDGHTXHODQWHVSRU DQWLFXHUSR  antineoplásico       240 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121   DUSUD]LTXDQWHOXP  DUSUD]LTXDQWHO ER  F\FORKH[DQHFDUERQ\O E KH[DK\GURHS\UD]LQR>a@LVRTXLQROLQRQH anthelmintic  DUSUD]LTXDQWHO ER  F\FORKH[DQHFDUERQ\O b KH[DK\GURHS\UD]LQR>a@LVRTXLQROpLQRQH antihelmintique  DUSUD]LFXDQWHO ER  FLFORKH[DQRFDUERQLO E KH[DKLGURHSLUD]LQR>a@LVRTXLQROHLQRQD antihelmíntico    &+12    2 1 1 + 2     DVWHJROLPDEXP  DVWHJROLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens ,/5/ LQWHUOHXNLQUHFHSWRUOLNH'(5),7JURZWK VWLPXODWLRQH[SUHVVHGJHQH67,/5 @Homo sapiensPRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*    &+  KLQJH   &+  &+  &+6    @  GLVXOILGHZLWKNDSSDOLJKWFKDLQ Homo sapiens   >9.$33$ Homo sapiens ,*.9   ,*.-   >@    Homo sapiens,*.&   .P$  9     @GLPHU   WHWUDNLVGLVXOILGHSURGXFHGLQ &KLQHVH+DPVWHU2YDU\ &+2 FHOOVJO\FRIRUPDOID immunomodulator  DVWpJROLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens ,/5/ UpFHSWHXUOLNHGHO LQWHUOHXNLQH'(5),7 JqQHH[SULPpORUVGHODVWLPXODWLRQGHOD FURLVVDQFH67,/5 @DQWLFRUSVPRQRFORQDOHomo sapiens FKDvQHORXUGHJDPPDHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*    &+  FKDUQLqUH  &+  &+  &+6      @  GLVXOIXUHDYHFODFKDvQH   241 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019  OpJqUHNDSSDHomo sapiens   >9.$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens,*.&   .P$  9     @ GLPqUH   WpWUDNLVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHV GHKDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID immunomodulateur  DVWHJROLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens ,/5/ UHFHSWRUOLNHGHODLQWHUOHXNLQD'(5 ),7JHQH[SUHVDGRHQODHVWLPXODFLyQGHO FUHFLPLHQWR67,/5 @DQWLFXHUSRPRQRFORQDO Homo sapiens FDGHQDSHVDGDJDPPDHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*    &+  ELVDJUD   &+  &+  &+6    @  GLVXOIXURFRQODFDGHQDOLJHUD NDSSDHomo sapiens   >9.$33$ Homo sapiens,*.9   ,*.-    >@   Homo sapiens,*.&   .P $  9     @GtPHUR   WHWUDNLVGLVXOIXUR SURGXFLGRHQODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID inmunomodulador          242 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121  DWOHUDGVWURFHOXP  DWOHUDGVWURFHO KXPDQFXOWXUHH[SDQGHGDXWRORJRXVDGLSRVHVWURPDO SURJHQLWRUFHOOV $6& IRUFHOOEDVHGWKHUDS\7KHFHOOV H[SUHVV&'DQG&'FHOOVXUIDFHPDUNHUVDQGDUH QHJDWLYHIRU&'&'DQG&'PDUNHUV cell therapy (neurology)  DWOpUDGVWURFHO FHOOXOHVSURJpQLWULFHVVWURPDOHVLVVXHVGXWLVVX DGLSHX[ $6& KXPDLQHVDXWRORJXHVHQFXOWXUH G¶H[SDQVLRQSRXUWKpUDSLHFHOOXODLUH/HVFHOOXOHV H[SULPHQWOHVPDUTXHXUVGHVXUIDFH&'HW&'HW VRQWQpJDWLYHVSRXUOHVPDUTXHXUVGHVXUIDFH&' &'DQG&' thérapie cellulaire (neurologie)  DWOHUDGVWURFHO FpOXODVSURJHQLWRUDVHVWURPDOHVGHWHMLGRDGLSRVR DXWyORJDVKXPDQDVH[SDQGLGDVHQFXOWLYRSDUD WHUDSLDFHOXODU/DVFpOXODVH[SUHVDQORVPDUFDGRUHV GHVXSHUILFLH&'\&'\VRQQHJDWLYDVSDUDORV PDUFDGRUHV&'&'\&'  terapia celular (neurología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gene therapy (ornithine transcarbamylase (OTC) deficiency)  DYDORWFDJqQHRQWDSDUYRYHF YHFWHXUYLUDODGpQRDVVRFLpGHW\SHUHFRPELQDQW QRQUpSOLTXDQW U$$95HS&DS FRGDQWSRXU O RUQLWKLQHWUDQVFDUEDP\ODVHKXPDLQHVDXYDJH 27&  DYHFGHVFRGRQVRSWLPLVpVVRXVOHFRQWU{OHGH O DFWLYDWHXUSURPRWHXUK\EULGHGHODJOREXOLQHOLDQWOD WK\UR[LQH 7%3 KXPDLQHSUpFXUVHXUGH PLFURJOREXOLQHDOSKDELNXQLQH $0%3 /HJpQRPH GXYHFWHXUHVWXQGLPqUHHQWrWHjWrWHDYHFOD FDVVHWWHFRQWHQDQWOHJpQRPHGXYHFWHXUHQSRVLWLRQ GHODVpTXHQFHLQYHUVHWHUPLQDOHUpSpWpH ,75  LQWHUQHHWPXWpHGRQWO RULHQWDWLRQHVWLQYHUVHHWOD FDVVHWWHFRQWHQDQWOHYHFWHXUGXJpQRPHHQSRVLWLRQ GHO ,75LQWHUQHHWPXWpHGRQWO RULHQWDWLRQHVWYHUV O DYDQW thérapie génique (déficit en ornithine transcarbamylase (OTC))  DYDORWFDJpQRQWDSDUYRYHF 8QYHFWRUGHYLUXVDGHQRDVRFLDGRUHFRPELQDQWHQR UHSOLFDWLYRGHOVHURWLSR U$$95HS&DS TXH  FRGLILFDSDUDODRUQLWLQDWUDQVFDUEDPLODVDVLOYHVWUH  243 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019    KXPDQD 27& FRQFRGRQHVRSWLPL]DGRVEDMRHO FRQWUROGHXQSURPRWRUSRWHQFLDGRUKtEULGRGHOD JOREXOLQDILMDGRUDGHWLUR[LQDKXPDQD 7%*  SUHFXUVRUGHPLFURJOREXOLQDDOIDKXPDQDELFXQLQD $0%3 (OJHQRPDGHOYHFWRUHVXQGtPHURGH FDEH]DFRQFDEH]DFRQHOFDVHWHGHOJHQRPDGHO YHFWRUHQSRVLFLyQ DODUHSHWLFLyQWHUPLQDOLQYHUWLGD ,75 LQWHUQD\PXWDGDORFDOL]DGRHQRULHQWDFLyQ LQYHUVD\HOFDVHWHGHOJHQRPDGHOYHFWRUHQSRVLFLyQ  DOD,75ORFDOL]DGRHQRULHQWDFLyQKDFLDDGHODQWH terapia génica (deficiencia en ornitina  transcarbamilasa (OTC))      DYGRUDOLPDEXP  DYGRUDOLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens&$5 FRPSOHPHQW&DUHFHSWRUFRPSOHPHQW& DQDSK\ODWR[LQ &D&3U UHFHSWRU &' @Homo sapiensPRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+* *P!*PQ*P &+.    KLQJH  &+/!$   /!(  *!$  $!6  3!6    &+(  0     &+6    @  GLVXOILGHZLWK NDSSDOLJKWFKDLQHomo sapiens   >9.$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens,*.&   .P$  9     @ GLPHU   ELVGLVXOILGHSURGXFHGLQ &KLQHVH+DPVWHU2YDU\ &+2 .69FHOOOLQH JO\FRIRUPDOID immunomodulator, antineoplastic  DYGRUDOLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens &$5 UpFHSWHXUGXFRPSOpPHQW&DUpFHSWHXU GHO DQDSK\ODWR[LQHGXFRPSOpPHQW& &D& 3U &' @DQWLFRUSVPRQRFORQDOHomo sapiens FKDvQHORXUGHJDPPDHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+* *P!*PQ*P &+.    FKDUQLqUH  &+/!$  /!(  *!$  $!6   3!6    &+(  0    &+6    @   GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSDHomo sapiens   >9.$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens,*.&   .P$  9     @GLPqUH    ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGH KDPVWHUVFKLQRLV &+2 OLJQpHFHOOXODLUH.69 JO\FRIRUPHDOID immunomodulateur, antinéoplasique   244 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121   DYGRUDOLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens&$5 UHFHSWRUGHO FRPSOHPHQWR&DUHFHSWRUGHODDQDILODWR[LQDGHOFRPSOHPHQWR& &D&3U &' @DQWLFXHUSRPRQRFORQDOHomo sapiens FDGHQDSHVDGDJDPPDHomo sapiens  >9+ Homo sapiens ,*+9    ,*+' ,*+-   >@   Homo sapiens,*+* *P!*PQ*P &+.     ELVDJUD  &+/!$  /!(  *!$  $!6  3!6    &+(  0    &+6    @  GLVXOIXURFRQOD FDGHQDOLJHUDNDSSDHomo sapiens   >9.$33$ Homo sapiens ,*.9   ,*.-   >@   Homo sapiens,*.&   .P$  9     @ GtPHUR   ELVGLVXOIXURSURGXFLGRHQODVFpOXODV RYiULFDVGHKDPVWHUVFKLQRV &+2 OtQHDFHOXODU.69JOLFRIRUPDDOID  inmunomodulador, antineoplásico      +HDY\ FKDLQ  &KDvQH ORXUGH  &DGHQD SHVDGD EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYVMHWVRQA TGKGLEWVSA 50 IDTGGGTYYA DSVKGRFTIS RENAKNSLYL QMNSLRAGDT AVYYCARDYY 100 YYASGSYYKA FDIWGQGTMV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150 CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200 GTQTYICNVN HKPSNTKVDK RVEPKSCDKT HTCPPCPAPE AEGAPSVFLF 250 PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE 300 EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPSSIE KTISKAKGQP 350 REPQVYTLPP SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 400 TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 450 SPGK 454 /LJKW FKDLQ  &KDvQH OpJqUH  &DGHQD OLJHUD EIVLTQSPGT LSLSPGERAT LSCRASQSVS SRYLAWYQQK PGQAPRLLIY 50 GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSPLTFGQ 100 GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150 DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200 LSSPVTKSFN RGEC 214 3RVWWUDQVODWLRQDO PRGLILFDWLRQV 'LVXOILGH EULGJHV ORFDWLRQ  3RVLWLRQ GHV SRQWV GLVXOIXUH  3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR ,QWUD+ &&             ,QWUD/ &&         ,QWHU+/ K &/     ,QWHU++ K  K    1JO\FRV\ODWLRQ VLWHV  6LWHV GH 1JO\FRV\ODWLRQ  3RVLFLRQHV GH 1JOLFRVLODFLyQ + &+ 1   )XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV  JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV  FRPSOH[HV IXFRV\OpV  JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV    DYL]DNLPDEXP  DYL]DNLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens,/ LQWHUOHXNLQ @ KXPDQL]HGPRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQKXPDQL]HG  >9+ Homo sapiens,*+9     ,*+' ,*+-   >@  Homo sapiens,*+* *PQ*P &+5    KLQJH   &+0!<  6!7  7!(   ,*+*Y   &+(  0    &+6     @  GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG   >9.$33$ Homo sapiens,*.91/   ,*.-   >@   Homo sapiens,*.&   .P$  9     @ GLPHU   ELVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU 2YDU\ &+2 FHOOVJO\FRIRUPDOID immunomodulator     245 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019 DYL]DNLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens,/ LQWHUOHXNLQH @DQWLFRUSVPRQRFORQDOKXPDQLVp FKDvQHORXUGHJDPPD  >9+ Homo sapiens ,*+9    ,*+' ,*+-    >@  Homo sapiens,*+* *P Q*P &+5    FKDUQLqUH  &+0!<  6!7  7!(   ,*+*Y   &+(  0    &+6    @   GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSDKXPDQLVpH   >9.$33$ Homo sapiens,*.91/   ,*.-   >@   Homo sapiens,*.&   .P$  9     @ GLPqUH   ELVGLVXOIXUHSURGXLWGDQV GHVFHOOXOHVRYDULHQQHVGHKDPVWHUVFKLQRLV &+2  JO\FRIRUPHDOID immunomodulateur  DYL]DNLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens,/ LQWHUOHXNLQD @DQWLFXHUSRPRQRFORQDOKXPDQL]DGR FDGHQDSHVDGDJDPPD  >9+ Homo sapiens ,*+9    ,*+' ,*+-    >@  Homo sapiens,*+* *P Q*P &+5    ELVDJUD  &+0!<  6!7  7!(   ,*+*Y   &+(  0    &+6    @   GLVXOIXURFRQODFDGHQDOLJHUDNDSSDKXPDQL]DGD   >9.$33$ Homo sapiens,*.91/   ,*.-   >@   Homo sapiens,*.&   .P$  9     @ GtPHUR   ELVGLVXOIXURSURGXFLGRHQ ODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2  JOLFRIRUPDDOID inmunomodulador          246 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121 D[DWLOLPDEXP  D[DWLOLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens &6)5 FRORQ\VWLPXODWLQJIDFWRUUHFHSWRU&6)5 &6)5PDFURSKDJHFRORQ\VWLPXODWLQJIDFWRU UHFHSWRUFIPV)06&' @KXPDQL]HG PRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQKXPDQL]HG  >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*  &+  KLQJH6!3   &+  &+  &+6    @  GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG   >9.$33$ Homo sapiens ,*.9   ,*.-   >@   Homo sapiens,*.&   .P$  9     @ GLPHU   ELVGLVXOILGHSURGXFHGLQ &KLQHVH+DPVWHU2YDU\ &+2 '*FHOOOLQH JO\FRIRUPDOID immunomodulator, antineoplastic  D[DWLOLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens &6)5 UpFHSWHXUGXIDFWHXUVWLPXODQWGHFRORQLHV &6)5&6)5UpFHSWHXUGXIDFWHXUVWLPXODQW GHVFRORQLHVGHPDFURSKDJHVFIPV)06&' @ DQWLFRUSVPRQRFORQDOKXPDQLVp FKDvQHORXUGHJDPPDKXPDQLVpH  >9+ +RPR VDSLHQV,*+9    ,*+' ,*+-   >@  Homo sapiens ,*+*  &+  FKDUQLqUH6!3    &+  &+  &+6     @  GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD KXPDQLVpH   >9.$33$ Homo sapiens ,*.9    ,*.-   >@    Homo sapiens,*.&   .P$   9     @GLPqUH    ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGH KDPVWHUVFKLQRLV &+2 OLJQpHFHOOXODLUH'* JO\FRIRUPHDOID immunomodulateur, antinéoplasique  D[DWLOLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens &6)5 UHFHSWRUGHOIDFWRUHVWLPXODQWHGHFRORQLDV &6)5&6)5UHFHSWRUGHOIDFWRUHVWLPXODQWHGH ODVFRORQLDVGHPDFUyIDJRVFIPV)06&' @ DQWLFXHUSRPRQRFORQDOKXPDQL]DGR FDGHQDSHVDGDJDPPDKXPDQL]DGD  >9+ +RPRVDSLHQV,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*  &+  ELVDJUD6!3    &+  &+  &+6    @  GLVXOIXURFRQODFDGHQDOLJHUD NDSSDKXPDQL]DGD   >9.$33$ Homo sapiens ,*.9   ,*.-   >@    Homo sapiens,*.&   .P$  9     @ GtPHUR   ELVGLVXOIXURSURGXFLGRHQ ODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2 OtQHD FHOXODU'*JOLFRIRUPDDOID  inmunomodulador, antineoplásico 247 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019      +HDY\ FKDLQ  &KDvQH ORXUGH  &DGHQD SHVDGD EVTLKESGPA LVKPTQTLTL TCTFSGFSLT TYGMGVGWIR QPPGKALEWL 50 ANIWWDDDKY YNPSLKNRLT ISKDTSKNQV VLTMTNMDPV DTATYYCARI 100 GPIKYPTAPY RYFDFWGQGT MVTVSSASTK GPSVFPLAPC SRSTSESTAA 150 LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS 200 SLGTKTYTCN VDHKPSNTKV DKRVESKYGP PCPPCPAPEF LGGPSVFLFP 250 PKPKDTLMIS RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEV HNAKTKPREE 300 QFNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR 350 EPQVYTLPPS QEEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400 PPVLDSDGSF FLYSRLTVDK SRWQEGNVFS CSVMHEALHN HYTQKSLSLS 450 LGK 453 /LJKW FKDLQ  &KDvQH OpJqUH  &DGHQD OLJHUD DIQMTQSPSS LSASVGDRVT ITCLASEDIY DNLAWYQQKP GKAPKLLIYY 50 ASSLQDGVPS RFSGSGSGTD YTLTISSLQP EDFATYYCLQ DSEYPWTFGG 100 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150 DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200 LSSPVTKSFN RGEC 214 3RVWWUDQVODWLRQDO PRGLILFDWLRQV 'LVXOILGH EULGJHV ORFDWLRQ  3RVLWLRQ GHV SRQWV GLVXOIXUH  3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR ,QWUD+ &&             ,QWUD/ &&         ,QWHU+/ &+ &/     ,QWHU++ K  K    1JO\FRV\ODWLRQ VLWHV  6LWHV GH 1JO\FRV\ODWLRQ  3RVLFLRQHV GH 1JOLFRVLODFLyQ + &+ 1   )XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV  JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV FRPSOH[HV IXFRV\OpV  JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV &WHUPLQDO O\VLQH FOLSSLQJ + &+6 .      EDPRFDIWRUXP  EDPRFDIWRU S N EHQ]HQHVXOIRQ\O WULPHWK\O WULIOXRURPHWK\O R[D  S\ULGLQD  S\UD]ROD   S\UUROLGLQD  F\FORSURSDQDKHSWDSKDQH FDUER[DPLGH cystic fibrosis transmembrane regulator (CFTR) protein modulator  EDPRFDIWRU S N EHQ]qQHVXOIRQ\O WULPpWK\O WULIOXRURPpWK\O R[D  S\ULGLQD  S\UD]ROD   S\UUROLGLQD  F\FORSURSDQDKHSWDSKDQH FDUER[DPLGH modulateur de la protéine régulatrice de la perméabilité transmembranaire impliquée dans la mucoviscidose (CFTR)  EDPRFDIWRU S N EHQFHQRVXOIRQLO WULPHWLO WULIOXRURPHWLO R[D  SLULGLQD  SLUD]ROD   SLUUROLGLQD  FLFORSURSDQDKHSWDIDQRFDUER[DPLGD modulador de la proteína reguladora de la conductancia transmembrana de la fibrosis quística (CFTR)    &+)126   + &+ +& +& 1 2 2 2 6 1 1 + )& 1 1  2  248 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121   EDWRFOLPDEXP  EDWRFOLPDE LPPXQRJOREXOLQ*ODPEGDDQWL>Homo sapiens)&*57 )FIUDJPHQWRI,J*UHFHSWRUDQGWUDQVSRUWHUQHRQDWDO)F UHFHSWRU)F5QWUDQVPHPEUDQHDOSKDFKDLQRIWKH QHRQDWDOUHFHSWRU @Homo sapiensPRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQHomo sapiens  >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*  *PQ*P &+5    KLQJH  &+/!$  /!$     &+(  0    &+6.!GHO    @  GLVXOILGHZLWKODPEGDOLJKWFKDLQ Homo sapiens   >9/$0%'$ Homo sapiens ,*/9   ,*/-   >@    Homo sapiens,*/&      @GLPHU    ELVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU 2YDU\ &+2 6FHOOOLQHJO\FRIRUPDOID immunomodulator  EDWRFOLPDE LPPXQRJOREXOLQH*ODPEGDDQWL>Homo sapiens)&*57 WUDQVSRUWHXUHWUpFHSWHXUGXIUDJPHQW)FGHV,J* UpFHSWHXU)FQpRQDWDO)F5QFKDvQHDOSKD WUDQVPHPEUDQDLUHGXUpFHSWHXUQpRQDWDO @DQWLFRUSV PRQRFORQDOHomo sapiens FKDvQHORXUGHJDPPDHomo sapiens  >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*  *PQ*P &+5    FKDUQLqUH  &+/!$  /!$     &+(  0    &+6.!GHO    @  GLVXOIXUHDYHFODFKDvQHOpJqUH ODPEGDHomo sapiens   >9/$0%'$ Homo sapiens,*/9   ,*/-   >@   Homo sapiens,*/&      @ GLPqUH   ELVGLVXOIXUHSURGXLWGDQVGHV FHOOXOHVRYDULHQQHVGHKDPVWHUVFKLQRLV &+2 OLJQpH FHOOXODLUH&+26JO\FRIRUPHDOID immunomodulateur  EDWRFOLPDE LQPXQRJOREXOLQD*ODPEGDDQWL>Homo sapiens)&*57 WUDQVSRUWDGRU\UHFHSWRUGHOIUDJPHQWR)FGHODV,J* UHFHSWRU)FQHRQDWDO)F5QFDGHQDDOID WUDQVPHPEUDQDULDGHOUHFHSWRUQHRQDWDO @DQWLFXHUSR PRQRFORQDOHomo sapiens FDGHQDSHVDGDJDPPDHomo sapiens  >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*  *PQ*P &+5    ELVDJUD  &+/!$  /!$     &+(  0    &+6.!GHO    @  GLVXOIXURFRQODFDGHQDOLJHUD ODPEGDHomo sapiens   >9/$0%'$ Homo sapiens,*/9   ,*/-   >@   Homo sapiens,*/&      @ GtPHUR   ELVGLVXOIXURSURGXFLGRHQODV FpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2 OtQHDFHOXODU &+26JOLFRIRUPDDOID  inmunomodulador 249 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019          EHIRYDFLPDEXP  EHIRYDFLPDE LPPXQRJOREXOLQ*ODPEGDDQWL>Homo sapiens 7)3, WLVVXHIDFWRUSDWKZD\LQKLELWRUOLSRSURWHLQDVVRFLDWHG FRDJXODWLRQLQKLELWRU @PRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*  &+  KLQJH  &+  &+  &+6.!GHO     @  GLVXOILGHZLWKODPEGDOLJKWFKDLQ KXPDQL]HG   >9/$0%'$ Homo sapiens ,*/9   ,*.-   >@    Homo sapiens,*/&      @ GLPHU   WHWUDNLVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 .69FHOOOLQHJO\FRIRUPDOID hemostatic  EpIRYDFLPDE LPPXQRJOREXOLQH*ODPEGDDQWL>Homo sapiens 7)3, LQKLELWHXUGHODYRLHGXIDFWHXUWLVVXODLUH LQKLELWHXUGHODFRDJXODWLRQDVVRFLpHDX[ OLSRSURWpLQHV @DQWLFRUSVPRQRFORQDO FKDvQHORXUGHJDPPDHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*  &+  FKDUQLqUH   &+  &+  &+6.!GHO    @  GLVXOIXUHDYHFODFKDvQHOpJqUH ODPEGDKXPDQLVpH   >9/$0%'$ Homo sapiens,*/9   ,*.-    >@   Homo sapiens,*/&      @GLPqUH   WpWUDNLVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHV RYDULHQQHVGHKDPVWHUVFKLQRLV &+2 OLJQpH FHOOXODLUH.69JO\FRIRUPHDOID  hémostatique 250 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121   EHIRYDFLPDE LQPXQRJOREXOLQD*ODPEGDDQWL>Homo sapiens7)3, LQKLELGRUGHODYtDGHOIDFWRUWLVXODULQKLELGRUGHOD FRDJXODFLyQDVRFLDGDFRQODVOLSRSURWHtQDV @ DQWLFXHUSRKXPDQL]DGR FDGHQDSHVDGDJDPPDHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*  &+  ELVDJUD   &+  &+  &+6.!GHO    @  GLVXOIXURFRQODFDGHQDOLJHUD ODPEGDKXPDQL]DGD   >9/$0%'$ Homo sapiens,*/9   ,*.-    >@   Homo sapiens,*/&      @GtPHUR   WHWUDNLVGLVXOIXURSURGXFLGRHQODVFpOXODV RYiULFDVGHKDPVWHUVFKLQRV &+2 OtQHDFHOXODU .69JOLFRIRUPDDOID hemostático        +HDY\ FKDLQ  &KDvQH ORXUGH  &DGHQD SHVDGD EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYGMDWVRQA PGKGLEWVSS 50 IRGSRGSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARLY 100 RYWFDYWGQG TLVTVSSAST KGPSVFPLAP CSRSTSESTA ALGCLVKDYF 150 PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SNFGTQTYTC 200 NVDHKPSNTK VDKTVERKCC VECPPCPAPP VAGPSVFLFP PKPKDTLMIS 250 RTPEVTCVVV DVSHEDPEVQ FNWYVDGVEV HNAKTKPREE QFNSTFRVVS 300 VLTVVHQDWL NGKEYKCKVS NKGLPAPIEK TISKTKGQPR EPQVYTLPPS 350 REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPMLDSDGSF 400 FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PG 442 /LJKW FKDLQ  &KDvQH OpJqUH  &DGHQD OLJHUD SYELTQPPSV SVSPGQTARI TCSGDNLPKY YAHWYQQKPG QAPVVVIFYD 50 VNRPSGIPER FSGSNSGNTA TLTISGTQAM DEADYYCQAW WSSTPVFGGG 100 TKLTVLGQPK AAPSVTLFPP SSEELQANKA TLVCLISDFY PGAVTVAWKA 150 DSSPVKAGVE TTTPSKQSNN KYAASSYLSL TPEQWKSHRS YSCQVTHEGS 200 TVEKTVAPTE CS 212 3RVWWUDQVODWLRQDO PRGLILFDWLRQV 'LVXOILGH EULGJHV ORFDWLRQ  3RVLWLRQ GHV SRQWV GLVXOIXUH  3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR ,QWUD+ &&             ,QWUD/ &&         ,QWHU+/ &+ &/     ,QWHU++ K  K  K  K      ,Q DGGLWLRQ WR WKH LVRIRUP $ LVRIRUP $% FKDUDFWHUL]HG E\ DQ LQWHU++ K   &+   DQG DQ LQWHU+/ K  &/     LQVWHDG RI WKH LQWHU++ K   K   DQG RI RQH RI WKH WZR LQWHU+/ &+ &/     (Q SOXV GH O LVRIRUPH $ LVRIRUPH $% FDUDFWpULVpH SDU XQ LQWHU++ K   &+   HW XQ LQWHU+/ K  &/     DX OLHX GH O LQWHU++ K   K   HW GH O XQ GHV GHX[ LQWHU+/ &+ &/     $GHPiV GH OD LVRIRUPD $ LVRIRUPD $% FDUDFWHUL]DGR SRU XQ LQWHU++ K  &+   \ XQ LQWHU+/ K  &/     HQ OXJDU GHO LQWHU++ K   K   \ XQR GH ORV GRV LQWHU+/ &+ &/     1JO\FRV\ODWLRQ VLWHV  6LWHV GH 1JO\FRV\ODWLRQ  3RVLFLRQHV GH 1JOLFRVLODFLyQ + &+ 1   )XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV  JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV FRPSOH[HV IXFRV\OpV  JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV     EHQXIXWDPDEXP  EHQXIXWDPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens 71)56)% WXPRUQHFURVLVIDFWRUUHFHSWRU VXSHUIDPLO\PHPEHU%GHDWKUHFHSWRU'571) UHODWHGDSRSWRVLVLQGXFLQJOLJDQGUHFHSWRU75$,/ 575&' @PRQRFORQDODQWLERG\    251 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019    JDPPDKHDY\FKDLQFKLPHULF  >9+ Mus musculus ,*+9 *!7     ,*+'  ,*+-   Homo sapiens,*+9 *!7     ,*+' ,*+-   >@   Homo sapiens,*+* *PQ*P &+ 5    KLQJH  &+  &+(  0  (!*    &+6.!GHO    @   GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG   >9 .$33$ Homo sapiens,*.9    ,*.-   >@   Homo sapiens ,*.&   .P$  9      @GLPHU   ELVGLVXOILGH SURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 '*FHOO OLQHJO\FRIRUPDOID immunomodulator, antineoplastic  EpQXIXWDPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens 71)56)% PHPEUH%GHODVXSHUIDPLOOHGHV UpFHSWHXUVGXIDFWHXUGHQpFURVHWXPRUDOHUpFHSWHXU GHPRUW'5UpFHSWHXUGH75$,/75$,/575 &' @DQWLFRUSVPRQRFORQDO FKDvQHORXUGHJDPPDFKLPpULTXH  >9+ Mus musculus ,*+9 *!7     ,*+'  ,*+-   Homo sapiens,*+9 *!7     ,*+' ,*+-   >@   Homo sapiens,*+* *PQ*P &+ 5    FKDUQLqUH  &+  &+(  0  (!*    &+6.!GHO    @   GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSDKXPDQLVpH    >9.$33$ Homo sapiens,*.9    ,*.-   >@   Homo sapiens ,*.&   .P$  9      @GLPqUH   ELVGLVXOIXUH SURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGHKDPVWHUV FKLQRLV &+2 OLJQpHFHOOXODLUH'*JO\FRIRUPHDOID immunomodulateur, antinéoplasique  EHQXIXWDPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens 71)56)% PLHPEUR%GHODVXSHUIDPLOLDGHORV UHFHSWRUHVGHOIDFWRUGHQHFURVLVWXPRUDOUHFHSWRUGH PXHUWH'5UHFHSWRUGH75$,/75$,/575 &' @DQWLFXHUSRPRQRFORQDO FDGHQDSHVDGDJDPPDTXLPpULFD  >9+ Mus musculus ,*+9 *!7     ,*+'  ,*+-   Homo sapiens ,*+9 *!7     ,*+' ,*+-   >@   Homo sapiens,*+* *PQ*P &+ 5    ELVDJUD  &+  &+(  0  (!*    &+6.!GHO    @   GLVXOIXURFRQODFDGHQDOLJHUDNDSSDKXPDQL]DGD    >9.$33$ Homo sapiens,*.9    ,*.-   >@   Homo sapiens ,*.&   .P$  9      @GtPHUR   ELVGLVXOIXUR SURGXFLGRHQODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2 OtQHDFHOXODU'*JOLFRIRUPDDOID inmunomodulador, antineoplásico   252 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121            EHWLEHJORJHQXPDXWRWHPFHOXP  EHWLEHJORJHQHDXWRWHPFHO DXWRORJRXV&'KHPDWRSRLHWLFVWHPFHOOV WUDQVGXFHGex vivoZLWKbetibeglogene darolentivec (116)(78)DVHOILQDFWLYDWLQJKXPDQLPPXQRGHILFLHQF\ YLUXV +,9 GHULYHGOHQWLYLUDOYHFWRUHQFRGLQJD 74PXWDWHGIRUPRIWKHKXPDQKHPRJORELQVXEXQLW EHWD +%%EHWDJORELQ JHQHXQGHUWKHFRQWURORID KXPDQȕJORELQSURPRWHUDQGD ȕJORELQHQKDQFHU cell therapy (beta-thalassemia and sickle cell disease)  EpWLEpJORJqQHDXWRWHPFHO FHOOXOHVVRXFKHVKpPDWRSRwpWLTXHV&'DXWRORJXHV WUDQVGXLWHVex vivoDYHFOHbétibéglogène darolentivec (116)(78)YHFWHXUOHQWLYLUDODXWRLQDFWLYDQWGpULYpGX YLUXVGHO LPPXQRGpILFLHQFHKXPDLQH +,9 FRGDQW SRXUXQHIRUPHPXWpH 74 GXJqQHGHODVRXV XQLWpErWDGHO KpPRJORELQHKXPDLQH +%%ErWD JORELQH VRXVOHFRQWU{OHG XQSURPRWHXUGHODȕ JORELQHKXPDLQHHWXQDFWLYDWHXUGHODȕJORELQHHQ SRVLWLRQ  thérapie cellulaire (bêta-thalassémie et anémie falciforme)  EHWLEHJORJpQDXWRWHPFHO FpOXODVPDGUHKHPDWRSR\pWLFDV&'DXWyORJDV WUDQVGXFLGDVex vivoFRQbetibeglogeéne darolentivec (116)(78)XQYHFWRUOHQWLYLUDODXWRLQDFWLYDQWH GHULYDGRGHOYLUXVGHODLQPXQRGHILFLHQFLDKXPDQD 9,+ TXHFRGLILFDSDUDXQDIRUPDPXWDGD74GHO JHQGHODVXEXQLGDGEHWDGHODKHPRJORELQDKXPDQD +%%EHWDJORELQD EDMRHOFRQWUROGHOSURPRWRUGHOD EJORELQDKXPDQD\XQSRWHQFLDGRUGHODEJORELQD ORFDOL]DGRHQSRVLFLyQ   terapia celular (beta-talasemia y anemia falciforme)   253 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019  EUDQHEUXWLQLEXP  EUDQHEUXWLQLE > S  EXW\QDPLGR SLSHULGLQ\O@IOXRUR GLPHWK\OHLQGROHFDUER[DPLGH Bruton's tyrosine kinase inhibitor  EUDQpEUXWLQLE > S  EXW\QDPLGR SLSpULGLQ\O@IOXRUR GLPpWK\OHLQGROHFDUER[DPLGH inhibiteur de la tyrosine kinase de Bruton  EUDQHEUXWLQLE > S  EXWLQDPLGR SLSHULGLQLO@IOXRUR GLPHWLOHLQGROFDUER[DPLGD inhibidor de la tirosina quinasa de Bruton    &+)12        EUHQVRFDWLEXP  EUHQVRFDWLE S N^ S F\DQR> PHWK\OR[R GLK\GUREHQ]R[D]RO\O SKHQ\O@HWK\O` R[D]HSDQHFDUER[DPLGH cathepsin C inhibitor  EUHQVRFDWLE S N^ S F\DQR> PpWK\OR[R GLK\GUREHQ]R[D]RO\O SKpQ\O@pWK\O` R[D]pSDQHFDUER[DPLGH inhibiteur de la cathepsine C  EUHQVRFDWLE S N^ S FLDQR> PHWLOR[RGLKLGUR EHQ]R[D]ROLO IHQLO@HWLO`R[D]HSDQR FDUER[DPLGD inhibidor de la catepsina C    &+12        EUHSRFLWLQLEXP  EUHSRFLWLQLE > S GLIOXRURF\FORSURS\O@ ^> PHWK\OH S\UD]RO\O DPLQR@S\ULPLGLQ\O` GLD]DELF\FOR>@RFWDQ\O PHWKDQRQH Janus kinase inhibitor    254 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121   EUpSRFLWLQLE > S GLIOXRURF\FORSURS\O@ ^> PpWK\OH S\UD]RO\O DPLQR@S\ULPLGLQ\O` GLD]DELF\FOR>@RFWDQ\O PpWKDQRQH inhibiteur de la kinase de Janus  EUHSRFLWLQLE > S GLIOXRURFLFORSURSLO@ ^> PHWLOHSLUD]RO LO DPLQR@SLULPLGLQLO`GLD]DELFLFOR>@RFWDQ LO PHWDQRQD inhibidor de la quinasa de Janus    &+)12        FDWHTXHQWLQLEXP  FDWHTXHQWLQLE > ^> IOXRURPHWK\OHLQGRO\O R[\@ PHWKR[\TXLQROLQ\O`R[\ PHWK\O@F\FORSURSDQDPLQH tyrosine kinase inhibitor, antineoplastic  FDWpTXHQWLQLE > ^> IOXRURPpWK\OHLQGRO\O R[\@ PpWKR[\TXLQROpLQ\O`R[\ PpWK\O@F\FORSURSDQ DPLQH inhibiteur de la tyrosine kinase, antinéoplasique  FDWHTXHQWLQLE > ^> IOXRURPHWLOHLQGROLO R[R@ PHWR[LTXLQROHLQLO`R[L PHWLO@FLFORSURSDQDPLQD inhibidor de la tirosina quinasa, antineoplásico    &+)12        FHQWKDTXLQXP  FHQWKDTXLQH ^> PHWK\OSKHQ\O SLSHUD]LQ\O@HWK\O@TXLQROLQH Į2-adrenoreceptor agonist  FHQWKDTXLQH ^> PpWK\OSKpQ\O SLSpUD]LQ\O@pWK\O@TXLQROpLQH agoniste des récepteurs Į2-adrénergiques  FHQWKDTXLQD ^> PHWLOIHQLO SLSHUD]LQLO@HWLO@TXLQROHLQD agonista de los receptores Į2-adrenérgicos   255 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019  &+1   &+ 1 1 1     FLQUHEDIXVSXPDOID  FLQUHEDIXVSDOID >6!3)!$/!$@LPPXQRJOREXOLQ*NDSSD FKLPHULFKXPDQMus musculusDQWL UHFHSWRUW\URVLQHSURWHLQNLQDVHHUE%(5%%+(5  IXVHGRQERWKKHDY\FKDLQV   YLDD *6 OLQNHU    WRD&' WXPRUQHFURVLVIDFWRUUHFHSWRUVXSHUIDPLO\ PHPEHU71)56)%% WDUJHWLQJPXWDQW H[FKDQJHGUHVLGXHV  RIKXPDQOLSRFDOLQ QHXWURSKLOJHODWLQDVHDVVRFLDWHGOLSRFDOLQ1*$/ RQFRJHQHSVLGHURFDOLQ     JDPPDKHDY\FKDLQIXVHGWROLSRFDOLQPXWHLQ  >Homo sapiens 9+&+&+&+ Homo sapiens,*+9  ,*+' ,*+-  >&'5.DEDW+'7<,+  &'5.DEDW+5,<371*<75<$'69.*  &'5.DEDW+:**'*)<$0'<  @  Homo sapiens,*+*  &+  KLQJH 6!3   &+ )!$/!$   &+  &+6     *6 OLQNHU  KXPDQOLSRFDOLQ>PXWDQW4!+/!4$!, ,!54!,<!01!'6!0/!.5!'.!''!0:!' 5!:&!61!.<!)/!+<!6.!)6!)<!( .!<  @  @  GLVXOILGHZLWKNDSSDOLJKWFKDLQ    >Homo sapiens9/&/ Homo sapiens,*.9 ,*.-  >&'5.DEDW/5$64'917$9$   &'5.DEDW/6$6)/<6    &'5.DEDW/44+<77337   @   Homo sapiens ,*.&    @GLPHU   ELVGLVXOILGHSURGXFHG LQ&KLQHVHKDPVWHURYDU\ &+2 FHOOVJO\FRIRUPDOID immunomodulator, antineoplastic  FLQUpEDIXVSDOID >6!3)!$/!$@LPPXQRJOREXOLQH*NDSSD FKLPpULTXHKXPDLQH Mus musculusDQWL UpFHSWHXUW\URVLQHSURWpLQHNLQDVHHUE%(5%% +(5 IXVLRQQpHVXUOHVGHX[FKDvQHVORXUGHV   YLDXQ OLQNHU *6    jXQPXWDQWGHODOLSRFDOLQH KXPDLQH OLSRFDOLQHDVVRFLpHjODJpODWLQDVHQHXWURSKLOH1*$/ RQFRJqQHSVLGpURFDOLQH FLEODQWOH&' PHPEUHGHOD VXSHUIDPLOOHGHVUpFHSWHXUVGXIDFWHXUGHQpFURVHWXPRUDOH71)56) %%  UpVLGXVpFKDQJpV     FKDvQHORXUGHJDPPDIXVLRQQpHjXQHPXWpLQHGHODOLSRFDOLQH   >Homo sapiens9+&+&+&+ Homo sapiens,*+9  ,*+' ,*+- >&'5.DEDW+'7<,+  &'5.DEDW+ 5,<371*<75<$'69.*  &'5.DEDW+:**'*)<$0'<   @  Homo sapiens,*+*  &+  FKDUQLqUH 6!3   &+ )!$/!$   &+   &+6     *6 OLQNHU  OLSRFDOLQHKXPDLQH >PXWDQW4!+/!4$!,,!54!,<!01!'6!0/!. 5!'.!''!0:!'5!:&!61!.<!)/!+ <!6.!)6!)<!(.!<  @  @   GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD   >Homo sapiens9/&/ Homo sapiens,*.9 ,*.- >&'5.DEDW/ 5$64'917$9$   &'5.DEDW/6$6)/<6    &'5.DEDW/44+<77337   @   Homo sapiens,*.&    @GLPqUH   ELVGLVXOIXUHSURGXLWSDUGHV FHOOXOHVRYDULHQQHVGHKDPVWHUFKLQRLV &+2 JO\FRIRUPHDOID  immunomodulateur, antinéoplasique 256 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121  FLQUHEDIXVSDOID >6!3)!$/!$@LQPXQRJOREXOLQD*NDSSD TXLPpULFDKXPDQDMus musculusDQWL UHFHSWRU WLURVLQDSURWHtQDNLQDVDHUE%(5%%+(5  IXVLRQDGDDODVGRVFDGHQDVSHVDGDV    DWUDYpVGHXQFRQHFWRU *6     FRQXQPXWDQWHGHODOLSRFDOLQDKXPDQD OLSRFDOLQD DVRFLDGDFRQODJHODWLQDVDQHXWUyILOD1*$/RQFRJHQ SVLGHURFDOLQD GLULJLGRVDO&' PLHPEURGH ODVXSHUIDPLOLDGHORVUHFHSWRUHVGHOIDFWRUGHQHFURVLV WXPRUDO71)56)%%  UHVLGXRV LQWHUFDPELDGRV     FDGHQDSHVDGDJDPPDIXVLRQDGDFRQXQHPXWHtQD GHODOLSRFDOLQD  >Homo sapiens9+&+&+ &+ Homo sapiens,*+9  ,*+' ,*+-  >&'5.DEDW+'7<,+  &'5.DEDW+ 5,<371*<75<$'69.*  &'5.DEDW+ :**'*)<$0'<  @  Homo sapiens ,*+*  &+  ELVDJUD 6!3    &+ )!$/!$   &+   &+6     *6 FRQHFWRU   OLSRFDOLQDKXPDQD>PXWDQWH4!+/!4$!, ,!54!,<!01!'6!0/!.5!' .!''!0:!'5!:&!61!.<!) /!+<!6.!)6!)<!(.!<  @  @  GLVXOIXURFRQODFDGHQDOLJHUD NDSSD   >Homo sapiens9/&/ Homo sapiens ,*.9 ,*.- >&'5.DEDW/ 5$64'917$9$   &'5.DEDW/6$6)/<6   &'5.DEDW/44+<77337   @    Homo sapiens,*.&    @GtPHUR   ELVGLVXOIXURSURGXFLGRSRUGHODV FHO~ODVRYiULFDVGHKDPVWHUFKLQRV &+2 JOLFRIRUPD DOID inmunomodulador, antineoplásico          257 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019   FRVLEHOLPDEXP  FRVLEHOLPDE LPPXQRJOREXOLQ*ODPEGDDQWL>Homo sapiens &' SURJUDPPHGGHDWKOLJDQG3'/3'/% KRPRORJ%+ @Homo sapiensPRQRFORQDO DQWLERG\ JDPPDKHDY\FKDLQHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*   *P &+.     KLQJH  &+  &+'  /    &+6    @  GLVXOILGHZLWKODPEGDOLJKWFKDLQHomo sapiens   >9/$0%'$ Homo sapiens,*/9    ,*/-   >@    Homo sapiens,*/&      @GLPHU   ELVGLVXOILGHSURGXFHGLQ&KLQHVH +DPVWHU2YDU\ &+2 FHOOVJO\FRIRUPDOID immunomodulator, antineoplastic  FRVLEpOLPDE LPPXQRJOREXOLQH*ODPEGDDQWL>Homo sapiens &' OLJDQGGHPRUWSURJUDPPpH3'/3'/ KRPRORJXHGH%%+ @DQWLFRUSVPRQRFORQDO Homo sapiens FKDvQHORXUGHJDPPDHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*   *P &+.     FKDUQLqUH  &+  &+ '  /    &+6     @  GLVXOIXUHDYHFODFKDvQHOpJqUH ODPEGDHomo sapiens   >9/$0%'$ Homo sapiens,*/9   ,*/-    >@   Homo sapiens,*/&      @GLPqUH   ELVGLVXOIXUH SURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGHKDPVWHUV FKLQRLV &+2 JO\FRIRUPHDOID immunomodulateur, antinéoplasique  FRVLEHOLPDE LQPXQRJOREXOLQD*ODPEGDDQWL>Homo sapiens &' OLJDQGRGHPXHUWHSURJUDPDGD3'/3' /KRPyORJRGH%%+ @DQWLFXHUSRPRQRFORQDO Homo sapiens FDGHQDSHVDGDJDPPDHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*   *P &+.     ELVDJUD  &+  &+ '  /    &+6     @  GLVXOIXURFRQODFDGHQDOLJHUDODPEGD Homo sapiens   >9/$0%'$ Homo sapiens ,*/9   ,*/-   >@    Homo sapiens,*/&      @ GtPHUR   ELVGLVXOIXURSURGXFLGRHQ ODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2  JOLFRIRUPDDOID inmunomodulador, antineoplásico   258 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121          GLUORFWRFRJHQXPVDPRSDUYRYHFXP  GLUORFWRFRJHQHVDPRSDUYRYHF $UHFRPELQDQWQRQUHSOLFDWLQJDGHQRDVVRFLDWHGYLUXV YHFWRUZLWKDELRHQJLQHHUHGFDSVLGGHULYHGE\'1$ VKXIIOLQJRI$$9FDSVLGVHTXHQFHV $$9% DYLDQDQGERYLQH$$9 IROORZHGE\in vivo VHOHFWLRQLQ)DKíí5DJíí,OUJíí )5* PLFH SDUWLDOO\UHSRSXODWHGZLWKKXPDQKHSDWRF\WHV7KH YHFWRUKDV$$9JHQRPLFLQYHUWHGWHUPLQDOUHSHDWV ,75 DQGHQFRGHVDKXPDQ%GRPDLQGHOHWHGEORRG FRDJXODWLRQIDFWRU9,,, K))9,,, XQGHUWKHFRQWURORI DPRGLILHGWUDQVWK\UHWLQ 775P SURPRWHU 1RWHWKHQXFOHRWLGHVHTXHQFHRIWKHYHFWRULVD PRGLILFDWLRQRIWKHRQHRIWKHYHFWRURIrovoctocogene durparvovec (proposed INN: List 120) gene therapy (hemophilia)  GLUORFWRFRJqQHVDPRSDUYRYHF 9HFWHXUYLUDODGpQRDVVRFLpUHFRPELQDQWQRQ UpSOLTXDQWDYHFXQHFDSVLGHREWHQXHSDUELRLQJpQLHULH GpULYpHGXPpODQJHGHVVpTXHQFHVGHO $'1GH FDSVLGHVGH$$9 $$9%$$9 DYLDLUHHW$$9ERYLQ VXLYLGHODVpOHFWLRQin vivoFKH] GHVVRXULV)DKíí5DJíí,OUJíí )5*  SDUWLHOOHPHQWUHSHXSOpVDYHFGHVKpSDWRF\WHV KXPDLQV/HYHFWHXUFRQWLHQWOHVVpTXHQFHVLQYHUVHV WHUPLQDOHVUpSpWpHV ,75 GH$$9HWFRGHSRXUOH IDFWHXUGHFRDJXODWLRQVDQJXLQH9,,,KXPDLQ K) )9,,, GRQWOHGRPDLQH%DpWpVXSSULPpVRXVOH FRQWU{OHG XQSURPRWHXUPRGLILpGHODWUDQVWK\UpWLQH 775P  1RWHODVpTXHQFHGHQXFOpRWLGHVGXYHFWHXUHVWXQH PRGLILFDWLRQGHFHOOHGXYHFWHXUGXrovoctocogène durparvovec (DCI proposées: Liste 120) thérapie génique (hémophilie)    259 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019  GLUORFWRFRJpQVDPRSDUYRYHF 8QYHFWRUGHYLUXVDGHQRDVRFLDGRUHFRPELQDQWHQR UHSOLFDWLYRFRQXQDFiSVLGDELRLQJHQLHUL]DGDPHGLDQWH ODPH]FODGHVHFXHQFLDVGH'1$GHFiSVLGDVGH $$9 $$9%$$9DYLDU\$$9 ERYLQR VHJXLGRGHVHOHFFLyQLQYLYRHQUDWRQHV )DKíí5DJíí,OUJíí )5* SDUFLDOPHQWH UHSREODGRVFRQKHSDWRFLWRVKXPDQRV(OYHFWRUWLHQH UHSHWLFLRQHVWHUPLQDOHVLQYHUWLGDV ,75 JHQyPLFDVGH $$9\FRGLILFDSDUDXQIDFWRUGHFRDJXODFLyQ VDQJXtQHR9,,,KXPDQR K))9,,, FRQHOGRPLQLR% GHOHFLRQDGREDMRHOFRQWUROGHXQSURPRWRUGH WUDQVWLUHWLQDPRGLILFDGR 775P  1RWDODVHFXHQFLDGHQXFOHyWLGRVGHOYHFWRUHVXQD PRGLILFDFLyQGHODGHOYHFWRUGHrovoctocogén durparvovec (DCI propuestas: Lista 120) terapia génica (hemofilia)         GRYDQYHWPDEXP  GRYDQYHWPDE LPPXQRJOREXOLQ*NDSSDDQWL>Felis catus ,/ LQWHUOHXNLQ @IHOLQL]HGPRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQIHOLQL]HG  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Felis catus ,*+*  &+  KLQJH  &+ 0/!$$  *!$     &+  &+6    @   GLVXOILGHZLWKNDSSDOLJKWFKDLQIHOLQL]HG    >9.$33$ Homo sapiens,*.9    ,*.-   >@   Felis catus ,*.&   1!4     @ GLPHU    WULVGLVXOILGH SURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 *6FHOO OLQHJO\FRIRUPDOID immunomodulator (veterinary use)  GRYDQYHWPDE LPPXQRJOREXOLQH*NDSSDDQWL>Felis catus ,/ LQWHUOHXNLQH @DQWLFRUSVPRQRFORQDOIpOLQLVp FKDvQHORXUGHJDPPDIpOLQLVpH  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Felis catus ,*+*  &+  FKDUQLqUH   &+0/!$$  *!$     &+  &+6    @  GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD IpOLQLVpH   >9.$33$ Homo sapiens,*.9    ,*.-   >@    Felis catus ,*.&   1!4      @GLPqUH     WULVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGH KDPVWHUVFKLQRLV &+2 OLJQpHFHOOXODLUH*6 JO\FRIRUPHDOID immunomodulateur (usage vétérinaire)     260 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121 GRYDQYHWPDE LQPXQRJOREXOLQD*NDSSDDQWL>Felis catus ,/ LQWHUOHXNLQD @DQWLFXHUSRPRQRFORQDOIHOLQL]DGR FDGHQDSHVDGDJDPPDIHOLQL]DGD  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Felis catus ,*+*  &+  ELVDJUD   &+0/!$$  *!$     &+  &+6    @  GLVXOIXURFRQODFDGHQDOLJHUDNDSSD IHOLQL]DGD   >9.$33$ Homo sapiens,*.9    ,*.-   >@    Felis catus ,*.&   1!4      @GtPHUR     WULVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDVGH KDPVWHUVFKLQRV &+2 OtQHDFHOXODU*6JOLFRIRUPD DOID inmunomodulador (uso veterinario)            HIEHPDOHQRJUDVWLPXPDOID  HIEHPDOHQRJUDVWLPDOID KXPDQJUDQXORF\WHFRORQ\VWLPXODWLQJIDFWRU *&6)  IUDJPHQWIXVHGYLDDSHSWLG\OOLQNHUWRDKXPDQ LPPXQRJOREXOLQ*)FIUDJPHQWYDULDQWGLPHU >KXPDQJUDQXORF\WHFRORQ\VWLPXODWLQJIDFWRU *&6) SOXULSRLHWLQ VKRUW>$96(!GHO@LVRIRUP  @ >*6*6 *6 OLQNHU  @>KXPDQ LPPXQRJOREXOLQ*)FIUDJPHQW &WHUPLQDO UHVLGXHV  Homo sapiens,*+*  QDWXUDO6!$ YDULDQW KLQJH  &+ 3!6    &+  &+6   @IXVLRQ SURWHLQGLPHU   ELVGLVXOILGH SURGXFHGLQ&KLQHVHKDPVWHURYDU\ &+2 FHOOV JO\FRIRUPDOID granulocyte colony stimulating factor   261 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019  HIEpPDOpQRJUDVWLPDOID IUDJPHQWGXIDFWHXUGHVWLPXODWLRQGHVFRORQLHVGH JUDQXORF\WHVKXPDLQ *&6) OLpSDUXQSHSWLGHjXQ YDULDQWGXIUDJPHQW)FGHO LPPXQRJOREXOLQHKXPDLQH *GLPqUH >IDFWHXUKXPDLQGHVWLPXODWLRQGHVFRORQLHVGH JUDQXORF\WHV *&6)SOXULSRwpWLQH  >$96(!GHO@LVRIRUPHFRXUWH  @ >*6*6 *6 OLQNHU  @>IUDJPHQW)FGH O LPPXQRJOREXOLQHKXPDLQH* UpVLGXV& WHUPLQDX[  Homo sapiens,*+*  YDULDQWQDWXUDO 6!$ FKDUQLqUH  &+ 3!6    &+  &+6   @SURWpLQHGH IXVLRQGLPqUH   ELVGLVXOIXUHSURGXLW SDUGHVFHOOXOHVRYDULHQQHVGHKDPVWHUFKLQRLV &+2  JO\FRIRUPHDOID facteur de stimulation des colonies de granulocytes  HIEHPDOHQRJUDVWLPDOID IUDJPHQWRGHOIDFWRUGHHVWLPXODFLyQGHODVFRORQLDV GHJUDQXORFLWRVKXPDQR *&6) TXHVHXQHSRUXQ SpSWLGRDXQDYDULDQWHGHOIUDJPHQW)FGHOD LQPXQRJOREXOLQDKXPDQD*GtPHUR >IDFWRUKXPDQRGHHVWLPXODFLyQGHODVFRORQLDVGH JUDQXORFLWRV *&6)SOXULSR\HWLQD >$96(!GHO@ LVRIRUPDFRUWD  @>*6*6 *6 FRQHFWRU   @>IUDJPHQWR)FGHODLQPXQRJOREXOLQDKXPDQD* UHVLGXR&WHUPLQDO  Homo sapiens,*+*  YDULDQWHQDWXUDO6!$ ELVDJUD  &+ 3!6   &+  &+6    @SURWHtQDGHIXVLyQGtPHUR    ELVGLVXOIXURSURGXFLGRSRUODVFpOXODV RYiULFDVGHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID factor estimulante de las colonias de granulocitos          HIPLWHUPDQWXPDOID  HIPLWHUPDQWDOID KXPDQIROOLVWDWLQIUDJPHQWIXVHGYLDDSHSWLG\OOLQNHUWR DKXPDQLPPXQRJOREXOLQ*)FIUDJPHQWGLPHU >KXPDQIROOLVWDWLQ )67)6DFWLYLQELQGLQJSURWHLQ    SHSWLGH@>7*OLQNHU  @>KXPDQ LPPXQRJOREXOLQ*)FIUDJPHQW &WHUPLQDO UHVLGXHV >Homo sapiens,*+* KLQJH   &+  &+  &+6  @    QDWXUDO6!$YDULDQW @IXVLRQSURWHLQGLPHU   ELVGLVXOILGHSURGXFHGLQ&KLQHVH KDPVWHURYDU\ &+2 FHOOVJO\FRIRUPDOID  anti-transforming growth factor 262 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121  HIPLWHUPDQWDOID IUDJPHQWGHODIROOLVWDWLQHKXPDLQHIXVLRQQpHYLDXQ SHSWLGHjXQIUDJPHQW)FGHO LPPXQRJOREXOLQH KXPDLQH*GLPqUH >IROOLVWDWLQHKXPDLQH )67)6SURWpLQHOLDQWO DFWLYLQH   SHSWLGH@>7*OLQNHU  @>IUDJPHQW)FGH O LPPXQRJOREXOLQH*KXPDLQH UpVLGXV& WHUPLQDX[ >Homo sapiens,*+* FKDUQLqUH   &+  &+  &+6  @   YDULDQWQDWXUHO6!$ @SURWpLQHGHIXVLRQ GLPqUH   ELVGLVXOIXUHSURGXLWGDQV GHVFHOOXOHVRYDULHQQHVGHKDPVWHUVFKLQRLV &+2  JO\FRIRUPHDOID anti-facteur de croissance transformant  HIPLWHUPDQWDOID IUDJPHQWRGHODIROLVWDWLQDKXPDQDIXVLRQDGDDWUDYpV GHXQSpSWLGRFRQXQIUDJPHQWR)FGHOD LQPXQRJOREXOLQDKXPDQD*GtPHUR >IROLVWDWLQDKXPDQD )67)6SURWHtQDTXHVHXQDDOD DFWLYLQD   SpSWLGR@>7*FRQHFWRU  @ >IUDJPHQWR)FGHODLQPXQRJOREXOLQD*KXPDQD UHVLGXR&WHUPLQDO >Homo sapiens,*+*  ELVDJUD  &+  &+   &+6  @   YDULDQWHQDWXUHO6!$ @ SURWHtQDGHIXVLyQGtPHUR    ELVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDVGH KDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID  anti-factor de crecimiento transformante     6HTXHQFH  6pTXHQFH  6HFXHQFLD GNCWLRQAKN GRCQVLYKTE LSKEECCSTG RLSTSWTEED VNDNTLFKWM 50 IFNGGAPNCI PCKETCENVD CGPGKKCRMN KKNKPRCVCA PDCSNITWKG 100 PVCGLDGKTY RNECALLKAR CKEQPELEVQ YQGRCKKTCR DVFCPGSSTC 150 VVDQTNNAYC VTCNRICPEP ASSEQYLCGN DGVTYSSACH LRKATCLLGR 200 SIGLAYEGKC IKAKSCEDIQ CTGGKKCLWD FKVGRGRCSL CDELCPDSKS 250 DEPVCASDNA TYASECAMKE AACSSGVLLE VKHSGSCNSI STGGGVECPP 300 CPAPPVAGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVQFNWYV 350 DGVEVHNAKT KPREEQFNST FRVVSVLTVV HQDWLNGKEY KCKVSNKGLP 400 APIEKTISKT KGQPREPQVY TLPPSREEMT KNQVSLTCLV KGFYPSDIAV 450 EWESNGQPEN NYKTTPPMLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH 500 EALHNHYTQK SLSLSPGK 518 'LVXOILGH EULGJH ORFDWLRQ  3RVLWLRQ GH OD SRQW GLVXOIXUH  3RVLFLyQ GHO SXHQWH GLVXOIXUR LQWUD+ LQWUD+  )67                   ,J*   LQWHU++     *O\FRV\ODWLRQ VLWHV  6LWHV GH JO\FRV\ODWLRQ  3RVLFLRQHV GH JOLFRVLODFLyQ  $VQ $VQ $VQ    HOH[DFDIWRUXP  HOH[DFDIWRU N GLPHWK\OHS\UD]ROHVXOIRQ\O >  WULIOXRURGLPHWK\OSURSR[\ HS\UD]RO\O@> S  WULPHWK\OS\UUROLGLQ\O@S\ULGLQHFDUER[DPLGH cystic fibrosis transmembrane regulator (CFTR) protein modulator  pOH[DFDIWRU N GLPpWK\OHS\UD]ROHVXOIRQ\O >  WULIOXRURGLPpWK\OSURSR[\ HS\UD]RO\O@> S  WULPpWK\OS\UUROLGLQ\O@S\ULGLQHFDUER[DPLGH modulateur de la protéine régulatrice de la perméabilité transmembranaire impliquée dans la  mucoviscidose (CFTR)  263 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019  HOH[DFDIWRU N GLPHWLOHSLUD]ROVXOIRQLO > WULIOXRUR GLPHWLOSURSR[L HSLUD]ROLO@> S WULPHWLOSLUUROLGLQ LO@SLULGLQDFDUER[DPLGD modulador de la proteína reguladora de la conductancia transmembrana de la fibrosis quística (CFTR)    &+)126   + &+ +& +& 1 2 2 2 6 1 1 + 1 &+ 1 1 &) +& +& 1 +&  2    HOLYDOGRJHQXPDXWRWHPFHOXP  HOLYDOGRJHQHDXWRWHPFHO DXWRORJRXV&'KHPDWRSRLHWLFVWHPFHOOVWUDQVGXFHGex vivoZLWKelivaldogene tavalentivec(115)(77)D969*  SVHXGRW\SHGVHOILQDFWLYDWLQJ+,9GHULYHGOHQWLYLUDOYHFWRU S/%3K$/' HQFRGLQJKXPDQDGUHQROHXNRG\VWURSK\ $/' SURWHLQ $%&'JHQH XQGHUWKHFRQWURORIDPRGLILHG P\HORSUROLIHUDWLYHVDUFRPDYLUXVSURPRWHU 01'  969* YHVLFXODUVWRPDWLWLVYLUXV*HQYHORSHSURWHLQ 01' P\HORSUROLIHUDWLYHVDUFRPDYLUXVHQKDQFHUZLWK QHJDWLYHFRQWUROUHJLRQGHOHWHGGOUHYSULPHUELQGLQJVLWH VXEVWLWXWHG cell therapy (adrenoleukodystrophy)  pOLYDOGRJqQHDXWRWHPFHO FHOOXOHVVRXFKHVKpPDWRSRwpWLTXHV&'DXWRORJXHV WUDQVGXLWHVex vivoDYHFO élivaldogène tavalentivecYHFWHXU OHQWLYLUDOGpULYpGX9,+DXWRLQDFWLYDQW S/%3K$/'  SVHXGRW\Sp969* FRGDQWSRXUODSURWpLQHKXPDLQHGH O DGUpQROHXFRG\VWURSKLH $/'  JqQH$%&' VRXVOH FRQWU{OHG XQSURPRWHXUGXYLUXVGXVDUFRPH P\pORSUROLIpUDWLIPRGLILp 01'  969* JO\FRSURWpLQH*GHO HQYHORSSHGXYLUXVGHOD VWRPDWLWHYpVLFXODLUH 01' DFWLYDWHXUGXYLUXVGXVDUFRPHP\pORSUROLIpUDWLI GRQWODUpJLRQGHFRQWU{OHQpJDWLIDpWpVXSSULPpHOHVLWHGH OLDLVRQGHO DPRUFHVXEVWLWXpSDUGOUHY thérapie cellulaire (adrénoleucodystrophie)  HOLYDOGRJpQDXWRWHPFHO FpOXODVPDGUHKHPDWRSR\pWLFDV&'DXWyORJDV WUDQVGXFLGDVex vivo FRQelivaldogéne tavalentivec (115)(77)XQYHFWRUOHQWLYLUDODXWRLQDFWLYDQWHGHULYDGRGHO 9,+\VHXGRWLSDGRFRQ969*  S/%3K$/' TXH FRGLILFDSDUDODSURWHtQDGHODDGUHQROHXFRGLVWURILD $/'  KXPDQD JHQ$%&' EDMRHOFRQWUROGHXQSURPRWRU PRGLILFDGRGHOYLUXVGHOVDUFRPDPLHORSUROLIHUDWLYR 01'  969* SURWHtQD*GHODHQYXHOWDGHOYLUXVGHOD HVWRPDWLWLVYHVLFXODU 01' DFWLYDWRUGHOYLUXVGHOVDUFRPDPLHORSUROLIHUDWLYR FRQODUHJLyQGHFRQWUROQHJDWLYRGHOHFLRQDGD\HOVLWLRGH XQLyQGHOSULPHUGOUHYVXEVWLWXtGR terapia celular (adrenoleucodistrofia)   264 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121  HOVXEUXWLQLEXP  HOVXEUXWLQLE > S  SURSHQR\O SLSHULGLQ\O@HLQGROH FDUER[DPLGH Bruton's tyrosine kinase inhibitor  HOVXEUXWLQLE > S  SURSpQR\O SLSpULGLQ\O@HLQGROH FDUER[DPLGH inhibiteur de la tyrosine kinase de Bruton  HOVXEUXWLQLE > S  SURSHQRLO SLSHULGLQLO@HLQGRO FDUER[DPLGD inhibidor de la tirosina quinasa de Bruton    &+12      HQDYRJOLIOR]LQXP  HQDYRJOLIOR]LQ S DQK\GURC^FKORUR>  F\FORSURS\OSKHQ\O PHWK\O@GLK\GUREHQ]RIXUDQ \O`'JOXFLWRO antidiabetic  pQDYRJOLIOR]LQH S DQK\GURC^FKORUR>  F\FORSURS\OSKpQ\O PpWK\O@GLK\GUREHQ]RIXUDQ \O`'JOXFLWRO hypoglycémiant  HQDYRJOLIOR]LQD S DQKLGURC^FORUR>  FLFORSURSLOIHQLO PHWLO@GLKLGUREHQ]RIXUDQLO`' JOXFLWRO hipoglucemiante    &+&O2       HQFHOLPDEXP  HQFHOLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens/$* O\PSKRF\WHDFWLYDWLQJO\PSKRF\WHDFWLYDWLRQ &' @KXPDQL]HGPRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQKXPDQL]HG  >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*  &+  KLQJH6!3     &+  &+  &+6      @  GLVXOILGHZLWKNDSSDOLJKWFKDLQ 265 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019   KXPDQL]HG   >9.$33$ Homo sapiens,*.9'    ,*.-   >@   Homo sapiens,*.&   .P $  9     @ GLPHU  ELVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 FHOOVJO\FRIRUPDOID immunomodulator, antineoplastic  HQFHOLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens/$* DFWLYDWHXUGHV O\PSKRF\WHVO\PSKRF\WHDFWLYDWLRQ&' @DQWLFRUSVPRQRFORQDO KXPDQLVp FKDvQHORXUGHJDPPDKXPDQLVpH  >9+ Homo sapiens,*+9     ,*+' ,*+-   >@  Homo sapiens ,*+*  &+  FKDUQLqUH6!3    &+  &+  &+6    @  GLVXOIXUH DYHFODFKDvQHOpJqUHNDSSDKXPDQLVpH   >9.$33$ Homo sapiens ,*.9'   ,*.-   >@   Homo sapiens ,*.&   .P$  9     @GLPqUH   ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGH KDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID immunomodulateur, antinéoplasique  HQFHOLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens/$* DFWLYDGRUGHORV OLQIRFLWRVDFWLYDFLyQGHOLQIRFLWR&' @DQWLFXHUSRPRQRFORQDO KXPDQL]DGR FDGHQDSHVDGDJDPPDKXPDQL]DGD  >9+ Homo sapiens,*+9     ,*+' ,*+-   >@  Homo sapiens ,*+*  &+  ELVDJUD6!3    &+   &+  &+6    @  GLVXOIXURFRQOD FDGHQDOLJHUDNDSSDKXPDQL]DGD   >9.$33$ Homo sapiens ,*.9'   ,*.-   >@   Homo sapiens ,*.&   .P$  9     @GtPHUR   ELVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDVGHKDPVWHUV FKLQRV &+2 JOLFRIRUPDDOID inmunomodulador, antineoplásico         266 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121   HQPHWD]REDFWDPXP  HQPHWD]REDFWDP SSR PHWK\O> PHWK\OHWULD]RO LXP\O PHWK\O@WULR[RȜWKLD D]DELF\FOR>@KHSWDQHFDUER[\ODWH beta-lactamase inhibitor  HQPpWD]REDFWDP SSR PpWK\O> PpWK\OHWULD]RO LXP\O PHWK\O@WULR[RȜWKLD D]DELF\FOR>@KHSWDQHFDUER[\ODWH inhibiteur de la bêta-lactamase  HQPHWD]REDFWDP SSR PHWLO> PHWLOHWULD]ROLXP LO PHWLO@WULR[RȜWLDD]DELFLFOR>@KHSWDQR FDUER[LODWR inhibidor de la beta-lactamasa    &+126      HSFRULWDPDEXP  HSFRULWDPDE LPPXQRJOREXOLQ*ODPEGDNDSSDDQWL>Homo sapiens&'( &'HSVLORQ @DQGDQWL>Homo sapiens 06$ PHPEUDQHVSDQQLQJGRPDLQVVXEIDPLO\$ PHPEHU&' @PRQRFORQDODQWLERG\ELVSHFLILF JDPPDKHDY\FKDLQFKLPHULFDQWL&'(  >9+ Mus musculus ,*+9    ,*+'  ,*+-   Homo sapiens ,*+9    ,*+' ,*+-   >@   Homo sapiens,*+* *PQ*P &+5    KLQJH  &+/!)  /!(  '!$    &+(  0  )!/    &+6 .!GHO    @  GLVXOILGHZLWK ODPEGDOLJKWFKDLQFKLPHULF   >9/$0%'$ Mus musculus,*/9   ,*/-   Homo sapiens,*/9   ,*/-    >@   Homo sapiens,*/&      @ JDPPDKHDY\FKDLQHomo sapiensDQWL06$    >9+ Homo sapiens ,*+9    ,*+' ,*+-   >@   Homo sapiens,*+* *P*P &+5    KLQJH  &+/!)   /!(  '!$    &+(   0  .!5    &+6.!GHO     @   GLVXOILGHZLWKNDSSD OLJKWFKDLQHomo sapiens   >9.$33$ Homo sapiens,*.9   ,*.-    >@   Homo sapiens,*.&    .P$  9     @GLPHU   ELVGLVXOILGHSURGXFHGLQ&KLQHVH +DPVWHU2YDU\ &+2 6FHOOOLQHJO\FRIRUPDOID  immunomodulator, antineoplastic   267 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019 pSFRULWDPDE LPPXQRJOREXOLQH*ODPEGDNDSSDDQWL>Homo sapiens&'( &'HSVLORQ @HWDQWL>Homo sapiens06$ PHPEUHGHOD VRXVIDPLOOH$jGRPDLQHVWUDQVPHPEUDQDLUHV&' @ DQWLFRUSVPRQRFORQDOELVSpFLILTXH FKDvQHORXUGHJDPPDFKLPpULTXHDQWL&'(  >9+ Mus musculus ,*+9    ,*+' ,*+-   Homo sapiens ,*+9    ,*+' ,*+-   >@  Homo sapiens,*+* *P Q*P &+5    FKDUQLqUH   &+/!)  /!(  '!$    &+ (  0  )!/    &+6.!GHO    @  GLVXOIXUHDYHFODFKDvQHOpJqUH ODPEGDFKLPpULTXH   >9/$0%'$ Mus musculus,*/9   ,*/-   Homo sapiens,*/9    ,*/-   >@   Homo sapiens,*/&      @ FKDvQHORXUGHJDPPDHomo sapiensDQWL06$   >9+ Homo sapiens ,*+9    ,*+' ,*+-    >@   Homo sapiens,*+* *PQ*P &+ 5    FKDUQLqUH  &+/!)  /!(  '!$    &+(  0  .!5    &+6.!GHO     @   GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSDHomo sapiens   >9.$33$ Homo sapiens,*.9    ,*.-   >@   Homo sapiens,*.&   .P$  9     @GLPqUH    ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHV GHKDPVWHUVFKLQRLV &+2 OLJQpHFHOOXODLUH&+26JO\FRIRUPH DOID immunomodulateur, antinéoplasique  HSFRULWDPDE LQPXQRJOREXOLQD*ODPEGDNDSSDDQWL>Homo sapiens&'( &'pSVLORQ @\DQWL>Homo sapiens06$ PLHPEURGHODVXE IDPLOLD$GHGRPLQLRVWUDQVPHPEUDQDULRV&' @DQWLFXHUSR PRQRFORQDOELHVSHFtILFR FDGHQDSHVDGDJDPPDTXLPpULFDDQWL&'(  >9+ Mus musculus ,*+9    ,*+' ,*+-   Homo sapiens ,*+9    ,*+' ,*+-   >@  Homo sapiens,*+* *P Q*P &+5    ELVDJUD  &+ /!)  /!(  '!$    &+(  0  )!/    &+6.!GHO    @  GLVXOIXURFRQODFDGHQDOLJHUDODPEGD TXLPpULFD   >9/$0%'$ Mus musculus,*/9    ,*/-   Homo sapiens,*/9   ,*/-   >@   Homo sapiens,*/&       @ FDGHQDSHVDGDJDPPDHomo sapiensDQWL06$   >9+ Homo sapiens ,*+9    ,*+' ,*+-    >@   Homo sapiens,*+* *PQ*P &+ 5    ELVDJUD  &+/!)   /!(  '!$    &+(  0   .!5    &+6.!GHO     @    GLVXOIXURFRQODFDGHQDOLJHUDNDSSDHomo sapiens    >9.$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens,*.&   .P $  9     @GtPHUR    ELVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDVGHKDPVWHUV FKLQRV &+2 OtQHDFHOXODU&+26JOLFRIRUPDDOID inmunomodulador, antineoplásico   268 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121           H]DODGFLJHQXPUHVRSDUYRYHFXP  H]DODGFLJHQHUHVRSDUYRYHF $UHFRPELQDQWQRQUHSOLFDWLQJDGHQRDVVRFLDWHGYLUXV VHURW\SH U$$9 YHFWRUHQFRGLQJKXPDQDURPDWLF /DPLQRDFLGGHFDUER[\ODVH $$'&'23$ GHFDUER[\ODVH''& XQGHUFRQWURORID F\WRPHJDORYLUXV &09 SURPRWHU gene therapy (antiparkinsonian)  p]DODGFLJqQHUpVRSDUYRYHF 9HFWHXUYLUDODGpQRDVVRFLpUHFRPELQDQWGHVpURW\SH QRQUpSOLTXDQW U$$9 FRGDQWSRXUOD GpFDUER[\ODVHGHVDFLGHV/DPLQpVDURPDWLTXHV $$'&'23$GpFDUER[\ODVH''& VRXVOHFRQWU{OH G XQSURPRWHXUGHF\WRPpJDORYLUXV &09  thérapie génique (antiparkinson)  H]DODGFLJpQUHVRSDUYRYHF 8QYHFWRUGHYLUXVDGHQRDVRFLDGRUHFRPELQDQWHQR UHSOLFDWLYRGHOVHURWLSR U$$9 TXHFRGLILFDSDUDOD /DPLQRiFLGRDURPiWLFRGHVFDUER[LODVD $$'&'23$ GHFDUER[LODVD''& EDMRHOFRQWUROGHXQSURPRWRUGH FLWRPHJDORYLUXV &09  terapia génica (antiparkinsoniano)   269 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019      IDGUDFLFOLEXP  IDGUDFLFOLE RS ^>^> GLPHWK\OS\ULGLQ \O PHWK\O@DPLQR` SURSDQ\O HSXULQ \O@DPLQR`SHQWDQRO cyclin-dependent kinase inhibitor, antineoplastic  IDGUDFLFOLE RS ^>^> GLPpWK\OS\ULGLQ \O PpWK\O@DPLQR` SURSDQ\O HSXULQ \O@DPLQR`SHQWDQRO inhibiteur des kinases dépendantes des cyclines, antinéoplasique  IDGUDFLFOLE RS ^>^> GLPHWLOSLULGLQLO PHWLO@DPLQR` SURSDQLO HSXULQLO@DPLQR`SHQWDQRO inhibidor de las quinasas dependientes de las ciclinas, antineoplásico    &+12      IHOFLVHWUDJXP  IHOFLVHWUDJ PHWK\O> ^> SURSDQ\O HEHQ]LPLGD]ROH FDUER[DPLGR@PHWK\O`SLSHULGLQ\O PHWK\O@SLSHULGLQH FDUER[\ODWH prokinetic agent  IHOFLVpWUDJ > ^> SURSDQ\O HEHQ]LPLGD]ROH FDUER[DPLGR@PpWK\O`SLSHULGLQ\O PpWK\O@SLSpULGLQH FDUER[\ODWHGHPpWK\OH accélérateur du transit intestinal  IHOFLVHWUDJ > ^> SURSDQLO HEHQ]LPLGD]RO FDUER[DPLGR@PHWLO`SLSHULGLQLO PHWLO@SLSHULGLQD FDUER[LODWRGHPHWLOR estimulante de la motilidad intestinal    &+12       IHOH]RQH[RUXP  IHOH]RQH[RU ^>FKORUR WULIOXRURPHWK\O S\ULGLQ\O@DPLQR` > GLPHWK\OEXWR[\ PHWK\O@PHWK\OHS\UUROH GLRQH  antineoplastic 270 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121   IpOp]RQH[RU ^>FKORUR WULIOXRURPpWK\O S\ULGLQ\O@DPLQR`>  GLPpWK\OEXWR[\ PpWK\O@PpWK\OHS\UUROHGLRQH antinéoplasique  IHOH]RQH[RU ^>FORUR WULIOXRURPHWLO SLULGLQLO@DPLQR`>  GLPHWLOEXWR[L PHWLO@PHWLOHSLUUROGLRQD antineoplásico    &+&O)12   + 2 &O 1 1 1 &+ )& 2 2 &+ &+ &+    IHUULEHSHFWDV  IHUULFEHSHFWDWH O K\GUR[HWK\O VXEVWLWXWHG aSHUJOXFRVHXQLW DFLG K\GURO\VHGSRWDWRVWDUFK Įĺ  RS 'glucoKHSWRQLF DFLG aJOXFRVHXQLWV FRPSOH[HVZLWKLURQ ,,, K\GUR[LGH R[LGHQDQRSDUWLFOHV a)HSHUSDUWLFOH  a  antianaemic  EpSHFWDWHIHUULTXH IpFXOHGHSRPPHGHWHUUH Įĺ DFLGH RS 'gluco  KHSWRQLTXH aXQLWpVGHJOXFRVH K\GURO\VpHHQPLOLHX DFLGHO K\GUR[pWK\O VXEVWLWXpH aSDUXQLWpGH JOXFRVH FRPSOH[pHDYHFGHVQDQRSDUWLFXOHVG¶K\GUR[\GH R[\GHGHIHU ,,,  a)HSDUSDUWLFXOH  a  antianémique  EHSHFWDWRIpUULFR DOPLGyQGHSDWDWD Įĺ iFLGR RS 'glucoKHSWyQLFR aXQLGDGHVGHJOXFRVD KLGUROL]DGRHQPHGLRiFLGR O KLGUR[LHWLO VXVWLWXLGR aSRUXQLGDGGHJOXFRVD  FRPSOHMRFRQODVQDQRSDUWtFXODVGHKLGUy[LGRGHKLHUUR ,,,  a)HSRUSDUWtFXOD  a  antianémico    )H+2 [^ &+2 P &+2 PQ &+2 `\  P§Q§[§\§    52 52 2 25 25 2 + + 2 2 2 2  2+ )H  )H   52 25 52 25 2 2 m+n y + x 555 ++&+&+2+ m 555 +++ n  m a n a   x a   y a     ILDQOLPDEXP  ILDQOLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens /$* O\PSKRF\WHDFWLYDWLQJO\PSKRF\WHDFWLYDWLRQ&' @ Homo sapiens PRQRFORQDODQWLERG\      271 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019   JDPPDKHDY\FKDLQHomo sapiens  >9+ Homo sapiens ,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*  &+  KLQJH6!3    &+(!3  /!9  *!$    &+  &+6    @  GLVXOILGHZLWKNDSSDOLJKWFKDLQHomo sapiens   >9.$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens ,*.&   .P$  9     @ GLPHU   ELVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 FHOOVJO\FRIRUPDOID immunomodulator, antineoplastic  ILDQOLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens /$* DFWLYDWHXUGHV O\PKRF\WHVO\PSKRF\WHDFWLYDWLRQ&' @DQWLFRUSVPRQRFORQDOHomo sapiens FKDvQHORXUGHJDPPDHomo sapiens  >9+ Homo sapiens ,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*  &+  FKDUQLqUH6!3    &+(!3   /!9  *!$    &+  &+6     @  GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD Homo sapiens    >9.$33$ Homo sapiens,*.9   ,*.-   >@    Homo sapiens ,*.&   .P$  9      @ GLPqUH   ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHV GHKDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID immunomodulateur, antinéoplasique  ILDQOLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens /$* DFWLYDGRUGHORV OLQIRFLWRVOLQIRFLWRDFWLYDFLyQ&' @DQWLFXHUSRPRQRFORQDOHomo sapiens FDGHQDSHVDGDJDPPDHomo sapiens  >9+ Homo sapiens ,*+9     ,*+' ,*+-   >@  Homo sapiens ,*+*  &+  ELVDJUD6!3    &+(!3  /!9  *!$    &+  &+6    @  GLVXOIXURFRQODFDGHQDOLJHUDNDSSD Homo sapiens    >9.$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens ,*.&   .P$  9      @ GtPHUR   ELVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDVGH KDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID  inmunomodulador, antineoplásico       272 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121  ILU]RWHPFHOXP  ILU]RWHPFHO DOORJHQLFKXPDQ&'KHPDWRSRLHWLF VWHPSURJHQLWRUFHOOV +63&V GHULYHGIURP JUDQXORF\WHFRORQ\VWLPXODWLQJIDFWRU *&6)  PRELOL]HGSHULSKHUDOKHPDWRSRLHWLFFHOOVIURPKXPDQ OHXNRF\WHDQWLJHQ +/$ PDWFKHGSURVSHFWLYH WUDQVSODQWRUJDQGRQRUV cell therapy (transplant)  ILU]RWHPFHO FHOOXOHVVRXFKHVFHOOXOHVSURJpQLWULFHV KpPDWRSRwpWLTXHV +63&V &'KXPDLQHV DOORJpQLTXHVGpULYpHVGHFHOOXOHVKpPDWRSRwpWLTXHV SpULSKpULTXHVPRELOLVpHVSDUOHIDFWHXUVWLPXODQWOHV FRORQLHVGHJUDQXORF\WHV *&6) GHGRQQHXUV SURVSHFWLIVSRXUWUDQVSODQWDWLRQG¶RUJDQHV FRPSDWLEOHVYLVjYLVGHO¶DQWLJqQHOHXFRF\WDLUH KXPDLQ +/$  thérapie cellulaire (greffe)  ILU]RWHPFHO FpOXODVWURQFDOHVSUHFXUVRUDVKHPDWRSR\pWLFDV &'KXPDQDVDORJpQLFDVGHULYDGDVGHFpOXODV KHPDWRSR\pWLFDVSHULIpULFDVPRYLOL]DGDVFRQHOIDFWRU HVWLPXODGRUGHFRORQLDVGHJUDQXORFLWRV *&6) GH GRQDQWHVSURVSHFWLYRVSDUDWUDVSODQWHGHyUJDQRV FRPSDWLEOHVSDUDHODQWtJHQROHXFRFLWDULRKXPDQR +/$   thérapie cellulaire (transplante)    IOXEUREHQJXDQXP )   IOXEUREHQJXDQH )  N^>EURPR   ) IOXRURSURSR[\ SKHQ\O@PHWK\O`JXDQLGLQH diagnostic imaging agent  IOXEUREHQJXDQH )  N^>EURPR   ) IOXRURSURSR[\ SKpQ\O@PpWK\O`JXDQLGLQH substance à usage diagnostique  IOXEUREHQJXDQR )  N^>EURPR   ) IOXRURSURSR[L IHQLO@PHWLO`JXDQLGLQD agente de diagnóstico    &+%U)12        IRVGHQRSWHULQXP  IRVGHQRSWHULQ DRDRDRDS DPLQRWULK\GUR[\ DDDDRFWDK\GURHȜ >@GLR[DSKRVSKLQLQR>  @S\UDQR> g@SWHULGLQH H GLRQH  molybdenum cofactor deficiency   273 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019 IRVGpQRSWpULQH DRDRDRDS DPLQRWULK\GUR[\ DDDDRFWDK\GURHȜ >@GLR[DSKRVSKLQLQR>  @S\UDQR> g@SWpULGLQH H GLRQH déficit à cofacteur en molybdène  IRVGHQRSWHULQD DRDRDRDS DPLQRWULKLGUR[L DDDDRFWDKLGURHȜ >@GLR[DIRVILQLQR>  @SLUDQR>g@SWHULGLQD  H GLRQD deficiencia del cofactor molibdeno    &+123        JDWUDOLPDEXP  JDWUDOLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens&' &'DQWLJHQ&$03$7+DQWLJHQ&': @ PRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQKXPDQL]HG  >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*   *P &+.    KLQJH   &+  &+'  /    &+6    @   GLVXOILGHZLWKNDSSDOLJKWFKDLQFKLPHULF    >9.$33$ Mus musculus ,*.9    ,*.-   Homo sapiens,*.9    ,*.-   >@   Homo sapiens ,*.&   .P$  9      @GLPHU   ELVGLVXOILGH SURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 FHOOV JO\FRIRUPDOID immunomodulator, antineoplastic  JDWUDOLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo &' &' DQWLJqQH&$03$7+DQWLJqQH&': @DQWLFRUSV PRQRFORQDO FKDvQHORXUGHJDPPDKXPDQLVpH  >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*   *P &+.     FKDUQLqUH  &+  &+'  /    &+6     @  GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD FKLPpULTXH   >9.$33$ Mus musculus ,*.9    ,*.-   Homo sapiens ,*.9   ,*.-   >@    Homo sapiens,*.&   .P$  9     @GLPqUH    ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHV RYDULHQQHVGHKDPVWHUVFKLQRLV &+2 JO\FRIRUPH DOID  immunomodulateur, antinéoplasique 274 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121   JDWUDOLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo &' &' DQWtJHQR&$03$7+DQWtJHQR&': @DQWLFXHUSR PRQRFORQDO FDGHQDSHVDGDJDPPDKXPDQL]DGD  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*   *P &+.     ELVDJUD  &+  &+ '  /    &+6     @  GLVXOIXURFRQODFDGHQDOLJHUDNDSSD TXLPpULFD   >9.$33$ Mus musculus ,*.9    ,*.-   Homo sapiens ,*.9   ,*.-   >@    Homo sapiens,*.&   .P$  9     @ GtPHUR   ELVGLVXOIXURSURGXFLGRHQ ODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2  JOLFRIRUPDDOID inmunomodulador, antineoplásico           JLURFWRFRJHQXPILWHOSDUYRYHFXP  JLURFWRFRJHQHILWHOSDUYRYHF $UHFRPELQDQWQRQUHSOLFDWLQJDGHQRDVVRFLDWHGYLUXV W\SH U$$95HS&DS YHFWRUHQFRGLQJKXPDQ %GRPDLQGHOHWHGEORRGFRDJXODWLRQIDFWRU9,,, K) )9,,, XQGHUWKHFRQWURORIDV\QWKHWLFOLYHUVSHFLILF SURPRWHU gene therapy (hemophilia)  JLURFWRFRJqQHILWHOSDUYRYHF 9HFWHXUYLUDODGpQRDVVRFLpGHW\SHUHFRPELQDQW QRQUpSOLTXDQW U$$95HS&DS FRGDQWSRXUOH IDFWHXUGHFRDJXODWLRQVDQJXLQH9,,,KXPDLQ K) )9,,, GRQWOHGRPDLQH%DpWpVXSSULPpVRXVOH FRQWU{OHG XQSURPRWHXUV\QWKpWLTXHVSpFLILTXHGXIRLH  thérapie génique (hémophilie)    275 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019   JLURFWRFRJpQILWHOSDUYRYHF 8QYHFWRUGHYLUXVDGHQRDVRFLDGRUHFRPELQDQWHQR UHSOLFDWLYRGHOWLSR U$$95HS&DS TXHFRGLILFD SDUDHOIDFWRUGHFRDJXODFLyQVDQJXtQHR9,,,KXPDQR K) )9,,, FRQHOGRPLQLR%GHOHFLRQDGREDMRHOFRQWUROGHXQ SURPRWRUVLQWpWLFRHVSHFtILFRGHOKtJDGR  terapia génica (hemofilia)        JORILWDPDEXP  JORILWDPDE LPPXQRJOREXOLQ*ODPEGDNDSSDZLWKGRPDLQFURVVRYHU DQWL>Homo sapiens06$ PHPEUDQHVSDQQLQJ GRPDLQVVXEIDPLO\$PHPEHU&' @DQGDQWL>Homo sapiens&'( &'HSVLORQ/HX @PRQRFORQDODQWLERG\ ELVSHFLILFWULYDOHQW JDPPDODPEGDKHDY\FKDLQDQWL06$DQGDQWL&'( 9+&+9/$0%'$&+&+&+   >KXPDQL]HG 9+DQWL06$ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens ,*+* *P &+.!(  .!(   .    KLQJH     PHUELV WHWUDJO\F\OVHU\O OLQNHU  9/$0''$ DQWL&'( Mus musculus,*/9   ,*/-   Homo sapiens,*/9   ,*/-   >@  PHUELVHU\OOLQNHU   Homo sapiens,*+* *P*P &+.    KLQJH  &+/!$   /!$  3!*    &+6!&   '  /  7!:    &+6     @  GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HGDQWL 06$   >KXPDQL]HG9.$33$ Homo sapiens ,*.9   ,*.-   >@    Homo sapiens,*.&   (!5  4!.  .P$  9     @  GLVXOILGHZLWK9+&NDSSDOLJKWFKDLQ KXPDQL]HGDQWL&'(   >KXPDQL]HG9+ Homo sapiens,*+9   ,*.-    >@   Homo sapiens,*.&    7!6  .P$  9     @ JDPPDKHDY\FKDLQKXPDQL]HGDQWL06$    >KXPDQL]HG9+ Homo sapiens,*+9    ,*+' ,*+-   >@   Homo sapiens,*+* *P &+.!(  .!(  .     KLQJH    &+/!$  /!$  3!*      &+<!&  '  /  7!6  /!$  <!9     &+6       @   GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG DQWL06$   >KXPDQL]HG9.$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens,*.&   (!5  4!.  .P$  9      @ GLPHU    WULVGLVXOILGH SURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 FHOOV JO\FRIRUPDOID  immunomodulator, antineoplastic 276 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121   JORILWDPDE LPPXQRJOREXOLQH*ODPEGDNDSSDDYHFGRPDLQHVpFKDQJpVDQWL>Homo sapiens06$ PHPEUHGHODVRXVIDPLOOH$jGRPDLQHV WUDQVPHPEUDQDLUHV&' @HWDQWL>Homo sapiens&'( &'HSVLORQ/HX  @DQWLFRUSVPRQRFORQDOELVSpFLILTXHWULYDOHQW FKDvQHORXUGHJDPPDODPEGDDQWL06$HWDQWL&'( 9+&+9 /$0%'$&+&+&+   >9+DQWL06$KXPDQLVp Homo sapiens ,*+9    ,*+' ,*+-   >@  Homo sapiens,*+* *P &+.!(  .!(  .    FKDUQLqUH    PHUELV WpWUDJO\F\OVpU\O  OLQNHU  9/$0''$DQWL&'( Mus musculus,*/9    ,*/-   Homo sapiens,*/9   ,*/-    >@  PHUELVpU\OOLQNHU  Homo sapiens,*+*  *P*P &+.    FKDUQLqUH  &+ /!$  /!$  3!*    &+6!&   '  /  7!:    &+6    @  GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSDDQWL06$KXPDQLVpH    >9.$33$KXPDQLVp Homo sapiens,*.9   ,*.-   >@   Homo sapiens,*.&   (!5   4!.  .P$  9     @  GLVXOIXUHDYHFODFKDvQHOpJqUH9+&NDSSDDQWL&'( KXPDQLVpH   >9+KXPDQLVp Homo sapiens,*+9    ,*.-   >@   Homo sapiens,*.&    7!6  .P$  9     @ FKDvQHORXUGHJDPPDDQWL06$KXPDQLVpH   >9+KXPDQLVp Homo sapiens,*+9    ,*+' ,*+-   >@   Homo sapiens,*+* *P &+.!(  .!(  .     FKDUQLqUH   &+/!$  /!$  3!*     &+<!&  '  /  7!6  /!$  <!9     &+6      @   GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSDDQWL06$KXPDQLVpH   >9.$33$KXPDQLVp Homo sapiens,*.9    ,*.-   >@   Homo sapiens,*.&    (!5  4!.  .P$  9     @ GLPqUH    WULVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHV RYDULHQQHVGHKDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID immunomodulateur, antinéoplasique  JORILWDPDE LQPXQRJOREXOLQD*ODPEGDNDSSDFRQGRPLQLRVFUX]DGRVDQWL>Homo sapiens06$ PLHPEURGHODVXEIDPLOLD$FRQGRPLQLRV WUDQVPHPEUDQDULRV&' @\DQWL>Homo sapiens&'( &'pSVLORQ/HX  @DQWLFXHUSRPRQRFORQDOELHVSHFtILFRWULYDOHQWH FDGHQDSHVDGDJDPPDODPEGDDQWL06$\DQWL&'( 9+&+9 /$0%'$&+&+&+   >9+DQWL06$KXPDQL]DGR Homo sapiens,*+9    ,*+' ,*+-   >@   Homo sapiens,*+* *P &+.!(  .!(  .    ELVDJUD    FRQHFWRUPHU ELV WHWUDJOLFLOVHULO   9/$0''$DQWL&'( Mus musculus ,*/9   ,*/-   Homo sapiens,*/9    ,*/-   >@  FRQHFWRUPHUELVHULO  Homo sapiens,*+* *P*P &+.    ELVDJUD  &+/!$  /!$  3!*    &+ 6!&  '  /  7!:    &+6     @  GLVXOIXURFRQODFDGHQDOLJHUDNDSSDDQWL06$KXPDQL]DGD    >9.$33$KXPDQL]DGR Homo sapiens,*.9    ,*.-   >@   Homo sapiens,*.&    (!5  4!.  .P$  9     @   277 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019     GLVXOIXURFRQODFDGHQDOLJHUD9+&NDSSDDQWL&'(KXPDQL]DGD    >9+KXPDQL]DGR Homo sapiens,*+9   ,*.-    >@   Homo sapiens,*.&   7!6  .P$  9     @ FDGHQDSHVDGDJDPPDDQWL06$KXPDQL]DGD   >9+KXPDQL]DGR Homo sapiens,*+9    ,*+' ,*+-   >@    Homo sapiens,*+* *P &+.!(  .!(   .     ELVDJUD   &+/!$  /!$  3!*     &+<!&  '  /  7!6  /!$  <!9     &+6      @ (  GLVXOIXURFRQODFDGHQDOLJHUDNDSSDDQWL06$KXPDQL]DGD    >9.$33$KXPDQL]DGR Homo sapiens,*.9   ,*.-   >@   Homo sapiens,*.&   (!5   4!.  .P$  9     @ GtPHUR    WULVGLVXOIXURSURGXFLGRHQODVFpOXODV RYiULFDVGHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID  inmunomodulador, antineoplásico        278 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121  JRQWLYLPDEXP  JRQWLYLPDE LPPXQRJOREXOLQVLQJOHFKDLQ9+9+9+DQWL>KXPDQ UHVSLUDWRU\V\QF\WLDOYLUXV 569 IXVLRQJO\FRSURWHLQ)@ Lama glamaPRQRFORQDODQWLERG\WULYDOHQW VF9+9+9+FKDLQ  >Lama glama9+ Vicugna pacos,*+9   ,*+' ,*+-   Homo sapiens,*+9 (!'     ,*+' ,*+-   >@   PHUOLQNHUWULV WHWUDJO\F\OVHU\O   Lama glama9+ Vicugna pacos,*+9   ,*+'  ,*+-   Homo sapiens,*+9    ,*+' ,*+-   >@   PHUOLQNHUWULV WHWUDJO\F\OVHU\O    Lama glama9+ Vicugna pacos,*+9   ,*+' ,*+-   Homo sapiens,*+9     ,*+' ,*+-   >@  SURGXFHGLQWKH\HDVWPichia pastoris Komagataella phaffii QRQJO\FRV\ODWHG immunomodulator, antiviral  JRQWLYLPDE LPPXQRJOREXOLQHFKDvQHXQLTXH9+9+9+DQWL >JO\FRSURWpLQHGHIXVLRQ)GXYLUXVUHVSLUDWRLUH V\QF\WLDO 956 KXPDLQ@Lama glamaDQWLFRUSV PRQRFORQDOWULYDOHQW VF9+9+9+FKDvQH  >Lama glama9+ Vicugna pacos,*+9   ,*+' ,*+-   Homo sapiens,*+9 (!'     ,*+' ,*+-   >@   PHUOLQNHUWULV WpWUDJO\F\OVpU\O   Lama glama9+ Vicugna pacos,*+9   ,*+'  ,*+-   Homo sapiens,*+9    ,*+' ,*+-   >@   PHUOLQNHUWULV WpWUDJO\F\OVpU\O    Lama glama9+ Vicugna pacos,*+9   ,*+' ,*+-   Homo sapiens,*+9     ,*+' ,*+-   >@  SURGXLWGDQVODOHYXUHPichia pastoris Komagataella phaffii QRQJO\FRV\Op immunomodulateur, antiviral  JRQWLYLPDE LQPXQRJOREXOLQDGHFDGHQD~QLFD9+9+9+DQWL >JOLFRSURWHtQDGHIXVLyQ)GHOYLUXVUHVSLUDWRULRVLQFLWLDO 956 KXPDQR@Lama glamaDQWLFXHUSRPRQRFORQDO WULYDOHQWH VF9+9+9+FDGHQD  >Lama glama9+ Vicugna pacos,*+9   ,*+' ,*+-   Homo sapiens,*+9 (!'     ,*+' ,*+-   >@   FRQHFWRUPHUWULV WHWUDJOLFLOVHULO   Lama glama9+ Vicugna pacos,*+9   ,*+'  ,*+-   Homo sapiens,*+9    ,*+' ,*+-   >@   FRQHFWRUPHUWULV WHWUDJOLFLOVHULO    Lama glama9+ Vicugna pacos,*+9   ,*+' ,*+-   Homo sapiens,*+9     ,*+' ,*+-   >@  SURGXFLGRHQODOHYDGXUDPichia pastoris Komagataella phaffii QRJOLFRVLODGR inmunomodulador, antiviral   279 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019          JUHPXEDPDEXP  JUHPXEDPDE LPPXQRJOREXOLQ*NDSSDDQWL>Pseudomonas aeruginosa SVO SRO\VDFFKDULGHV\QWKHVLVORFXVVXUIDFHH[RSRO\VDFFKDULGH DQG DQWL>Pseudomonas aeruginosa W\SH,,,VHFUHWLRQV\VWHP 7766 76 3FU9SURWHLQ@PRQRFORQDODQWLERG\ELVSHFLILF JDPPDKHDY\FKDLQ9+&+9+9.$33$&+&+KXPDQL]HG  >9+DQWL3FU9 Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens,*+*   *P &+5    KLQJH   PHUOLQNHU  9+DQWLSV, Homo sapiens,*+9   ,*+9    ,*+' ,*+-   >@  PHUOLQNHU  9.$33$DQWLSV, Homo sapiens,*.9   ,*.-   >@   PHUOLQNHU  Homo sapiens,*+*   Q*P KLQJH  &+  &+(  0    &+6    @  GLVXOILGHZLWK NDSSDOLJKWFKDLQHomo sapiens   >9.$33$DQWL3FU9 Homo sapiens,*.9   ,*.-   >@    Homo sapiens,*.&   .P$  9    @ GLPHU    ELVGLVXOILGHSURGXFHGLQ&KLQHVH +DPVWHU2YDU\ &+2 FHOOVJO\FRIRUPDOID immunomodulator, antibacterial  JUpPXEDPDE LPPXQRJOREXOLQH*NDSSDDQWL>Pseudomonas aeruginosa SVO ORFXVGHV\QWKqVHGHVSRO\VDFFKDULGHVH[RSRO\VDFFKDULGHGH VXUIDFH @HWDQWL>SURWpLQH3FU9GXV\VWqPHGHVpFUpWLRQW\SH,,, 776676 GH Pseudomonas aeruginosa @DQWLFRUSVPRQRFORQDO ELVSpFLILTXH FKDvQHORXUGHJDPPD9+&+9+9.$33$&+&+KXPDQLVpH  >9+DQWL3FU9 Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens,*+*   *P &+5    FKDUQLqUH   PHUOLQNHU  9+DQWLSV, Homo sapiens,*+9   ,*+9    ,*+' ,*+-   >@  PHUOLQNHU  9.$33$DQWLSV, Homo sapiens,*.9   ,*.-   >@   PHUOLQNHU  Homo sapiens,*+*   Q*P FKDUQLqUH  &+  &+(  0    &+6    @  GLVXOIXUH DYHFODFKDvQHOpJqUHNDSSDHomo sapiens   >9.$33$DQWL 3FU9 Homo sapiens,*.9   ,*.-   >@   Homo sapiens,*.&   .P$  9    @GLPqUH    ELVGLVXOIXUHSURGXLW GDQVGHVFHOOXOHVRYDULHQQHVGHKDPVWHUVFKLQRLV &+2  JO\FRIRUPHDOID  immunomodulateur, antibactérien 280 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121  JUHPXEDPDE LQPXQRJOREXOLQD*NDSSDDQWL>Pseudomonas aeruginosa SVO OXJDUGHVtQWHVLVGHORVSROLVDFiULGRV H[RSROLVDFiULGRGHVXSHUILFLH @\DQWL>SURWHtQD3FU9 GHOVLVWHPDGHVHFUHFLyQWLSR,,, 776676 GH Pseudomonas aeruginosa @DQWLFXHUSRPRQRFORQDO ELHVSHFtILFR FDGHQDSHVDGDJDPPD9+&+9+9.$33$&+ &+KXPDQL]DGD  >9+DQWL3FU9 Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*   *P &+5    ELVDJUD  FRQHFWRUPHU  9+DQWLSV, Homo sapiens,*+9   ,*+9    ,*+' ,*+-   >@   FRQHFWRUPHU  9.$33$DQWLSV, Homo sapiens,*.9   ,*.-   >@  FRQHFWRUPHU   Homo sapiens,*+*   Q*P ELVDJUD   &+  &+(  0    &+6    @   GLVXOIXURFRQODFDGHQDOLJHUDNDSSDHomo sapiens   >9.$33$DQWL3FU9 Homo sapiens ,*.9   ,*.-   >@    Homo sapiens,*.&   .P$  9    @GtPHUR     ELVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDV GHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID inmunomodulador, antibacteriano            281 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019 LPLIRSODWLQXP  LPLIRSODWLQ GLK\GURJHQ SP > RR F\FORKH[DQH GLDPLQHțNN@>GLSKRVSKDWR í  țOO@SODWLQDWH í  antineoplastic  LPLIRSODWLQH GLK\GURJqQR SP > RR F\FORKH[DQH GLDPLQHțNțN@>GLSKRVSKDWR   țOO3@SODWLQDWH   antinéoplasique  LPLIRSODWLQR GLKLGUyJHQR SP > RR FLFORKH[DQR GLDPLQDțNțN@>GLIRVIDWR  țOO3@SODWLQDWR   antineoplásico    &+1233W        LPQRSLWDQWXP  LPQRSLWDQW N^>ELV WULIOXRURPHWK\O SKHQ\O@PHWK\O`NPHWK\O PHWK\OSKHQ\O  PHWK\OSLSHUD]LQ\O S\ULGLQH FDUER[DPLGH neurokinin NK1 receptor antagonist  LPQRSLWDQW N^>ELV WULIOXRURPpWK\O SKpQ\O@PpWK\O`NPpWK\O PpWK\OSKpQ\O  PpWK\OSLSpUD]LQ\O S\ULGLQH FDUER[DPLGH antagoniste du récepteur NK1 de la neurokinine  LPQRSLWDQW N^>ELV WULIOXRURPHWLO IHQLO@PHWLO`NPHWLO  PHWLOIHQLO  PHWLOSLSHUD]LQLO SLULGLQD FDUER[DPLGD antagonista del receptor NK1 de neurokinina    &+)12    +& &) 1 1 2 &) 1 1  +& +&    LYDOWLQRVWDWXP  LYDOWLQRVWDW E N> GLPHWK\ODPLQR SURS\O@NK\GUR[\ ^> QDSKWKDOHQ\O R[\@PHWK\O`RFWHQHGLDPLGH histone deacetylase inhibitor, antineoplastic  LYDOWLQRVWDW E N> GLPpWK\ODPLQR SURS\O@NK\GUR[\ ^> QDSKWDOpQ\O R[\@PpWK\O`RFWqQHGLDPLGH  inhibiteur de l'histone désacétylase, antinéoplasique 282 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121    LYDOWLQRVWDW E N> GLPHWLODPLQR SURSLO@NKLGUR[L ^> QDIWDOHQLO R[L@PHWLO`RFWHQRGLDPLGD inhibidor de la histona desacetilasa, antineoplásico    &+12        LYX[ROLPDEXP  LYX[ROLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens 71)56) WXPRUQHFURVLVIDFWRUUHFHSWRU 71)5  VXSHUIDPLO\PHPEHU2;&' @Homo sapiens PRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQ Homo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*  &+  KLQJH  &+  &+  &+6    @  GLVXOILGHZLWKNDSSDOLJKWFKDLQHomo sapiens   >9.$33$ Homo sapiens,*.9'    ,*.-   >@    Homo sapiens ,*.&   .P$   9     @ GLPHU     WHWUDNLVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 .69FHOOOLQHJO\FRIRUPDOID immunomodulator, antineoplastic  LYX[ROLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens 71)56) PHPEUHGHODVXSHUIDPLOOHGHV UpFHSWHXUVGXIDFWHXUGHQpFURVHWXPRUDOH$&7 2;&' @DQWLFRUSVPRQRFORQDOHomo sapiens FKDvQHORXUGHJDPPDHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*  &+  FKDUQLqUH   &+  &+  &+6     @  GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD Homo sapiens   >9.$33$ Homo sapiens ,*.9'   ,*.-   >@    Homo sapiens ,*.&   .P$  9     @ GLPqUH     WpWUDNLVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHV GHKDPVWHUVFKLQRLV &+2 OLJQpHFHOOXODLUH.69 JO\FRIRUPHDOID immunomodulateur, antinéoplasique     283 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019 LYX[ROLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens 71)56) PLHPEURGHODVXSHUIDPLOLDGHORV UHFHSWRUHVGHOIDFWRUGHQHFURVLVWXPRUDO$&7 2;&' @DQWLFXHUSRPRQRFORQDOHomo sapiens FDGHQDSHVDGDJDPPDHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*  &+  ELVDJUD   &+  &+  &+6     @  GLVXOIXURFRQODFDGHQDOLJHUDNDSSD Homo sapiens   >9.$33$ Homo sapiens ,*.9'   ,*.-   >@    Homo sapiens ,*.&   .P$  9     @ GtPHUR     WHWUDNLVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDVGH KDPVWHUVFKLQRV &+2 OtQHDFHOXODU.69JOLFRIRUPD DOID inmunomodulador, antineoplásico           L]HQFLWLQLEXP  L]HQFLWLQLE > RsS  ^> PHWK\OHS\UD]RO\O DPLQR@ QDSKWK\ULGLQ\O`DPLQR D]DELF\FOR>@RFWDQ \O@SURSDQHQLWULOH Janus kinase inhibitor  L]HQFLWLQLE > RsS  ^> PpWK\OHS\UD]RO\O DPLQR@ QDSKW\ULGLQ\O`DPLQR D]DELF\FOR>@RFWDQ \O@SURSDQHQLWULOH inhibiteur de la kinase de Janus  L]HQFLWLQLE > RsS  ^> PHWLOHSLUD]ROLO DPLQR@ QDIWLULGLQLO`DPLQR D]DELFLFOR>@RFWDQ LO@SURSDQRQLWULOR inhibidor de la quinasa de Janus   284 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121    &+1       OHQDFDSDYLUXP  OHQDFDSDYLU N> S ^>FKORUR PHWKDQHVXOIRQDPLGR   WULIOXRURHWK\O HLQGD]RO\O@> PHWKDQHVXOIRQ\O  PHWK\OEXW\Q\O@S\ULGLQ\O` GLIOXRURSKHQ\O HWK\O@ > ESDR GLIOXRUR WULIOXRURPHWK\O EDWHWUDK\GUR HF\FORSURSD>@F\FORSHQWD>c@S\UD]RO\O@DFHWDPLGH antiviral  OpQDFDSDYLU N> S ^>FKORUR PpWKDQHVXOIRQDPLGR   WULIOXRURpWK\O HLQGD]RO\O@> PpWKDQHVXOIRQ\O  PpWK\OEXW\Q\O@S\ULGLQ\O` GLIOXRURSKpQ\O pWK\O@ > ESDR GLIOXRUR WULIOXRURPpWK\O EDWpWUDK\GUR HF\FORSURSD>@F\FORSHQWD>c@S\UD]RO\O@DFpWDPLGH antiviral  OHQDFDSDYLU N> S ^>FORUR PHWDQRVXOIRQDPLGR   WULIOXRURHWLO HLQGD]ROLO@> PHWDQRVXOIRQLO PHWLOEXWLQ LO@SLULGLQLO` GLIOXRURIHQLO HWLO@> ESDR GLIOXRUR  WULIOXRURPHWLO EDWHWUDKLGURH FLFORSURSD>@FLFORSHQWD>c@SLUD]ROLO@DFHWDPLGD antiviral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cell therapy (antineoplastic)   285 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019  OHWHWUHVJpQHDXWROHXFHO /\PSKRF\WHV7&'HW&'DXWRORJXHVWUDQVGXLWVSDUXQ YHFWHXUDXWRLQDFWLYDQW 6,1 QRQUpSOLTXDQWGpULYpGXYLUXV GHO LPPXQRGpILFLHQFHQFHKXPDLQH 9,+ FRQWHQDQWXQH VpTXHQFH/75 WHUPLQDOHORQJXHUpSpWpH HQ  569 58  HWXQHVpTXHQFH/75GRQWOHGRPDLQH8HVWVXSSULPp 85 +,9'HOWD /75 HWTXLFRGHSRXUXQUpFHSWHXUGHV O\PSKRF\WHV7 7&5 GRQWO DIILQLWpHVWDXJPHQWpHVSpFLILTXH GX1<(62 DQWLJqQHDXWRLPPXQRJpQLTXHDVVRFLpDX FDQFHUGXWHVWLFXOH1<(62&7$*$PHPEUHGHOD IDPLOOHGHO DQWLJqQH//$*( VRXVOHFRQWU{OHG XQ SURPRWHXUGXIDFWHXUG pORQJDWLRQDOSKD ()D /HYHFWHXU HVWSVHXGRW\SpDYHFODJO\FRSURWpLQH*GHO HQYHORSSHGHOD VWRPDWLWHYpVLFXODLUH 969*  569YLUXVGXVDUFRPHGH5RXV thérapie cellulaire (antinéoplasique)  OHWHWUHVJqQDXWROHXFHO /LQIRFLWRV7&'\&'DXWyORJRVWUDQVGXFLGRVFRQXQ YHFWRUDXWRLQDFWLYDQWH 6,1 QRUHSOLFDWLYRGHULYDGRGHOYLUXV GHODLQPXQRGHILFLHQFLDKXPDQD 9,+ TXHFRQWLHQHXQD/75 HQ  569 58 \XQD/75FRQ8GHOHFLRQDGDHQ  8 5+,9'HOWD /75 \TXHFRGLILFDSDUDXQUHFHSWRUGH OLQIRFLWRV7 7&5 FRQDILQLGDGDXPHQWDGDHVSHFtILFRSDUD 1<(62 DQWtJHQRGHFiQFHUWHVWtFXORVDXWRLQPXQRJpQLFR 1<(62&7$*$PLHPEURGHODIDPLOLDGHDQWtJHQRV/ /$*( EDMRHOFRQWUROGHOSURPRWRUGHOIDFWRUGHHORQJDFLyQ DOID ()D (OYHFWRUHVWiVHXGRWLSDGRFRQODJOLFRSURWHtQD *GHOYLUXVGHODHVWRPDWLWLVYHVLFXODU 969*  569YLUXVGHOVDUFRPDGH5RXV  terapia celular (antineoplásico)   OLQSHUOLVLEXP  OLQSHUOLVLE N^>IOXRUR^> K\GUR[\SURSDQ\O SLSHULGLQ \O@PHWK\O` PRUSKROLQ\O TXLQD]ROLQ\O@PHWKR[\S\ULGLQ \O`PHWKDQHVXOIRQDPLGH phosphatidylinositol 3-kinase (PI3K) inhibitor, antineoplastic  OLQSHUOLVLE N^>IOXRUR^> K\GUR[\SURSDQ\O SLSpULGLQ \O@PpWK\O` PRUSKROLQ\O TXLQD]ROLQ\O@PpWKR[\S\ULGLQ \O`PpWKDQHVXOIRQDPLGH inhibiteur de phosphatidylinositol 3-kinase (PI3K), antinéoplasique  OLQSHUOLVLE N^>IOXRUR^> KLGUR[LSURSDQLO SLSHULGLQLO@PHWLO` PRUIROLQLO TXLQD]ROLQLO@PHWR[LSLULGLQ LO`PHWDQRVXOIRQDPLGD inhibidor de fosfatidilinositol 3-quinasa (PI3K), antineoplásico    &+)126        286 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121 ORGDSROLPDEXP  ORGDSROLPDE LPPXQRJOREXOLQ*ODPEGDDQWL>Homo sapiens 3'&' SURJUDPPHGFHOOGHDWK3'3' &' @Homo sapiensPRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+* *PQ*P &+5     KLQJH  &+/!$  /!(  *!$  $!6  3!6     &+(  0    &+6     @  GLVXOILGHZLWKODPEGDOLJKW FKDLQHomo sapiens   >9/$0%'$ Homo sapiens,*/9   ,*/-    >@   Homo sapiens,*/& 7!$       @GLPHU    ELVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 FHOOVJO\FRIRUPDOID immunomodulator, antineoplastic  ORGDSROLPDE LPPXQRJOREXOLQH*ODPEGDDQWL>Homo sapiens 3'&' SURWpLQHGHPRUWFHOOXODLUHSURJUDPPpH 3'3'&' @DQWLFRUSVPRQRFORQDOHomo sapiens FKDvQHORXUGHJDPPDHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+* *PQ*P &+5     FKDUQLqUH  &+/!$  /!(  *!$  $!6  3!6     &+(  0    &+6     @  GLVXOIXUHDYHFODFKDvQH OpJqUHODPEGDHomo sapiens   >9/$0%'$ Homo sapiens,*/9   ,*/-   >@   Homo sapiens,*/&  7!$       @GLPqUH    ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHV RYDULHQQHVGHKDPVWHUVFKLQRLV &+2 JO\FRIRUPH DOID immunomodulateur, antinéoplasique  ORGDSROLPDE LQPXQRJOREXOLQD*ODPEGDDQWL>Homo sapiens 3'&' SURWHtQDGHPXHUWHFHOXODUSURJUDPDGD 3'3'&' @DQWLFXHUSRPRQRFORQDOHomo sapiens FDGHQDSHVDGDJDPPDHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+* *PQ*P &+5     ELVDJUD  &+/!$  /!(  *!$  $!6  3!6     &+(  0    &+6     @  GLVXOIXURFRQODFDGHQD OLJHUDODPEGDHomo sapiens   >9/$0%'$ Homo sapiens,*/9   ,*/-   >@   Homo sapiens,*/&  7!$       @GtPHUR    ELVGLVXOIXURSURGXFLGRHQODVFpOXODV RYiULFDVGHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID inmunomodulador, antineoplásico   287 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019          ORPDUGH[DPIHWDPLQXP  ORPDUGH[DPIHWDPLQH S DPLQR FDUEDPLPLGR\ODPLQR N> S  SKHQ\OSURSDQ\O@KH[DQDPLGH central nervous system stimulant  ORPDUGH[DPIpWDPLQH S DPLQR FDUEDPLPLGR\ODPLQR N> S  SKpQ\OSURSDQ\O@KH[DQDPLGH stimulant du système nerveux central  ORPDUGH[DPIHWDPLQD S DPLQR FDUEDPLPLGRLODPLQR N> S  IHQLOSURSDQLO@KH[DQDPLGD estimulante del sistema nervioso central    &+12       ORQRGHOHVWDWXP  ORQRGHOHVWDW DQK\GUR>/DODQ\O/VHU\O/LVROHXF\O/SURO\O/ SURO\O/JOXWDPLQ\O/O\V\O/W\URV\O'SURO\O/SURO\O S DPLQRGHFDQR\O/ĮJOXWDP\O/WKUHRQLQH@ elastase inhibitor  ORQRGpOHVWDW DQK\GUR>/DODQ\O/VpU\O/LVROHXF\O/SURO\O/ SURO\O/JOXWDPLQ\O/O\V\O/W\URV\O'SURO\O/SURO\O S DPLQRGpFDQR\O/ĮJOXWDP\O/WKUpRQLQH@  inhibiteur de l'élastase   288 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121 ORQRGHOHVWDW DQKLGUR>/DODQLO/VHULO/LVROHXFLO/SUROLO/SUROLO/ JOXWDPLQLO/OLVLO/WLURVLO'SUROLO/SUROLO S  DPLQRGHFDQRLO/ĮJOXWDPLO/WUHRQLQD@ inhibidor de la elastasa    &+12        PDQHOLPDEXP  PDQHOLPDE LPPXQRJOREXOLQ*ODPEGDDQWL>Homo sapiens &' SURJUDPPHGGHDWKOLJDQG3'/3'/% KRPRORJ%+ @Homo sapiensPRQRFORQDO DQWLERG\ JDPPDKHDY\FKDLQ  >9+ Homo sapiens ,*+9    ,*+' ,*+-    >@  Homo sapiens,*+* Y *P!*P*P &+5     KLQJH  &+/!$  /!$    &+'  /    &+6    @  GLVXOILGHZLWKODPEGD OLJKWFKDLQ   >9/$0%'$ Homo sapiens ,*/9   ,*/-   >@    Homo sapiens ,*/&      @ GLPHU   ELVGLVXOILGHSURGXFHGLQ &KLQHVH+DPVWHU2YDU\ &+2 .6FHOOOLQH JO\FRIRUPDOID immunomodulator, antineoplastic  PDQpOLPDE LPPXQRJOREXOLQH*ODPEGDDQWL>Homo sapiens &' OLJDQGGHPRUWSURJUDPPpH3'/3'/ KRPRORJXHGH%%+ @DQWLFRUSVPRQRFORQDO Homo sapiens FKDvQHORXUGHJDPPD  >9+ Homo sapiens ,*+9    ,*+' ,*+-    >@  Homo sapiens,*+* Y *P!*P*P &+5     FKDUQLqUH  &+/!$  /!$    &+'  /     &+6    @  GLVXOIXUHDYHF ODFKDvQHOpJqUHODPEGD   >9/$0%'$ Homo sapiens,*/9   ,*/-    >@   Homo sapiens ,*/&      @GLPqUH   ELVGLVXOIXUH SURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGHKDPVWHUV FKLQRLV &+2 OLJQpHFHOOXODLUH.6JO\FRIRUPHDOID immunomodulateur, antinéoplasique  PDQHOLPDE LQPXQRJOREXOLQD*ODPEGDDQWL>Homo sapiens &' OLJDQGRGHPXHUWHSURJUDPDGD3'/3' /KRPyORJRGH%%+ @DQWLFXHUSRPRQRFORQDO  Homo sapiens   289 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019    FDGHQDSHVDGDJDPPD  >9+ Homo sapiens ,*+9    ,*+' ,*+-    >@  Homo sapiens,*+* Y *P!*P*P &+5     ELVDJUD  &+/!$  /!$    &+'  /     &+6    @  GLVXOIXURFRQOD FDGHQDOLJHUDODPEGD   >9/$0%'$ Homo sapiens,*/9   ,*/-    >@   Homo sapiens ,*/&      @GtPHUR   ELVGLVXOIXUR SURGXFLGRHQODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2 OtQHDFHOXODU.6JOLFRIRUPDDOID inmunomodulador, antineoplásico           PDYH]HOLPDEXP  PDYH]HOLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens /$* O\PSKRF\WHDFWLYDWLQJO\PSKRF\WHDFWLYDWLRQ &' @KXPDQL]HGPRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQKXPDQL]HG  >9+ Homo sapiens ,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*  &+  KLQJH  &+   &+  &+6    @   GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG    >9.$33$ Homo sapiens,*.9'   ,*.-   >@   Homo sapiens ,*.&   .P$  9     @ GLPHU   ELVGLVXOILGHSURGXFHGLQ &KLQHVH+DPVWHU2YDU\ &+2 FHOOVJO\FRIRUPDOID immunomodulator, antineoplastic    290 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121   PDYp]pOLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens /$* DFWLYDWHXUGHVO\PKRF\WHVO\PSKRF\WHDFWLYDWLRQ&' @ DQWLFRUSVPRQRFORQDOKXPDQLVp FKDvQHORXUGHJDPPDKXPDQLVpH  >9+ Homo sapiens ,*+9    ,*+' ,*+-   >@   Homo sapiens,*+*  &+  FKDUQLqUH  &+  &+  &+6    @  GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD KXPDQLVpH   >9.$33$ Homo sapiens,*.9'   ,*.-   >@   Homo sapiens ,*.&   .P$  9     @ GLPqUH   ELVGLVXOIXUHSURGXLWGDQVGHV FHOOXOHVRYDULHQQHVGHKDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID immunomodulateur, antinéoplasique  PDYH]HOLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens /$* DFWLYDGRU GHORVOLQIRFLWRVOLQIRFLWRDFWLYDFLyQ&' @DQWLFXHUSR PRQRFORQDOKXPDQL]DGR FDGHQDSHVDGDJDPPDKXPDQL]DGD  >9+ Homo sapiens ,*+9    ,*+' ,*+-    >@  Homo sapiens,*+*  &+   ELVDJUD  &+  &+  &+6    @  GLVXOIXURFRQODFDGHQDOLJHUD NDSSDKXPDQL]DGD   >9.$33$ Homo sapiens,*.9'    ,*.-   >@   Homo sapiens ,*.&   .P$  9      @ GtPHUR   ELVGLVXOIXURSURGXFLGRHQODV FpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID inmunomodulador, antineoplásico           291 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019 PHVGRSHWDPXP  PHVGRSHWDP N^>IOXRUR PHWKDQHVXOIRQ\O SKHQR[\@HWK\O`SURSDQDPLQH dopamine D3 receptor blocker  PHVGRSpWDP N^>IOXRUR PpWKDQHVXOIRQ\O SKpQR[\@pWK\O`SURSDQDPLQH bloqueur des récepteurs à la dopamine D3  PHVGRSHWDP N^>IOXRUR PHWDQRVXOIRQLO IHQR[L@HWLO`SURSDQ DPLQD bloqueante del receptor de la dopamina D3    &+)126      PHYRFLFOLEXP  PHYRFLFOLE N> SR ^>FKORUR HLQGRO\O S\ULPLGLQ \O@DPLQR`PHWK\OF\FORKH[\O@> E  GLPHWK\ODPLQR EXWHQDPLGR@S\ULGLQHFDUER[DPLGH cyclin-dependent kinase inhibitor, antineoplastic  PpYRFLFOLE N> SR ^>FKORUR HLQGRO\O S\ULPLGLQ \O@DPLQR`PpWK\OF\FORKH[\O@> E  GLPpWK\ODPLQR EXWpQDPLGR@S\ULGLQHFDUER[DPLGH inhibiteur des kinases dépendantes des cyclines, antinéoplasique  PHYRFLFOLE N> SR ^>FORUR HLQGROLO SLULPLGLQ LO@DPLQR`PHWLOFLFORKH[LO@> E  GLPHWLODPLQR EXW HQDPLGR@SLULGLQDFDUER[DPLGD inhibidor de las quinasas dependientes de las ciclinas, antineoplásico    &+&O12      PH]DJLWDPDEXP  PH]DJLWDPDE LPPXQRJOREXOLQ*ODPEGDDQWL>Homo sapiens&' $'3ULERV\OF\FODVH @PRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQKXPDQL]HG  >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*   *PQ*P &+5     KLQJH  &+  &+(   0    &+6    @  GLVXOILGHZLWKODPEGDOLJKWFKDLQKXPDQL]HG   292 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121     >9/$0%'$ Homo sapiens,*/9   ,*/-   >@   Homo sapiens,*/&      @GLPHU   ELVGLVXOILGHSURGXFHGLQ&KLQHVH +DPVWHU2YDU\ &+2 .69FHOOOLQHJO\FRIRUPDOID immunomodulator, antineoplastic  Pp]DJLWDPDE LPPXQRJOREXOLQH*ODPEGDDQWL>Homo sapiens&' $'3ULERV\O F\FODVH @DQWLFRUSVPRQRFORQDO FKDvQHORXUGHJDPPDKXPDQLVpH  >9+ Homo sapiens ,*+9    ,*+' ,*+-   >@   Homo sapiens,*+*   *PQ*P &+5    FKDUQLqUH  &+  &+(   0    &+6    @  GLVXOIXUH DYHFODFKDvQHOpJqUHODPEGDKXPDQLVpH   >9/$0%'$ Homo sapiens,*/9   ,*/-   >@    Homo sapiens,*/&     @GLPqUH    ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGHKDPVWHUV FKLQRLV &+2 OLJQpHFHOOXODLUH.69JO\FRIRUPHDOID immunomodulateur, antinéoplasique  PH]DJLWDPDE LQPXQRJOREXOLQD*ODPEGDDQWL>Homo sapiens&' $'3ULERVLO FLFODVD @DQWLFXHUSRPRQRFORQDO FDGHQDSHVDGDJDPPDKXPDQL]DGD  >9+ Homo sapiens ,*+9    ,*+' ,*+-   >@   Homo sapiens,*+*   *PQ*P &+5    ELVDJUD  &+  &+(   0    &+6    @  GLVXOIXUR FRQODFDGHQDOLJHUDODPEGDKXPDQL]DGD   >9/$0%'$ Homo sapiens,*/9   ,*/-   >@    Homo sapiens,*/&     @GtPHUR    ELVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDVGHKDPVWHUV FKLQRV &+2 OtQHDFHOXODU.69JOLFRIRUPDDOID inmunomodulador, antineoplásico       +HDY\ FKDLQ  &KDvQH ORXUGH  &DGHQD SHVDGD EVQLLESGGG LVQPGGSLRL SCAASGFTFD DYGMSWVRQA PGKGLEWVSD 50 ISWNGGKTHY VDSVKGQFTI SRDNSKNTLY LQMNSLRAED TAVYYCARGS 100 LFHDSSGFYF GHWGQGTLVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150 LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200 TQTYICNVNH KPSNTKVDKR VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP 250 PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300 QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR 350 EPQVYTLPPS REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400 PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS 450 PGK 453 /LJKW FKDLQ  &KDvQH OpJqUH  &DGHQD OLJHUD QSVLTQPPSA SGTPGQRVTI SCSGSSSNIG DNYVSWYQQL PGTAPKLLIY 50 RDSQRPSGVP DRFSGSKSGT SASLAISGLR SEDEADYYCQ SYDSSLSGSV 100 FGGGTKLTVL GQPKANPTVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV 150 AWKADGSPVK AGVETTKPSK QSNNKYAASS YLSLTPEQWK SHRSYSCQVT 200 HEGSTVEKTV APTECS 216 3RVWWUDQVODWLRQDO PRGLILFDWLRQV 'LVXOILGH EULGJHV ORFDWLRQ  3RVLWLRQ GHV SRQWV GLVXOIXUH  3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR ,QWUD+ &&             ,QWUD/ &&         ,QWHU+/ K &/     ,QWHU++ K  K    1WHUPLQDO JOXWDPLQH F\FOL]DWLRQ WR S\URJOXWDPDWH S( R[RSUROLQH / 9/ 4   1JO\FRV\ODWLRQ VLWHV  6LWHV GH 1JO\FRV\ODWLRQ  3RVLFLRQHV GH 1JOLFRVLODFLyQ + &+ 1   )XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV  JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV FRPSOH[HV IXFRV\OpV  JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV    293 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019  PLODWHJUDVWXP  PLODWHJUDVW  F\FORSURS\OPHWK\O >  WHWUDPHWK\OF\FORKH[\O SKHQ\O@SLSHUD]LQH non-steroidal anti-inflammatory  PLODWpJUDVW  F\FORSURS\OPpWK\O >  WpWUDPpWK\OF\FORKH[\O SKpQ\O@SLSpUD]LQH anti-inflammatoire non-stéroïdien  PLODWHJUDVW  FLFORSURSLOPHWLO >  WHWUDPHWLOFLFORKH[LO IHQLO@SLSHUD]LQD antiinflamatorio no esteroideo    &+1        PLSHWUHVJHQXPDXWROHXFHOXP  PLSHWUHVJHQHDXWROHXFHO $XWRORJRXV7FHOOVWUDQVGXFHGZLWKDUHSOLFDWLRQ LQFRPSHWHQW0RORQH\PXULQHOHXNHPLDYLUXV 0R0/9  DUHWURYLUXV YHFWRUWKDWHQFRGHVD7FHOOUHFHSWRU 7&5 WKDWUHFRJQL]HV1<(62SURWHLQ FDQFHUWHVWLV DQWLJHQDXWRLPPXQRJHQLFFDQFHUWHVWLVDQWLJHQ1< (62&7$*$/DQWLJHQIDPLO\PHPEHU/$*(   cell therapy (antineoplastic)  PLSHWUHVJqQHDXWROHXFHO /\PSKRF\WHV7DXWRORJXHVWUDQVGXLWVSDUXQYHFWHXU GXYLUXVGHODOHXFpPLHPXULQHGH0RORQH\ 0R0/9  XQUHWURYLUXV LQFRPSpWHQWSRXUODUHSOLFDWLRQHW FRGDQWSRXUXQUpFHSWHXUGHVO\PSKRF\WHV7 7&5  UHFRQQDLVVDQWODSURWpLQH1<(62 DQWLJqQH DXWRLPPXQRJpQLTXHDVVRFLpDXFDQFHUGXWHVWLFXOH 1<(62&7$*$PHPEUHGHODIDPLOOHGH O DQWLJqQH//$*(  thérapie cellulaire (antinéoplasique)  PLSHWUHVJpQDXWROHXFHO /LQIRFLWRV7DXWyORJRVWUDQVGXFLGRVFRQXQYHFWRUGHO YLUXVGHODOHXFHPLDPXULQDGH0RORQH\ 0R0/9  XQ UHWURYLUXV LQFRPSHWHQWHSDUDUHSOLFDFLyQTXHFRGLILFD SDUDXQUHFHSWRUGHOLQIRFLWRV7 7&5 TXHUHFRQRFHOD SURWHtQD1<(62 DQWtJHQRGHFiQFHUWHVWtFXORV DQWtJHQRDXWRLQPXQRJpQLFRGHFiQFHUWHVWtFXORV1< (62&7$*$PLHPEURGHODIDPLOLDGH DQWtJHQRV//$*(  terapia celular (antineoplásico)    PLU]RWDPDEXP  PLU]RWDPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens &' %+%+%53 @PRQRFORQDO DQWLERG\  294 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121    JDPPDKHDY\FKDLQFKLPHULF  >9+ Mus musculus,*+9    ,*+' ,*+-   Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+* Y*P!*PQ*P &+ 5!.    KLQJH  &+ /!$  /!$    &+(   0    &+6    @  GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG   >9.$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens,*.&   .P$  9     @GLPHU    ELVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 FHOOVJO\FRIRUPDOID immunomodulator, antineoplastic  PLU]RWDPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens &' %+%+%53 @DQWLFRUSV PRQRFORQDO FKDvQHORXUGHJDPPDFKLPpULTXH  >9+ Mus musculus,*+9    ,*+' ,*+-   Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+* Y*P!*PQ*P &+ 5!.    FKDUQLqUH   &+/!$  /!$    &+(  0    &+6     @  GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD KXPDQLVpH   >9.$33$ Homo sapiens,*.9    ,*.-   >@    Homo sapiens,*.&   .P$   9     @GLPqUH    ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGH KDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID immunomodulateur, antinéoplasique  PLU]RWDPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens &' %+%+%53 @DQWLFXHUSR PRQRFORQDO FDGHQDSHVDGDJDPPDTXLPpULFD  >9+ Mus musculus,*+9    ,*+' ,*+-   Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+* Y*P!*PQ*P &+ 5!.    ELVDJUD  &+ /!$  /!$    &+(   0    &+6    @  GLVXOIXURFRQODFDGHQDOLJHUDNDSSD KXPDQL]DGD   >9.$33$ Homo sapiens ,*.9   ,*.-   >@    Homo sapiens,*.&   .P$  9     @GtPHUR    ELVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDV GHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID inmunomodulador, antineoplásico   295 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019         PLU]RWDPDEXPFOH]XWRFOD[XP  PLU]RWDPDEFOH]XWRFOD[ LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens&' %+% +%53 @PRQRFORQDODQWLERG\FRQMXJDWHGZLWKFOH]XWRFOD[DQ LQKLELWRURI%&// %&/OLNH%&/;/  JDPPDKHDY\FKDLQFKLPHULF  >9+ Mus musculus,*+9     ,*+' ,*+-   Homo sapiens,*+9     ,*+' ,*+-   >@  Homo sapiens,*+* Y*P!*PQ*P &+5!.    KLQJH  &+/!$  /!$    &+(  0    &+6    @  GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG    >9.$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens,*.&   .P $  9     @ GLPHU   ELVGLVXOILGHSURGXFHGLQ&KLQHVH +DPVWHU2YDU\ &+2 FHOOVJO\FRIRUPDOIDFRQMXJDWHGRQDQ DYHUDJHRIF\VWHLQ\OZLWKFOH]XWRFOD[FRPSULVLQJDFOHDYDEOH GLSHSWLGH YDOLQHDODQLQH OLQNHU immunomodulator, antineoplastic  PLU]RWDPDEFOH]XWRFOD[ LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens&' %+% +%53 @DQWLFRUSVPRQRFORQDOFRQMXJXpDXFOp]XWRFOD[XQ LQKLELWHXUGH%&// SURWpLQHDSSDUHQWpHDX%&/%&/;/  FKDvQHORXUGHJDPPDFKLPpULTXH  >9+ Mus musculus ,*+9    ,*+' ,*+-   Homo sapiens ,*+9    ,*+' ,*+-   >@   Homo sapiens,*+* Y*P!*PQ*P &+5!.    FKDUQLqUH  &+/!$   /!$    &+(  0    &+6    @  GLVXOIXUHDYHFODFKDvQHOpJqUH NDSSDKXPDQLVpH   >9.$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens ,*.& .P$  9     @ GLPqUH   ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHV RYDULHQQHVGHKDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOIDFRQMXJXp   296 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121    VXUF\VWpLQHVHQPR\HQQHDXFOp]XWRFOD[FRPSUHQDQWXQOLQNHU GLSHSWLGH YDOLQHDODQLQH FOLYDEOH immunomodulateur, antinéoplasique  PLU]RWDPDEFOH]XWRFOD[ LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens&' %+ %+%53 @DQWLFXHUSRPRQRFORQDOFRQMXJDGRFRQ FOH]XWRFOD[XQLQKLELGRUGH%&// SURWHtQDYLQFXODGDFRQ %&/%&/;/  FDGHQDSHVDGDJDPPDTXLPpULFD  >9+ Mus musculus ,*+9    ,*+' ,*+-   Homo sapiens ,*+9    ,*+' ,*+-   >@   Homo sapiens,*+* Y*P!*PQ*P &+ 5!.    ELVDJUD  &+/!$  /!$    &+(  0     &+6    @  GLVXOIXURFRQOD FDGHQDOLJHUDNDSSDKXPDQL]DGD   >9.$33$ Homo sapiens,*.9   ,*.-   >@    Homo sapiens,*.& .P$  9      @ GtPHUR   ELVGLVXOIXURSURGXFLGRHQODVFpOXODV RYiULFDVGHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOIDFRQMXJDGR FRQUHVWRVGHFLVWHtQDVSRUWpUPLQRPHGLRFRQFOp]XWRFOD[TXH FRPSUHQGHXQYLQFXODGRUGLSpSWLGR YDOLQDDODQLQD HVFLQGLEOH inmunomodulador, antineoplásico          297 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019  PRERFHUWLQLEXP  PRERFHUWLQLE SURSDQ\O>^> GLPHWK\ODPLQR HWK\O@ PHWK\O DPLQR`PHWKR[\ SURS HQDPLGR DQLOLQR@ PHWK\OHLQGRO\O S\ULPLGLQH FDUER[\ODWH tyrosine kinase inhibitor, antineoplastic  PRERFHUWLQLE >^> GLPpWK\ODPLQR pWK\O@ PpWK\O DPLQR`PpWKR[\  SURSpQDPLGR DQLOLQR@ PpWK\OHLQGRO \O S\ULPLGLQHFDUER[\ODWHGHSURSDQ\OH inhibiteur de la tyrosine kinase, antinéoplasique  PRERFHUWLQLE >^> GLPHWLODPLQR HWLO@ PHWLO DPLQR`PHWR[L SURSHQDPLGR DQLOLQR@ PHWLOHLQGRO LO SLULPLGLQDFDUER[LODWRGHSURSDQLOR inhibidor de la tirosina quinasa, antineoplásico    &+12    2 +& + 1 &+ +1 1 1 &+ 1 1 2 &+ +& 1 2  &+ &+ 2 &+   PRQRPHWK\OLVIXPDUDV  PRQRPHWK\OIXPDUDWH E PHWKR[\R[REXWHQRLFDFLG anti-inflammatory  IXPDUDWHGHPRQRPpWK\OH DFLGH E PpWKR[\R[REXWpQRwTXH anti-inflammatoire  IXPDUDWRGHPRQRPHWLOR iFLGR E PHWR[LR[REXWHQRLFR antiinflamatorio    &+2       QDUVRSOLPDEXP  QDUVRSOLPDE LPPXQRJOREXOLQ*ODPEGDDQWL>Homo sapiens0$63 PDQQDQELQGLQJOHFWLQVHULQHSHSWLGDVHPDQQDQ ELQGLQJOHFWLQVHULQHSURWHDVHPDQQDQELQGLQJOHFWLQ VHULQHSURWHDVHSVHXGRJHQH0$633 @Homo sapiensPRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQHomo sapiens  >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*  &+  KLQJH6!3     &+  &+  &+6     @  GLVXOILGHZLWKODPEGDOLJKWFKDLQHomo sapiens   >9/$0%'$ Homo sapiens,*/9    ,*/-   >@   Homo  sapiens,*/&      @  298 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121     GLPHU   ELVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 6FHOOOLQHJO\FRIRUPDOID immunomodulator  QDUVRSOLPDE LPPXQRJOREXOLQH*ODPEGDDQWL>Homo sapiens 0$63 VpULQHSHSWLGDVH GHODOHFWLQHOLDQWOHPDQQDQHVpULQHSURWpDVHGHODOHFWLQHOLDQWOH PDQQDQHSVHXGRJqQHGHODSURWpDVHGHODOHFWLQHOLDQWOHPDQQDQH 0$633 @DQWLFRUSVPRQRFORQDOHomo sapiens FKDvQHORXUGHJDPPDHomo sapiens  >9+ Homo sapiens,*+9     ,*+' ,*+-   >@  Homo sapiens ,*+*  &+  FKDUQLqUH6!3    &+  &+  &+6    @  GLVXOIXUH DYHFODFKDvQHOpJqUHODPEGDHomo sapiens   >9/$0%'$ Homo sapiens,*/9   ,*/-   >@   Homo sapiens,*/&      @ GLPqUH   ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHV RYDULHQQHVGHKDPVWHUVFKLQRLV &+2 OLJQpHFHOOXODLUH6JO\FRIRUPHDOID immunomodulateur  QDUVRSOLPDE LQPXQRJOREXOLQD*ODPEGDDQWL>Homo sapiens 0$63 VHULQDSHSWLGDVD GHODOHFWLQDTXHVHXQHDOPDQDQRVHULQDSURWHDVDGHODOHFWLQDXQLGDDO PDQDQRSVHXGRJHQGHODSURWHDVDGHODOHFWLQDXQLGDDOPDQDQR 0$633 @DQWLFXHUSRPRQRFORQDOHomo sapiens FDGHQDSHVDGDJDPPDHomo sapiens  >9+ Homo sapiens,*+9     ,*+' ,*+-   >@  Homo sapiens ,*+*  &+  ELVDJUD6!3    &+   &+  &+6    @  GLVXOIXURFRQOD FDGHQDOLJHUDODPEGDHomo sapiens   >9/$0%'$ Homo sapiens ,*/9   ,*/-   >@   Homo sapiens ,*/&      @ GtPHUR   ELVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDV GHKDPVWHUVFKLQRV &+2 OtQHDFHOXODU6JOLFRIRUPDDOID inmunomodulador         299 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019   QDYDIHQWHUROXP  QDYDIHQWHURO trans>^> ^> R K\GUR[\ K\GUR[\R[R GLK\GURTXLQROLQ\O HWK\O@DPLQR`PHWK\O H EHQ]RWULD]RO\O@SURS\O` PHWK\O DPLQR@F\FORKH[\O K\GUR[\GL WKLRSKHQ\O DFHWDWH bronchodilator  QDYDIHQWpURO K\GUR[\GL WKLRSKpQ\O DFpWDWHGHtrans>^> ^> R K\GUR[\ K\GUR[\R[R GLK\GURTXLQROpLQ\O pWK\O@DPLQR`PpWK\O H EHQ]RWULD]RO\O@SURS\O` PpWK\O DPLQR@F\FORKH[\OH bronchodilateur  QDYDIHQWHURO KLGUR[LGL WLRIHQLO DFHWDWRGHtrans>^> ^> R  KLGUR[L KLGUR[LR[RGLKLGURTXLQROHLQ LO HWLO@DPLQR`PHWLO HEHQ]RWULD]RO LO@SURSLO` PHWLO DPLQR@FLFORKH[LOR broncodilatador    &+126        QDYRFDIWRUXP  QDYRFDIWRU ^DPLQR> WULIOXRURPHWKR[\ EHQ]HQH VXOIRQ\O@S\ULGLQ\O`R[DGLD]RO\O PHWKDQRO cystic fibrosis transmembrane regulator (CFTR) protein modulator  QDYRFDIWRU ^DPLQR> WULIOXRURPpWKR[\ EHQ]qQH VXOIRQ\O@S\ULGLQ\O`R[DGLD]RO\O PpWKDQRO modulateur de la protéine régulatrice de la perméabilité transmembranaire impliquée dans la mucoviscidose (CFTR)  QDYRFDIWRU ^DPLQR> WULIOXRURPHWR[L EHQFHQR VXOIRQLO@SLULGLQLO`R[DGLD]ROLO PHWDQRO modulador de la proteína reguladora de la conductancia transmembrana de la fibrosis quística (CFTR)    &+)126        300 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121   QHORQHPGD]XP  QHORQHPGD] K\GUR[\ ^>WHWUDIOXRUR WULIOXRURPHWK\O SKHQ\O@PHWK\O`DPLQR EHQ]RLFDFLG N-methyl-D-aspartate (NMDA) receptor antagonist  QpORQHPGD] DFLGHK\GUR[\ ^>WpWUDIOXRUR WULIOXRURPpWK\O SKpQ\O@PpWK\O`DPLQR EHQ]RwTXH antagoniste des récepteurs du NMDA  QHORQHPGD] iFLGRKLGUR[L ^>WHWUDIOXRUR WULIOXRURPHWLO IHQLO@PHWLO`DPLQR EHQ]RLFR antagonista del receptor de NMDA    &+)12        QHULQGRFLDQLQXP  QHULQGRFLDQLQH ^ E >^ E >GLPHWK\OVXOIR  VXOIREXW\O GLK\GURHLQGRO\OLGHQH@HWK\OLGHQH`  VXOIRSKHQR[\ F\FORKH[HQ\O@HWKHQ\O` GLPHWK\O VXOIREXW\O HLQGROLXPVXOIRQDWH fluorescent diagnostic contrast agent  QpULQGRFLDQLQH ^ E >^ E >GLPpWK\OVXOIR  VXOIREXW\O GLK\GURHLQGRO\OLGqQH@pWK\OLGqQH`  VXOIRSKpQR[\ F\FORKH[pQ\O@pWKpQ\O` GLPpWK\O VXOIREXW\O HLQGROLXPVXOIRQDWH substance fluorescente à usage diagnostique  QHULQGRFLDQLQD ^ E >^ E >GLPHWLOVXOIR VXOIREXWLO  GLKLGURHLQGROLOLGHQR@HWLOLGHQR`  VXOIRIHQR[L FLFORKH[HQLO@HWHQLO`GLPHWLO  VXOIREXWLO HLQGROLXPVXOIRQDWR agente de contraste fluorescente de diagnóstico    &+126       QRJDSHQGHNLQXPDOID  QRJDSHQGHNLQDOID KXPDQLQWHUOHXNLQ>DVSDUWLFDFLG@ KXPDQ,/ 1!'LVRIRUP SURGXFHGLQ&KLQHVHKDPVWHURYDU\ &+2 FHOOVJO\FRIRUPDOID  interleukin type substance 301 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019   QRJDSHQGpNLQHDOID LQWHUOHXNLQHKXPDLQH>DFLGHDVSDUWLTXH@ ,/ KXPDLQHLVRIRUPH1!' SURGXLWSDUGHVFHOOXOHV RYDULHQQHVGHKDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID dérivé de l'interleukine  QRJDSHQGHNLQDDOID LQWHUOHXNLQDKXPDQD>iFLGRDVSiUWLFR@ ,/KXPDQD LVRIRUPD1!' SURGXFLGRSRUODVFpOXODVRYiULFDVGH KDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID derivado de la interleukina           QXPLGDUJLVWDWXP  QXPLGDUJLVWDW RS DPLQR> S DPLQRSURSDQR\O@  ERURQRSURS\O S\UUROLGLQHFDUER[\OLFDFLG arginase inhibitor, antineoplastic  QXPLGDUJLVWDW DFLGH RS DPLQR> S DPLQRSURSDQR\O@  ERURQRSURS\O S\UUROLGLQHFDUER[\OLTXH inhibiteur de l'arginase, antinéoplasique  QXPLGDUJLVWDW iFLGR RS DPLQR> S DPLQRSURSDQRLO@  ERURQRSURSLO SLUUROLGLQDFDUER[tOLFR inhibidor de la arginasa, antineoplásico    &+%12       QXUXOLPDEXP  QXUXOLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens&7/$ F\WRWR[LF7O\PSKRF\WHDVVRFLDWHGSURWHLQ&7/$ &' @Homo sapiensPRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQHomo sapiens  >9+ Homo sapiens,*+9    ,*+' ,*+-    >@  Homo sapiens,*+* Y*P!*P *P &+.!5    KLQJH   &+  &+'  /    &+6 *!GHO.!GHO   @  GLVXOILGHZLWKNDSSD OLJKWFKDLQHomo sapiens   >9.$33$ Homo sapiens ,*.9   ,*.-   >@    Homo sapiens,*.&   .P$  9     @GLPHU   ELVGLVXOILGH SURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 .6FHOOOLQH JO\FRIRUPDOID  immunomodulator, antineoplastic 302 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121    QXUXOLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens&7/$ SURWpLQHDVVRFLpHDX[O\PSKRF\WHV7F\WRWR[LTXHV&7/$ &' @DQWLFRUSVPRQRFORQDOHomo sapiens FKDvQHORXUGHJDPPDHomo sapiens  >9+ Homo sapiens,*+9    ,*+' ,*+-    >@  Homo sapiens,*+* Y*P!*P *P &+.!5    FKDUQLqUH   &+  &+'  /     &+6*!GHO.!GHO   @  GLVXOIXUHDYHFOD FKDvQHOpJqUHNDSSDHomo sapiens   >9.$33$ Homo sapiens,*.9   ,*.-    >@   Homo sapiens,*.&   .P$  9     @GLPqUH    ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGHKDPVWHUV FKLQRLV &+2 OLJQpHFHOOXODLUH.6JO\FRIRUPHDOID immunomodulateur, antinéoplasique  QXUXOLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens&7/$ SURWHtQDDVRFLDGDFRQOLQIRFLWRV7FLWRWy[LFDV&7/$ &' @DQWLFXHUSRPRQRFORQDOHomo sapiens FDGHQDSHVDGDJDPPDHomo sapiens  >9+ Homo sapiens,*+9    ,*+' ,*+-    >@  Homo sapiens,*+* Y*P!*P *P &+.!5    ELVDJUD   &+  &+'  /    &+6 *!GHO.!GHO   @  GLVXOIXURFRQODFDGHQD OLJHUDNDSSDHomo sapiens   >9.$33$ Homo sapiens,*.9   ,*.-   >@    Homo sapiens,*.&   .P$   9     @GtPHUR    ELVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDVGHKDPVWHUV FKLQRV &+2 OtQHDFHOXODU.6JOLFRIRUPDDOID inmunomodulador, antineoplásico           303 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019 REDILVWDWXP  REDILVWDW > IOXRUREHQ]HQHVXOIRQ\O  GLD]DELF\FOR>@RFWDQ\O@ HWULD]RO \O PHWKDQRQH aldo-keto reductase AKR1C3 inhibitor  REDILVWDW > IOXRUREHQ]qQHVXOIRQ\O  GLD]DELF\FOR>@RFWDQ\O@ HWULD]RO \O PpWKDQRQH inhibiteur de l'aldo-cétoréductase AKR1C3  REDILVWDW > IOXRUREHQFHQRVXOIRQLO  GLD]DELFLFOR>@RFWDQLO@ HWULD]ROLO PHWDQRQD inhibidor de la aldo-ceto reductasa AKR1C3    &+)126        RGHVLYLPDEXP  RGHVLYLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Zaire ebolavirus =DLUH (ERODYLUXV (%29 HQYHORSHJO\FRSURWHLQ *3 @Homo sapiensPRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQHomo sapiens  >9+ Homo sapiens,*+9    ,*+' ,*+-    >@  Homo sapiens,*+*    *P &+.    KLQJH   &+  &+'  /     &+6    @  GLVXOILGHZLWK NDSSDOLJKWFKDLQHomo sapiens   >9.$33$ Homo sapiens,*.9   ,*.-    >@   Homo sapiens,*.&   .P $  9     @ GLPHU   ELVGLVXOILGHSURGXFHGLQ &KLQHVH+DPVWHU2YDU\ &+2 FHOOVJO\FRIRUPDOID immunomodulator, antiviral  RGpVLYLPDE LPPXQRJOREXOLQH*NDSSDDQWL>JO\FRSURWpLQH G HQYHORSSH *3 GHZaire ebolaviruV YLUXV(EROD=DwUH (%29 @DQWLFRUSVPRQRFORQDOHomo sapiens FKDvQHORXUGHJDPPDHomo sapiens  >9+ Homo sapiens,*+9    ,*+' ,*+-    >@  Homo sapiens,*+*    *P &+.    FKDUQLqUH  &+  &+'  /    &+6    @  GLVXOIXUH DYHFODFKDvQHOpJqUHNDSSDHomo sapiens   >9 .$33$ Homo sapiens ,*.9   ,*.-   >@   Homo sapiens,*.&    .P$  9     @GLPqUH    ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHV RYDULHQQHVGHKDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID  immunomodulateur, antiviral  304 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121  RGHVLYLPDE LQPXQRJOREXOLQD*NDSSDDQWL>JOLFRSURWHtQDGH HQYROWXUD *3 GHZaire ebolaviruV YLUXV(EROD=DwUH (%29 @DQWLFXHUSRPRQRFORQDOHomo sapiens FDGHQDSHVDGDJDPPDHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*   *P &+.     ELVDJUD  &+  &+ '  /    &+6     @  GLVXOIXURFRQODFDGHQDOLJHUDNDSSD Homo sapiens   >9.$33$ Homo sapiens ,*.9   ,*.-   >@    Homo sapiens,*.&   .P$  9     @GtPHUR    ELVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDV GHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID inmunomodulador, antiviral           RGURQH[WDPDEXP  RGURQH[WDPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens 06$ PHPEUDQHVSDQQLQJGRPDLQVVXEIDPLO\$ PHPEHU&' @DQGDQWL>Homo sapiens&'( &'HSVLORQ @Homo sapiensPRQRFORQDODQWLERG\ ELVSHFLILF JDPPDKHDY\FKDLQHomo sapiensDQWL06$   >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*  &+  KLQJH6!3    &+()  !3  /!9   *!$    &+  &+6     @  GLVXOILGHZLWKNDSSDOLJKW FKDLQHomo sapiens   >9.$33$ Homo sapiens,*.9   ,*.-    >@   Homo sapiens,*.&   .P  $  9     @  305 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019  JDPPDKHDY\FKDLQHomo sapiensDQWL&'(    >9+ Homo sapiens ,*+9    ,*+' ,*+-   >@   Homo sapiens,*+*  &+  KLQJH6!3   ´´ &+()   !3  /!9  *!$   ´´ &+ +!5  <!)   ´´ &+6     @   GLVXOILGHZLWKNDSSDOLJKWFKDLQ Homo sapiens   >9.$33$ Homo sapiens,*.9    ,*.-   >@   Homo sapiens,*.&   .P$  9     @GLPHU   ELVGLVXOILGH SURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 FHOOVJO\FRIRUP DOID immunomodulator, antineoplastic  RGURQH[WDPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens06$ PHPEUHGHODVRXVIDPLOOH$jGRPDLQHV WUDQVPHPEUDQDLUHV&' @HWDQWL>Homo sapiens&'( &'HSVLORQ @DQWLFRUSVPRQRFORQDOHomo sapiens ELVSpFLILTXH FKDvQHORXUGHJDPPDHomo sapiensDQWL06$   >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*  &+  FKDUQLqUH6!3    &+ ()  !3  /!9  *!$     &+  &+6    @   GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSDHomo sapiens ¶ ¶ >9.$33$ Homo sapiens,*.9    ,*.-   >@   Homo sapiens,*.&   .P$  9     @ FKDvQHORXUGHJDPPDHomo sapiensDQWL&'(    >9+ Homo sapiens ,*+9    ,*+' ,*+-   >@   Homo sapiens,*+*  &+  FKDUQLqUH6!3    &+ ()  !3  /!9  *!$     &++!5  <!)    &+6      @   GLVXOIXUHDYHFODFKDvQH OpJqUHNDSSDHomo sapiens   >9.$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens,*.&   .P$  9     @GLPqUH    ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGH KDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID immunomodulateur, antinéoplasique  RGURQH[WDPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens06$ PLHPEURGHODVXEIDPLOLD$GHGRPLQLRV WUDQVPHPEUDQDULRV&' @\DQWL>Homo sapiens&'( &'pSVLORQ @DQWLFXHUSRPRQRFORQDOHomo sapiens ELHVSHFtILFR FDGHQDSHVDGDJDPPDHomo sapiensDQWL06$   >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*  &+  ELVDJUD6!3    &+ ()  !3  /!9  *!$     &+  &+6    @   GLVXOIXURFRQODFDGHQDOLJHUDNDSSDHomo sapiens ¶¶  >9.$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens,*.&    .P$  9     @   306 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121   FDGHQDSHVDGDJDPPDHomo sapiensDQWL&'(   >9+ Homo sapiens ,*+9    ,*+' ,*+-   >@   Homo sapiens,*+*  &+  ELVDJUD 6!3    &+()  !3   /!9  *!$    &++!5  <!)    &+6      @   GLVXOIXURFRQODFDGHQDOLJHUD NDSSDHomo sapiens   >9.$33$ Homo sapiens,*.9   ,*.-    >@   Homo sapiens,*.&    .P$  9     @GtPHUR   ELVGLVXOIXURSURGXFLGRHQODV FpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2  JOLFRIRUPDDOID inmunomodulador, antineoplásico        +HDY\ FKDLQ  &KDvQH ORXUGH  &DGHQD SHVDGD DQWL&' EVQLVESGGG LVQPGRSLRL SCVASGFTFN DYAMHWVRQA PGKGLEWVSV 50 ISWNSDSIGY ADSVKGRFTI SRDNAKNSLY LQMHSLRAED TALYYCAKDN 100 HYGSGSYYYY QYGMDVWGQG TTVTVSSAST KGPSVFPLAP CSRSTSESTA 150 ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS 200 SSLGTKTYTC NVDHKPSNTK VDKRVESKYG PPCPPCPAPP VAGPSVFLFP 250 PKPKDTLMIS RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEV HNAKTKPREE 300 QFNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR 350 EPQVYTLPPS QEEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400 PPVLDSDGSF FLYSRLTVDK SRWQEGNVFS CSVMHEALHN HYTQKSLSLS 450 LGK 453 +HDY\ FKDLQ  &KDvQH ORXUGH  &DGHQD SHVDGD DQWL&' EVQLVESGGG LVQPGRSLRL SCAASGFTFD DYTMHWVRQA PGKGLEWVSG 50 ISWNSGSIGY ADSVKGRFTI SRDNAKKSLY LQMNSLRAED TALYYCAKDN 100 SGYGHYYYGM DVWGQGTTVT VASASTKGPS VFPLAPCSRS TSESTAALGC 150 LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200 TKTYTCNVDH KPSNTKVDKR VESKYGPPCP PCPAPPVAGP SVFLFPPKPK 250 DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300 TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV 350 YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400 DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNRFTQ KSLSLSLGK 449 /LJKW FKDLQ  &KDvQH OpJqUH  &DGHQD OLJHUD EIVMTQSPAT LSVSPGERAT LSCRASQSVS SNLAWYQQKP GQAPRLLIYG 50 ASTRATGIPA RFSGSGSGTE FTLTISSLQS EDFAVYYCQH YINWPLTFGG 100 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150 DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200 LSSPVTKSFN RGEC 214 3RVWWUDQVODWLRQDO PRGLILFDWLRQV 'LVXOILGH EULGJHV ORFDWLRQ  3RVLWLRQ GHV SRQWV GLVXOIXUH  3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR ,QWUD+ &&             ,QWUD/ &&         ,QWHU+/ &+ &/     ,QWHU++ K  K    1JO\FRV\ODWLRQ VLWHV  6LWHV GH 1JO\FRV\ODWLRQ  3RVLFLRQHV GH 1JOLFRVLODFLyQ + &+ 1   )XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV  JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV FRPSOH[HV IXFRV\OpV  JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV     RODIHUWLQLEXP  RODIHUWLQLE N> ^GLIOXRUR> K\GUR[\HWK\O SLSHUD]LQ \O@DQLOLQR`TXLQD]ROLQ\O SKHQ\O@SURSHQDPLGH tyrosine kinase inhibitor, antineoplastic  RODIHUWLQLE N> ^GLIOXRUR> K\GUR[\pWK\O SLSpUD]LQ \O@DQLOLQR`TXLQD]ROLQ\O SKpQ\O@SURSpQDPLGH  inhibiteur de la tyrosine kinase, antinéoplasique   307 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019 RODIHUWLQLE N> ^GLIOXRUR> KLGUR[LHWLO SLSHUD]LQ LO@DQLOLQR`TXLQD]ROLQLO IHQLO@SURSHQDPLGD inhibidor de la tirosina quinasa, antineoplásico    &+)12       ROLWUHVJHQXPDXWROHXFHOXP  ROLWUHVJHQHDXWROHXFHO DXWRORJRXV&'DQG&'7FHOOVWUDQVGXFHGZLWKD QRQUHSOLFDWLQJKXPDQLPPXQRGHILFLHQF\YLUXV +,9  GHULYHGVHOILQDFWLYDWLQJ 6,1 YHFWRUWKDWFRPSULVHVD  /75 569 58 DQGD 8GHOHWHG/75 85+,9 'HOWD /75 HQFRGLQJD0$*($ 0$*(IDPLO\ PHPEHU$0$*(DQWLJHQPHODQRPDDQWLJHQIDPLO\ $ VSHFLILF7FHOOUHFHSWRU 7&5 XQGHUWKHFRQWURORI HORQJDWLRQIDFWRUDOSKD ()D SURPRWHU7KHYHFWRULV SVHXGRW\SHGZLWKYHVLFXODUVWRPDWLWLVYLUXVJO\FRSURWHLQ* 969*  5695RXVVDUFRPDYLUXV cell therapy (antineoplastic)  ROLWUHVJqQHDXWROHXFHO O\PSKRF\WHV7&'HW&'DXWRORJXHVWUDQVGXLWVSDU XQYHFWHXUDXWRLQDFWLYDQW 6,1 QRQUpSOLTXDQWGpULYpGX YLUXVGHO LPPXQRGpILFLHQFHQFHKXPDLQH 9,+ FRQWHQDQW XQHVpTXHQFH/75 WHUPLQDOHORQJXHUpSpWpH HQ  569 58 HWXQHVpTXHQFH/75GRQWOHGRPDLQH8 HVWVXSSULPp 859,+'HOWD /75 HWTXLFRGHSRXU XQUpFHSWHXUGHVO\PSKRF\WHV7 7&5 VSpFLILTXHGX 0$*($ PHPEUH$GHODIDPLOOH0$*(DQWLJqQH 0$*(IDPLOOHGHVDQWLJHQVGHPpODQRPH$ VRXV OHFRQWU{OHG XQSURPRWHXUGXIDFWHXUG pORQJDWLRQDOSKD ()D /HYHFWHXUHVWSVHXGRW\SpDYHFODJO\FRSURWpLQH* GHO HQYHORSSHGHODVWRPDWLWHYpVLFXODLUH 969*  569YLUXVGXVDUFRPHGH5RXV thérapie cellulaire (antinéoplasique)  ROLWUHVJpQDXWROHXFHO OLQIRFLWRV7&'\&'DXWyORJRVWUDQVGXFLGRVFRQXQ YHFWRUDXWRLQDFWLYDQWH 6,1 QRUHSOLFDWLYRGHULYDGRGHO YLUXVGHODLQPXQRGHILFLHQFLDKXPDQD 9,+ TXHFRQWLHQH XQD/75HQ  569 58 \XQD/75FRQ8 GHOHFLRQDGDHQ  85+,9'HOWD /75 \TXHFRGLILFD SDUDXQUHFHSWRUGHOLQIRFLWRV7 7&5 HVSHFtILFRSDUD 0$*($ PLHPEUR$GHODIDPLOLD0$*(DQWtJHQR 0$*(IDPLOLDGHDQWtJHQRVGHPHODQRPD$ EDMR HOFRQWUROGHOSURPRWRUGHOIDFWRUGHHORQJDFLyQDOID ()D (OYHFWRUHVWiVHXGRWLSDGRFRQODJOLFRSURWHtQD* GHOYLUXVGHODHVWRPDWLWLVYHVLFXODU 969*  569YLUXVGHOVDUFRPDGH5RXV  terapia celular (antineoplásico) 308 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121   ROSDVLUDQXP  ROSDVLUDQ allPambo O^ SS > DFHWDPLGRGHR[\ȕ' JDODFWRS\UDQRV\O R[\@ELV> ^> DFHWDPLGRGHR[\ȕ 'JDODFWRS\UDQRV\O R[\@HWKR[\`HWK\O FDUEDPR\O@K\GUR[\ WULR[RVXOIDQ\OLGHQHRFWDR[D WULD]DȜSKRVSKDQRQDWULDFRQWDQ\O` OPHWK\OP WKLRF\WLG\O\O  ĺ  OPHWK\ODGHQ\O\O  ĺ  O PHWK\OJXDQ\O\O  ĺ  OPHWK\OF\WLG\O\O  ĺ  O PHWK\OF\WLG\O\O  ĺ  OPHWK\OF\WLG\O\O  ĺ  O PHWK\OF\WLG\O\O  ĺ  OPHWK\OXULG\O\O  ĺ  GHR[\  IOXRURXULG\O\O  ĺ  GHR[\ IOXRURDGHQ\O\O  ĺ  GHR[\  IOXRURXULG\O\O  ĺ  OPHWK\OXULG\O\O  ĺ  O PHWK\OJXDQ\O\O  ĺ  OPHWK\OXULG\O\O  ĺ  O PHWK\OXULG\O\O  ĺ  OPHWK\ODGHQ\O\O  ĺ  O PHWK\OXULG\O\O  ĺ  OPHWK\ODGHQ\O\O  ĺ  O PHWK\OF\WLG\O\O  ĺ  OPHWK\OPWKLRJXDQ\O\O  ĺ   GHR[\DGHQRVLQHGXSOH[ZLWKallPambo OPHWK\OP WKLRJXDQ\O\O  ĺ  GHR[\ IOXRURPWKLRXULG\O\O  ĺ   OPHWK\OF\WLG\O\O  ĺ  GHR[\ IOXRURJXDQ\O\O  ĺ  O PHWK\OJXDQ\O\O  ĺ  GHR[\ IOXRURJXDQ\O\O  ĺ  O PHWK\OJXDQ\O\O  ĺ  GHR[\ IOXRURDGHQ\O\O  ĺ  O PHWK\ODGHQ\O\O  ĺ  GHR[\ IOXRURXULG\O\O  ĺ  O PHWK\ODGHQ\O\O  ĺ  OPHWK\ODGHQ\O\O  ĺ  O PHWK\OF\WLG\O\O  ĺ  OPHWK\ODGHQ\O\O  ĺ  O PHWK\ODGHQ\O\O  ĺ  GHR[\ IOXRURXULG\O\O  ĺ  O PHWK\ODGHQ\O\O  ĺ  GHR[\ IOXRURXULG\O\O  ĺ  O PHWK\OPWKLRJXDQ\O\O  ĺ  GHR[\ IOXRURPWKLRF\WLG\O\O  ĺ  OPHWK\OXULGLQH antiatherosclerosis  ROSDVLUDQ toutPambo O^ SS > DFpWDPLGRGpVR[\ȕ' JDODFWRS\UDQRV\O R[\@ELV> ^> DFpWDPLGRGpVR[\ȕ 'JDODFWRS\UDQRV\O R[\@pWKR[\`pWK\O FDUEDPR\O@K\GUR[\ WULR[RVXOIDQ\OLGqQHRFWDR[D WULD]DȜSKRVSKDQRQDWULDFRQWDQ\O` OPpWK\OP WKLRF\WLG\O\O  ĺ  OPpWK\ODGpQ\O\O  ĺ  O PpWK\OJXDQ\O\O  ĺ  OPpWK\OF\WLG\O\O  ĺ  O PpWK\OF\WLG\O\O  ĺ  OPpWK\OF\WLG\O\O  ĺ  O PpWK\OF\WLG\O\O  ĺ  OPpWK\OXULG\O\O  ĺ  GpVR[\  IOXRURXULG\O\O  ĺ  GpVR[\ IOXRURDGpQ\O\O  ĺ   GpVR[\ IOXRURXULG\O\O  ĺ  OPpWK\OXULG\O\O  ĺ  O PpWK\OJXDQ\O\O  ĺ  OPpWK\OXULG\O\O  ĺ  O PpWK\OXULG\O\O  ĺ  OPpWK\ODGpQ\O\O  ĺ  O PpWK\OXULG\O\O  ĺ  OPpWK\ODGpQ\O\O  ĺ  O PpWK\OF\WLG\O\O  ĺ  OPpWK\OPWKLRJXDQ\O\O  ĺ   GpVR[\DGpQRVLQHGXSOH[DYHFtoutPambo OPpWK\OP WKLRJXDQ\O\O  ĺ  GpVR[\ IOXRURPWKLRXULG\O\O  ĺ   OPpWK\OF\WLG\O\O  ĺ  GpVR[\ IOXRURJXDQ\O\O  ĺ   OPpWK\OJXDQ\O\O  ĺ  GpVR[\ IOXRURJXDQ\O\O  ĺ   OPpWK\OJXDQ\O\O  ĺ  GpVR[\ IOXRURDGpQ\O\O  ĺ   OPpWK\ODGpQ\O\O  ĺ  GpVR[\ IOXRURXULG\O\O  ĺ   OPpWK\ODGpQ\O\O  ĺ  OPpWK\ODGpQ\O\O  ĺ  O PpWK\OF\WLG\O\O  ĺ  OPpWK\ODGpQ\O\O  ĺ  O PpWK\ODGpQ\O\O  ĺ  GpVR[\ IOXRURXULG\O\O  ĺ  O PpWK\ODGpQ\O\O  ĺ  GpVR[\ IOXRURXULG\O\O  ĺ  O PpWK\OPWKLRJXDQ\O\O  ĺ  GpVR[\ IOXRURPWKLRF\WLG\O\O  ĺ  OPpWK\OXULGLQH  antiathérosclérose  309 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019  ROSDVLUiQ todoPambo O^ SS > DFHWDPLGRGHVR[Lȕ' JDODFWRSLUDQRVLO R[L@ELV> ^> DFHWDPLGRGHVR[Lȕ' JDODFWRSLUDQRVLO R[L@HWR[L`HWLO FDUEDPRLO@KLGUR[LWULR[R VXOIDQLOLGHQRRFWDR[DWULD]DȜ IRVIDQRQDWULDFRQWDQLO` OPHWLOPWLRFLWLGLOLO  ĺ  O PHWLODGHQLOLO  ĺ  OPHWLOJXDQLOLO  ĺ  OPHWLOFLWLGLOLO  ĺ   OPHWLOFLWLGLOLO  ĺ  OPHWLOFLWLGLOLO  ĺ  OPHWLOFLWLGLOLO  ĺ  OPHWLOXULGLOLO  ĺ  GHVR[L IOXRURXULGLOLO  ĺ   GHVR[L IOXRURDGHQLOLO  ĺ  GHVR[L IOXRURXULGLOLO  ĺ  O PHWLOXULGLOLO  ĺ  OPHWLOJXDQLOLO  ĺ  OPHWLOXULGLOLO  ĺ   OPHWLOXULGLOLO  ĺ  OPHWLODGHQLOLO  ĺ  OPHWLOXULGLOLO  ĺ  OPHWLODGHQLOLO  ĺ  OPHWLOFLWLGLOLO  ĺ  OPHWLOP WLRJXDQLOLO  ĺ  GHVR[LDGHQRVLQDG~SOH[FRQtodoPambo O PHWLOPWLRJXDQLOLO  ĺ  GHVR[L IOXRURPWLRXULGLOLO  ĺ  O PHWLOFLWLGLOLO  ĺ  GHVR[L IOXRURJXDQLOLO  ĺ  OPHWLOJXDQLOLO  ĺ  GHVR[L IOXRURJXDQLOLO  ĺ  OPHWLOJXDQLOLO  ĺ   GHVR[L IOXRURDGHQLOLO  ĺ  OPHWLODGHQLOLO  ĺ  GHVR[L  IOXRURXULGLOLO  ĺ  OPHWLODGHQLOLO  ĺ  OPHWLODGHQLOLO  ĺ   OPHWLOFLWLGLOLO  ĺ  OPHWLODGHQLOLO  ĺ  OPHWLODGHQLOLO  ĺ  GHVR[L IOXRURXULGLOLO  ĺ  OPHWLODGHQLOLO  ĺ   GHVR[L IOXRURXULGLOLO  ĺ  OPHWLOPWLRJXDQLOLO  ĺ  GHVR[L  IOXRURPWLRFLWLGLOLO  ĺ  OPHWLOXULGLQD antiateroesclerosis    &+)1236        RPLGXELFHOXP  RPLGXELFHO DOORJHQHLFKXPDQXPELOLFDOFRUGEORRGGHULYHGKHPDWRSRLHWLF&' SURJHQLWRUFHOOVex-vivoH[SDQGHGLQWKHSUHVHQFHRIQLFRWLQDPLGH DQGF\WRNLQHV cell therapy (stem cell transplantation)  RPLGXELFHO FHOOXOHVSURJpQLWULFHVKpPDWRSRwpWLTXHV&'KXPDLQHV DOORJpQLTXHVGpULYpHVGXVDQJGHFRUGRQRPELOLFDOHQFXOWXUH G¶H[SDQVLRQex vivoHQSUpVHQFHGHQLFRWLQDPLGHHWGHF\WRNLQHV thérapie cellulaire (greffe de cellules souches)  RPLGXELFHO FpOXODVSURJHQLWRUDVKHPDWRSR\pWLFDV&'DORJpQLFDVKXPDQDV GHULYDGDVGHVDQJUHGHFRUGyQXPELOLFDOH[SDQGLGDVex vivoHQ SUHVHQFLDGHQLFRWLQDPLGD \FLWRFLQDV  terapia celular (transplante de células madres  310 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121  RQYDQVHUWLEXP  RQYDQVHUWLE  K\GUR[\HWK\O > PHWK\OSLSHUD]LQ\O  WULIOXRURPHWKR[\ DQLOLQR@GLK\GURHS\UD]ROR> h@TXLQD]ROLQHFDUER[DPLGH antineoplastic  RQYDQVHUWLE  K\GUR[\pWK\O > PpWK\OSLSpUD]LQ\O  WULIOXRURPpWKR[\ DQLOLQR@GLK\GURHS\UD]ROR> h@TXLQD]ROLQHFDUER[DPLGH antinéoplasique  RQYDQVHUWLE  KLGUR[LHWLO > PHWLOSLSHUD]LQLO  WULIOXRURPHWR[L DQLOLQR@GLKLGURHSLUD]ROR> h@TXLQD]ROLQDFDUER[DPLGD antineoplásico    &+)12       RULVPLODVWXP  RULVPLODVW GLFKORUR^> GLIOXRURPHWKR[\   GLR[R Ȝ VSLUR>>@EHQ]RGLR[ROH WKLDQ@\O@ R[RHWK\O`S\ULGLQHR[LGH phosphodiesterase IV inhibitor  RULVPLODVW R[\GHGHGLFKORUR^> GLIOXRURPpWKR[\    GLR[R ȜVSLUR>>@EHQ]RGLR[ROH WKLDQ@\O@ R[RpWK\O`S\ULGLQH inhibiteur de la phosphodiestérase IV  RULVPLODVW y[LGRGHGLFORUR^> GLIOXRURPHWR[L    GLR[R ȜVSLUR>>@EHQ]RGLR[RO WLDQ@LO@ R[RHWLO`SLULGLQD inhibidor de la fosfodiesterasa IV    &+&O)126       RWHQDSUR[HVXOXP  RWHQDSUR[HVXO FDUEDPRWKLR\OSKHQ\O S  PHWKR[\QDSKWKDOHQ \O SURSDQRDWH non-steroidal anti-inflammatory    311 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019  RWpQDSUR[pVXO S  PpWKR[\QDSKWDOpQ\O SURSDQRDWHGH FDUEDPRWKLR\OSKpQ\OH anti-inflammatoire non-stéroïdien  RWHQDSUR[HVXO S  PHWR[LQDIWDOHQLO SURSDQRDWRGH FDUEDPRWLRLOIHQLOR antiinflamatorio no esteroideo    &+126      SDFPLOLPDEXP  SDFPLOLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens &' SURJUDPPHGFHOOGHDWKOLJDQG%+%+ 3'/3'/3'&'/%KRPRORJ% KRPRORJXH @Homo sapiensPRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*  &+  KLQJH6!3    &+  &+  &+6 .!GHO    @  GLVXOILGHZLWK NDSSDOLJKWFKDLQHomo sapiens   >1WHUPLQDO UHJLRQ   PHUOLQNHU   SURWHDVH FOHDYDEOHUHJLRQ   PHUOLQNHU   9 .$33$ Homo sapiens,*.9    ,*.-   >@   Homo sapiens ,*.&   .P$  9      @GLPHU   ELVGLVXOILGH SURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 GHULYHG FHOOOLQHJO\FRIRUPDOID immunomodulator, antineoplastic  SDFPLOLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens &' OLJDQGGHPRUWSURJUDPPpH%+%+ 3'/3'/3'&'/KRPRORJXHGH% @ DQWLFRUSVPRQRFORQDOHomo sapiens FKDvQHORXUGHJDPPDHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*  &+  FKDUQLqUH6!3    &+  &+  &+6 .!GHO    @  GLVXOIXUHDYHFOD FKDvQHOpJqUHNDSSDHomo sapiens   >UpJLRQ 1WHUPLQDOH   PHUOLQNHU   UpJLRQ FOLYDEOHSDUGHVSURWpDVHV   PHUOLQNHU    9.$33$ Homo sapiens,*.9    ,*.-   >@   Homo sapiens ,*.&   .P$  9      @GLPqUH   ELVGLVXOIXUH SURGXLWHGDQVXQHOLJQpHFHOOXODLUHGpULYpHGHVFHOOXOHV RYDULHQQHVGHKDPVWHUVFKLQRLV &+2 JO\FRIRUPH DOID  immunomodulateur, antinéoplasique  312 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121  SDFPLOLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens &' OLJDQRGHPXHUWHSURJUDPDGD%+% +3'/3'/3'&'/KRPyORJRGH% @ DQWLFXHUSRPRQRFORQDOHomo sapiens FDGHQDSHVDGDJDPPDHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*  &+  ELVDJUD6!3    &+  &+  &+6 .!GHO    @  GLVXOIXURFRQOD FDGHQDOLJHUDNDSSDHomo sapiens   >UHJLyQ 1WHUPLQDO   FRQHFWRUPHU   UHJLyQ HVFLQGLEOHSRUODVSURWHDVDV   FRQHFWRUPHU   9.$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens,*.&   .P$  9     @GtPHUR    ELVGLVXOIXURSURGXFLGRHQXQDOtQHDFHOXODUGHULYDGD GHODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2  JOLFRIRUPDDOID inmunomodulador, antineoplásico       +HDY\ FKDLQ  &KDvQH ORXUGH  &DGHQD SHVDGD EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSS 50 IWRNGIVTVY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWS 100 AAFDYWGQGT LVTVSSASTK GPSVFPLAPC SRSTSESTAA LGCLVKDYFP 150 EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTKTYTCN 200 VDHKPSNTKV DKRVESKYGP PCPPCPAPEF LGGPSVFLFP PKPKDTLMIS 250 RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEV HNAKTKPREE QFNSTYRVVS 300 VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR EPQVYTLPPS 350 QEEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF 400 FLYSRLTVDK SRWQEGNVFS CSVMHEALHN HYTQKSLSLS LG 442 /LJKW FKDLQ  &KDvQH OpJqUH  &DGHQD OLJHUD QGQSGSGIAL CPSHFCQLPQ TGGGSSGGSG GSGGISSGLL SGRSDNHGGS 50 DIQMTQSPSS LSASVGDRVT ITCRASQSIS SYLNWYQQKP GKAPKLLIYA 100 ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ DNGYPSTFGG 150 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 200 DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 250 LSSPVTKSFN RGEC 264 3RVWWUDQVODWLRQDO PRGLILFDWLRQV 'LVXOILGH EULGJHV ORFDWLRQ  3RVLWLRQ GHV SRQWV GLVXOIXUH  3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR ,QWUD+ &&             ,QWUD/ &&         ,QWUD/ 1WHUPLQDO UHJLRQ     ,QWHU+/ &+ &/     ,QWHU++ K  K    1JO\FRV\ODWLRQ VLWHV  6LWHV GH 1JO\FRV\ODWLRQ  3RVLFLRQHV GH 1JOLFRVLODFLyQ + &+ 1   )XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV  JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV  FRPSOH[HV IXFRV\OpV  JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV    SDOWXVRWLQXP  SDOWXVRWLQH > DPLQRSLSHULGLQ\O   GLIOXRURSKHQ\O TXLQROLQ\O@K\GUR[\EHQ]RQLWULOH somatostatin receptor agonist  SDOWXVRWLQH > DPLQRSLSpULGLQ\O   GLIOXRURSKpQ\O TXLQROpLQ\O@K\GUR[\EHQ]RQLWULOH agoniste des récepteurs de la somatostatine  SDOWXVRWLQD > DPLQRSLSHULGLQLO   GLIOXRURIHQLO TXLQROHLQLO@KLGUR[LEHQ]RQLWULOR agonista de los receptores de la somatostatina   313 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019  &+)12       SDPXIHWLQLEXP  SDPXIHWLQLE  IOXRUR ^> SKHQ\ODFHW\O FDUEDPRWKLR\O@DPLQR`SKHQR[\  PHWKR[\NPHWK\OTXLQROLQHFDUER[DPLGH tyrosine kinase inhibitor, antineoplastic  SDPXIpWLQLE  IOXRUR ^> SKpQ\ODFpW\O FDUEDPRWKLR\O@DPLQR`SKpQR[\  PpWKR[\NPpWK\OTXLQROpLQHFDUER[DPLGH inhibiteur de la tyrosine kinase, antinéoplasique  SDPXIHWLQLE  IOXRUR^> IHQLODFHWLO FDUEDPRWLRLO@DPLQR`IHQR[L  PHWR[LNPHWLOTXLQROHtQDFDUER[DPLGD inhibidor de la tirosina quinasa, antineoplásico    &+)126        SDWULWXPDEXPGHUX[WHFDQXP  SDWULWXPDEGHUX[WHFDQ LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens (5%% UHFHSWRUW\URVLQHSURWHLQNLQDVHHUE% +(5 @Homo sapiensPRQRFORQDODQWLERG\ FRQMXJDWHGWRGHUX[WHFDQFRPSULVLQJDOLQNHUDQGD FDPSWRWKHFLQGHULYDWLYH JDPPDKHDY\FKDLQHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*   *PQ*P &+5    KLQJH  &+  &+ (  0    &+6     @  GLVXOILGHZLWKNDSSDOLJKWFKDLQHomo sapiens   >9.$33$ Homo sapiens,*.9    ,*.-   >@    Homo sapiens,*.&   .P$   9     @     314 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121    GLPHU   ELVGLVXOILGHSURGXFHGLQ &KLQHVH+DPVWHU2YDU\ &+2 FHOOOLQHJO\FRIRUP DOIDFRQMXJDWHGRQDQDYHUDJHRIF\VWHLQ\OWR GHUX[WHFDQFRPSULVLQJDOLQNHUDQGDFDPSWRWKHFLQ GHULYDWLYH )RUWKHderuxtecanSDUWSOHDVHUHIHUWRWKHSURS,11/LVW SXEOLVKHGLQthe WHO Drug Information, Vol.30, No.4, 2016. immunomodulator, antineoplastic  SDWULWXPDEGpUX[WHFDQ LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens (5%% UpFHSWHXUW\URVLQHSURWpLQHNLQDVHHUE% +(5 @DQWLFRUSVPRQRFORQDOHomo sapiens, FRQMXJXpDXGpUX[WpFDQFRPSUHQDQWXQOLQNHUHWXQ GpULYpGHODFDPSWRWKpFLQH FKDvQHORXUGHJDPPDHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*   *PQ*P &+5    FKDUQLqUH  &+   &+(  0    &+6    @  GLVXOIXUHDYHFODFKDvQHOpJqUH NDSSDHomo sapiens   >9.$33$ Homo sapiens,*.9   ,*.-    >@   Homo sapiens,*.&   .P $  9     @ GLPqUH   ELVGLVXOIXUHSURGXLWGDQV GHVFHOOXOHVRYDULHQQHVGHKDPVWHUVFKLQRLV &+2  JO\FRIRUPHDOIDFRQMXJXpVXUXQHPR\HQQHGH F\VWpLQ\ODXGpUX[WpFDQFRPSUHQDQWXQOLQNHUHWXQ GpULYpGHODFDPSWRWKpFLQH 3RXUODSDUWLHdéruxtécanYHXLOOH]YRXVUpIpUHUjOD/LVWH GHV'&,SURSSXEOLpHGDQVOHWHO Drug Information, Vol.30, No.4, 2016. immunomodulateur, antinéoplasique  SDWULWXPDEGHUX[WHFiQ LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens (5%% UHFHSWRUWLURVLQDSURWHtQDNLQDVDHUE% +(5 @DQWLFXHUSRPRQRFORQDOHomo sapiens, FRQMXJDGRFRQGHUX[WHFiQTXHFRPSUHQGHXQ FRQHFWRU\XQGHULYDGRGHODFDPSWRWHFLQD FDGHQDSHVDGDJDPPDHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*   *PQ*P &+5    ELVDJUD  &+   &+(  0    &+6    @  GLVXOIXURFRQODFDGHQDOLJHUD NDSSDHomo sapiens   >9.$33$ Homo sapiens,*.9   ,*.-    >@   Homo sapiens,*.&   .P $  9     @ GtPHUR   ELVGLVXOIXURSURGXFLGRHQ ODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2  JOLFRIRUPDDOIDFRQMXJDGRFRQUHVWRVFLVWHLQLOSRU WpUPLQRPHGLRFRQGHUX[WHFiQTXHFRPSUHQGHXQ FRQHFWRU\XQGHULYDGRGHODFDPSRWHFLQD 3DUDODIUDFFLyQderuxtecánVHSXHGHUHIHULUDOD/LVWDGH '&,SURSSXEOLFDGDHQHOWHO Drug Information, Vol.30, No.4, 2016. inmunomodulador, antineoplásico   315 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019      +HDY\ FKDLQ  &KDvQH ORXUGH  &DGHQD SHVDGD QVQLQQWGAG LLKPSETLSL TCAVYGGSFS GYYWSWIRQP PGKGLEWIGE 50 INHSGSTNYN PSLKSRVTIS VETSKNQFSL KLSSVTAADT AVYYCARDKW 100 TWYFDLWGRG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150 PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200 NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250 LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300 RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350 LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400 DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK 447 /LJKW FKDLQ  &KDvQH OpJqUH  &DGHQD OLJHUD DIEMTQSPDS LAVSLGERAT INCRSSQSVL YSSSNRNYLA WYQQNPGQPP 50 KLLIYWASTR ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCQQYYST 100 PRTFGQGTKV EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150 KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200 EVTHQGLSSP VTKSFNRGEC 220 3RVWWUDQVODWLRQDO PRGLILFDWLRQV 'LVXOILGH EULGJHV ORFDWLRQ  3RVLWLRQ GHV SRQWV GLVXOIXUH  3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR ,QWUD+ &&             ,QWUD/ &&         ,QWHU+/ K &/     ,QWHU++ K  K    1RQH RI WKH IRXU LQWHUFKDLQ GLVXOILGH EULGJHV LV SUHVHQW DQ DYHUDJH RI  F\VWHLQ\O EHLQJ FRQMXJDWHG HDFK YLD D WKLRHWKHU ERQG WR D GUXJ OLQNHU $XFXQ GHV TXDWUH SRQWV GLVXOIXUHV LQWHUFKDvQHV HVW SUpVHQW  F\VWpLQ\O HQ PR\HQQH pWDQW FKDFXQ FRQMXJXp YLD XQH OLDLVRQ WKLRpWKHU j XQ OLQNHUSULQFLSH DFWLI 1LQJXQR GH ORV FXDWUR SXHQWHV GLVXOIXUR LQWHUFDWHQDULRV HVWD SUHVHQWH XQD PHGLD GH  FLVWHLQLO HVWi FRQMXJDGD D FRQHFWRUHV GH SULQFLSLR DFWLYR 1JO\FRV\ODWLRQ VLWHV  6LWHV GH 1JO\FRV\ODWLRQ  3RVLFLRQHV GH 1JOLFRVLODFLyQ + &+ 1   )XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV  JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV FRPSOH[HV IXFRV\OpV  JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV &WHUPLQDO O\VLQH FOLSSLQJ + &+6 .   3RWHQWLDO PRGLILHG UHVLGXHV  UpVLGXV PRGLILpV SRWHQWLHOV  UHVWRV PRGLILFDGRV SRWHQFLDOHV 2 2 + *O\ *O\ 3KH *O\ 1 2 2 1+ + 1 2 & 2 2 1 1 &2+ 2+ + +& 6 &+ 2 + 1+ )     SD[DOLVLEXP  SD[DOLVLE >GLPHWK\O PRUSKROLQ\O GLK\GURH >@R[D]LQR>e@SXULQ\O@S\ULPLGLQDPLQH phosphatidylinositol 3-kinase (PI3K) inhibitor, antineoplastic  SD[DOLVLE >GLPpWK\O PRUSKROLQ\O GLK\GURH >@R[D]LQR>e@SXULQ\O@S\ULPLGLQDPLQH inhibiteur de phosphatidylinositol 3-kinase (PI3K), antinéoplasique  SD[DOLVLE >GLPHWLO PRUIROLQLO GLKLGURH >@R[D]LQR>e@SXULQLO@SLULPLGLQDPLQD inhibidor de fosfatidilinositol 3-quinasa (PI3K), antineoplásico   316 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121  &+12        SHWRVHPWDPDEXP  SHWRVHPWDPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens (*)5 HSLGHUPDO JURZWKIDFWRUUHFHSWRUUHFHSWRUW\URVLQHSURWHLQNLQDVHHUE% (5%%+(5+(5(5%% @DQGDQWL>Homo sapiens /*5 OHXFLQHULFKUHSHDWFRQWDLQLQJ*SURWHLQFRXSOHGUHFHSWRU* SURWHLQFRXSOHGUHFHSWRU*35*35 @Homo sapiens PRQRFORQDODQWLERG\ELVSHFLILF JDPPDKHDY\FKDLQHomo sapiens DQWL(*)5  >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*    *PQ*P &+5    KLQJH   &+  &+/!'  (  0  /!(    &+6.!GHO    @   GLVXOILGHZLWKNDSSDOLJKWFKDLQHomo sapiens   >9.$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens,*.&   .P$  9     @ JDPPDKHDY\FKDLQHomo sapiens DQWL/*5  >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*    *PQ*P &+5    KLQJH   &+  &+/!.  (  0  7!.    &+6.!GHO    @   GLVXOILGHZLWKNDSSDOLJKWFKDLQHomo sapiens   >9.$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens,*.&   .P$  9     @ GLPHU   ELVGLVXOILGHSURGXFHGLQ&KLQHVH +DPVWHU2YDU\ &+2 FHOOVJO\FRIRUPDOID immunomodulator, antineoplastic  SpWRVHPWDPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens(*)5 UpFHSWHXU GXIDFWHXUGHFURLVVDQFHpSLGHUPLTXHUpFHSWHXUW\URVLQHSURWpLQH NLQDVHHUE(5%%+(5+(5(5%% @HWDQWL>Homo sapiens /*5 UpFHSWHXUjUpSpWLWLRQVULFKHVHQOHXFLQHFRXSOpj ODSURWpLQH*UpFHSWHXUFRXSOpjODSURWpLQH**35 *35 @DQWLFRUSVPRQRFORQDOHomo sapiens,ELVSpFLILTXH FKDvQHORXUGHJDPPDHomo sapiensDQWL(*)5  >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*    *PQ*P &+5    FKDUQLqUH   &+  &+/!'  (  0   /!(    &+6.!GHO    @   GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSDHomo sapiens   >9 .$33$ Homo sapiens,*.9   ,*.-    >@   Homo sapiens,*.&   .P$   9     @ 317 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019     FKDvQHORXUGHJDPPDHomo sapiensDQWL/*5   >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*   *PQ*P &+5    FKDUQLqUH  &+   &+/!.  (  0  7!.    &+6.!GHO    @   GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSDHomo sapiens   >9.$33$ Homo sapiens,*.9    ,*.-   >@    Homo sapiens,*.&   .P$   9     @ GLPqUH   ELVGLVXOIXUHSURGXLWGDQV GHVFHOOXOHVRYDULHQQHVGHKDPVWHUVFKLQRLV &+2  JO\FRIRUPHDOID immunomodulateur, antinéoplasique  SHWRVHPWDPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens(*)5 UHFHSWRUGHOIDFWRUGHFUHFLPLHQWRHSLGpUPLFR UHFHSWRUWLURVLQDSURWHtQDNLQDVDHUE(5%%+(5 +(5(5%% @\DQWL>Homo sapiens /*5 UHFHSWRU GHDUHSHWLFLRQHVULFDVHQOHXFLQDDFRSODGDDOD SURWHtQD*UHFHSWRUDFRSODGRDODSURWHtQD* *35*35 @DQWLFXHUSRPRQRFORQDOHomo sapiens,ELHVSHFtILFR FDGHQDSHVDGDJDPPDHomo sapiensDQWL/*5   >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*   *PQ*P &+5    ELVDJUD  &+   &+/!.  (  0  7!.    &+6.!GHO    @   GLVXOIXURFRQODFDGHQDOLJHUDNDSSDHomo sapiens   >9.$33$ Homo sapiens,*.9    ,*.-   >@    Homo sapiens,*.&   .P$   9     @ FDGHQDSHVDGDJDPPDHomo sapiensDQWL(*)5   >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*   *PQ*P &+5    ELVDJUD  &+   &+/!'  (  0  /!(    &+6.!GHO    @   GLVXOIXURFRQODFDGHQDOLJHUDNDSSDHomo sapiens   >9.$33$ Homo sapiens,*.9    ,*.-   >@    Homo sapiens,*.&   .P$   9     @ GtPHUR   ELVGLVXOIXURSURGXFLGRHQ ODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2  JOLFRIRUPDDOID inmunomodulador, antineoplásico   318 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121      +HDY\ FKDLQ  &KDvQH ORXUGH  &DGHQD SHVDGD DQWL(*)5 QVQLVQSGSE LKKPGASVKI SCKASGYDFT NYAMNWVRQA PGHGLEWMGW 50 INANTGDPTY AQGFTGRFVF SLDTSVSTAY LQISSLKAED SAVYYCTRER 100 FLEWLHFDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150 DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200 YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250 KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300 STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350 VYTDPPSREE MTKNQVSLTC EVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400 LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG 449 +HDY\ FKDLQ  &KDvQH ORXUGH  &DGHQD SHVDGD DQWL/*5 EVQLVQSGSK LKKPGASVKV SCKASGYTFT SYTMNWVRQA PGQGLEWMGW 50 INTDTGDPTY AQGFTGRFVF SLDTSVSTAF LQINSLKAED TAVYYCARGD 100 CDSTSCYRYS YGYEDYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA 150 ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS 200 SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV 250 FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK 300 PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK 350 GQPREPQVYT KPPSREEMTK NQVSLKCLVK GFYPSDIAVE WESNGQPENN 400 YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS 450 LSLSPG 456 /LJKW FKDLQ  &KDvQH OpJqUH  &DGHQD OLJHUD DIQMTQSPSS LSASVGDRVT ITCRASQSIS SYLNWYQQKP GKAPKLLIYA 50 ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ SYSTPPTFGQ 100 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150 DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200 LSSPVTKSFN RGEC 214 3RVWWUDQVODWLRQDO PRGLILFDWLRQV 'LVXOILGH EULGJHV ORFDWLRQ  3RVLWLRQ GHV SRQWV GLVXOIXUH  3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR ,QWUD+ &&             ,QWUD&'5 &&   ,QWUD/ &&         ,QWHU+/ K &/     ,QWHU++ K  K    1JO\FRV\ODWLRQ VLWHV  6LWHV GH 1JO\FRV\ODWLRQ  3RVLFLRQHV GH 1JOLFRVLODFLyQ + &+ 1   'HIXFRV\ODWHG ! FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV  JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV FRPSOH[HV GpIXFRV\OpV !  JOLFDQRV GH WLSR &+2 ELDQWHQDULRV  FRPSOHMRV GHIXFRVLODGRV !    SLPLWHVSLEXP  SLPLWHVSLE HWK\O^> PHWK\OHS\UD]RO\O HLPLGD]RO \O@ SURSDQ\O HS\UD]ROR>b@S\ULGLQ \O`EHQ]DPLGH antineoplastic  SLPLWHVSLE pWK\O^> PpWK\OHS\UD]RO\O HLPLGD]RO \O@ SURSDQ\O HS\UD]ROR>b@S\ULGLQ \O`EHQ]DPLGH antinéoplasique  SLPLWHVSLE HWLO^> PHWLOHSLUD]ROLO HLPLGD]ROLO@  SURSDQLO HSLUD]ROR>b@SLULGLQLO`EHQ]DPLGD antineoplásico    &+12      319 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019   SUDOX]DWDPDEXP  SUDOX]DWDPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens&' DFWLYDWHGOHXFRF\WHFHOODGKHVLRQPROHFXOH$/&$0 @ KXPDQL]HGPRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQKXPDQL]HG  >9+ Homo sapiens ,*+9    ,*+' ,*+-   >@   Homo sapiens,*+* Y*P!*PQ*P &+ .  KLQJH  &+  &+ (  0    &+6.!GHO     @  GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG   >1WHUPLQDOUHJLRQ   PHUOLQNHU    SURWHDVHFOHDYDEOHUHJLRQ   PHUOLQNHU   9 .$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens,*.&    .P$  9     @GLPHU   ELVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU 2YDU\ &+2 GHULYHGFHOOOLQHJO\FRIRUPDOID immunomodulator, antineoplastic  SUDOX]DWDPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens &' PROpFXOHG DGKpVLRQFHOOXODLUHGHOHXFRF\WHVDFWLYpH $/&$0 @DQWLFRUSVPRQRFORQDOKXPDQLVp FKDvQHORXUGHJDPPDKXPDQLVpH  >9+ Homo sapiens ,*+9    ,*+' ,*+-   >@   Homo sapiens,*+* Y*P!*PQ*P &+.    FKDUQLqUH  &+  &+(  0    &+6.!GHO    @  GLVXOIXUHDYHFODFKDvQHOpJqUH NDSSDKXPDQLVpH   >UpJLRQ1WHUPLQDOH   PHU OLQNHU   UpJLRQFOLYDEOHSDUGHVSURWpDVHV    PHUOLQNHU   9.$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens ,*.&   .P$  9     @ GLPqUH  ELVGLVXOIXUHSURGXLWHGDQVXQH OLJQpHFHOOXODLUHGpULYpHGHVFHOOXOHVRYDULHQQHVGHKDPVWHUV FKLQRLV &+2 JO\FRIRUPHDOID immunomodulateur, antinéoplasique  SUDOX]DWDPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens &' PROpFXODGHDGKHVLyQFHOXODUGHOHXFRFLWRVDFWLYDGRV $/&$0 @DQWLFXHUSRPRQRFORQDOKXPDQL]DGR FDGHQDSHVDGDJDPPDKXPDQL]DGD  >9+ Homo sapiens,*+9    ,*+' ,*+-    >@  Homo sapiens,*+* Y*P!*P Q*P &+.    ELVDJUD   &+  &+(  0    &+6 .!GHO    @  GLVXOIXURFRQODFDGHQD OLJHUDNDSSDKXPDQL]DGD   >UHJLyQ1WHUPLQDO    FRQHFWRUPHU   UHJLyQHVFLQGLEOHSRUODVSURWHDVDV   FRQHFWRUPHU   9.$33$ Homo sapiens ,*.9   ,*.-   >@    Homo sapiens,*.&   .P$  9     @GtPHUR  ELVGLVXOIXUR SURGXFLGRHQXQDOtQHDFHOXODUGHULYDGDGHODVFpOXODVRYiULFDV GHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID inmunomodulador, antineoplásico   320 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121         SUDOX]DWDPDEXPUDYWDQVLQXP  SUDOX]DWDPDEUDYWDQVLQH LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens&' DFWLYDWHGOHXFRF\WHFHOODGKHVLRQPROHFXOH$/&$0 @ KXPDQL]HGPRQRFORQDODQWLERG\FRQMXJDWHGWR PD\WDQVLQRLG'0 JDPPDKHDY\FKDLQKXPDQL]HG  >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+* Y *P!*PQ*P &+.     KLQJH  &+  &+(   0    &+6.!GHO    @  GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG   >1WHUPLQDOUHJLRQ   PHUOLQNHU    SURWHDVHFOHDYDEOHUHJLRQ   PHUOLQNHU   9.$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens,*.&   .P$  9     @GLPHU   ELVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 GHULYHGFHOOOLQHJO\FRIRUPDOIDFRQMXJDWHGRQ DQDYHUDJHRIWRO\V\OWRPD\WDQVLQRLG'0>N  GHDFHW\ON  PHUFDSWRPHWK\OR[RSHQW\O  PD\WDQVLQH@YLDWKHUHGXFLEOH63'%OLQNHU>N VXFFLQLPLG\O S\ULG\OGLWKLR EXWDQRDWH@ )RUWKHravtansine SDUWSOHDVHUHIHUWRWKHGRFXPHQW"INN for pharmaceutical substances: Names for radicals, groups and others"* immunomodulator, antineoplastic  SUDOX]DWDPDEUDYWDQVLQH LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens &' PROpFXOHG DGKpVLRQFHOOXODLUHGHOHXFRF\WHV DFWLYpH$/&$0 @DQWLFRUSVPRQRFORQDOKXPDQLVp FRQMXJXpDXPD\WDQVLQRwGH'0   321 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019     FKDvQHORXUGHJDPPDKXPDQLVpH  >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+* Y *P!*PQ*P &+.     FKDUQLqUH  &+  &+(  0    &+6.!GHO     @  GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD KXPDQLVpH   >UpJLRQ1WHUPLQDOH    PHUOLQNHU   UpJLRQFOLYDEOHSDUGHVSURWpDVHV   PHUOLQNHU   9.$33$ Homo sapiens,*.9   ,*.-    >@   Homo sapiens,*.&    .P$  9     @GLPqUH  ELVGLVXOIXUHSURGXLWHGDQVXQH OLJQpHFHOOXODLUHGpULYpHGHVFHOOXOHVRYDULHQQHVGH KDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOIDFRQMXJXp VXURXO\V\OHQPR\HQQHDXPD\WDQVLQRwGH'0 >N GpDFpW\ON  PHUFDSWRPpWK\OR[RSHQW\O  PD\WDQVLQH@YLDOHOLQNHU63'%UpGXFWLEOH>  S\ULG\OGLWKLR EXWDQRDWHGHNVXFFLQLPLG\OH@ 3RXUODSDUWLHravtansineYHXLOOH]YRXVUpIpUHUDXGRFXPHQW "INN for pharmaceutical substances: Names for radicals, groups and others"*. immunomodulateur, antinéoplasique   SUDOX]DWDPDEUDYWDQVLQD LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens &' PROpFXODGHDGKHVLyQFHOXODUGHOHXFRFLWRV DFWLYDGRV$/&$0 @DQWLFXHUSRPRQRFORQDO KXPDQL]DGRFRQMXJDGRFRQPDLWDQVLQRLGH'0 FDGHQDSHVDGDJDPPDKXPDQL]DGD  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+* Y*P!*PQ*P &+.    ELVDJUD  &+   &+(  0    &+6.!GHO    @  GLVXOIXURFRQODFDGHQD OLJHUDNDSSDKXPDQL]DGD   >UHJLyQ1WHUPLQDO   FRQHFWRUPHU   UHJLyQHVFLQGLEOHSRU ODVSURWHDVDV   FRQHFWRPHU   9 .$33$ Homo sapiens,*.9    ,*.-   >@   Homo sapiens ,*.&   .P$  9      @GtPHUR  ELVGLVXOIXUR SURGXFLGRHQXQDOtQHDFHOXODUGHULYDGDGHODVFpOXODV RYiULFDVGHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID FRQMXJDGRHQRUHVLGXRVOLVLOSRUWpUPLQRPHGLR FRQHOPDLWDQVLQRLGH'0>N GHDFHWLON   PHUFDSWRPHWLOR[RSHQWLO PDLWDQVLQD@PHGLDQWHHO HVSDFLDGRU63'%UHGXFLEOH> SLULGLOGLWLR EXWDQRDWR GHNVXFFLQLPLGLOR@ 3DUDODIUDFFLyQravtansineVHSXHGHUHIHULUVHDOGRFXPHQWR "INN for pharmaceutical substances: Names for radicals, groups and others"*. inmunomodulador, antineoplásico   322 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121     +HDY\ FKDLQ  &KDvQH ORXUGH  &DGHQD SHVDGD QITLKESGPT LVKPTQTLTL TCTFSGFSLS TYGMGVGWIR QPPGKALEWL 50 ANIWWSEDKH YSPSLKSRLT ITKDTSKNQV VLTITNVDPV DTATYYCVQI 100 DYGNDYAFTY WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150 KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200 TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250 PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300 NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350 QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400 VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450 /LJKW FKDLQ  &KDvQH OpJqUH  &DGHQD OLJHUD QGQSGQGLCH PAVLSAWESC SSGGGSSGGS AVGLLAPPGG LSGRSDNHGG 50 SDIVMTQSPL SLPVTPGEPA SISCRSSKSL LHSNGITYLY WYLQKPGQSP 100 QLLIYQMSNL ASGVPDRFSG SGSGTDFTLK ISRVEAEDVG VYYCAQNLEL 150 PYTFGQGTKL EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 200 KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 250 EVTHQGLSSP VTKSFNRGEC 270 3RVWWUDQVODWLRQDO PRGLILFDWLRQV 'LVXOILGH EULGJHV ORFDWLRQ  3RVLWLRQ GHV SRQWV GLVXOIXUH  3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR ,QWUD+ &&             ,QWUD/ &&         ,QWUD/ 1WHUPLQDO UHJLRQ     ,QWHU+/ K &/     ,QWHU++ K  K    1JO\FRV\ODWLRQ VLWHV  6LWHV GH 1JO\FRV\ODWLRQ  3RVLFLRQHV GH 1JOLFRVLODFLyQ + &+ 1   )XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV  JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV FRPSOH[HV IXFRV\OpV  JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV )RU WKH ravtansine SDUW SOHDVH UHIHU WR WKH GRFXPHQW INN for pharmaceutical substances: Names for radicals, groups and others" 3RXU OD SDUWLH ravtansine, YHXLOOH] YRXV UpIpUHU DX GRFXPHQW INN for pharmaceutical substances: Names for radicals, groups and others  3DUD OD IUDFFLyQ ravtansina, VH SXHGHQ GLULJLU DO GRFXPHQWR INN for pharmaceutical substances: Names for radicals, groups and others     SUHJDEDOLQXPDUHQDFDUELOXP  SUHJDEDOLQDUHQDFDUELO S PHWK\O^> ^ R >  PHWK\OSURSDQR\O R[\@HWKR[\`FDUERQ\O DPLQR@PHWK\O` KH[DQRLFDFLG gabamimetic  SUpJDEDOLQHDUpQDFDUELO DFLGH S PpWK\O^> ^ R >  PpWK\OSURSDQR\O R[\@pWKR[\`FDUERQ\O DPLQR@PpWK\O` KH[DQRwTXH gabamimétique  SUHJDEDOLQDDUHQDFDUELOR iFLGR S PHWLO^> ^ R >  PHWLOSURSDQRLO R[L@HWR[L`FDUERQLO DPLQR@PHWLO` KH[DQRLFR gabamimético    &+12        UDOPLWDURQWXP  UDOPLWDURQW HWK\OPHWK\ON^> S PRUSKROLQ\O@SKHQ\O`H S\UD]ROHFDUER[DPLGH  neuroleptic  323 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019  UDOPLWDURQW pWK\OPpWK\ON^> S PRUSKROLQ\O@SKpQ\O`H S\UD]ROHFDUER[DPLGH neuroleptique  UDOPLWDURQW HWLOPHWLON^> S PRUIROLQLO@IHQLO`HSLUD]RO FDUER[DPLGD neuroléptico    &+12        UHEDPLSLGXPPRIHWLOXP  UHEDPLSLGHPRIHWLO rac PRUSKROLQ\O HWK\O R   FKORUREHQ]DPLGR  R[RGLK\GURTXLQROLQ \O SURSDQRDWH antiulcer  UpEDPLSLGHPRIpWLO rac R  FKORUREHQ]DPLGR  R[R GLK\GURTXLQROpLQ\O SURSDQRDWHGH PRUSKROLQ \O pWK\OH antiulcéreux  UHEDPLSLGDGHPRIHWLOR rac R  FORUREHQ]DPLGR  R[R GLKLGURTXLQROHLQLO SURSDQRDWRGH PRUIROLQLO HWLOR antiulceroso    &+&O12        UHPHVWHPFHOXP  UHPHVWHPFHO KXPDQFXOWXUHH[SDQGHGDOORJHQHLFDGKHUHQW PHVHQFK\PDOOLNHVWURPDOFHOOVGHULYHGIURPERQH PDUURZRIKXPDQOHXNRF\WHDQWLJHQ +/$ ±XQPDWFKHG KHDOWK\DGXOWGRQRUV&HOOVH[SUHVVFHOOVXUIDFH PDUNHUV&'&'&'&'&'&' &'&'D&'DQG&'DQGVHFUHWH LQWHUOHXNLQ ,/ LQWHUOHXNLQ ,/ YDVFXODU HQGRWKHOLDOJURZWKIDFWRU 9(*) SURVWDJODQGLQ( 3*( VWURPDOGHULYHGIDFWRU 6') LQGROHDPLQH GLR[\JHQDVH ,'2 DQGNHUDWLQRF\WHJURZWKIDFWRU .*) 7KHFHOOVDUHQHJDWLYHIRU&'&'&' &'&'DQG+/$FODVV,,KLVWRFRPSDWLELOLW\ DQWLJHQJDPPDFKDLQ +/$'5 PDUNHUV  cell therapy (acute graft versus host disease)  324 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121   UpPHVWHPFHO FHOOXOHVVWURPDOHVVHPEODEOHVDXPpVHQFK\PH KXPDLQHVDOORJpQLTXHVGpULYpHVGHODPRHOOH RVVHXVHG¶XQGRQQHXUDGXOWHVDLQLQFRPSDWLEOHSRXU O¶DQWLJqQHOHXFRF\WDLUHKXPDLQ +/$ HQFXOWXUH G¶H[SDQVLRQSRXUWKpUDSLHFHOOXODLUH/HVFHOOXOHV H[SULPHQWjOHXUVXUIDFHOHVPDUTXHXUV&'&' &'&'&'&'&'&'D&' DQG&'HWVHFUqWHQWO¶LQWHUOHXNLQH ,/  O¶LQWHUOHXNLQH ,/ IDFWHXUGHFURLVVDQFHGH O¶HQGRWKpOLXPYDVFXODLUH 9(*) SURVWDJODQGLQH( 3*( IDFWHXUGpULYpGXSDUHQFK\PH 6')  LQGROHDPLQHGLR[\JHQDVH ,'2 HWOHIDFWHXUGH FURLVVDQFHGHVNpUDWLQRF\WHV/HVFHOOXOHVVRQW QpJDWLYHVSRXU&'&'&'&'&'HWOD FKDvQHJDPPDGHO¶DQWLJqQHPDMHXU G¶KLVWRFRPSDWLELOLWp &0+ GHFODVVH,, +/$'5  thérapie cellulaire (maladie aiguë du greffon contre l'hôte)  UHPHVWHPFHO FpOXODVHVWURPDOHVSDUHFLGDVDPHVHQTXLPDOHV DORJpQLFDVKXPDQDVDGKHUHQWHV\H[SDQGLGDVHQ FXOWLYRGHULYDGDVGHODPpGXODyVHDGHGRQDQWHV DGXOWRVVDQRVQRFRPSDWLEOHVSDUDHODQWtJHQR OHXFRFLWDULRKXPDQR +/$ /DVFpOXODVH[SUHVDQORV PDUFDGRUHVGHVXSHUILFLH&'&'&'&' &'&'&'D&'\&'\VHFUHWDQ LQWHUOHXNLQD ,/ LQWHUOHXNLQD ,/ IDFWRUGH FUHFLPLHQWRGHOHQGRWHOLRYDVFXODU 9(*)  SURVWDJODQGLQD( 3*( IDFWRUGHULYDGRGHOHVWURPD  6') LQGROHDPLQDGLR[LJHQDVD ,'2 \IDFWRU GHFUHFLPLHQWRGHTXHUDWLQRFLWRV .*) /DVFpOXODV VRQQHJDWLYDVSDUDORVPDUFDGRUHV&'&' &'&'&'\ODFDGHQDJDPPDGHODQWtJHQR GHKLVWRFRPSDWLELOLGDGGH+/$FODVH,, +/$'5  terapia celular (enfermedad aguda de injerto contra  huésped)    UHPLEUXWLQLEXP  UHPLEUXWLQLE N ^DPLQR> NPHWK\OSURS HQDPLGR HWKR[\@S\ULPLGLQ\O`IOXRUR PHWK\OSKHQ\O F\FORSURS\OIOXRUREHQ]DPLGH Bruton's tyrosine kinase inhibitor  UpPLEUXWLQLE N ^DPLQR> NPpWK\OSURS pQDPLGR pWKR[\@S\ULPLGLQ\O`IOXRUR PpWK\OSKpQ\O F\FORSURS\OIOXRUREHQ]DPLGH inhibiteur de la tyrosine kinase de Bruton  UHPLEUXWLQLE N ^DPLQR> NPHWLOSURS HQDPLGR HWR[L@SLULPLGLQLO`IOXRURPHWLOIHQLO  FLFORSURSLOIOXRUREHQ]DPLGD inhibidor de la tirosina quinasa de Bruton   325 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019  &+)12        UHWLIDQOLPDEXP  UHWLIDQOLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens 3'&' SURJUDPPHGFHOOGHDWK3'3' &' @ PRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQKXPDQL]HG  >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*  &+  KLQJH6!3     &+  &+  &+6.!GHO    @  GLVXOILGHZLWKNDSSDOLJKWFKDLQ FKLPHULF ¶¶ >9.$33$ Mus musculus,*.9    ,*.-  Homo sapiens,*.9'    ,*.-   >@    Homo sapiens,*.&   .P$   9     @GLPHU   ELVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 FHOOOLQHJO\FRIRUPDOID immunomodulator, antineoplastic  UpWLIDQOLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens 3'&' SURWpLQHGHPRUWFHOOXODLUHSURJUDPPpH 3'3'&' @DQWLFRUSVPRQRFORQDO FKDvQHORXUGHJDPPDKXPDQLVpH  >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*  &+  FKDUQLqUH6!3     &+  &+  &+6.!GHO    @  GLVXOIXUHDYHFODFKDvQH OpJqUHNDSSDFKLPpULTXH ¶¶ >9.$33$ Mus musculus,*.9   ,*.-  Homo sapiens,*.9'   ,*.-    >@   Homo sapiens,*.&    .P$  9     @GLPqUH  ELVGLVXOIXUHSURGXLWGDQVGHV FHOOXOHVRYDULHQQHVGHKDPVWHUVFKLQRLV &+2  JO\FRIRUPHDOID immunomodulateur, antinéoplasique  UHWLIDQOLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens 3'&' SURWHtQDGHPXHUWHFHOXODUSURJUDPDGD 3'3'&' @ DQWLFXHUSRPRQRFORQDO     326 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121  FDGHQDSHVDGDJDPPDKXPDQL]DGD  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*  &+  ELVDJUD6!3    &+  &+  &+6 .!GHO    @  GLVXOIXURFRQOD FDGHQDOLJHUDNDSSDTXLPpULFD ¶¶ >9.$33$ Mus musculus,*.9   ,*.-  Homo sapiens,*.9'    ,*.-   >@   Homo sapiens ,*.&   .P$  9      @GtPHUR  ELVGLVXOIXUR SURGXFLGRHQODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID inmunomodulador, antineoplásico            ULO]DEUXWLQLEXP  ULO]DEUXWLQLE ȄR DPLQRIOXRURGLPHWK\OR[R R[D  S\UD]ROR>d@S\ULPLGLQD  SLSHUD]LQD   SLSHULGLQD  R[HWDQD     GLEHQ]HQDXQGHFDSKDQHQHFDUERQLWULOH Bruton's tyrosine kinase inhibitor  ULO]DEUXWLQLE ȄR DPLQRIOXRURGLPpWK\OR[R R[D  S\UD]ROR>d@S\ULPLGLQD  SLSpUD]LQD   SLSpULGLQD  R[pWDQD     GLEHQ]pQDXQGpFDSKDQqQHFDUERQLWULOH  inhibiteur de la tyrosine kinase de Bruton   327 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019 ULO]DEUXWLQLE ȄR DPLQRIOXRURGLPHWLOR[RR[D   SLUD]ROR>d@SLULPLGLQD  SLSHUD]LQD   SLSHULGLQD  R[HWDQD     GLEHQFHQDXQGHFDIDQHQRFDUERQLWULOR inhibidor de la tirosina quinasa de Bruton    &+)12        ULPWX]DOFDSXP  ULPWX]DOFDS N GLIOXRURF\FORKH[\O  PHWK\OHS\UD]RO \O  PRUSKROLQ\O S\ULPLGLQDPLQH modulator of small-conductance calcium-activated potassium channels  ULPWX]DOFDS N GLIOXRURF\FORKH[\O  PpWK\OHS\UD]RO \O  PRUSKROLQ\O S\ULPLGLQDPLQH modulateur des canaux potassiques actives par le calcium de petite conductance  ULPWX]DOFDS N GLIOXRURFLFORKH[LO  PHWLOHSLUD]ROLO  PRUIROLQLO SLULPLGLQDPLQD modulador de los canales de potasio activados por calcio de pequeña conductancia    &+)12        ULWOHFLWLQLEXP  ULWOHFLWLQLE ^ SR PHWK\O> HS\UUROR>d@S\ULPLGLQ \O DPLQR@SLSHULGLQ\O`SURSHQRQH Janus kinase inhibitor  ULWOpFLWLQLE ^ SR PpWK\O> HS\UUROR>d@S\ULPLGLQ \O DPLQR@SLSpULGLQ\O`SURSpQRQH  inhibiteur de la kinase de Janus   328 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121 ULWOHFLWLQLE ^ SR PHWLO> HSLUUROR>d@SLULPLGLQ LO DPLQR@SLSHULGLQLO`SURSHQRQD inhibidor de la quinasa de Janus    &+12        URSRFDPSWLGXP  URSRFDPSWLGH DQWLEDFWHULDOSHSWLGH// KXPDQ  /OHXF\O/OHXF\OJO\F\O/ĮDVSDUW\O/SKHQ\ODODQ\O/ SKHQ\ODODQ\O/DUJLQ\O/O\V\O/VHU\O/O\V\O/Į JOXWDP\O/O\V\O/LVROHXF\OJO\F\O/O\V\O/ĮJOXWDP\O/ SKHQ\ODODQ\O/O\V\O/DUJLQ\O/LVROHXF\O/YDO\O/ JOXWDPLQ\O/DUJLQ\O/LVROHXF\O/O\V\O/ĮDVSDUW\O/ SKHQ\ODODQ\O/OHXF\O/DUJLQ\O/DVSDUDJLQ\O/OHXF\O/ YDO\O/SURO\O/DUJLQ\O/WKUHRQ\O/ĮJOXWDP\O/VHULQH antimicrobial, immunomodulator  URSRFDPSWLGH SHSWLGHDQWLEDFWpULHQ// KXPDLQ  /OHXF\O/OHXF\OJO\F\O/ĮDVSDUW\O/SKpQ\ODODQ\O/ SKpQ\ODODQ\O/DUJLQ\O/O\V\O/VpU\O/O\V\O/Į JOXWDP\O/O\V\O/LVROHXF\OJO\F\O/O\V\O/ĮJOXWDP\O/ SKpQ\ODODQ\O/O\V\O/DUJLQ\O/LVROHXF\O/YDO\O/ JOXWDPLQ\O/DUJLQ\O/LVROHXF\O/O\V\O/ĮDVSDUW\O/ SKpQ\ODODQ\O/OHXF\O/DUJLQ\O/DVSDUDJLQ\O/OHXF\O/ YDO\O/SURO\O/DUJLQ\O/WKUpRQ\O/ĮJOXWDP\O/VpULQH antimicrobien, immunomodulateur  URSRFDPSWLGD SpSWLGRDQWLEDFWHULDO// KXPDQR  /OHXF\O/OHXF\OJO\F\O/ĮDVSDUW\O/SKHQ\ODODQ\O/ SKHQ\ODODQ\O/DUJLQ\O/O\V\O/VHU\O/O\V\O/Į JOXWDP\O/O\V\O/LVROHXF\OJO\F\O/O\V\O/ĮJOXWDP\O/ SKHQ\ODODQ\O/O\V\O/DUJLQ\O/LVROHXF\O/YDO\O/ JOXWDPLQ\O/DUJLQ\O/LVROHXF\O/O\V\O/ĮDVSDUW\O/ SKHQ\ODODQ\O/OHXF\O/DUJLQ\O/DVSDUDJLQ\O/OHXF\O/ YDO\O/SURO\O/DUJLQ\O/WKUHRQ\O/ĮJOXWDP\O/VHULQD antimicrobiano, inmunomodulador    &+12        URYDOHXFHOXP  URYDOHXFHO KXPDQFXOWXUHHQULFKHGH[SDQGHGDXWRORJRXV(SVWHLQ %DUUYLUXVVSHFLILFF\WRWR[LF7FHOOV (%9&7/ GHULYHG IURPSHULSKHUDOEORRGPRQRQXFOHDUFHOOV 3%0&V IRU FHOOEDVHGWKHUDS\&HOOVDUHJHQHUDWHGE\FRFXOWXUH ZLWKJDPPDLUUDGLDWHGDXWRORJRXVO\PSKREODVWRLGFHOO OLQHV /&/ DQGLQWHUOHXNLQ ,/ VWLPXODWLRQ  cell therapy (antineoplastic)  329 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019  URYDOHXFHO O\PSKRF\WHV7F\WRWR[LTXHVVSpFLILTXHVGXYLUXVG¶(SVWHLQ%DUU (%9&7/ KXPDLQVDXWRORJXHVHQFXOWXUHG¶H[SDQVLRQHQULFKLH GpULYpVGHVFHOOXOHVPRQRQXFOpHVGXVDQJSpULSKpULTXH 3%0&V  SRXUWKpUDSLHFHOOXODLUH/HVFHOOXOHVVRQWJpQpUpHVSDUFRFXOWXUH DYHFGHVOLJQpHVFHOOXODLUHVO\PSKREODVWRwGHV /&/ DXWRORJXHV LUUDGLpHVSDUGHVUD\RQVJDPPDHWXQHVWLPXODWLRQSDULQWHUOHXNLQH ,/  thérapie cellulaire (antinéoplasique)  URYDOHXFHO OLQIRFLWRV7FLWRWy[LFRVHVSHFtILFRVGHOYLUXVGH(SVWHLQ%DUU (%9 &7/ DXWyORJRVKXPDQRVH[SDQGLGRVHQULTXHFLGRVHQFXOWLYR GHULYDGRVGHFpOXODVPRQRQXFOHDUHVGHVDQJUHSHULIpULFD 3%0&V  SDUDWHUDSLDFHOXODU/DVFpOXODVVHJHQHUDQPHGLDQWHFRFXOWLYRFRQ OtQHDVFHOXODUHVOLQIREODVWRLGHVDXWyORJDVLUUDGLDGDVFRQUDGLDFLyQ JDPPD\HVWLPXODFLyQFRQLQWHUOHXNLQD ,/   terapia celular (antineoplásico) VDPRWROLVLEXP  VDPRWROLVLE > K\GUR[\SURSDQ\O S\ULGLQ\O@> S PHWKR[\SURS\O@ PHWK\OGLK\GURHLPLGD]R>c@TXLQROLQRQH phosphatidylinositol 3-kinase (PI3K) inhibitor, antineoplastic  VDPRWROLVLE > K\GUR[\SURSDQ\O S\ULGLQ\O@> S PpWKR[\SURS\O@ PpWK\OGLK\GURHLPLGD]R>c@TXLQROpLQRQH inhibiteur de phosphatidylinositol 3-kinase (PI3K), antinéoplasique  VDPRWROLVLE > KLGUR[LSURSDQLO SLULGLQLO@> S PHWR[LSURSLO@PHWLO GLKLGURHLPLGD]R>c@TXLQROHLQRQD inhibidor de fosfatidilinositol 3-quinasa (PI3K), antineoplásico    &+12        VDVDQOLPDEXP  VDVDQOLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens3'&' SURJUDPPHGFHOOGHDWK3'3'&' @KXPDQL]HG PRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQKXPDQL]HG  >9+ Homo sapiens ,*+9    ,*+' ,*+-   >@   Homo sapiens,*+*  &+  KLQJH6!3     &+  &+  &+6    @  GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG   >9 .$33$ Homo sapiens,*.9   ,*.-    >@   Homo sapiens,*.&   .P$   9     @ GLPHU  ELVGLVXOILGHSURGXFHGLQDJOXWDPLQH V\QWKHWDVHNQRFNRXW&KLQHVH+DPVWHU2YDU\ &+2 EDVHG H[SUHVVLRQV\VWHP &+2.69*6.2 JO\FRIRUPDOID immunomodulator, antineoplastic     330 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121 VDVDQOLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens3'&' SURWpLQHGHPRUWFHOOXODLUHSURJUDPPpH3'3' &' @DQWLFRUSVPRQRFORQDOKXPDQLVp FKDvQHORXUGHJDPPDKXPDQLVpH  >9+ Homo sapiens ,*+9    ,*+' ,*+-   >@   Homo sapiens,*+*  &+  FKDUQLqUH 6!3    &+  &+  &+6    @  GLVXOIXUHDYHFODFKDvQH OpJqUHNDSSDKXPDQLVpH   >9.$33$ Homo sapiens ,*.9   ,*.-   >@    Homo sapiens,*.&   .P$  9     @GLPqUH  ELVGLVXOIXUHSURGXLW GDQVXQV\VWqPHG H[SUHVVLRQEDVpVXUGHVFHOOXOHV RYDULHQQHVGHKDPVWHUVFKLQRLV &+2 JOXWDPLQHV\QWKpWDVH NQRFNRXW &+2.69*6.2 JO\FRIRUPHDOID immunomodulateur, antinéoplasique  VDVDQOLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens3'&' SURWHtQDGHPXHUWHFHOXODUSURJUDPDGD3'3' &' @DQWLFXHUSRPRQRFORQDOKXPDQL]DGR FDGHQDSHVDGDJDPPDKXPDQL]DGD  >9+ Homo sapiens,*+9    ,*+' ,*+-    >@  Homo sapiens,*+*  &+   ELVDJUD6!3    &+  &+   &+6    @  GLVXOIXURFRQOD FDGHQDOLJHUDNDSSDKXPDQL]DGD   >9.$33$ Homo sapiens,*.9   ,*.-   >@    Homo sapiens,*.&   .P$   9     @GtPHUR   ELVGLVXOIXURSURGXFLGRHQXQVLVWHPDGHH[SUHVLyQEDVDGRHQ FpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2 JOXWDPLQD VLQWHWDVDNQRFNRXW &+2.69*6.2 JOLFRIRUPDDOID inmunomodulador, antineoplásico        +HDY\ FKDLQ  &KDvQH ORXUGH  &DGHQD SHVDGD QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYWINWVRQA PGQGLEWMGN 50 IYPGSSLTNY NEKFKNRVTM TRDTSTSTVY MELSSLRSED TAVYYCARLS 100 TGTFAYWGQG TLVTVSSAST KGPSVFPLAP CSRSTSESTA ALGCLVKDYF 150 PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTKTYTC 200 NVDHKPSNTK VDKRVESKYG PPCPPCPAPE FLGGPSVFLF PPKPKDTLMI 250 SRTPEVTCVV VDVSQEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTYRVV 300 SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE KTISKAKGQP REPQVYTLPP 350 SQEEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS 400 FFLYSRLTVD KSRWQEGNVF SCSVMHEALH NHYTQKSLSL SLGK 444 /LJKW FKDLQ  &KDvQH OpJqUH  &DGHQD OLJHUD DIVMTQSPDS LAVSLGERAT INCKSSQSLW DSGNQKNFLT WYQQKPGQPP 50 KLLIYWTSYR ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCQNDYFY 100 PHTFGGGTKV EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150 KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200 EVTHQGLSSP VTKSFNRGEC 220 3RVWWUDQVODWLRQDO PRGLILFDWLRQV 'LVXOILGH EULGJHV ORFDWLRQ  3RVLWLRQ GHV SRQWV GLVXOIXUH  3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR ,QWUD+ &&             ,QWUD/ &&         ,QWHU+/ &+ &/     ,QWHU++ K  K    1JO\FRV\ODWLRQ VLWHV  6LWHV GH 1JO\FRV\ODWLRQ  3RVLFLRQHV GH 1JOLFRVLODFLyQ + &+ 1   )XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV  JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV FRPSOH[HV IXFRV\OpV  JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV &WHUPLQDO O\VLQH FOLSSLQJ + &+6 .     331 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019  VHSRIDUVHQXP  VHSRIDUVHQ allPambo OPHWK\OPWKLRJXDQ\O\O  ĺ  OPHWK\OP WKLRJXDQ\O\O  ĺ  OPHWK\OPWKLRXULG\O\O  ĺ  O PHWK\OPWKLRJXDQ\O\O  ĺ  OPHWK\OPWKLRJXDQ\O\O  ĺ  OPHWK\OPWKLRDGHQ\O\O  ĺ  OPHWK\OP WKLRXULG\O\O  ĺ  OPHWK\OPWKLRF\WLG\O\O  ĺ  O PHWK\OPWKLRDGHQ\O\O  ĺ  OPHWK\OPWKLRF\WLG\O\O  ĺ  OPHWK\OPWKLRJXDQ\O\O  ĺ  OPHWK\OP WKLRDGHQ\O\O  ĺ  OPHWK\OPWKLRJXDQ\O\O  ĺ  O PHWK\OPWKLRXULG\O\O  ĺ  OPHWK\OPWKLRXULG\O\O  ĺ   OPHWK\OPWKLRF\WLG\O\O  ĺ  OPHWK\ODGHQRVLQH promotion of functional centrosomal protein (Cep290) synthesis  VpSRIDUVHQ toutPambo OPpWK\OPWKLRJXDQ\O\O  ĺ  OPpWK\OP WKLRJXDQ\O\O  ĺ  OPpWK\OPWKLRXULG\O\O  ĺ  O PpWK\OPWKLRJXDQ\O\O  ĺ  OPpWK\OPWKLRJXDQ\O\O  ĺ  OPpWK\OPWKLRDGpQ\O\O  ĺ  OPpWK\OP WKLRXULG\O\O  ĺ  OPpWK\OPWKLRF\WLG\O\O  ĺ  O PpWK\OPWKLRDGpQ\O\O  ĺ  OPpWK\OPWKLRF\WLG\O\O  ĺ  OPpWK\OPWKLRJXDQ\O\O  ĺ  OPpWK\OP WKLRDGpQ\O\O  ĺ  OPpWK\OPWKLRJXDQ\O\O  ĺ  O PpWK\OPWKLRXULG\O\O  ĺ  OPpWK\OPWKLRXULG\O\O  ĺ   OPpWK\OPWKLRF\WLG\O\O  ĺ  OPpWK\ODGpQRVLQH stimulation de la synthèse de la protéine centrosomale (Cep290) fonctionnelle  VHSRIDUVpQ todoPambo OPHWLOPWLRJXDQLOLO  ĺ  OPHWLOP WLRJXDQLOLO  ĺ  OPHWLOPWLRXULGLOLO  ĺ  OPHWLOP WLRJXDQLOLO  ĺ  OPHWLOPWLRJXDQLOLO  ĺ  OPHWLOP WLRDGHQLOLO  ĺ  OPHWLOPWLRXULGLOLO  ĺ  OPHWLOP WLRFLWLGLOLO  ĺ  OPHWLOPWLRDGHQLOLO  ĺ  OPHWLOP WLRFLWLGLOLO  ĺ  OPHWLOPWLRJXDQLOLO  ĺ  OPHWLOP WLRDGHQLOLO  ĺ  OPHWLOPWLRJXDQLOLO  ĺ  OPHWLOP WLRXULGLOLO  ĺ  OPHWLOPWLRXULGLOLO  ĺ  OPHWLOP WLRFLWLGLOLO  ĺ  OPHWLODGHQRVLQD estimulación de la síntesis de proteína centrosomal (Cep290) funcional    &+1236        VHUSOXOLPDEXP  VHUSOXOLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens3'&' SURJUDPPHGFHOOGHDWK3'3'&' @KXPDQL]HG PRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQHomo sapiens  >9+ Homo sapiens,*+9    ,*+' ,*+-    >@  Homo sapiens,*+*  &+   KLQJH6!3    &+  &+   &+6    @  GLVXOILGHZLWK NDSSDOLJKWFKDLQKXPDQL]HG   >9.$33$ Homo sapiens,*.9   ,*.-   >@    Homo sapiens,*.&   .P$  9     @ GLPHU   ELVGLVXOILGHSURGXFHGLQ&KLQHVH +DPVWHU2YDU\ &+2 FHOOVJO\FRIRUPDOID  immunomodulator, antineoplastic 332 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121  VHUSOXOLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens3'&' SURWpLQH GHPRUWFHOOXODLUHSURJUDPPpH3'3'&' @DQWLFRUSV PRQRFORQDOKXPDQLVp FKDvQHORXUGHJDPPDHomo sapiens  >9+ Homo sapiens ,*+9    ,*+' ,*+-   >@   Homo sapiens,*+*  &+  FKDUQLqUH6!3    &+  &+  &+6    @  GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD KXPDQLVpH   >9.$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens ,*.&   .P$  9     @ GLPqUH   ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHV RYDULHQQHVGHKDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID immunomodulateur, antinéoplasique  VHUSOXOLPDE PXQRJOREXOLQD*NDSSDDQWL>Homo sapiens3'&' SURWHtQD GHPXHUWHFHOXODUSURJUDPDGD3'3'&' @DQWLFXHUSR PRQRFORQDOKXPDQL]DGR FDGHQDSHVDGDJDPPDHomo sapiens  >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*  &+  ELVDJUD 6!3    &+  &+  &+6    @  GLVXOIXURFRQODFDGHQDOLJHUD NDSSDKXPDQL]DGD   >9.$33$ Homo sapiens,*.9    ,*.-   >@   Homo sapiens ,*.&   .P$  9     @ GtPHUR   ELVGLVXOIXURSURGXFLGRHQODVFpOXODV RYiULFDVGHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID inmunomodulador, antineoplásico        +HDY\ FKDLQ  &KDvQH ORXUGH  &DGHQD SHVDGD QVQLVESGGG LVKPGGSLRL SCAASGFTFS NYGMSWIRQA PGKGLEWVST 50 ISGGGSNIYY ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCVSYY 100 YGIDFWGQGT SVTVSSASTK GPSVFPLAPC SRSTSESTAA LGCLVKDYFP 150 EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTKTYTCN 200 VDHKPSNTKV DKRVESKYGP PCPPCPAPEF LGGPSVFLFP PKPKDTLMIS 250 RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEV HNAKTKPREE QFNSTYRVVS 300 VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR EPQVYTLPPS 350 QEEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF 400 FLYSRLTVDK SRWQEGNVFS CSVMHEALHN HYTQKSLSLS LGK 443 /LJKW FKDLQ  &KDvQH OpJqUH  &DGHQD OLJHUD DIQMTQSPSS LSASVGDRVT ITCKASQDVT TAVAWYQQKP GKAPKLLIYW 50 ASTRHTGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ HYTIPWTFGG 100 GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150 DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200 LSSPVTKSFN RGEC 214 3RVWWUDQVODWLRQDO PRGLILFDWLRQV 'LVXOILGH EULGJHV ORFDWLRQ  3RVLWLRQ GHV SRQWV GLVXOIXUH  3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR ,QWUD+ &&             ,QWUD/ &&         ,QWHU+/ &+ &/     ,QWHU++ K  K    1WHUPLQDO JOXWDPLQH F\FOL]DWLRQ WR S\URJOXWDPDWH S( R[RSUROLQH + 9+ 4   1JO\FRV\ODWLRQ VLWHV  6LWHV GH 1JO\FRV\ODWLRQ  3RVLFLRQHV GH 1JOLFRVLODFLyQ + &+ 1   )XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV  JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV FRPSOH[HV IXFRV\OpV  JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV &WHUPLQDO O\VLQH FOLSSLQJ + &+6 .       333 Proposed INN: List 121 WHO Drug Information, Vol. 33, No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cell therapy (veterinary use)  VpWDPpYHWFHO FHOOXOHVVWURPDOHVVHPEODEOHVDXPpVHQFK\PHFDQLQHV DOORJpQLTXHVGpULYpHVGHWLVVXVDGLSHX[HQFXOWXUH G¶H[SDQVLRQSRXUWKpUDSLHFHOOXODLUH/HVFHOOXOHV H[SHULPHQWOHVPDUTXHXUVGHVXUIDFH&'HW&' JO\FRSURWpLQHPHPEUDQDLUHWK\ HWVHFUqWHQWGH O¶LQWHUOHXNLQH ,/ SURWpLQHFKLPLRDWWUDFWLYHGX PRQRF\WH 0&3FKLPLRNLQHGHPRWLI&& IDFWHXU GHFURLVVDQFHGHO KpSDWRF\WH +*)IDFWHXUGLVSHUVDQW 6)KpSDWRSRwpWLQH$ LQKLELWHXUGHPHWDOORSURWHLQDVH 7,03 FKLPLRNLQHGHPRWLI&;& &;&/SURWpLQHGHN'DLQGXLWHSDUO¶LQWHUIpURQ JDPPD,3 SURWpLQHDQWDJRQLVWHGXUpFHSWHXUGH O¶LQWHUOHXNLQH ,/51,/UD HWO¶LQGROHDPLQH GLR[\JpQDVH ,'2,'2 /HVFHOOXOHVVRQWQpJDWLYHV SRXUOHVPDUTXHXUV&'&'HWO¶DQWLJqQHPDMHXU G¶KLVWRFRPSDWLELOLWp &0+ GHFODVVH,, thérapie cellulaire (usage vétérinaire)  VHWDPHYHWFHO FpOXODVHVWURPDOHVSDUHFLGDVDPHVHQTXLPDOHV DORJpQLFDVGHSHUURGHULYDGDVGHWHMLGRDGLSRVR\ H[SDQGLGDVHQFXOWLYRSDUDWHUDSLDFHOXODU/DVFpOXODV H[SUHVDQORVPDUFDGRUHVGHVXSHUILFLH&'\&' JOLFRSURWHtQDGHPHPEUDQDWK\ \VHFUHWDQ LQWHUOHXNLQD ,/ SURWHtQDTXLPLRWiFWLFDGHPRQRFLWRV  0&3TXLPRTXLQDFRQPRWLYR&& IDFWRUGH FUHFLPLHQWRGHKHSDWRFLWRV +*)IDFWRUGLVSHUVDQWH 6)KHSDWRSR\HWLQD$ LQKLELGRUGHPHWDORSURWHLQDVD 7,03 TXLPRTXLQDFRQPRWLYR&;& &;&/ SURWHtQDGHN'DLQGXFWRUDGHLQWHUIHUyQJDPPD,3  SURWHtQDDQWDJRQLVWDGHOUHFHSWRUGHLQWHUOHXNLQD ,/51,/UD HLQGROHDPLQDGLR[LJHQDVD ,'2 ,'2 /DVFpOXODVVRQQHJDWLYDVSDUDORVPDUFDGRUHV &'&'\HODQWtJHQRSULQFLSDOGH KLVWRFRPSDWLELOLGDG 0+& GHFODVH,,  terapia celular (uso veterinario)   VLPOXNDIXVSXPDOID  VLPOXNDIXVSDOID LPPXQRJOREXOLQ*NDSSD DQWL KXPDQVHSUDVH VXUIDFHH[SUHVVHGSURWHDVHILEUREODVWDFWLYDWLRQSURWHLQ DOSKD)$3ĮSURO\OHQGRSHSWLGDVH)$3 HQJLQHHUHG KXPDQPRQRFORQDODQWLERG\ IXVHGWRRQHLQWHUOHXNLQ  ,/ FKDLQKHWHURGLPHU  334 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121    JDPPDKHDY\FKDLQ  >Homo sapiens9+ Homo sapiens,*+9  ,*+' ,*+- >&'5.DEDW+ 6<$06  &'5.DEDW+$,,*6*$67<<$'69.*   &'5.DEDW+*:)**)1<  @  Homo sapiens,*+*  &+  KLQJH  &+ /!$/!$3!*   &+ <!&7!6 /!$<!9   &+6    @   GLVXOILGHZLWKNDSSDOLJKWFKDLQ   >9.$33$ Homo sapiens,*.9 ,*.- >&'5.DEDW/ 5$6469766</$   &'5.DEDW/>@9*655$7    &'5.DEDW/>@44*,0/337   @   Homo sapiens,*.&    @ JDPPDKHDY\FKDLQIXVHGWR,/   >Homo sapiens 9+ Homo sapiens,*+9  ,*+' ,*+-  >&'5.DEDW+6<$06   &'5.DEDW+ $,,*6*$67<<$'69.*   &'5.DEDW+ *:)**)1<   @   Homo sapiens,*+*  &+   KLQJH   &+ /!$/!$ 3!*    &+ 6!&7!:    &+6    .GHO     *6 OLQNHU    Homo sapiens,/ 3U 7!$  )!$   <!$  /!*  &!$     @    GLVXOILGHZLWKNDSSDOLJKWFKDLQ   >9.$33$ Homo sapiens,*.9 ,*.- >&'5.DEDW/ 5$6469766</$   &'5.DEDW/9*655$7    &'5.DEDW/44*,0/337   @    Homo sapiens,*.&    @GLPHU   WULVGLVXOILGHSURGXFHGLQ&KLQHVHKDPVWHU RYDU\ &+2 FHOOVJO\FRIRUPDOID immunomodulator, antineoplastic  VLPOXNDIXVSDOID LPPXQRJOREXOLQH*NDSSDDQWL>VpSUDVHKXPDLQH SURWpDVH H[SULPpHjODVXUIDFHSURWpLQHDOSKDG DFWLYDWLRQGHV ILEUREODVWHV)$3ĮSURO\OHQGRSHSWLGDVH)$3 @DQWLFRUSV PRQRFORQDOKXPDLQLVVXGHO LQJpQpUHULH IXVLRQQpHjXQH FKDvQHGHO LQWHUOHXNLQHKXPDLQH ,/ KpWpURGLPqUH FKDvQHORXUGHJDPPD  >Homo sapiens9+ Homo sapiens,*+9  ,*+' ,*+- >&'5.DEDW+ 6<$06  &'5.DEDW+$,,*6*$67<<$'69.*   &'5.DEDW+*:)**)1<  @  Homo sapiens,*+*  &+  FKDUQLqUH  &+ /!$/!$3!*   &+ <!&7!6 /!$<!9   &+6    @   GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD   >9.$33$ Homo sapiens,*.9 ,*.- >&'5.DEDW/ 5$6469766</$   &'5.DEDW/>@9*655$7    &'5.DEDW/>@44*,0/337   @   Homo sapiens,*.&    @ FKDvQHORXUGHJDPPDIXVLRQQpjO ,/   >Homo sapiens9+ Homo sapiens,*+9  ,*+' ,*+-  >&'5.DEDW+6<$06   &'5.DEDW+ $,,*6*$67<<$'69.*   &'5.DEDW+ *:)**)1<   @   Homo sapiens,*+*  &+   FKDUQLqUH   &+ /!$/!$ 3!*    &+ 6!&7!:    &+6    .GHO     *6 OLQNHU    Homo sapiens,/ 3U 7!$  )!$   <!$  /!*  &!$     @     GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD    335 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019      >9.$33$ Homo sapiens,*.9 ,*.-  >&'5.DEDW/5$6469766</$    &'5.DEDW/9*655$7   &'5.DEDW/ 44*,0/337   @   Homo sapiens ,*.&    @GLPqUH   WULVGLVXOIXUHSURGXLWSDUGHVFHOOXOHV RYDULHQQHVGHKDPVWHUFKLQRLV &+2 JO\FRIRUPHDOID immunomodulateur, antinéoplasique  VLPOXNDIXVSDOID LQPXQRJOREXOLQD*NDSSDDQWL>VHSUDVDKXPDQD SURWHDVDH[SUHVDGDHQODVXSHUILFHSURWHtQDDOIDGH DFWLYDFLyQGHORVILEUREODVWRV)$3ĮSUROLO HQGRSHSWLGDVD)$3 @DQWLFXHUSRPRQRFORQDOKXPDQR UHDOL]DGRDWUDYpVGH,QJHQLHUD IXVLRQDGDFRQXQD FDGHQDGHODLQHUOHXNLQDKXPDQD ,/  KHWHURGtPHUR FDGHQDSHVDGDJDPPD  >Homo sapiens9+ Homo sapiens,*+9  ,*+' ,*+-  >&'5.DEDW+6<$06  &'5.DEDW+ $,,*6*$67<<$'69.*  &'5.DEDW+ *:)**)1<  @  Homo sapiens ,*+*  &+  ELVDJUD  &+ /!$/!$3!*   &+ <!& 7!6/!$<!9   &+6    @  GLVXOIXURFRQODFDGHQDOLJHUD NDSSD   >9.$33$ Homo sapiens,*.9  ,*.- >&'5.DEDW/5$6469766</$   &'5.DEDW/>@9*655$7    &'5.DEDW/>@44*,0/337   @    Homo sapiens,*.&    @ FDGHQDSHVDGDJDPPDIXVLRQDGDDO,/    >Homo sapiens9+ Homo sapiens,*+9  ,*+' ,*+- >&'5.DEDW+6<$06    &'5.DEDW+$,,*6*$67<<$'69.*    &'5.DEDW+*:)**)1<   @    Homo sapiens,*+*  &+   ELVDJUD   &+ /!$/!$3!*     &+ 6!&7!:    &+6    .GHO     *6 OLQNHU    Homo sapiens,/ 3U 7!$  )!$  <!$  /!*  &!$     @   GLVXOIXURFRQODFDGHQD OLJHUDNDSSD   >9.$33$ Homo sapiens ,*.9 ,*.- >&'5.DEDW/ 5$6469766</$   &'5.DEDW/ 9*655$7   &'5.DEDW/44*,0/337   @   Homo sapiens,*.&     @GtPHUR  WULVGLVXOIXURSURGXFLGRSRUODVFpOXODVRYiULFDVGH KDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID inmunomodulador, antineoplásico   336 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121     6HTXHQFH  6pTXHQFH  6HFXHQFLD +HDY\ FKDLQ  &KDvQH ORXUGH  &DGHQD SHVDGD DQWL)$3  EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSA 50 IIGSGASTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGW 100 FGGFNYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150 PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200 NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APEAAGGPSV FLFPPKPKDT 250 LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300 RVVSVLTVLH QDWLNGKEYK CKVSNKALGA PIEKTISKAK GQPREPQVCT 350 LPPSRDELTK NQVSLSCAVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400 DGSFFLVSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK 447 /LJKW FKDLQ  &KDvQH OpJqUH  &DGHQD OLJHUD EIVLTQSPGT LSLSPGERAT LSCRASQSVT SSYLAWYQQK PGQAPRLLIN 50 VGSRRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QGIMLPPTFG 100 QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150 VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200 GLSSPVTKSF NRGEC 215 +HDY\ FKDLQ  &KDvQH ORXUGH  &DGHQD SHVDGD DQWL)$3 IXVHG ZLWK ,/  EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSA 50 IIGSGASTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGW 100 FGGFNYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150 PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200 NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APEAAGGPSV FLFPPKPKDT 250 LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300 RVVSVLTVLH QDWLNGKEYK CKVSNKALGA PIEKTISKAK GQPREPQVYT 350 LPPCRDELTK NQVSLWCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400 DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGGGGG 450 SGGGGSGGGG SAPASSSTKK TQLQLEHLLL DLQMILNGIN NYKNPKLTRM 500 LTAKFAMPKK ATELKHLQCL EEELKPLEEV LNGAQSKNFH LRPRDLISNI 550 NVIVLELKGS ETTFMCEYAD ETATIVEFLN RWITFAQSII STLT 694 /LJKW FKDLQ  &KDvQH OpJqUH  &DGHQD OLJHUD EIVLTQSPGT LSLSPGERAT LSCRASQSVT SSYLAWYQQK PGQAPRLLIN 50 VGSRRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QGIMLPPTFG 100 QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150 VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200 GLSSPVTKSF NRGEC 215 'LVXOILGH EULGJH ORFDWLRQ  3RVLWLRQ GH OD SRQW GLVXOIXUH  3RVLFLyQ GHO SXHQWH GLVXOIXUR LQWUD+ ,J*                ,/   LQWUD/            LQWHU+/     LQWHU++      *O\FRV\ODWLRQ VLWHV  6LWHV GH JO\FRV\ODWLRQ  3RVLFLRQHV GH JOLFRVLODFLyQ  1 1  VLQEDJOXVWDWXP  VLQEDJOXVWDW SRRS  K\GUR[\PHWK\O SHQW\OSLSHULGLQH WULRO ceramide glucosyltransferase inhibitor  VLQEDJOXVWDW SRRS  K\GUR[\PpWK\O SHQW\OSLSpULGLQH WULRO inhibiteur de la céramide glucosyltransférase  VLQEDJOXVWDW SRRS  KLGUR[LPHWLO SHQWLOSLSHULGLQD WULRO inhibidor de la ceramida glucosiltransferasa    &+12        337 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019 VRQHORNLPDEXP  VRQHORNLPDE LPPXQRJOREXOLQVLQJOHFKDLQ9+9+ 9+DQWL>Homo sapiens ,/$ LQWHUOHXNLQ$,/$ DQGHomo sapiens,/) LQWHUOHXNLQ),/) @DQGDQWL>Homo sapiens$/% DOEXPLQKXPDQVHUXPDOEXPLQ+$6 @KXPDQL]HGLama glamaPRQRFORQDODQWLERG\ELVSHFLILFWULYDOHQW VF9+9+ 9+  >KXPDQL]HG9+DQWL,/) Vicugna pacos,*+9    ,*+' ,*+-   Homo sapiens,*+9    ,*+' ,*+-    >@  PHUOLQNHU WHWUDJO\F\OVHU\OWULJO\F\OVHU\O   KXPDQL]HG9+ DQWL$/% Homo sapiens,*+9     ,*+' ,*+- :!6  *    >@  PHUOLQNHU WHWUDJO\F\OVHU\O WULJO\F\OVHU\O   KXPDQL]HG9+DQWL,/$DQGDQWL ,/) Vicugna pacos,*+9    ,*+'  ,*+-   Homo sapiens,*+9    ,*+' ,*+-   >@  SURGXFHGLQ WKH\HDVWPichia pastoris Komagataella phaffii QRQ JO\FRV\ODWHG immunomodulator  VRQpORNLPDE LPPXQRJOREXOLQHFKDvQHXQLTXH9+9+ 9+DQWL>Homo sapiens,/$ LQWHUOHXNLQH$,/$ HWHomo sapiens ,/) LQWHUOHXNLQH),/) @HWDQWL>Homo sapiens$/% DOEXPLQHVpUXPDOEXPLQHKXPDLQH6$+ @DQWLFRUSV PRQRFORQDOLama glamaKXPDQLVpELVSpFLILTXHWULYDOHQW VF9+9+ 9+  >9+FKLPpULTXHDQWL,/) Vicugna pacos,*+9    ,*+' ,*+-   Homo sapiens,*+9    ,*+' ,*+-    >@  PHUOLQNHU WpWUDJO\F\OVpU\OWULJO\F\OVpU\O   9+ KXPDQLVpDQWL$/% Homo sapiens,*+9     ,*+' ,*+- :!6  *    >@  PHUOLQNHU WpWUDJO\F\OVpU\O WULJO\F\OVpU\O   9+FKLPpULTXHDQWL,/$DQGDQWL ,/) Vicugna pacos,*+9    ,*+'  ,*+-   Homo sapiens,*+9    ,*+' ,*+-   >@  SURGXLWGDQVOD OHYXUHPichia pastoris Komagataella phaffii QRQJO\FRV\Op immunomodulateur  VRQHORNLPDE LQPXQRJOREXOLQDFDGHQD~QLFD9+9+ 9+DQWL>Homo sapiens,/$ LQWHUOHXNLQD$,/$ \Homo sapiens ,/) LQWHUOHXNLQD),/) @\DQWL>Homo sapiens$/% DOE~PLQDDOE~PLQDVpULFDKXPDQD6$+ @DQWLFXHUSR PRQRFORQDOLama glamaKXPDQL]DGRELHVSHFtILFRWULYDOHQWH VF9+9+ 9+  >9+TXLPpULFRDQWL,/) Vicugna pacos,*+9    ,*+' ,*+-   Homo sapiens,*+9    ,*+' ,*+-    >@  FRQHFWRUPHU WHWUDJOLFLOVHULOWULJOLFLOVHULO   9+ KXPDQL]DGRDQWL$/% Homo sapiens,*+9     ,*+' ,*+- :!6  *    >@  FRQHFWRPHU WHWUDJOLFLOVHULO WULJOLFLOVHULO   9+TXLPpULFRDQWL,/$\DQWL,/) Vicugna pacos,*+9    ,*+' ,*+-   Homo sapiens,*+9    ,*+'  ,*+-   >@  SURGXFLGRHQOD OHYDGXUDPichia pastoris Komagataella phaffii QRJOLFRVLODGR inmunomodulador   338 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121        VRYDWHOWLGXP  VRYDWHOWLGH N FDUER[\SURSDQR\O HQGRWKHOLQ KXPDQ   SHSWLGH   >.!(&!$&!$@ N FDUER[\SURSDQR\O /ĮDVSDUW\O/ĮJOXWDP\O/ĮJOXWDP\O/ DODQ\O/YDO\O/W\URV\O/SKHQ\ODODQ\O/DODQ\O/KLVWLG\O/OHXF\O /ĮDVSDUW\O/LVROHXF\O/LVROHXF\O/WU\SWRSKDQ endothelin receptor agonist  VRYDWHOWLGH N FDUER[\SURSDQR\O HQGRWKpOLQH KXPDLQH   SHSWLGH  >.!(&!$&!$@ N FDUER[\SURSDQR\O /ĮDVSDUW\O/ĮJOXWDP\O/ĮJOXWDP\O/ DODQ\O/YDO\O/W\URV\O/SKpQ\ODODQ\O/DODQ\O/KLVWLG\O/OHXF\O /ĮDVSDUW\O/LVROHXF\O/LVROHXF\O/WU\SWRSKDQH antagoniste du récepteur de l'endothéline  VRYDWHOWLGD N FDUER[LSURSDQRLO HQGRWHOLQD KXPDQD   SpSWLGR   >.!(&!$&!$@ N FDUER[LSURSDQRLO /ĮDVSDUWLO/ĮJOXWDPLO/ĮJOXWDPLO/ DODQLO/YDOLO/WLURVLO/IHQLODODQLO/DODQLO/KLVWLGLO/OHXFLO/Į DVSDUWLO/LVROHXFLO/LVROHXFLO/WULSWyIDQR antagonista del receptor de la endotelina    &+12       VWDSXOGHQFHOXP  VWDSXOGHQFHO KXPDQDXWRORJRXVPRQRF\WHGHULYHGGHQGULWLFFHOOV 0R'&V  JHQHUDWHGex-vivoIURPSDWLHQW¶VSHULSKHUDOEORRGPRQRQXFOHDU FHOOV 3%0&V IRUFHOOEDVHGWKHUDS\7KHFHOOVDUHGLIIHUHQWLDWHG IURPDXWRORJRXVDGKHUHQWPRQRF\WHVE\FXOWXULQJLQWKH SUHVHQFHRILQWHUOHXNLQ ,/ DQGJUDQXORF\WHPDFURSKDJH FRORQ\VWLPXODWLQJIDFWRU *0&6) DQGSXOVHGZLWKDNLOOHG KXPDQSURVWDWHDGHQRFDUFLQRPDFHOOOLQH cell therapy (antineoplastic)  VWDSXOGHQFHO FHOOXOHVGHQGULWLTXHVDXWRORJXHVKXPDLQHVGpULYpHVGHV PRQRF\WHVJpQpUpHVex vivojSDUWLUGHFHOOXOHVPRQRQXFOpHV GXVDQJSpULSKpULTXHGHVSDWLHQWVSRXUWKpUDSLHFHOOXODLUH/HV FHOOXOHVVHGLIIpUHQFLHQWjSDUWLUGHVPRQRF\WHVDGKpUHQWV DXWRORJXHVSDUFXOWXUHHQSUpVHQFHG¶LQWHUOHXNLQH ,/ HWGX IDFWHXUVWLPXODQWOHVFRORQLHVGHJUDQXORF\WHVHWGH PDFURSKDJHV *0&6) HWSXOVpHVSDUGHVFHOOXOHVWXpHVG¶XQH OLJQpHFHOOXODLUHKXPDLQHG¶DGpQRFDUFLQRPHGHODSURVWDWH  thérapie cellulaire (antinéoplasique)  339 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019  HVWDSXOGHQFHO FpOXODVGHQWUtWLFDVDXWyORJDVKXPDQDVGHULYDGDVGH PRQRFLWRVJHQHUDGDVex vivoDSDUWLUGHFpOXODV PRQRQXFOHDUHVGHVDQJUHSHULIpULFDGHSDFLHQWHV SDUDWHUDSLDFHOXODU/DVFpOXODVVHGLIHUHQFLDQDSDUWLU GHPRQRFLWRVDGKHUHQWHVDXWyORJRVPHGLDQWHFXOWLYR HQSUHVHQFLDGHLQOHUOHXFLQD ,/ \IDFWRU HVWLPXODGRUGHFRORQLDVGHJUDQXORFLWRV\PDFUyIDJRV *0&6) \SXOVDGDVFRQFpOXODVPDWDGDVGHXQD OtQHDFHOXODUGHDGHQRFDUFLQRPDSURVWiWLFRKXPDQD terapia celular (antineoplásico)     VXYRGLUVHQXP  VXYRGLUVHQ >allPS S @ GHR[\ IOXRURPWKLRXULG\O\O  ĺ   GHR[\ IOXRURPWKLRF\WLG\O\O  ĺ  GHR[\  IOXRURPWKLRDGHQ\O\O  ĺ  GHR[\ IOXRURP WKLRDGHQ\O\O  ĺ  GHR[\ IOXRURPWKLRJXDQ\O\O  ĺ  GHR[\ IOXRURPWKLRJXDQ\O\O  ĺ  O PHWK\ODGHQ\O\O  ĺ  GHR[\ IOXRURP WKLRDGHQ\O\O  ĺ  OPHWK\OJXDQ\O\O  ĺ  O PHWK\OPWKLRDGHQ\O\O  ĺ  GHR[\ IOXRURP WKLRXULG\O\O  ĺ  OPHWK\OJXDQ\O\O  ĺ  O PHWK\OJXDQ\O\O  ĺ  GHR[\ IOXRURP WKLRF\WLG\O\O  ĺ  GHR[\ IOXRURPWKLRDGHQ\O\O  ĺ  GHR[\ IOXRURPWKLRXULG\O\O  ĺ   GHR[\ IOXRURPWKLRXULG\O\O  ĺ  GHR[\  IOXRURPWKLRXULG\O\O  ĺ  GHR[\ IOXRURP WKLRF\WLG\O\O  ĺ  GHR[\ IOXRURXULGLQH promotion of functional dystrophin synthesis  VXYRGLUVHQ >toutPS S @ GpVR[\ IOXRURPWKLRXULG\O\O  ĺ   GpVR[\ IOXRURPWKLRF\WLG\O\O  ĺ  GpVR[\  IOXRURPWKLRDGpQ\O\O  ĺ  GpVR[\ IOXRURP WKLRDGpQ\O\O  ĺ  GpVR[\ IOXRURPWKLRJXDQ\O\O  ĺ  GpVR[\ IOXRURPWKLRJXDQ\O\O  ĺ  O PpWK\ODGpQ\O\O  ĺ  GpVR[\ IOXRURP WKLRDGpQ\O\O  ĺ  OPpWK\OJXDQ\O\O  ĺ  O PpWK\OPWKLRDGpQ\O\O  ĺ  GpVR[\ IOXRURP WKLRXULG\O\O  ĺ  OPpWK\OJXDQ\O\O  ĺ  O PpWK\OJXDQ\O\O  ĺ  GpVR[\ IOXRURP WKLRF\WLG\O\O  ĺ  GpVR[\ IOXRURPWKLRDGpQ\O\O  ĺ  GpVR[\ IOXRURPWKLRXULG\O\O  ĺ   GpVR[\ IOXRURPWKLRXULG\O\O  ĺ  GpVR[\  IOXRURPWKLRXULG\O\O  ĺ  GpVR[\ IOXRURP WKLRF\WLG\O\O  ĺ  GpVR[\ IOXRURXULGLQH stimulation de la synthèse de dystrophine fonctionnelle  VXYRGLUVpQ >todoPS S @ GHVR[L IOXRURPWLRXULGLOLO  ĺ   GHVR[L IOXRURPWLRFLWLGLOLO  ĺ  GHVR[L IOXRUR PWLRDGHQLOLO  ĺ  GHVR[L IOXRURPWLRDGHQLOLO  ĺ  GHVR[L IOXRURPWLRJXDQLOLO  ĺ   GHVR[L IOXRURPWLRJXDQLOLO  ĺ  OPHWLODGHQLOLO  ĺ  GHVR[L IOXRURPWLRDGHQLOLO  ĺ  O PHWLOJXDQLOLO  ĺ  OPHWLOPWLRDGHQLOLO  ĺ   GHVR[L IOXRURPWLRXULGLOLO  ĺ  OPHWLOJXDQLOLO   ĺ  OPHWLOJXDQLOLO  ĺ  GHVR[L IOXRURP   340 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121  WLRFLWLGLOLO  ĺ  GHVR[L IOXRURPWLRDGHQLOLO  ĺ  GHVR[L IOXRURPWLRXULGLOLO  ĺ   GHVR[L IOXRURPWLRXULGLOLO  ĺ  GHVR[L IOXRUR PWLRXULGLOLO  ĺ  GHVR[L IOXRURPWLRFLWLGLOLO  ĺ  GHVR[L IOXRURXULGLQD estimulación de la síntesis de distrofina funcional    &+)1236        WDIROHFLPDEXP  WDIROHFLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens 3&6. SURSURWHLQFRQYHUWDVHVXEWLOLVLQNH[LQW\SH QHXUDODSRSWRVLVUHJXODWHGFRQYHUWDVH1$5& 1$5&SURSURWHLQHFRQYHUWDVH3& @Homo sapiensPRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*  &+  KLQJH  &+  &+  &+6.!GHO     @  GLVXOILGHZLWKNDSSDOLJKWFKDLQHomo sapiens   >9.$33$ Homo sapiens,*.9    ,*.-   >@    Homo sapiens,*.&   .P$   9     @GLPHU   WHWUDNLVGLVXOILGHSURGXFHGLQ &KLQHVH+DPVWHU2YDU\ &+2 6FHOOOLQHJO\FRIRUP DOID antihypercholesterolemic  WDIROpFLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens 3&6. SURSURWpLQHFRQYHUWDVHVXEWLOLVLQHNH[LQHW\SH FRQYHUWDVHUpJXOpHSDUO DSRSWRVHQHXURQDOH 1$5&1$5&SURSURWpLQHFRQYHUWDVH3& @ DQWLFRUSVPRQRFORQDOHomo sapiens FKDvQHORXUGHJDPPDHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*  &+  FKDUQLqUH   &+  &+  &+6.!GHO    @  GLVXOIXUHDYHFODFKDvQHOpJqUH NDSSDHomo sapiens   >9.$33$ Homo sapiens,*.9   ,*.-    >@   Homo sapiens,*.&   .P $  9     @GLPqUH   WpWUDNLVGLVXOIXUH SURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGHKDPVWHUV FKLQRLV &+2 OLJQpHFHOOXODLUH&+26JO\FRIRUPHDOID  antihypercholestérolémique  341 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019  WDIROHFLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens 3&6. SURSURWHtQDFRQYHUWDVDVXEWLOLVLQDNH[LQDWLSR FRQYHUWDVDUHJXODGDSRUODDSRSWRVDQHXURQDO 1$5&1$5&SURSURWHtQDFRQYHUWDVD3& @ DQWLFXHUSRPRQRFORQDOHomo sapiens FDGHQDSHVDGDJDPPDHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*  &+  ELVDJUD   &+  &+  &+6.!GHO    @  GLVXOIXURFRQODFDGHQDOLJHUD NDSSDHomo sapiens   >9.$33$ Homo sapiens,*.9   ,*.-    >@   Homo sapiens,*.&   .P $  9     @GtPHUR   WHWUDNLVGLVXOIXUR SURGXFLGRHQODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2 OtQHDFHOXODU&+26JOLFRIRUPDDOID antihipercolesterolémico       +HDY\ FKDLQ  &KDvQH ORXUGH  &DGHQD SHVDGD QLQLQESGPG LVKPSETLSL TCTVSGGSIS SASYYWSWIR QPPGKGLEWI 50 GSINYRGSTY YNPSLKSRVT ISVDTSKNQF SLKLSSVTAA DTAVYYCARE 100 NSGVVPAAGP NWFGPWGQGT LVTVSSASTK GPSVFPLAPC SRSTSESTAA 150 LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS 200 NFGTQTYTCN VDHKPSNTKV DKTVERKCCV ECPPCPAPPV AGPSVFLFPP 250 KPKDTLMISR TPEVTCVVVD VSHEDPEVQF NWYVDGVEVH NAKTKPREEQ 300 FNSTFRVVSV LTVVHQDWLN GKEYKCKVSN KGLPAPIEKT ISKTKGQPRE 350 PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400 PMLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450 G 451 /LJKW FKDLQ  &KDvQH OpJqUH  &DGHQD OLJHUD EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD 50 ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RRNWFTFGGG 100 TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150 NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200 SSPVTKSFNR GEC 213 3RVWWUDQVODWLRQDO PRGLILFDWLRQV 'LVXOILGH EULGJHV ORFDWLRQ  3RVLWLRQ GHV SRQWV GLVXOIXUH  3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR ,QWUD+ &&             ,QWUD/ &&         ,QWHU+/ &+ &/     ,QWHU++ K  K  K  K      1WHUPLQDO JOXWDPLQH F\FOL]DWLRQ WR S\URJOXWDPDWH S( R[RSUROLQH + 9+ 4   1JO\FRV\ODWLRQ VLWHV  6LWHV GH 1JO\FRV\ODWLRQ  3RVLFLRQHV GH 1JOLFRVLODFLyQ + &+ 1   )XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV  JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV  FRPSOH[HV IXFRV\OpV  JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV    WDOTXHWDPDEXP  WDOTXHWDPDE LPPXQRJOREXOLQ*NDSSD*ODPEGDDQWL>Homo sapiens*35&' *SURWHLQFRXSOHGUHFHSWRUFODVV& JURXSPHPEHU' @DQGDQWL>Homo sapiens&'( &'HSVLORQ/HX @KXPDQL]HGDQGFKLPHULF PRQRFORQDODQWLERG\ELVSHFLILF JDPPDKHDY\FKDLQKXPDQL]HGDQWL*35&'   >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*  &+  KLQJH6!3    &+)!$  /!$    &+  &+6    @   GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG 342 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121    DQWL*35&'   >9.$33$ Homo sapiens,*.9    ,*.-   >@   Homo sapiens,*.&   .P $  9     @ JDPPDKHDY\FKDLQFKLPHULFDQWL&'(  >9+ Mus musculus ,*+9   Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens,*+*  &+  KLQJH6!3    &+)!$  /!$    &+)!/  5!.    &+6     @  GLVXOILGHZLWKODPEGDOLJKWFKDLQKXPDQL]HG DQWL&'(   >9/$0%'$ Homo sapiens,*/9    ,*/-   >@   Homo sapiens,*/&       @ GLPHU   ELVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU 2YDU\ &+2 .FHOOOLQHJO\FRIRUPDOID immunomodulator, antineoplastic  WDOTXpWDPDE LPPXQRJOREXOLQH*NDSSD*ODPEGDDQWL>Homo sapiens *35&' PHPEUH'GXJURXSHGHODFODVVH&GXUpFHSWHXUFRXSOpDX[SURWpLQHV * @HWDQWL>Homo sapiens&'( &'HSVLORQ/HX @DQWLFRUSV PRQRFORQDOKXPDQLVpHWFKLPpULTXHELVSpFLILTXH FKDvQHORXUGHJDPPDDQWL*35&'KXPDQLVpH  >9+ Homo sapiens,*+9    ,*+' ,*+-   >@   Homo sapiens,*+*  &+  FKDUQLqUH6!3    &+)!$  /!$    &+   &+6    @  GLVXOIXUHDYHFODFKDvQH OpJqUHNDSSDDQWL*35&'KXPDQLVpH   >9.$33$ Homo sapiens ,*.9   ,*.-   >@   Homo sapiens ,*.&   .P$  9     @ FKDvQHORXUGHJDPPDDQWL&'FKLPpULTXH  >9+ Mus musculus ,*+9   Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens,*+*  &+  FKDUQLqUH6!3    &+)!$   /!$    &+)!/  5!.    &+6    @  GLVXOIXUHDYHFODFKDvQHOpJqUHODPEGD DQWL&'(KXPDQLVpH   >9/$0%'$ Homo sapiens,*/9   ,*/-   >@   Homo sapiens,*/&      @GLPqUH   ELVGLVXOIXUHSURGXLWGDQV GHVFHOOXOHVRYDULHQQHVGHKDPVWHUVFKLQRLV &+2 OLJQpHFHOOXODLUH. JO\FRIRUPHDOID immunomodulateur, antinéoplasique  WDOTXHWDPDE LQPXQRJOREXOLQD*NDSSD*ODPEGDDQWL>Homo sapiens *35&' PLHPEUR'GHOJUXSRGHODFODVH&GHOUHFHSWRUDFRSODGRFRQSURWHtQDV * @\DQWL>Homo sapiens&'( &'pSVLORQ/HX @DQWLFXHUSR PRQRFORQDOKXPDQL]DGR\TXLPpULFRELHVSHFtILFR FDGHQDSHVDGDJDPPDDQWL*35&'KXPDQL]DGD  >9+ Homo sapiens,*+9    ,*+' ,*+-   >@   Homo sapiens,*+*  &+  ELVDJUD6!3    &+)!$  /!$    &+   &+6    @  GLVXOIXURFRQODFDGHQDOLJHUD NDSSDDQWL*35&'KXPDQL]DGD   >9.$33$ Homo sapiens ,*.9   ,*.-   >@   Homo sapiens ,*.&   .P$  9     @ FDGHQDSHVDGDJDPPDDQWL&'TXLPpULFD  >9+ Mus musculus ,*+9   Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens,*+*  &+  ELVDJUD6!3    &+)!$   /!$    &+)!/  5!.    &+6     @  GLVXOIXURFRQODFDGHQDOLJHUD 343 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019    ODPEGDDQWL&'(KXPDQL]DGD   >9/$0%'$ Homo sapiens,*/9   ,*/-   >@   Homo sapiens,*/&      @GtPHUR    ELVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDVGH KDPVWHUVFKLQRV &+2 OtQHDFHOXODU.JOLFRIRUPD DOID inmunomodulador, antineoplásico       +HDY\ FKDLQ  &KDvQH ORXUGH  &DGHQD SHVDGD DQWL*35&' QVQLVQSGAE VKKPGASVKV SCKASGYSFT GYTMNWVRQA PGQGLEWMGL 50 INPYNSDTNY AQKLQGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARVA 100 LRVALDYWGQ GTLVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150 FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTKTYT 200 CNVDHKPSNT KVDKRVESKY GPPCPPCPAP EAAGGPSVFL FPPKPKDTLM 250 ISRTPEVTCV VVDVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTYRV 300 VSVLTVLHQD WLNGKEYKCK VSNKGLPSSI EKTISKAKGQ PREPQVYTLP 350 PSQEEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400 SFFLYSRLTV DKSRWQEGNV FSCSVMHEAL HNHYTQKSLS LSLGK 445 /LJKW FKDLQ  &KDvQH OpJqUH  &DGHQD OLJHUD DQWL*35&' DIQMTQSPSS LSASVGDRVT ITCKASQNVA THVGWYQQKP GKAPKRLIYS 50 ASYRYSGVPS RFSGSGSGTE FTLTISNLQP EDFATYYCQQ YNRYPYTFGQ 100 GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150 DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200 LSSPVTKSFN RGEC 214 +HDY\ FKDLQ  &KDvQH ORXUGH  &DGHQD SHVDGD DQWL&'( EVQLVESGGG LVQPGGSLRL SCAASGFTFN TYAMNWVRQA PGKGLEWVAR 50 IRSKYNNYAT YYAASVKGRF TISRDDSKNS LYLQMNSLKT EDTAVYYCAR 100 HGNFGNSYVS WFAYWGQGTL VTVSSASTKG PSVFPLAPCS RSTSESTAAL 150 GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS 200 LGTKTYTCNV DHKPSNTKVD KRVESKYGPP CPPCPAPEAA GGPSVFLFPP 250 KPKDTLMISR TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ 300 FNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT ISKAKGQPRE 350 PQVYTLPPSQ EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400 PVLDSDGSFL LYSKLTVDKS RWQEGNVFSC SVMHEALHNH YTQKSLSLSL 450 GK 452 /LJKW FKDLQ  &KDvQH OpJqUH  &DGHQD OLJHUD DQWL&'( QTVVTQEPSL TVSPGGTVTL TCRSSTGAVT TSNYANWVQQ KPGQAPRGLI 50 GGTNKRAPGT PARFSGSLLG GKAALTLSGV QPEDEAEYYC ALWYSNLWVF 100 GGGTKLTVLG QPKAAPSVTL FPPSSEELQA NKATLVCLIS DFYPGAVTVA 150 WKADSSPVKA GVETTTPSKQ SNNKYAASSY LSLTPEQWKS HRSYSCQVTH 200 EGSTVEKTVA PTECS 215 3RVWWUDQVODWLRQDO PRGLILFDWLRQV 'LVXOILGH EULGJHV ORFDWLRQ  3RVLWLRQ GHV SRQWV GLVXOIXUH  3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR ,QWUD+ &&             ,QWUD/ &&         ,QWHU+/ &+ &/     ,QWHU++ K  K    1JO\FRV\ODWLRQ VLWHV  6LWHV GH 1JO\FRV\ODWLRQ  3RVLFLRQHV GH 1JOLFRVLODFLyQ + &+ 1   )XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV  JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV  FRPSOH[HV IXFRV\OpV  JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV    WDQLPLODVWXP  WDQLPLODVW GLFKORUR> S > F\FORSURS\OPHWKR[\  GLIOXRURPHWKR[\ SKHQ\O@^> F\FORSURS\OPHWKR[\  PHWKDQHVXOIRQDPLGR EHQ]R\O@R[\`HWK\O@S\ULGLQH R[LGH phosphodiesterase IV inhibitor  WDQLPLODVW R[\GHGHGLFKORUR> S > F\FORSURS\OPpWKR[\  GLIOXRURPpWKR[\ SKpQ\O@^> F\FORSURS\OPpWKR[\  PpWKDQHVXOIRQDPLGR EHQ]R\O@R[\`pWK\O@S\ULGLQH  inhibiteur de la phosphodiestérase IV  344 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121  WDQLPLODVW y[LGRGHGLFORUR> S > FLFORSURSLOPHWR[L   GLIOXRURPHWR[L IHQLO@^> FLFORSURSLOPHWR[L  PHWDQRVXOIRQDPLGR EHQ]RLO@R[L`HWLO@SLULGLQD inhibidor de la fosfodiesterasa IV    &+&O)126       WDSRWRFOD[XP  WDSRWRFOD[ SRRSESR  FKORURPHWKR[\ GLPHWK\O  GLK\GURHH HȜWKLD D]DVSLUR>  >@EHQ]R[D]HSLQD   F\FOREXWDQDF\FORGRGHFDSKDQHQH  QDSKWKDOHQH@WULRQH antineoplastic  WDSRWRFOD[ SRRSESR  FKORURPpWKR[\ GLPpWK\O  GLK\GURHH HȜWKLD D]DVSLUR>  >@EHQ]R[D]pSLQD   F\FOREXWDQDF\FORGRGpFDSKDQqQH QDSKWDOqQH@ WULRQH antinéoplasique  WDSRWRFOD[ SRRSESR  FORURPHWR[L GLPHWLO  GLKLGURHH HȜWLD D]DVSLUR>  >@EHQ]R[D]HSLQD   FLFOREXWDQDFLFORGRGHFDIDQHQR QDIWDOHQR@ WULRQD antineoplásico    &+&O126        345 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019 WHEURFDEWDJHQXPDXWROHXFHOXP  WHEURFDEWDJHQHDXWROHXFHO DXWRORJRXV7FHOOVWUDQVGXFHGZLWKDUHSOLFDWLRQ LQFRPSHWHQW0RORQH\PXULQHOHXNHPLDYLUXV 0R0/9  DUHWURYLUXV YHFWRUWKDWHQFRGHVDFKLPHULFDQWLJHQ UHFHSWRU &$5 WDUJHWLQJKXPDQ%O\PSKRF\WHDQWLJHQ &' &'PROHFXOH%/\PSKRF\WH6XUIDFH$QWLJHQ %7&HOO6XUIDFH$QWLJHQ/HX&9,'  cell therapy (antineoplastic)  WpEURFDEWDJqQHDXWROHXFHO O\PSKRF\WHV7DXWRORJXHVWUDQVGXLWVSDUXQYHFWHXUGX YLUXVGHODOHXFpPLHPXULQHGH0RORQH\ 0R0/9  XQ UHWURYLUXV LQFRPSpWHQWSRXUODUHSOLFDWLRQHWFRGDQW SRXUXQUpFHSWHXUDQWLJpQLTXHFKLPpULTXH &$5 GLULJp FRQWUHO DQWLJqQH&'GHVO\PSKRF\WHV%KXPDLQV PROHFXOH&'DQWLJqQHGHVXUIDFH%GHV O\PSKRF\WHV%DQWLJqQHGHVXUIDFH/HXGHV O\PSKRF\WHV7&9,'  thérapie cellulaire (antinéoplasique)  WHEURFDEWDJpQDXWROHXFHO OLQIRFLWRV7DXWyORJRVWUDQVGXFLGRVFRQXQYHFWRUGHO YLUXVGHODOHXFHPLDPXULQDGH0RORQH\ 0R0/9  XQ UHWURYLUXV LQFRPSHWHQWHSDUDUHSOLFDFLyQTXHFRGLILFD SDUDXQUHFHSWRUGHDQWtJHQRVTXLPpULFR &$5  GLULJLGRDODQWtJHQRGHOLQIRFLWRV%KXPDQRV&' PROpFXOD&'DQWtJHQR%GHVXSHUILFLHGH OLQIRFLWRV%DQWtJHQRGHVXSHUILFLHGHOLQIRFLWRV7/HX &9,'  terapia celular (antineoplásico)      WLOYHVWDPDEXP  WLOYHVWDPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens$;/ $;/UHFHSWRUW\URVLQHNLQDVHW\URVLQHSURWHLQNLQDVH UHFHSWRU8)2 @KXPDQL]HGPRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQKXPDQL]HG  >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+* Y *P!*PQ*P &+5!.     KLQJH  &+  &+(  0    &+6     @  GLVXOILGHZLWKNDSSDOLJKWFKDLQ KXPDQL]HG   >9.$33$ Homo sapiens,*.9    ,*.-   >@    Homo sapiens,*.&   .P$   9     @GLPHU   ELVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 FHOOVJO\FRIRUPDOID immunomodulator, antineoplastic  WLOYHVWDPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens $;/ UpFHSWHXUW\URVLQHNLQDVH$;/UpFHSWHXUW\URVLQH SURWpLQHNLQDVH8)2 @DQWLFRUSVPRQRFORQDO KXPDQLVp     346 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121  FKDvQHORXUGHJDPPDKXPDQLVpH  >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+* Y *P!*PQ*P &+5!.     FKDUQLqUH  &+  &+ (  0    &+6     @  GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD KXPDQLVpH   >9.$33$ Homo sapiens,*.9    ,*.-   >@    Homo sapiens,*.&   .P$   9     @GLPqUH   ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGH KDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID immunomodulateur, antinéoplasique  WLOYHVWDPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens $;/ UHFHSWRUWLURVLQDNLQDVD$;/UHFHSWRUWLURVLQD SURWHtQDNLQDVD8)2 @DQWLFXHUSRPRQRFORQDO KXPDQL]DGR FDGHQDSHVDGDJDPPDKXPDQL]DGD  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+* Y*P!*PQ*P &+5!.    ELVDJUD  &+   &+(  0    &+6     @  GLVXOIXURFRQODFDGHQD OLJHUDNDSSDKXPDQL]DGD   >9.$33$ Homo sapiens,*.9   ,*.-    >@   Homo sapiens,*.&   .P $  9     @GtPHUR   ELVGLVXOIXURSURGXFLGRHQODVFpOXODV RYiULFDVGHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID inmunomodulador, antineoplásico         347 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019    WLQODUHEDQWXP  WLQODUHEDQW  ^>GLIOXRUR WULIOXRURPHWK\O SKHQ\O@SLSHULGLQHFDUERQ\O` WHWUDK\GURHS\UD]ROR>c@S\ULGLQ\O HWKDQRQH retinol binding protein-4 antagonist  WLQODUpEDQW  ^>GLIOXRUR WULIOXRURPpWK\O SKpQ\O@SLSpULGLQHFDUERQ\O` WpWUDK\GURHS\UD]ROR>c@S\ULGLQ\O pWKDQRQH antagoniste de la protéine 4 se liant au rétinol  WLQODUHEDQW  ^>GLIOXRUR WULIOXRURPHWLO IHQLO@SLSHULGLQD FDUERQLO`WHWUDKLGURHSLUD]ROR>c@SLULGLQ LO HWDQRQD antagonista de la proteína 4 de unión a retinol    &+)12         WLQXULOLPDEXP  WLQXULOLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens &($&$0 FDUFLQRHPEU\RQLFDQWLJHQUHODWHGFHOO DGKHVLRQPROHFXOH&'F @KXPDQL]HGPRQRFORQDO DQWLERG\ JDPPDKHDY\FKDLQHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*  &+  KLQJH  &+  &+  &+6.!GHO     @  GLVXOILGHZLWKNDSSDOLJKWFKDLQ KXPDQL]HG   >9.$33$ Homo sapiens,*.9    ,*.-   >@    Homo sapiens,*.&   .P$   9     @ GLPHU   WHWUDNLVGLVXOILGHSURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 FHOOVJO\FRIRUPDOID immunomodulator, antineoplastic  WLQXULOLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens &($&$0 PROpFXOHG DGKpVLRQFHOOXODLUH DSSDUHQWpHjO DQWLJqQHFDUFLQRHPEU\RQQDLUH &'F @DQWLFRUSVPRQRFORQDOKXPDQLVp     348 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121  FKDvQHORXUGHJDPPDHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*  &+  FKDUQLqUH   &+  &+  &+6.!GHO    @  GLVXOIXUHDYHFODFKDvQHOpJqUH NDSSDKXPDQLVpH   >9.$33$ Homo sapiens ,*.9   ,*.-   >@    Homo sapiens,*.&   .P$  9     @ GLPqUH   WpWUDNLVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHV GHKDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID immunomodulateur, antinéoplasique  WLQXULOLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens &($&$0 PROpFXODGHDGKHVLyQFHOXODU UHODFLRQDGDFRQHODQWtJHQRFDUFLQRHPEULRQDULR &'F @DQWLFXHUSRPRQRFORQDOKXPDQL]DGR FDGHQDSHVDGDJDPPDHomo sapiens  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*  &+  ELVDJUD   &+  &+  &+6.!GHO    @  GLVXOIXURFRQODFDGHQDOLJHUD NDSSDKXPDQL]DGD   >9.$33$ Homo sapiens ,*.9   ,*.-   >@    Homo sapiens,*.&   .P$  9     @ GtPHUR   WHWUDNLVGLVXOIXURSURGXFLGRHQODVFpOXODVRYiULFDVGH KDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID inmunomodulador, antineoplásico            349 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019 WROXGHVYHQODID[LQXP  WROXGHVYHQODID[LQH rac> R  GLPHWK\ODPLQR   K\GUR[\F\FORKH[\O HWK\O@SKHQ\OPHWK\OEHQ]RDWH antidepressant  WROXGHVYHQODID[LQH PpWK\OEHQ]RDWHGHrac> R  GLPpWK\ODPLQR   K\GUR[\F\FORKH[\O pWK\O@SKpQ\OH antidépresseur  WROXGHVYHQODID[LQD PHWLOEHQ]RDWRGHrac> R  GLPHWLODPLQR   KLGUR[LFLFORKH[LO HWLO@IHQLOR antidepresivo    &+12        WRPLQHUVHQXP  WRPLQHUVHQ allPambo O PHWKR[\HWK\O PHWK\OPWKLRF\WLG\O\O  ĺ  O PHWKR[\HWK\O PHWK\OXULG\O\O  ĺ   O PHWKR[\HWK\O PHWK\OF\WLG\O\O  ĺ  O  PHWKR[\HWK\O DGHQ\O\O  ĺ  O PHWKR[\HWK\O P WKLRJXDQ\O\O  ĺ PWKLRWK\PLG\O\O  ĺ  GHR[\P WKLRDGHQ\O\O  ĺ  GHR[\PWKLRDGHQ\O\O  ĺ   GHR[\PHWK\OPWKLRF\WLG\O\O  ĺ  GHR[\P WKLRDGHQ\O\O  ĺ PWKLRWK\PLG\O\O  ĺ P WKLRWK\PLG\O\O  ĺ  GHR[\PWKLRJXDQ\O\O  ĺ   GHR[\PWKLRDGHQ\O\O  ĺ  GHR[\PHWK\OP WKLRF\WLG\O\O  ĺ  O PHWKR[\HWK\O DGHQ\O\O  ĺ   O PHWKR[\HWK\O PHWK\OF\WLG\O\O  ĺ  O  PHWKR[\HWK\O PHWK\OF\WLG\O\O  ĺ  O  PHWKR[\HWK\O PWKLRDGHQ\O\O  ĺ  O  PHWKR[\HWK\O PHWK\OF\WLGLQH reduction of abnormal huntingtin synthesis  WRPLQHUVHQ toutPambo O PpWKR[\pWK\O PpWK\OP WKLRF\WLG\O\O  ĺ  O PpWKR[\pWK\O  PpWK\OXULG\O\O  ĺ  O PpWKR[\pWK\O  PpWK\OF\WLG\O\O  ĺ  O PpWKR[\pWK\O DGpQ\O\O  ĺ  O PpWKR[\pWK\O PWKLRJXDQ\O\O  ĺ P WKLRWK\PLG\O\O  ĺ  GpVR[\PWKLRDGpQ\O\O  ĺ   GpVR[\PWKLRDGpQ\O\O  ĺ  GpVR[\PpWK\OP WKLRF\WLG\O\O  ĺ  GpVR[\PWKLRDGpQ\O\O  ĺ P WKLRWK\PLG\O\O  ĺ PWKLRWK\PLG\O\O  ĺ  GpVR[\ PWKLRJXDQ\O\O  ĺ  GpVR[\PWKLRDGpQ\O\O  ĺ   GpVR[\PpWK\OPWKLRF\WLG\O\O  ĺ  O  PpWKR[\pWK\O DGpQ\O\O  ĺ  O PpWKR[\pWK\O  PpWK\OF\WLG\O\O  ĺ  O PpWKR[\pWK\O  PpWK\OF\WLG\O\O  ĺ  O PpWKR[\pWK\O P WKLRDGpQ\O\O  ĺ  O PpWKR[\pWK\O  PpWK\OF\WLGLQH  réduction de la synthèse de huntingtine anormale  350 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121  WRPLQHUVpQ todoPambo O PHWR[LHWLO PHWLOPWLRFLWLGLOLO  ĺ  O PHWR[LHWLO PHWLOXULGLOLO  ĺ  O PHWR[LHWLO PHWLOFLWLGLOLO  ĺ  O  PHWR[LHWLO DGHQLOLO  ĺ  O PHWR[LHWLO P WLRJXDQLOLO  ĺ PWLRWLPLGLOLO  ĺ  GHVR[LP WLRDGHQLOLO  ĺ  GHVR[LPWLRDGHQLOLO  ĺ   GHVR[LPHWLOPWLRFLWLGLOLO  ĺ  GHVR[LP WLRDGHQLOLO  ĺ PWLRWLPLGLOLO  ĺ PWLRWLPLGLOLO  ĺ  GHVR[LPWLRJXDQLOLO  ĺ  GHVR[LP WLRDGHQLOLO  ĺ  GHVR[LPHWLOPWLRFLWLGLOLO  ĺ   O PHWR[LHWLO DGHQLOLO  ĺ  O PHWR[LHWLO  PHWLOFLWLGLOLO  ĺ  O PHWR[LHWLO PHWLOFLWLGLOLO  ĺ  O PHWR[LHWLO PWLRDGHQLOLO  ĺ  O  PHWR[LHWLO PHWLOFLWLGLQD reducción de la síntesis de huntingtina anormale    &+1236        WUD]SLUREHQXP  WUD]SLUREHQ ^>F\FORKH[\OR[R R[RSKHQ\OEXW\O  WULD]DVSLUR>@GHFDQ\O@PHWK\O`EHQ]RLFDFLG prokinetic agent  WUD]SLUREqQH DFLGH^>F\FORKH[\OR[R R[RSKpQ\OEXW\O  WULD]DVSLUR>@GpFDQ\O@PpWK\O`EHQ]RwTXH accélérateur du transit intestinal  WUD]SLUREpQ iFLGR^>FLFORKH[LOR[R R[RIHQLOEXWLO  WULD]DVSLUR>@GHFDQLO@PHWLO`EHQ]RLFR estimulante de la motilidad intestinal    &+12       WUHSURVWLQLOXPSDOPLWLOXP  WUHSURVWLQLOSDOPLWLO KH[DGHF\O ^ RRDSDS K\GUR[\> S  K\GUR[\RFW\O@DDKH[DK\GURH F\FORSHQWD>b@QDSKWKDOHQ\O`R[\ DFHWDWH vasodilator     351 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019 WUpSURVWLQLOSDOPLWLO ^ RRDSDS K\GUR[\> S K\GUR[\RFW\O@ DDKH[DK\GURHF\FORSHQWD>b@QDSKWDOpQ \O`R[\ DFpWDWHGHKH[DGpF\OH vasodilatateur  WUHSURVWLQLOSDOPLWLOR ^ RRDSDS KLGUR[L> S KLGUR[LRFWLO@ DDKH[DKLGURHFLFORSHQWD>b@QDIWDOHQ LO`R[L DFHWDWRGHKH[DGHFLOR vasodilatador    &+2      YHOVHFRUDWXP  YHOVHFRUDW ^> RS  GLIOXRURSURSDQDPLGR   GLK\GUREHQ]RGLR[LQ\O SURSR[\@HLQGD]RO \O`N> R R[RODQ\O@EHQ]DPLGH glucocorticoid receptor agonist, anti-inflammatory  YHOVpFRUDW ^> RS  GLIOXRURSURSDQDPLGR   GLK\GUREHQ]RGLR[LQ\O SURSR[\@HLQGD]RO \O`N> R R[RODQ\O@EHQ]DPLGH agoniste des récepteurs glucocorticoids, anti- inflamamtoire  YHOVHFRUDW ^> RS  GLIOXRURSURSDQDPLGR   GLKLGUREHQ]RGLR[LQLO SURSR[L@HLQGD]ROLO` N> R R[RODQLO@EHQ]DPLGD agonista de los receptores glucocorticoides, antiinflamatorio    &+)12       YHYHULPHUXP  YHYHULPHU SRO\>NNGL SURSHQ\O HWKDQHGLDPLQHco NNGL SURSHQ\O SURSDQHGLDPLQHcoSURS HQDPLQH § @SURGXFHGE\FURVVOLQNLQJRI SRO\>NNGL SURSHQ\O SURSDQHGLDPLQH co SURSHQDPLQH § @ZLWKGLFKORURHWKDQH  PRO DQGQHXWUDOL]DWLRQ  hydrochloric acid binding polymer 352 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121   YpYpULPqUH SRO\>NNGL SURSpQ\O pWKDQHGLDPLQHco NNGL SURSpQ\O SURSDQHGLDPLQHcoSURS pQDPLQH § @SURGXLWSDUUpWLFXODWLRQGH SRO\>NNGL SURSpQ\O SURSDQHGLDPLQH co SURSpQDPLQH § @DYHFOHGLFKORURpWKDQH PRO HWQHXWUDOLVDWLRQ polymère liant l'acide chlorhydrique  YHYHUtPHUR SROL>NNGL SURSHQLO HWDQRGLDPLQDco NNGL SURSHQLO SURSDQRGLDPLQDcoSURS HQDPLQD § @SURGXFLGRSRUHQWUHFUX]DPLHQWR GHSROL>NNGL SURSHQLO SURSDQRGLDPLQD  coSURSHQDPLQD § @FRQGLFORURHWDQR  PRO \QHXWUDOL]DFLyQ polímero de unión al ácido clorhídrico    > &+1 a &+1 a  &+1 a@QQ ’      YLERVWROLPDEXP  YLERVWROLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens 7,*,7 7FHOOLPPXQRUHFHSWRUZLWK,JGRPDLQDQG,7,09VHW ,JPHPEHU96,*9VHWDQGWUDQVPHPEUDQH PHPEHU9670 @KXPDQL]HGPRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQKXPDQL]HG  >9+ Homo sapiens ,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*   *P &+.    KLQJH   &+  &+'  /    &+6    @   GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG    >9.$33$ Homo sapiens,*.9    ,*.-   >@   Homo sapiens ,*.&   .P$  9      @GLPHU   ELVGLVXOILGH SURGXFHGLQ&KLQHVH+DPVWHU2YDU\ &+2 FHOOV JO\FRIRUPDOID immunomodulator, antineoplastic  YLERVWROLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens 7,*,7 LPPXQRUpFHSWHXUGHVO\PSKRF\WHV7DYHFGRPDLQH,J HW,7,0PHPEUHGHO ,J9VHW96,*PHPEUHGH O ,J9VHWHWUpJLRQWUDQVPHPEUDQH9670 @ DQWLFRUSVPRQRFORQDOKXPDQLVp    353 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019   FKDvQHORXUGHJDPPDKXPDQLVpH  >9+ Homo sapiens ,*+9    ,*+' ,*+-    >@  Homo sapiens,*+*   *P &+.    FKDUQLqUH  &+  &+'  /    &+6     @  GLVXOIXUHDYHFODFKDvQHOpJqUH NDSSDKXPDQLVpH   >9.$33$ Homo sapiens ,*.9   ,*.-   >@    Homo sapiens ,*.&   .P$  9     @ GLPqUH   ELVGLVXOIXUHSURGXLWGDQVGHV FHOOXOHVRYDULHQQHVGHKDPVWHUVFKLQRLV &+2 JO\FRIRUPH DOID immunomodulateur, antinéoplasique  YLERVWROLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens 7,*,7 LQPXQRUHFHSWRUGHORVOLQIRFLWRV7FRQGRPLQLR,JH,7,0 PLHPEURGHOD,J9VHW96,*PLHPEURGHOD,J9VHW\ UHJLyQWUDQVPHPEUDQD9670 @DQWLFXHUSRPRQRFORQDO KXPDQL]DGR FDGHQDSHVDGDJDPPDKXPDQL]DGD  >9+ Homo sapiens ,*+9    ,*+' ,*+-    >@  Homo sapiens,*+*   *P &+.    ELVDJUD  &+  &+'  /    &+6     @  GLVXOIXURFRQODFDGHQDOLJHUD NDSSDKXPDQL]DGD   >9.$33$ Homo sapiens ,*.9   ,*.-   >@    Homo sapiens ,*.&   .P$  9     @ GtPHUR   ELVGLVXOIXURSURGXFLGRHQODV FpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID inmunomodulador, antineoplásico       +HDY\ FKDLQ  &KDvQH ORXUGH  &DGHQD SHVDGD EVQLVQSGAE VKKPGSSVKV SCKASGYTFS SYVMHWVRQA PGQGLEWIGY 50 IDPYNDGAKY AQKFQGRVTL TSDKSTSTAY MELSSLRSED TAVYYCARGG 100 PYGWYFDVWG QGTTVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150 YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200 ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250 DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300 TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350 YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400 DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK 449 /LJKW FKDLQ  &KDvQH OpJqUH  &DGHQD OLJHUD DIQMTQSPSS LSASVGDRVT ITCRASEHIY SYLSWYQQKP GKVPKLLIYN 50 AKTLAEGVPS RFSGSGSGTD FTLTISSLQP EDVATYYCQH HFGSPLTFGQ 100 GTRLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150 DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200 LSSPVTKSFN RGEC 214 3RVWWUDQVODWLRQDO PRGLILFDWLRQV 'LVXOILGH EULGJHV ORFDWLRQ  3RVLWLRQ GHV SRQWV GLVXOIXUH  3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR ,QWUD+ &&             ,QWUD/ &&         ,QWHU+/ K &/     ,QWHU++ K  K    1JO\FRV\ODWLRQ VLWHV  6LWHV GH 1JO\FRV\ODWLRQ  3RVLFLRQHV GH 1JOLFRVLODFLyQ + &+ 1   )XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV  JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV FRPSOH[HV IXFRV\OpV  JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV &WHUPLQDO O\VLQH FOLSSLQJ + &+6 .      354 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121   YXSDQRUVHQXP  YXSDQRUVHQ allPambo O > DFHWDPLGRGHR[\ȕ' JDODFWRS\UDQRV\O R[\@ELV^> ^> DFHWDPLGRGHR[\ ȕ'JDODFWRS\UDQRV\O R[\@KH[\O`DPLQR R[RSURSR[\@PHWK\O` K\GUR[\WHWUDR[RGLR[DWULD]DȜ SKRVSKDRFWDFRVDQ\O  O PHWKR[\HWK\O PWKLRJXDQ\O\O  ĺ  O PHWKR[\HWK\O JXDQ\O\O  ĺ  O  PHWKR[\HWK\O DGHQ\O\O  ĺ  O PHWKR[\HWK\O  PHWK\OF\WLG\O\O  ĺ  O PHWKR[\HWK\O DGHQ\O\O  ĺ  PWKLRWK\PLG\O\O  ĺ PWKLRWK\PLG\O\O  ĺ  GHR[\P WKLRJXDQ\O\O  ĺ  GHR[\PHWK\OPWKLRF\WLG\O\O  ĺ   GHR[\PHWK\OPWKLRF\WLG\O\O  ĺ  GHR[\P WKLRDGHQ\O\O  ĺ  GHR[\PWKLRJXDQ\O\O  ĺ P WKLRWK\PLG\O\O  ĺ  GHR[\PWKLRDGHQ\O\O  ĺ   GHR[\PWKLRDGHQ\O\O  ĺ  O PHWKR[\HWK\O  PHWK\OXULG\O\O  ĺ  O PHWKR[\HWK\O PHWK\OF\WLG\O\O  ĺ  O PHWKR[\HWK\O PWKLRJXDQ\O\O  ĺ  O  PHWKR[\HWK\O PHWK\OPWKLRF\WLG\O\O  ĺ  O  PHWKR[\HWK\O DGHQRVLQH antihyperlipidaemic  YXSDQRUVHQ toutPambo O > DFpWDPLGRGpVR[\ȕ' JDODFWRS\UDQRV\O R[\@ELV^> ^> DFpWDPLGR GpVR[\ȕ'JDODFWRS\UDQRV\O R[\@KH[\O`DPLQR  R[RSURSR[\@PpWK\O`K\GUR[\WpWUDR[RGLR[D WULD]DȜSKRVSKDRFWDFRVDQ\O  O  PpWKR[\pWK\O PWKLRJXDQ\O\O  ĺ  O  PpWKR[\pWK\O JXDQ\O\O  ĺ  O PpWKR[\pWK\O DGpQ\O\O  ĺ  O PpWKR[\pWK\O PpWK\OF\WLG\O\O  ĺ  O PpWKR[\pWK\O DGpQ\O\O  ĺ PWKLRWK\PLG\O\O  ĺ P WKLRWK\PLG\O\O  ĺ  GpVR[\PWKLRJXDQ\O\O  ĺ   GpVR[\PpWK\OPWKLRF\WLG\O\O  ĺ  GpVR[\PpWK\OP WKLRF\WLG\O\O  ĺ  GpVR[\PWKLRDGpQ\O\O  ĺ   GpVR[\PWKLRJXDQ\O\O  ĺ PWKLRWK\PLG\O\O  ĺ   GpVR[\PWKLRDGpQ\O\O  ĺ  GpVR[\PWKLRDGpQ\O\O  ĺ  O PpWKR[\pWK\O PpWK\OXULG\O\O  ĺ  O  PpWKR[\pWK\O PpWK\OF\WLG\O\O  ĺ  O PpWKR[\pWK\O  PWKLRJXDQ\O\O  ĺ  O PpWKR[\pWK\O PpWK\OP WKLRF\WLG\O\O  ĺ  O PpWKR[\pWK\O DGpQRVLQH antihyperlipidémiant  YXSDQRUVpQ todoPambo O > DFHWDPLGRGHVR[Lȕ' JDODFWRSLUDQRVLO R[L@ELV^> ^> DFHWDPLGRGHVR[Lȕ 'JDODFWRSLUDQRVLO R[L@KH[LO`DPLQR R[RSURSR[L@PHWLO` KLGUR[LWHWUDR[RGLR[DWULD]DȜ IRVIDRFWDFRVDQLO  O PHWR[LHWLO PWLRJXDQLOLO  ĺ   O PHWR[LHWLO JXDQLOLO  ĺ  O PHWR[LHWLO DGHQLOLO  ĺ  O PHWR[LHWLO PHWLOFLWLGLOLO  ĺ  O  PHWR[LHWLO DGHQLOLO  ĺ PWLRWLPLGLOLO  ĺ PWLRWLPLGLOLO  ĺ  GHVR[LPWLRJXDQLOLO  ĺ  GHVR[LPHWLOP WLRFLWLGLOLO  ĺ  GHVR[LPHWLOPWLRFLWLGLOLO  ĺ   GHVR[LPWLRDGHQLOLO  ĺ  GHVR[LPWLRJXDQLOLO  ĺ P WLRWLPLGLOLO  ĺ  GHVR[LPWLRDGHQLOLO  ĺ  GHVR[LP WLRDGHQLOLO  ĺ  O PHWR[LHWLO PHWLOXULGLOLO  ĺ  O PHWR[LHWLO PHWLOFLWLGLOLO  ĺ  O PHWR[LHWLO P WLRJXDQLOLO  ĺ  O PHWR[LHWLO PHWLOPWLRFLWLGLOLO  ĺ  O PHWR[LHWLO DGHQRVLQD antihiperlipémico   355 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019  &+1236       [LOLHUWLQLEXP  [LOLHUWLQLE DRDR N> HWK\Q\ODQLOLQR PHWKR[\TXLQD]ROLQ \O@PHWK\OKH[DK\GURS\UUROR>b@S\UUROH H  FDUER[DPLGH tyrosine kinase inhibitor, antineoplastic  [LOLHUWLQLE DRDR N> pWK\Q\ODQLOLQR PpWKR[\TXLQD]ROLQ \O@PpWK\OKH[DK\GURS\UUROR>b@S\UUROH H  FDUER[DPLGH inhibiteur de la tyrosine kinase, antinéoplasique  [LOLHUWLQLE DRDR N> HWLQLODQLOLQR PHWR[LTXLQD]ROLQLO@ PHWLOKH[DKLGURSLUUROR>b@SLUURO H FDUER[DPLGD inhibidor de la tirosina quinasa, antineoplásico    &+12   &+ 2 1 2 + 1 1 1 + &+ +1 1 +  &+   ]DJRWHQHPDEXP  ]DJRWHQHPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens0$37 PLFURWXEXOHDVVRFLDWHGSURWHLQWDXWDX @KXPDQL]HG PRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQKXPDQL]HG  >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*  &+  KLQJH6!3    &+   &+  &+6.!GHO    @   GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG    >9.$33$ Homo sapiens,*.9    ,*.-   >@   Homo sapiens ,*.&   .P$  9      @GLPHU  ELVGLVXOILGHSURGXFHGLQ &KLQHVH+DPVWHU2YDU\ &+2 *6FHOOOLQHJO\FRIRUPDOID  immunomodulator (Alzheimer's disease)   356 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121 ]DJRWpQpPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens 0$37 SURWpLQHWDXDVVRFLpHDX[PLFURWXEXOHVWDX @ DQWLFRUSVPRQRFORQDOKXPDQLVp FKDvQHORXUGHJDPPDKXPDQLVpH  >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*  &+  FKDUQLqUH6!3     &+  &+  &+6.!GHO    @  GLVXOIXUHDYHFODFKDvQH OpJqUHNDSSDKXPDQLVpH   >9.$33$ Homo sapiens,*.9   ,*.-    >@   Homo sapiens,*.&    .P$  9     @GLPqUH  ELVGLVXOIXUHSURGXLWGDQVGHV FHOOXOHVRYDULHQQHVGHKDPVWHUVFKLQRLV &+2 OLJQpH FHOOXODLUH*6JO\FRIRUPHDOID immunomodulateur (maladie d'Alzheimer)  ]DJRWHQHPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens0$37 SURWHtQDWDXDVRFLDGDDORVPLFURW~EXORVWDX @ DQWLFXHUSRPRQRFORQDOKXPDQL]DGR FDGHQDSHVDGDJDPPDKXPDQL]DGD  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+*  &+  ELVDJUD6!3    &+  &+  &+6 .!GHO    @  GLVXOIXURFRQOD FDGHQDOLJHUDNDSSDKXPDQL]DGD   >9.$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens,*.&   .P$  9     @ GtPHUR  ELVGLVXOIXURSURGXFLGRHQ ODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2 OtQHD FHOXODU*6JOLFRIRUPDDOID inmunomodulador (enfermedad de Alzheimer)          357 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019   ]DQLGDWDPDEXP  ]DQLGDWDPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens (5%% HSLGHUPDOJURZWKIDFWRUUHFHSWRUUHFHSWRUW\URVLQHSURWHLQ NLQDVHHUE%(*)5+(5+(5SFHUE%1(8 &' @KXPDQL]HGPRQRFORQDODQWLERG\ELSDUDWRSLF WDUJHWLQJWZRGLIIHUHQWQRQRYHUODSSLQJHSLWRSHVRQ(5%%  JDPPDKHDY\FKDLQKXPDQL]HG  >9+ Homo sapiens ,*+9    ,*+' ,*+-   >@   Homo sapiens,*+* *P &+.    KLQJH  &+  &+7!9  /!<  '  /  )!$   <!9    &+6.!GHO    @   GLVXOILGHZLWKNDSSDOLJKWFKDLQKXPDQL]HG   >9 .$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens,*.&   .P $  9     @ JDPPDKHDY\FKDLQ9.$33$9+&+&+KXPDQL]HG    >9.$33$ Homo sapiens,*.9    ,*.-   >@   PHUOLQNHU    9+ Homo sapiens,*+9    ,*+' ,*+-   >@   GLDODQ\O   Homo sapiens,*+*  KLQJH&!6    &+  &+7!9  '  /  7!/  .!/  7!:    &+6.!GHO     @ GLPHU   ELVGLVXOILGHSURGXFHGLQ&KLQHVH +DPVWHU2YDU\ &+2 JO\FRIRUPDOID immunomodulator, antineoplastic  ]DQLGDWDPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens(5%% UpFHSWHXUGXIDFWHXUGHFURLVVDQFHpSLGHUPLTXH UpFHSWHXUW\URVLQHSURWpLQHNLQDVHHUE%(*)5+(5 +(5SFHUE%1(8&' @DQWLFRUSV PRQRFORQDOKXPDQLVpELSDUDWRSLTXH FLEODQWGHX[ pSLWRSHVGLIIpUHQWVQRQFKHYDXFKDQWVVXU(5%%  FKDvQHORXUGHJDPPDKXPDQLVpH  >9+ Homo sapiens,*+9    ,*+' ,*+-    >@  Homo sapiens,*+* *P &+     FKDUQLqUH  &+   &+7!9  /!<  '  /   )!$  <!9    &+6.!GHO    @  GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSD KXPDQLVpH   >9.$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens ,*.&   .P$  9     @ FKDvQHORXUGHJDPPD9.$33$9+&+&+KXPDQLVpH   >9.$33$ Homo sapiens,*.9    ,*.-   >@   PHUOLQNHU    9+ Homo sapiens,*+9    ,*+'  ,*+-   >@   GLDODQ\O    Homo sapiens,*+*  FKDUQLqUH&!6     &+  &+7!9  '  /  7!/  .!/  7!:     &+6.!GHO     @GLPqUH    ELVGLVXOIXUHSURGXLWGDQVGHVFHOOXOHVRYDULHQQHVGH KDPVWHUVFKLQRLV &+2 JO\FRIRUPHDOID immunomodulateur, antinéoplasique    358 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121  ]DQLGDWDPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens(5%% UHFHSWRUGHOIDFWRUGHFUHFLPLHQWRHSLGpUPLFRUHFHSWRU WLURVLQDSURWHtQDNLQDVDHUE%(*)5+(5+(5 SFHUE%1(8&' @DQWLFXHUSRPRQRFORQDO KXPDQL]DGRELSDUDWySLFR FX\DGLDQDVRQGRVHStWRSRV GLIHUHQWHVQRVRODSDEOHVHQ(5%%  FDGHQDSHVDGDJDPPDKXPDQL]DGD  >9+ Homo sapiens,*+9    ,*+' ,*+-    >@  Homo sapiens,*+* *P &+    ELVDJUD  &+  &+ 7!9  /!<  '  /  )!$   <!9    &+6.!GHO    @   GLVXOIXURFRQODFDGHQDOLJHUDNDSSDKXPDQL]DGD    >9.$33$ Homo sapiens,*.9    ,*.-   >@   Homo sapiens,*.&   .P$  9     @ FDGHQDSHVDGDJDPPD9.$33$9+&+&+KXPDQL]DGD   >9.$33$ Homo sapiens,*.9    ,*.-   >@   FRQHFWRUPHU    9+ Homo sapiens,*+9    ,*+'  ,*+-   >@   GLDODQLO    Homo sapiens,*+*  ELVDJUD&!6     &+  &+7!9  '  /  7!/  .!/  7!:    &+6.!GHO     @ GtPHUR   ELVGLVXOIXURSURGXFLGRHQODV FpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2 JOLFRIRUPDDOID inmunomodulador, antineoplásico       +HDY\ FKDLQ  &KDvQH ORXUGH  &DGHQD SHVDGD GEVQLVESGG GLVQPGGSLR LSCAASGFTF ADYTMDWVRQ APGKGLEWVG 50 DVNPNSGGSI YNQRFKGRFT FSVDRSKNTL YLQMNSLRAE DTAVYYCARN 100 LGPSFYFDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150 DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200 YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250 KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300 STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350 VYVYPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400 LDSDGSFALV SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG 449 +HDY\ FKDLQ  &KDvQH ORXUGH  &DGHQD SHVDGD GDIQMTQSPS SLSASVGDRV TITCRASQDV NTAVAWYQQK PGKAPKLLIY 50 SASFLYSGVP SRFSGSRSGT DFTLTISSLQ PEDFATYYCQ QHYTTPPTFG 100 QGTKVEIKGG SGGGSGGGSG GGSGGGSGEV QLVESGGGLV QPGGSLRLSC 150 AASGFNIKDT YIHWVRQAPG KGLEWVARIY PTNGYTRYAD SVKGRFTISA 200 DTSKNTAYLQ MNSLRAEDTA VYYCSRWGGD GFYAMDYWGQ GTLVTVSSAA 250 EPKSSDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR TPEVTCVVVD 300 VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN 350 GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYVLPPSR DELTKNQVSL 400 LCLVKGFYPS DIAVEWESNG QPENNYLTWP PVLDSDGSFF LYSKLTVDKS 450 RWQQGNVFSC SVMHEALHNH YTQKSLSLSP G 481 /LJKW FKDLQ  &KDvQH OpJqUH  &DGHQD OLJHUD GDIQMTQSPS SLSASVGDRV TITCKASQDV SIGVAWYQQK PGKAPKLLIY 50 SASYRYTGVP SRFSGSGSGT DFTLTISSLQ PEDFATYYCQ QYYIYPATFG 100 QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150 VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200 GLSSPVTKSF NRGEC 215 3RVWWUDQVODWLRQDO PRGLILFDWLRQV 'LVXOILGH EULGJHV ORFDWLRQ  3RVLWLRQ GHV SRQWV GLVXOIXUH  3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR ,QWUD+ &&             ,QWUD/ &&     ,QWHU+/ K &/   ,QWHU++ K  K    1JO\FRV\ODWLRQ VLWHV  6LWHV GH 1JO\FRV\ODWLRQ  3RVLFLRQHV GH 1JOLFRVLODFLyQ + &+ 1   )XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV  JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV FRPSOH[HV IXFRV\OpV  JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV     359 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019 ]HOPLQHPDEXP  ]HOPLQHPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens $'&<$35 DGHQ\ODWHF\FODVHDFWLYDWLQJSRO\SHSWLGH $'&<$3 W\SH,UHFHSWRUSLWXLWDU\DGHQ\ODWHF\FODVH DFWLYDWLQJSRO\SHSWLGH 3$&$3 W\SH,UHFHSWRU3$& 3$&5 @PRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQKXPDQL]HG  >9+ Homo sapiens,*+9    ,*+' ,*+-    >@  Homo sapiens,*+* Y*P!*P Q*P &+.    KLQJH   &+1!*    &+(  0    &+6    @  GLVXOILGH ZLWKNDSSDOLJKWFKDLQKXPDQL]HG   >9.$33$ Homo sapiens,*.9   ,*.-   >@    Homo sapiens,*.&   .P$   9     @ GLPHU  ELVGLVXOILGHSURGXFHGLQ&KLQHVH +DPVWHU2YDU\ &+2 FHOOOLQHQRQJO\FRV\ODWHG immunomodulator  ]HOPLQpPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens $'&<$35 UpFHSWHXUGHW\SH,GXSRO\SHSWLGHDFWLYDQW O DGpQ\ODWHF\FODVH $'&<$3 UpFHSWHXUGHW\SH,GX SRO\SHSWLGHDFWLYDQWO DGpQ\ODWHF\FODVHSLWXLWDLUH 3$&$3  3$&3$&5 @DQWLFRUSVPRQRFORQDO FKDvQHORXUGHJDPPDKXPDQLVpH  >9+ Homo sapiens,*+9    ,*+' ,*+-    >@  Homo sapiens,*+* Y*P!*P Q*P &+.    FKDUQLqUH   &+1!*    &+(  0    &+6    @   GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSDKXPDQLVpH    >9.$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens,*.&    .P$  9     @ GLPqUH  ELVGLVXOIXUHSURGXLWGDQVGHV FHOOXOHVRYDULHQQHVGHKDPVWHUVFKLQRLV &+2 QRQ JO\FRV\Op immunomodulateur  ]HOPLQHPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens $'&<$35 UHFHSWRUGHWLSR,GHSROLSpSWLGRDFWLYDGRUGH ODDGHQLODWRFLFODVD $'&<$3 UHFHSWRUGHWLSR,GH SROLSpSWLGRDFWLYDGRUGHODDGHQLODWRFLFODVDSLWXLWDULD 3$&$3 3$&3$&5 @DQWLFXHUSRPRQRFORQDO FDGHQDSHVDGDJDPPDKXPDQL]DGD  >9+ Homo sapiens,*+9    ,*+' ,*+-    >@  Homo sapiens,*+* Y*P!*P Q*P &+.    ELVDJUD   &+1!*    &+(  0    &+6    @  GLVXOIXUR FRQODFDGHQDOLJHUDNDSSDKXPDQL]DGD   >9.$33$ Homo sapiens,*.9   ,*.-    >@   Homo sapiens,*.&   .P$  9     @ GtPHUR  ELVGLVXOIXURSURGXFLGRHQODV FpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2 QRJOLFRVLODGR inmunomodulador   360 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121        ]HOTXLVWLQHOXP  ]HOTXLVWLQHO tertEXW\O S > SR DPLQRK\GUR[\ R[REXWDQ\O@R[RGLD]DVSLUR>@RFWDQH FDUER[\ODWH N-methyl-D-aspartate (NMDA) receptor partial agonist  ]HOTXLVWLQHO S > SR DPLQRK\GUR[\R[REXWDQ\O@ R[RGLD]DVSLUR>@RFWDQHFDUER[\ODWHGHtert EXW\OH agoniste partiel des récepteurs du NMDA  ]HOTXLVWLQHO S > SR DPLQRKLGUR[LR[REXWDQLO@ R[RGLD]DVSLUR>@RFWDQRFDUER[LODWRGHterc EXWLOR agonista parcial del receptor de NMDA    &+12        ]LOGLVWURJHQXPYDURSDUYRYHFXP  ]LOGLVWURJHQHYDURSDUYRYHF $UHFRPELQDQWQRQUHSOLFDWLQJDGHQRDVVRFLDWHGYLUXV W\SH U$$95HS&DS YHFWRUHQFRGLQJKXPDQ PLFURG\VWURSKLQ Kȝ' XQGHUFRQWURORI&. PXVFOHFUHDWLQHNLQDVHSURPRWHUDQGHQKDQFHU HOHPHQWV  gene therapy (Duchenne muscular dystrophy) 361 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019   ]LOGLVWURJqQHYDURSDUYRYHF YHFWHXUYLUDODGpQRDVVRFLpGHW\SHUHFRPELQDQW QRQUpSOLTXDQW U$$95HS&DS FRGDQWSRXUOD PLFURG\VWURSKLQHKXPDLQH KP' VRXVOHFRQWU{OH GHO DFWLYDWHXUSURPRWHXUGHODFUpDWLQHNLQDVH PXVFXODLUH&. thérapie génique (dystrophie musculaire de Duchenne)  ]LOGLVWURJpQYDURSDUYRYHF 8QYHFWRUGHYLUXVDGHQRDVRFLDGRUHFRPELQDQWHQR UHSOLFDWLYRGHOWLSR U$$95HS&DS TXHFRGLILFD SDUDODPLFURGLVWURILQDKXPDQD KP' EDMRHO FRQWUROGHOSURPRWRU\HOHPHQWRVSRWHQFLDGRUHV HQKDQFHU GHODFUHDWLQDTXLQDVD&.GHP~VFXOR terapia génica (distrofia muscular de Duchenne)         ]LOWLYHNLPDEXP  ]LOWLYHNLPDE LPPXQRJOREXOLQ*NDSSDDQWL>Homo sapiens,/ LQWHUOHXNLQ,/ @PRQRFORQDODQWLERG\ JDPPDKHDY\FKDLQKXPDQL]HG  >9+ Homo sapiens ,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*  *PQ*P &+5    KLQJH  &+0!<  6!7  7!(    &+(  0     &+6    @  GLVXOILGHZLWK NDSSDOLJKWFKDLQHomo sapiens   >9.$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens ,*.&   .P$  9     @ GLPHU   ELVGLVXOILGHSURGXFHGLQ &KLQHVH+DPVWHU2YDU\ &+2 *6FHOOOLQHJO\FRIRUP DOID immunomodulator  ]LOWLYpNLPDE LPPXQRJOREXOLQH*NDSSDDQWL>Homo sapiens ,/ LQWHUOHXNLQH,/ @DQWLFRUSVPRQRFORQDO FKDvQHORXUGHJDPPDKXPDQLVpH  >9+ Homo sapiens,*+9    ,*+' ,*+-   >@  Homo sapiens,*+*  *PQ*P &+5    FKDUQLqUH   &+0!<  6!7   7!(    &+(  0    &+6    @   GLVXOIXUHDYHFODFKDvQHOpJqUHNDSSDHomo sapiens   >9.$33$ Homo sapiens,*.9   ,*.-   >@   Homo sapiens ,*.&   .P$  9     @ GLPqUH   ELVGLVXOIXUHSURGXLWGDQV GHVFHOOXOHVRYDULHQQHVGHKDPVWHUVFKLQRLV &+2  OLJQpHFHOOXODLUH*6JO\FRIRUPHDOID immunomodulateur  ]LOWLYHNLPDE LQPXQRJOREXOLQD*NDSSDDQWL>Homo sapiens ,/ LQWHUOHXNLQD,/ @DQWLFXHUSRPRQRFORQDO    362 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121      FDGHQDSHVDGDJDPPDKXPDQL]DGD  >9+ Homo sapiens,*+9    ,*+'  ,*+-   >@  Homo sapiens ,*+* *PQ*P &+5     ELVDJUD  &+0!<  6!7  7!(    &+(  0    &+6    @   GLVXOIXURFRQODFDGHQDOLJHUDNDSSDHomo sapiens   >9.$33$ Homo sapiens,*.9    ,*.-   >@    Homo sapiens ,*.&   .P$   9     @ GtPHUR   ELVGLVXOIXURSURGXFLGRHQ ODVFpOXODVRYiULFDVGHKDPVWHUVFKLQRV &+2 OtQHD FHOXODU*6JOLFRIRUPDDOID inmunomodulador       +HDY\ FKDLQ  &KDvQH ORXUGH  &DGHQD SHVDGD EVQLVESGGG LVQPGGSLRL SCAASGFTIS SNYMIWVRQA PGKGLEWVSD 50 LYYYAGDTYY ADSVKGRFTM SRDISKNTVY LQMNSLRAED TAVYYCARWA 100 DDHPPWIDLW GRGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150 DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200 YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250 KDTLYITREP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300 STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350 VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400 LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450 /LJKW FKDLQ  &KDvQH OpJqUH  &DGHQD OLJHUD DIQMTQSPST LSASVGDRVT ITCRASQGIS SWLAWYQQKP GKAPKVLIYK 50 ASTLESGVPS RFSGSGSGTE FTLTISSLQP DDFATYYCQQ SWLGGSFGQG 100 TKLEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150 NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200 SSPVTKSFNR GEC 213 3RVWWUDQVODWLRQDO PRGLILFDWLRQV 'LVXOILGH EULGJHV ORFDWLRQ  3RVLWLRQ GHV SRQWV GLVXOIXUH  3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR ,QWUD+ &&             ,QWUD/ &&         ,QWHU+/ K &/     ,QWHU++ K  K    1JO\FRV\ODWLRQ VLWHV  6LWHV GH 1JO\FRV\ODWLRQ  3RVLFLRQHV GH 1JOLFRVLODFLyQ + &+ 1   )XFRV\ODWHG FRPSOH[ ELDQWHQQDU\ &+2W\SH JO\FDQV  JO\FDQHV GH W\SH &+2 ELDQWHQQDLUHV  FRPSOH[HV IXFRV\OpV  JOLFDQRV GH WLSR &+2 ELDQWHQDULRV FRPSOHMRV IXFRVLODGRV    ]RULIHUWLQLEXP  ]RULIHUWLQLE  FKORURIOXRURDQLOLQR PHWKR[\TXLQD]ROLQ\O R GLPHWK\OSLSHUD]LQHFDUER[\ODWH tyrosine kinase inhibitor, antineoplastic  ]RULIHUWLQLE R GLPpWK\OSLSpUD]LQHFDUER[\ODWHGH  FKORURIOXRURDQLOLQR PpWKR[\TXLQD]ROLQ\OH inhibiteur de la tyrosine kinase, antinéoplasique  ]RULIHUWLQLE R GLPHWLOSLSHUD]LQDFDUER[LODWRGH FORUR IOXRURDQLOLQR PHWR[LTXLQD]ROLQLOR inhibidor de la tirosina quinasa, antineoplásico   363 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019  &+&O)12      # Electronic structure available on Mednet: http://mednet.who.int/ # Structure électronique disponible sur Mednet: http://mednet.who.int/ # Estructura electrónica disponible en Mednet: http://mednet.who.int/ KWWSZZZZKRLQWPHGLFLQHVVHUYLFHVLQQSXEOLFDWLRQHQ 364 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121 Names for Radicals and Groups Some substances for which a proposed international nonproprietary name has been established may be used in the form of salts or esters. The radicals or groups involved may be of complex composition and it is then inconvenient to refer to them in a systematic chemical nomenclature. Consequently, shorter nonproprietary names for some radicals and groups have been devised or selected, and they are suggested for use with the proposed international nonproprietary names. Dénominations applicables aux radicaux et groupes Certaines substances pour lesquelles une dénomination commune internationale proposée a été établie sont parfois utilisées sous forme de sels ou d'esters. Les radicaux ou groupes correspondants sont alors quelques fois si complexes qu'il est malcommode de les désigner conformément à la nomenclature chimique systématique. Des dénominations communes abrégées ont donc été formées ou choisies pour certains d'entre eux et il est suggéré de les employer avec les dénominations communes internationales proposées. Denominaciones para Radicales y Grupos Ciertas sustancias para las cuales hay establecidas una denominación común internacional pueden usarse en forma de sales o de ésteres. Los radicales o grupos correspondientes pueden llegar a tener una composición tan compleja que resulte incómodo referirse a ellos mediante la nomenclatura química sistemática. Las siguientes denominaciones comunes abreviadas han sido ideadas o elegidas para algunos de estos radicales y grupos y se sugiere que se empleen con las denominaciones comunes internacionales propuestas     DUHQDFDUELOXP  DUHQDFDUELO ^ R > PHWK\OSURSDQR\O R[\@HWKR[\`FDUERQ\O  DUpQDFDUELO ^ R > PpWK\OSURSDQR\O R[\@pWKR[\`FDUERQ\OH  DUHQDFDUELO ^ R > PHWLOSURSDQRLO R[L@HWR[L`FDUERQLOR    &+2         FOH]XWRFOD[XP  FOH]XWRFOD[ RS  ^ SSSS  DQK\GURGLGHR[\/ glycero/guloRFW\ORQLFDFLG FDUER[\> S  GLK\GUR[\EXW\O@WHWUDPHWK\OKH[DR[R  SURSDQ\O > VXOIRHWKR[\ PHWK\O@GLK\GURH GLR[DSHQWDD]D  LVRTXLQROLQD   >@EHQ]RWKLD]ROD  S\ULGLQD  S\UD]ROD  S\UUROLGLQD   DGDPDQWDQD  EHQ]HQDKH[DFRVDSKDQ\O`DPLQR  FDUER[\R[RSURSDQ\ODQG RS  ^ SSSS  KH[DFRVDSKDQ\O`DPLQR FDUER[\R[RSURS\O   365 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019  FOp]XWRFOD[ RS  ^ SSSS  DFLGHDQK\GURGLGpVR[\/ glycéro/guloRFW\ORQLTXH FDUER[\> S GLK\GUR[\EXW\O@ WpWUDPpWK\OKH[DR[R SURSDQ\O  > VXOIRpWKR[\ PpWK\O@GLK\GURHGLR[D SHQWDD]D  LVRTXLQROLQD  >@EHQ]RWKLD]ROD   S\ULGLQD  S\UD]ROD  S\UUROLGLQD  DGDPDQWDQD   EHQ]pQDKH[DFRVDSKDQ\O`DPLQR FDUER[\R[RSURSDQ \OHHW RS  ^ SSSS «KH[DFRVDSKDQ \O`DPLQR FDUER[\R[RSURS\OH  FOH]XWRFOD[ RS  ^ SSSS  iFLGRDQKLGURGLGHVR[\/ glicero/guloRFWLORQLFR FDUER[L> S GLKLGUR[LEXWLO@ WHWUDPHWLOKH[DR[R SURSDQLO  > VXOIRHWR[L PHWLO@GLKLGURHGLR[D SHQWDD]D  LVRTXLQROLQD  >@EHQ]RWLD]ROD  SLULGLQD   SLUD]ROD  SLUUROLGLQD  DGDPDQWDQD   EHQFHQDKH[DFRVDIDQLO`DPLQR FDUER[LR[RSURSDQLOR\ RS  ^ SSSS KH[DFRVDIDQLO`DPLQR FDUER[L R[RSURSLOR    &+126 IRUWKH (for the reagent) VXFFLQLPLGHSUHFXUVRUJURXS    2 2 2 2 +& &+ 1 1 1+ 1+ FRQMXJDLVRQ +2& +& 2  + 2  2 +2& &2+ 2 1+ 62+ 1+ +& +2 2 2 +& 1+ 2 +2 2+ +2& 1 1 2 2 &+ 2 1+ 1 1 1 &+ 6 1 +2 2 &+  2+   FRUL[HWDQXP  FRUL[HWDQ ^>^ELV> K\GUR[\PHWK\OR[RGLK\GURS\ULGLQH FDUER[DPLGR HWK\O@DPLQR` ^ELV> K\GUR[\PHWK\OR[R GLK\GURS\ULGLQHFDUER[DPLGR HWK\O@DPLQR`PHWK\O SURS\O@DQLOLQR` R[REXWDQR\O  FRUL[pWDQ ^>^ELV> K\GUR[\PpWK\OR[RGLK\GURS\ULGLQH FDUER[DPLGR pWK\O@DPLQR` ^ELV> K\GUR[\PpWK\OR[R GLK\GURS\ULGLQHFDUER[DPLGR pWK\O@DPLQR`PpWK\O SURS\O@DQLOLQR` R[REXWDQR\OH  FRUL[HWiQ ^>^ELV> KLGUR[LPHWLOR[RGLKLGURSLULGLQD FDUER[DPLGR HWLO@DPLQR` ^ELV> KLGUR[LPHWLOR[R GLKLGURSLULGLQDFDUER[DPLGR HWLO@DPLQR`PHWLO SURSLO@DQLOLQR` R[REXWDQRLOR   366 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121    &+12 (for the acid)     GHUX[WHFDQXP  GHUX[WHFDQ RS > S EHQ]\O^> SS HWK\OIOXRURK\GUR[\ PHWK\OGLR[RKH[DK\GURHH EHQ]R>de@S\UDQR>  @LQGROL]LQR>b@TXLQROLQ\O@DPLQR` KH[DR[RR[DSHQWDD]DWULFRVDQ \O@GLR[RS\UUROLGLQ\O  GpUX[WpFDQ RS > S EHQ]\O^> SS pWK\OIOXRURK\GUR[\ PpWK\OGLR[RKH[DK\GURHH EHQ]R>de@S\UDQR>  @LQGROL]LQR>b@TXLQROLQ\O@DPLQR` KH[DR[RR[DSHQWDD]DWULFRVDQ \O@GLR[RS\UUROLGLQ\OH  GHUX[WHFiQ RS > S EHQFLO^> SS HWLOIOXRURKLGUR[L PHWLOGLR[RKH[DKLGURHH EHQ]R>de@SLUDQR>  @LQGROL]LQR>b@TXLQROLQLO@DPLQR` KH[DR[RR[DSHQWDD]DWULFRVDQ LO@GLR[RSLUUROLGLQLOR    &+)12  reagent       SDOPLWLOXP  SDOPLWLO KH[DGHF\O  SDOPLWLO Kp[DGpF\OH  SDOPLWLO KH[DGHFLOR    &+     367 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019  AMENDMENTS TO PREVIOUS LISTS MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES MODIFICACIONES A LAS LISTAS ANTERIORES 'HQRPLQDFLRQHV&RPXQHV,QWHUQDFLRQDOHV3URSXHVWDV '&,3URS /LVWD (Crónica de la OMS, Vol. 25, No. 3, 1971)  S suprimáse insertese  IOXRFLQyQLGR IOXRFLQRQLGD   'HQRPLQDFLRQHV&RPXQHV,QWHUQDFLRQDOHV3URSXHVWDV '&,3URS /LVWD (Crónica de la OMS, Vol. 26, No. 9, 1972)  S suprimáse insertese  FLFRUWyQLGR FLFRUWRQLGD   'HQRPLQDFLRQHV&RPXQHV,QWHUQDFLRQDOHV3URSXHVWDV '&,3URS /LVWD (Crónica de la OMS, Vol. 29, No. 3, 1975)  S suprimáse insertese  DPFLQyQLGR DPFLQRQLGD   'HQRPLQDFLRQHV&RPXQHV,QWHUQDFLRQDOHV3URSXHVWDV '&,3URS /LVWD (Crónica de la OMS, Vol. 31, No. 3, 1976)  S suprimáse insertese  EXGHVyQLGR EXGHVRQLGD    3URSRVHG,QWHUQDWLRQDO1RQSURSULHWDU\1DPHV 3URS,11 /LVW 'pQRPLQDWLRQVFRPPXQHVLQWHUQDWLRQDOHVSURSRVpHV '&,3URS /LVWH 'HQRPLQDFLRQHV&RPXQHV,QWHUQDFLRQDOHV3URSXHVWDV '&,3URS /LVWD (WHO Drug Information, Vol. 20, No. 2, 2006)   S LPLVRSDVHPXPPDQJDQXP   LPLVRSDVHPPDQJDQHVH replace the chemical name by the following  LPLVRSDVHPPDQJDQqVH remplacer le nom chimique par le suivant  LPLVRSDVHPPDQJDQHVR sustitúyase el nombre químico por el siguiente    PBPY  GLFKORULGR> RRRR WHWUDD]D   S\ULGLQD  GLF\FORKH[DQDF\FORXQGHFDSKDQH țNNNNN@PDQJDQHVH    PBPY  GLFKORULGR> RRRR WHWUDD]D   S\ULGLQD  GLF\FORKH[DQDF\FORXQGpFDSKDQH țNNNNN@PDQJDQqVH    PBPY  GLFORULGR> RRRR WHWUDD]D   SLULGLQD  GLFLFORKH[DQDFLFORXQGHFDIDQR țNNNNN@PDQJDQHVR  368 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121   3URSRVHG,QWHUQDWLRQDO1RQSURSULHWDU\1DPHV 3URS,11 /LVW 'pQRPLQDWLRQVFRPPXQHVLQWHUQDWLRQDOHVSURSRVpHV '&,3URS /LVWH 'HQRPLQDFLRQHV&RPXQHV,QWHUQDFLRQDOHV3URSXHVWDV '&,3URS /LVWD (WHO Drug Information, Vol. 21, No. 4, 2007)   S LPHJOLPLQXP   LPHJOLPLQ replace the chemical name and the structure by the following ones  LPpJOLPLQH remplacer le nom chimique et la structure par les suivants  LPHJOLPLQD sustitúyase el nombre químico y la estructura por los siguientes    R NNWULPHWK\OGLK\GURWULD]LQHGLDPLQH   R NNWULPpWK\OGLK\GURWULD]LQHGLDPLQH   R NNWULPHWLOGLKLGURWULD]LQDGLDPLQD      3URSRVHG,QWHUQDWLRQDO1RQSURSULHWDU\1DPHV 3URS,11 /LVW 'pQRPLQDWLRQVFRPPXQHVLQWHUQDWLRQDOHVSURSRVpHV '&,3URS /LVWH 'HQRPLQDFLRQHV&RPXQHV,QWHUQDFLRQDOHV3URSXHVWDV '&,3URS /LVWD (WHO Drug Information, Vol. 22, No. 2, 2008)  S suprimáse insertese  GHUTXDQWHO GHUFXDQWHO   3URSRVHG,QWHUQDWLRQDO1RQSURSULHWDU\1DPHV 3URS,11 /LVW 'pQRPLQDWLRQVFRPPXQHVLQWHUQDWLRQDOHVSURSRVpHV '&,3URS /LVWH 'HQRPLQDFLRQHV&RPXQHV,QWHUQDFLRQDOHV3URSXHVWDV '&,3URS /LVWD (WHO Drug Information, Vol. 24, No. 4, 2010)  S VROLWKURP\FLQ   VROLWKURP\FLQ replace the chemical name by the following one  VROLWKURP\FLQH remplacer le nom chimique par le suivant  VROLWURPLFLQD sustitúyase el nombre químico por el siguiente    DSRSRRRRRDR ^> DPLQRSKHQ\O H WULD]RO\O@EXW\O`HWK\OIOXRURPHWKR[\D KH[DPHWK\O^>WULGHR[\ GLPHWK\ODPLQR ȕ'xylo KH[RS\UDQRV\O@R[\`RFWDK\GURH>@R[DF\FORWHWUDGHFLQR> d@>@R[D]ROH HHH WHWURQH   DSRSRRRRRDR ^> DPLQRSKpQ\O H WULD]RO\O@EXW\O`pWK\OIOXRURPpWKR[\D KH[DPpWK\O^>WULGpVR[\ GLPpWK\ODPLQR ȕ'xylo KH[RS\UDQRV\O@R[\`RFWDK\GURH>@R[DF\FORWpWUDGpFLQR>d@R[D]ROH  HHH WpWURQH    DSRSRRRRRDR ^> DPLQRIHQLO H WULD]ROLO@EXWLO`HWLOIOXRURDKH[DPHWLO PHWR[L^>WULGHVR[L GLPHWLODPLQR ȕ'xilo KH[RSLUDQRVLO@R[L`RFWDKLGURH>@R[DFLFORWHWUDGHFLQR>d@>@R[D]RO  HHH WHWURQD  369 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019    3URSRVHG,QWHUQDWLRQDO1RQSURSULHWDU\1DPHV 3URS,11 /LVW 'pQRPLQDWLRQVFRPPXQHVLQWHUQDWLRQDOHVSURSRVpHV '&,3URS /LVWH 'HQRPLQDFLRQHV&RPXQHV,QWHUQDFLRQDOHV3URSXHVWDV '&,3URS /LVWD (WHO Drug Information, Vol. 31, No. 2, 2017)  S DUIROLWL[RULQXP   DUIROLWL[RULQ replace the CAS RN by the following  DUIROLWL[RULQH remplacer le numéro de registre du CAS par le suivant  DUIROLWL[RULQD sustitúyase el número de registro del CAS por el siguiente       S DYDOJOXFRVLGDVXPDOID   DYDOJOXFRVLGDVHDOID replace the description by the following one  DYDOJOXFRVLGDVHDOID remplacer la description par la suivante  DYDOJOXFRVLGDVDDOID sustitúyase la descripción por la siguiente    PRGLILHGKXPDQDFLGĮJOXFRVLGDVHSURGXFHGLQ&KLQHVHKDPVWHURYDU\ &+2 FHOOV JO\FRIRUPDOIDFRQMXJDWHGWRDV\QWKHWLFEUDQFKHGKH[DVDFFKDULGHFRQWDLQLQJWZR WHUPLQDOPDQQRVHSKRVSKDWH 03 YLDDPLQRR[\OLQNHUV SUHSURO\VRVRPDOĮJOXFRVLGDVH (&   KXPDQ   SHSWLGHQDWXUDO >$UJ+LV,OH@YDULDQWH[SUHVVHGLQ&+2FHOOVJO\FRIRUPDOIDZLWKaVLDO\O HQGJURXSVRIJO\FDQUHVLGXHVEHLQJR[LGL]HGDQGFKHPLFDOO\PRGLILHGWR DFHWDPLGRWULGHR[\> E  R[R^> ^O OSKRVSKRQRĮ' PDQQRS\UDQRV\O  ĺ OĮ'PDQQRS\UDQRV\O ĺ OĮ'PDQQRS\UDQRV\O ĺ O>O OSKRVSKRQRĮ'PDQQRS\UDQRV\O  ĺ OĮ'PDQQRS\UDQRV\O ĺ @ȕ'PDQQRS\UDQRV\O`R[\ EXWDQR\O@K\GUD]LQ\O`HWKR[\ LPLQR@ȕ/arabino KHSWXORS\UDQRV\ORQLFDFLGJURXSV   ĮJOXFRVLGDVHDFLGHKXPDLQHPRGLILpHSURGXLWHGDQVGHVFHOOXOHVRYDULHQQHVGH KDPVWHUFKLQRLV &+2 JO\FRIRUPHDOIDOLpHjXQKH[DVDFFKDULGHGHV\QWKqVHGRQW OHVUpVLGXVWHUPLQDX[VRQWGHX[PDQQRVHSKRVSKDWHVYLDXQJURXSHDPLQR[\ SUpSURĮJOXFRVLGDVHO\VRVRPDOH (&   KXPDLQH   SHSWLGHYDULDQW QDWXUHO>$UJ+LV,OH@H[SULPpGDQVGHVFHOOXOHV&+2JO\FRIRUPHDOIDa UpVLGXVVLDO\OWHUPLQDX[VRQWR[LGpVHWFKLPLTXHPHQWPRGLILpVHQDFLGHDFpWDPLGR WULGpVR[\> E  R[R^> ^O OSKRVSKRQRĮ'PDQQRS\UDQRV\O  ĺ OĮ'PDQQRS\UDQRV\O ĺ OĮ'PDQQRS\UDQRV\O ĺ O>O O SKRVSKRQRĮ'PDQQRS\UDQRV\O  ĺ OĮ'PDQQRS\UDQRV\O ĺ @ȕ' PDQQRS\UDQRV\O`R[\ EXWDQR\O@K\GUD]LQ\O`pWKR[\ LPLQR@ȕ/arabinoKHSWXOR S\UDQRV\ORQLTXH   ĮJOXFRVLGDVDiFLGDKXPDQDPRGLILFDGDSURGXFLGDHQODVFpOXODVRYiULFDVGH KDPVWHUFKLQR &+2 JOLFRIRUPDDOIDFRQMXJDGDFRQXQJOLFDQRKH[DVDFDUtGLFR VLQWpWLFRTXHFRQWLHQHGRVPDQRVDIRVIDWRV 03V WHUPLQDOHVYtDXQJUXSR DPLQR[L SUHSURĮJOXFRVLGDVDOLVRVRPDO (&   KXPDQD   SpSWLGRYDULDQWH QDWXUDO>$UJ+LV,OH@H[SUHVDGDHQODVFpOXODV&+2JOLFRIRUPDDOIDFRQORV aUHVWRVVLDOLOWHUPLQDOHVHVWiQR[LGDGRV\TXtPLFDPHQWHPRGLILFDGRVHQiFLGR DFHWDPLGRWULGHVR[L> E  R[R^> ^O OIRVIRQRĮ'PDQRSLUDQRVLO  ĺ OĮ'PDQRSLUDQRVLO ĺ OĮ'PDQRSLUDQRVLO ĺ O>O OIRVIRQRĮ 'PDQRSLUDQRVLO  ĺ OĮ'PDQRSLUDQRVLO ĺ @ȕ' PDQRSLUDQRVLO`R[L EXWDQRLO@KLGUD]LQLO`HWR[L LPLQR@ȕ/arabinoKHSWXOR SLUDQRVLOyQLFR  370 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121  3URSRVHG,QWHUQDWLRQDO1RQSURSULHWDU\1DPHV 3URS,11 /LVW 'pQRPLQDWLRQVFRPPXQHVLQWHUQDWLRQDOHVSURSRVpHV '&,3URS /LVWH 'HQRPLQDFLRQHV&RPXQHV,QWHUQDFLRQDOHV3URSXHVWDV '&,3URS /LVWD (WHO Drug Information, Vol. 32, No. 2, 2018)  S DYRSODFHOXP   DYRSODFHO replace the description by the following one  DYRSODFHO remplacer la description par la suivante  DYRSODFHO sustitúyase la descripción por la siguiente    KXPDQFXOWXUHH[SDQGHGDOORJHQLFPHVHQFK\PDOOLNHDGKHUHQWVWURPDO FHOOVIRUFHOOEDVHGWKHUDS\&HOOVDUHRIIHWDORULJLQDQGGHULYHGIURP SODFHQWDHRIKHDOWK\GRQRUVIROORZLQJDFHVDUHDQVHFWLRQ&HOOVH[SUHVV FHOOVXUIDFHPDUNHUV&'&'DQG&'DQGVHFUHWH WKHIDFWRUV ,/,/DQG0&3   FHOOXOHVVWURPDOHVVHPEODEOHVDXPpVHQFK\PHKXPDLQHV DOORJpQLTXHVDGKpUHQWHVHQFXOWXUHG H[SDQVLRQSRXUWKpUDSLH FHOOXODLUH/HVFHOOXOHVVRQWG RULJLQHI°WDOHHWGpULYHQWGXSODFHQWDGH GRQQHXVHVHQERQQHVDQWpjODVXLWHG XQHFpVDULHQQH/HVFHOOXOHV H[SULPHQWOHVPDUTXHXUVGHVXUIDFH&'&'HW&'HW VHFUqWHQWOHVIDFWHXUV,/,/HW0&3    FpOXODVVLPLODUHVDPHVHQTXLPDOHVHVWURPDOHVDORJpQLFDVKXPDQDV DGKHUHQWHVH[SDQGLGDVHQFXOWLYRSDUDWHUDSLDFHOXODU/DVFpOXODVVRQ GHRULJHQIHWDO\GHULYDGDVGHSODFHQWDVGHGRQDQWHVVDQDVWUDVXQD FHViUHD/DVFpOXODVH[SUHVDQORVPDUFDGRUHVGHVXSHUILFLH&' &'\&'\VHFUHWDQORVIDFWRUHV,/,/\0&3   S ELQWUDIXVSXPDOID   ELQWUDIXVSDOID replace the structure by the following one  ELQWUDIXVSDOID remplacer la structure par la suivante  ELQWUDIXVSDOID sustitúyase la estructura por la siguiente   +HDY\ FKDLQ  &KDvQH ORXUGH  &DGHQD SHVDGD EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYIMMWVRQA PGKGLEWVSS 50 IYPSGGITFY ADTVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARIK 100 LGTVTTVDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150 DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200 YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250 KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300 STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350 VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400 LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGA 450 GGGGSGGGGS GGGGSGGGGS GIPPHVQKSV NNDMIVTDNN GAVKFPQLCK 500 FCDVRFSTCD NQKSCMSNCS ITSICEKPQE VCVAVWRKND ENITLETVCH 550 DPKLPYHDFI LEDAASPKCI MKEKKKPGET FFMCSCSSDE CNDNIIFSEE 600 YNTSNPD 607 /LJKW FKDLQ  &KDvQH OpJqUH  &DGHQD OLJHUD QSALTQPASV SGSPGQSITI SCTGTSSDVG GYNYVSWYQQ HPGKAPKLMI 50 YDVSNRPSGV SNRFSGSKSG NTASLTISGL QAEDEADYYC SSYTSSSTRV 100 FGTGTKVTVL GQPKANPTVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV 150 AWKADGSPVK AGVETTKPSK QSNNKYAASS YLSLTPEQWK SHRSYSCQVT 200 HEGSTVEKTV APTECS 216 'LVXOILGH EULGJHV ORFDWLRQ  3RVLWLRQ GHV SRQWV GLVXOIXUH  3RVLFLRQHV GH ORV SXHQWHV GLVXOIXUR ,QWUD+             ,QWUD+ 7*)5                   ,QWUD/         ,QWHU+/    ,QWHU++   *O\FRV\ODWLRQ VLWHV 1  6LWHV GH JO\FRV\ODWLRQ 1  3RVLFLRQHV GH JOLFRVLODFLyQ 1 + &+ $VQ 7*)5 $VQ $VQ $VQ   371 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019 S   FLQWLURUJRQXP  FLQWLURUJRQ replace the CAS RN by the following one  FLQWLURUJRQ remplacer le numéro de registre du CAS par le suivant  FLQWLURUJyQ sustitúyase el número de registro del CAS por el siguiente        S GLOSDFLPDEXP   GLOSDFLPDE replace the structure by the following one  GLOSDFLPDE remplacer la structure par la suivante  GLOSDFLPDE sustitúyase la estructura por la siguiente       S HORSXOWLGXP   HORSXOWLGH replace the structure by the following one  pORSXOWLGH remplacer la structure par la suivante  HORSXOWLGD sustitúyase la estructura por la siguiente        372 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121    S URGDWULVWDWXP  URGDWULVWDW replace the chemical name, the molecular formula, the CAS RN and the structure by the following ones  URGDWULVWDW remplacer le nom chimique, la formule moléculaire brute, le numéro de registre du CAS et la structure par les suivants  URGDWULVWDW sustitúyase el nombre químico, la fórmula molecular, el número de registro del CAS y la estructura por los siguientes    S ^DPLQR> R  FKORUR> ELSKHQ\O@\O  WULIOXRURHWKR[\@S\ULPLGLQ\O`GLD]DVSLUR>@GHFDQH FDUER[\OLFDFLG    DFLGH S ^DPLQR> R  FKORUR> ELSKpQ\O@\O  WULIOXRURpWKR[\@S\ULPLGLQ\O`GLD]DVSLUR>@GpFDQH FDUER[\OLTXH    iFLGR S ^DPLQR> R  FORUR> ELIHQLO@LO  WULIOXRURHWR[L@SLULPLGLQLO`GLD]DVSLUR>@GHFDQRFDUER[tOLFR    &+&O)12          S delete/supprimer/suprimáse insert/insérer/insertese  VHWRJHSUDPXP IH]DJHSUDVXP  VHWRJHSUDP IH]DJHSUDV  VpWRJpSUDP Ip]DJpSUDV  VHWRJHSUDP IH]DJHSUDV  S delete/supprimer/suprimáse insert/insérer/insertese  WDOGLWHUFHSWXPDOID WDOGHIJUREHSDOID  WDOGLWHUFHSWDOID WDOGHIJUREHSDOID  WDOGLWHUFHSWDOID WDOGpIJUREHSDOID  WDOGLWHUFHSWDOID WDOGHIJUREHSDOID   3URSRVHG,QWHUQDWLRQDO1RQSURSULHWDU\1DPHV 3URS,11 /LVW 'pQRPLQDWLRQVFRPPXQHVLQWHUQDWLRQDOHVSURSRVpHV '&,3URS /LVWH 'HQRPLQDFLRQHV&RPXQHV,QWHUQDFLRQDOHV3URSXHVWDV '&,3URS /LVWD (WHO Drug Information, Vol. 32, No. 4, 2018)  S EHGLQYHWPDEXP   EHGLQYHWPDE replace the description by the following one  EpGLQYHWPDE remplacer la description par la suivante  EHGLQYHWPDE sustitúyase la descripción por la siguiente    LPPXQRJOREXOLQ*ODPEGDDQWL>Canis lupus familiaris 1*) QHUYHJURZWKIDFWRUEHWDSRO\SHSWLGH1*)% @Canis lupus familiarisPRQRFORQDODQWLERG\ 373 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019  JDPPDKHDY\FKDLQCanis lupus familiaris  >9+ &DQOXSIDP,*+9    ,*+' ,*+-    >@  &DQOXSIDP,*+*  &+  KLQJH   &+0!$  /!$  *!$    &+  &+6    @   GLVXOILGHZLWKODPEGDOLJKWFKDLQCanis lupus familiaris    >9/$0%'$ &DQOXSIDP,*/9   ,*/-   >@   &DQOXSIDP&/$0%'$,*/&    @GLPHU   ELVGLVXOILGH   LPPXQRJOREXOLQH*ODPEGDDQWL>Canis familiaris 1*) IDFWHXU GHFURLVVDQFHGXQHUISRO\SHSWLGHErWD @DQWLFRUSVPRQRFORQDO Canis lupus familiaris FKDvQHORXUGHJDPPDCanis lupus familiaris  >9+ &DQOXSIDP,*+9    ,*+' ,*+-    >@  &DQOXSIDP,*+*  &+   FKDUQLqUH  &+0!$  /!$   *!$    &+  &+6     @  GLVXOIXUHDYHFODFKDvQHOpJqUHODPEGDCanis lupus familiaris   >9/$0%'$ &DQOXSIDP,*/9   ,*/-   >@   &DQOXSIDP& /$0%'$,*/&    @GLPqUH    ELVGLVXOIXUH   LQPXQRJOREXOLQD*ODPEGDDQWL>Canis familiaris 1*) IDFWRUGH FUHFLPLHQWRGHOQHUYLRSROLSpSWLGREHWD @DQWLFXHUSRPRQRFORQDO Canis lupus familiaris FDGHQDSHVDGDJDPPDCanis lupus familiaris  >9+ &DQOXSIDP,*+9    ,*+' ,*+-    >@  &DQOXSIDP,*+*  &+  ELVDJUD   &+0!$  /!$  *!$    &+  &+6    @   GLVXOIXURFRQODFDGHQDOLJHUDODPEGDCanis lupus familiaris   >9/$0%'$ &DQOXSIDP,*/9    ,*/-   >@   &DQOXSIDP&/$0%'$ ,*/&    @GtPHUR   ELVGLVXOIXUR  S GHYDILGXJHQXPFLYDSDUYRYHFXP   GHYDILGXJHQHFLYDSDUYRYHF replace the description by the following one  GHYDILGXJqQHFLYDSDUYRYHF remplacer la description par la suivante  GHYDILGXJpQFLYDSDUYRYHF sustitúyase la descripción por la siguiente    DUHFRPELQDQWQRQUHSOLFDWLQJDGHQRDVVRFLDWHGYLUXVW\SH U$$95HS&DS YHFWRUZKLFKFRQWDLQVDSURPRWHUOHVV KXPDQDOSKD/LGXURQLGDVH K,'8$ WUDQVJHQHFDVVHWWH HQFRGLQJSDUWLDOH[RQDQGIXOOH[RQVZLWKWKHILUVW DPLQRDFLGVUHPRYHGDQGVSOLFHDFFHSWRUVLWHVHTXHQFH 6$  IURPK)H[RQIODQNHGE\DVHTXHQFHKRPRORJRXVWRWKH]LQF ILQJHUQXFOHDVH =)1 FOHDYDJHVLWHRIWKHKXPDQDOEXPLQ K$/% LQWURQ    YHFWHXUYLUDODGpQRDVVRFLpGHW\SHUHFRPELQDQW U$$9 5HS&DS QRQUpSOLTXDQWFRQWHQDQWODFDVVHWWHGXWUDQVJqQH GHO DOSKD/LGXURQLGDVHKXPDLQH K,'8$ VDQVSURPRWHXU FRGDQWSDUWLHOOHPHQWO H[RQHWHQWLqUHPHQWOHVH[RQVGRQW ODSDUWLHFRUUHVSRQGDQWDX[SUHPLHUVDFLGHVDPLQpVDpWp UHWLUpHHWODVpTXHQFHGXVLWHDFFHSWHXU 6$ G pSLVVDJHGH O H[RQGHO¶K)IODQTXpG XQHVpTXHQFHKRPRORJXHDXVLWHGH FOLYDJHGHODQXFOpDVHjGRLJWVGH]LQF =)1 GHO LQWURQGH 374 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121 O DOEXPLQHKXPDLQH K$/%     XQYHFWRUGHYLUXVDGHQRDVRFLDGRWLSRUHFRPELQDQWH U$$9 5HS&DS QRUHSOLFDWLYRTXHFRQWLHQHXQFDVHWHFRQHO WUDQVJHQGHODDOID/LGXURQLGDVDKXPDQD K,'8$ VLQSURPRWRU TXHFRGLILFDSDUDHOH[yQSDUFLDO\ORVH[RQHVFRPSOHWRV FRQORVSULPHURVDPLQRiFLGRVHOLPLQDGRV\ODVHFXHQFLDGHO VLWLRDFHSWRU 6$ GHOVSOLFLQJGHOH[yQGHK)IODQTXHDGRSRU XQDVHFXHQFLDKRPyORJDDOVLWLRGHURWXUDSRUODQXFOHDVHFRQ GHGRVGH]LQF =)1 GHOLQWURQGHODDOE~PLQDKXPDQD K$/%   S ODFXWDPDEXP   ODFXWDPDE replace the CAS RN by the following one  ODFXWDPDE remplacer le numéro de registre du CAS par le suivant  ODFXWDPDE sustitúyase el número de registro del CAS por el siguiente      S UDQX]LILJHQXPFLYDSDUYRYHFXP   UDQX]LILJHQHFLYDSDUYRYHF replace the description by the following one  UDQX]LILJqQHFLYDSDUYRYHF remplacer la description par la suivante  UDQX]LILJpQFLYDSDUYRYHF sustitúyase la descripción por la siguiente    DUHFRPELQDQWQRQUHSOLFDWLQJDGHQRDVVRFLDWHGYLUXVW\SH U$$95HS&DS YHFWRUH[SUHVVLQJDF'1$WKDWWDUJHWV ESRIWKHDOEXPLQORFXV UHODWLYHWRWKHWUDQVFULSWLRQLQLWLDWLRQ VLWH IXVHGWRWKHREOLJDWHKHWHURGLPHULF)RN,QXFOHDVHGRPDLQ ..5XQGHUWKHFRQWURORIDQDSROLSRSURWHLQ(KHSDWLFFRQWURO UHJLRQDQGKXPDQDOSKDDQWLWU\SVLQSURPRWHU $SR(K$$7     YHFWHXUYLUDODGpQRDVVRFLpGHW\SHUHFRPELQDQW U$$9 5HS&DS QRQUpSOLTXDQWH[SULPDQWXQ$'1FFLEODQWOHV SDLUHVGHEDVHVGXORFXVGHO DOEXPLQH HQUHODWLRQ DYHFOHVLWHLQLWLDOGHWUDQVFULSWLRQ IXVLRQQpDXGRPDLQH KpWpURGLPpULTXH..5GHODQXFOpDVH)RNOVRXVOHFRQWU{OHG XQH UpJLRQGHFRQWU{OHGHO DSROLSRSURWpLQH( $SR( VSpFLILTXHGX IRLHHWGXSURPRWHXUGHO DOSKDDQWLWU\SVLQHKXPDLQH $SR(K$$7     XQYHFWRUGHYLUXVDGHQRDVRFLDGRWLSRUHFRPELQDQWH U$$9 5HS&DS QRUHSOLFDWLYRTXHH[SUHVDXQF'1$GLULJLGRD XQLUVHDORVSDUHVGHEDVHV HQUHODFLyQDOVLWLRGH LQLFLDFLyQGHODWUDQVFULSFLyQ GHOORFXVGHODDOE~PLQDIXVLRQDGR DOGRPLQLRKHWHURGLPpULFR..5GHODQXFOHDVH)RN,EDMRHO FRQWUROGHXQDUHJLyQGHFRQWUROKHSiWLFRGHODDSROLSRSURWHtQD( \HOSURPRWRUGHODDOIDDQWLWULSVLQDKXPDQD $SR(K$$7   375 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019 ANNEX 1 PROCEDURE FOR THE SELECTION OF RECOMMENDED INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES1 The following procedure shall be followed by the World Health Organization (hereinafter also referred to as “WHO”) in the selection of recommended international nonproprietary names for pharmaceutical substances, in accordance with resolution WHA3.11 of the World Health Assembly, and in the substitution of such names. Article 1 - Proposals for recommended international nonproprietary names and proposals for substitution of such names shall be submitted to WHO on the form provided therefore. The consideration of such proposals shall be subject to the payment of an administrative fee designed only to cover the corresponding costs of the Secretariat of WHO (“the Secretariat”). The amount of this fee shall be determined by the Secretariat and may, from time to time, be adjusted. Article 2 - Such proposals shall be submitted by the Secretariat to the members of the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations designated for this purpose, such designated members hereinafter referred to as “the INN Expert Group”, for consideration in accordance with the “General principles for guidance in devising International Nonproprietary Names for Pharmaceutical Substances”, annexed to this procedure2. The name used by the person discovering or first developing and marketing a pharmaceutical substance shall be accepted, unless there are compelling reasons to the contrary. Article 3 - Subsequent to the examination provided for in article 2, the Secretariat shall give notice that a proposed international nonproprietary name is being considered. a) Such notice shall be given by publication in WHO Drug Information3and by letter to Member States and to national and regional pharmacopoeia commissions or other bodies designated by Member States. i) Notice shall also be sent to the person who submitted the proposal (“the original applicant”) and other persons known to be concerned with a name under consideration. b) Such notice shall: i) set forth the name under consideration; ii) identify the person who submitted the proposal for naming the substance, if so requested by such person; iii) identify the substance for which a name is being considered; iv) set forth the time within which comments and objections will be received and the person and place to whom they should be directed; v) state the authority under which WHO is acting and refer to these rules of procedure. 1 See Annex 1 in WHO Technical Report Series, No. 581, 1975. The original text was adopted by the Executive Board in resolution EB15.R7 and amended in resolutions EB43.R9 and EB115.R4. 2 See Annex 2. 3 Before 1987, lists of international nonproprietary names were published in the Chronicle of the World Health Organization. 376 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121 c) In forwarding the notice, the Secretariat shall request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the proposed name during the period it is under consideration by WHO. Article 4 - Comments on the proposed name may be forwarded by any person to WHO within four months of the date of publication, under article 3, of the name in WHO Drug Information. Article 5 - A formal objection to a proposed name may be filed by any interested person within four months of the date of publication, under article 3, of the name in WHO Drug Information. Such objection shall: i) identify the person objecting; ii) state his or her interest in the name; iii) set forth the reasons for his or her objection to the name proposed. Article 6 - Where there is a formal objection under article 5, WHO may either reconsider the proposed name or use its good offices to attempt to obtain withdrawal of the objection. Without prejudice to the consideration by WHO of a substitute name or names, a name shall not be selected by WHO as a recommended international nonproprietary name while there exists a formal objection thereto filed under article 5 which has not been withdrawn. Article 7 - Where no objection has been filed under article 5, or all objections previously filed have been withdrawn, the Secretariatshall give notice in accordance with subsection (a) of article 3 that the name has been selected by WHO as a recommended international nonproprietary name. Article 8 - In forwarding a recommended international nonproprietary name to Member States under article 7, the Secretariat shall: a) request that it be recognized as the nonproprietary name for the substance; and b) request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the name and to prohibit registration of the name as a trademark or trade name. Article 9 a) In the extraordinary circumstance that a previously recommended international nonproprietary name gives rise to errors in medication, prescription or distribution, or a demonstrable risk thereof, because of similarity with another name in pharmaceutical and/or prescription practices, and it appears that such errors or potential errors cannot readily be resolved through other interventions than a possible substitution of a previously recommended international nonproprietary name, or in the event that a previously recommended international nonproprietary name differs substantially from the nonproprietary name approved in a significant number of Member States, or in other such extraordinary circumstances that justify a substitution of a recommended international nonproprietary name, proposals to that effect may be filed by any interested person. Such proposals shall be submitted on the form provided therefore and shall: i) identify the person making the proposal; ii) state his or her interest in the proposed substitution; and 377 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019 iii) set forth the reasons for the proposal; and iv) describe, and provide documentary evidence regarding the other interventions undertaken in an effort to resolve the situation, and the reasons why these other interventions were inadequate. Such proposals may include a proposal for a new substitute international nonproprietary name, devised in accordance with the General principles, which takes into account the pharmaceutical substance for which the new substitute international nonproprietary name is being proposed. The Secretariat shall forward a copy of the proposal, for consideration in accordance with the procedure described in subsection (b) below, to the INN Expert Group and the original applicant or its successor (if different from the person bringing the proposal for substitution and provided that the original applicant or its successor is known or can be found through diligent effort, including contacts with industry associations). In addition, the Secretariat shall request comments on the proposal from: i) MemberStates and national and regional pharmacopoeia commissions or other bodies designated by Member States (by including a notice to that effect in the letter referred to in article 3(a), and ii) any other persons known to be concerned by the proposed substitution. The request for comments shall: i) state the recommended international nonproprietary name that is being proposed for substitution (and the proposed substitute name, if provided); ii) identify the person who submitted the proposal for substitution (if so requested by such person); iii) identify the substance to which the proposed substitution relates and reasons put forward for substitution; iv) set forth the time within which comments will be received and the person and place to whom they should be directed; and v) state the authority under which WHO is acting and refer to these rules of procedure. Comments on the proposed substitution may be forwarded by any person to WHO within four months of the date of the request for comments. b) After the time period for comments referred to above has elapsed, the Secretariat shall forward any comments received to the INN Expert Group, the original applicant or its successor and the person bringing the proposal for substitution. If, after consideration of the proposal for substitution and the comments received, the INN Expert Group, the person bringing the proposal for substitution and the original applicant or its successor all agree that there is a need to substitute the previously recommended international nonproprietary name, the Secretariat shall submit the proposal for substitution to the INN Expert Group for further processing. 378 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121 Notwithstanding the foregoing, the original applicant or its successor shall not be entitled to withhold agreement to a proposal for substitution in the event the original applicant or its successor has no demonstrable continuing interest in the recommended international nonproprietary name proposed for substitution. In the event that a proposal for substitution shall be submitted to the INN Expert Group for further processing, the INN Expert Group will select a new international nonproprietary name in accordance with the General principles referred to in article 2 and the procedure set forth in articles 3 to 8 inclusive. The notices to be given by the Secretariat under article 3 and article 7, respectively, including to the original applicant or its successor (if not the same as the person proposing the substitution, and provided that the original applicant or its successor is known or can be found through diligent effort, including contacts with industry associations), shall in such event indicate that the new name is a substitute for a previously recommended international nonproprietary name and that Member States may wish to make transitional arrangements in order to accommodate existing products that use the previously recommended international nonproprietary name on their label in accordance with national legislation. If, after consideration of the proposal for substitution and the comments received in accordance with the procedure described above, the INN Expert Group, the original applicant or its successor and the person bringing the proposal for substitution do not agree that there are compelling reasons for substitution of a previously recommended international nonproprietary name, this name shall be retained (provided always that the original applicant or its successor shall not be entitled to withhold agreement to a proposal for substitution in the event that the original applicant or its successor has no demonstrable continuing interest in the recommended international nonproprietary name proposed to be substituted). In such an event, the Secretariat shall advise the person having proposed the substitution, as well as the original applicant or its successor (if not the same as the person proposing the substitution, and provided that the original applicant or its successor is known or can be found through diligent effort, including contacts with industry associations), Member States, national and regional pharmacopoeia commissions, other bodies designated by Member States, and any other persons known to be concerned by the proposed substitution that, despite a proposal for substitution, it has been decided to retain the previously recommended international nonproprietary name (with a description of the reason(s) why the proposal for substitution was not considered sufficiently compelling). ANNEX 2 GENERAL PRINCIPLES FOR GUIDANCE IN DEVISING INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES1 1. International Nonproprietary Names (INN) should be distinctive in sound and spelling. They should not be inconveniently long and should not be liable to confusion with names in common use. 2. The INN for a substance belonging to a group of pharmacologically related substances should, where appropriate, show this relationship. Names that are likely to convey to a patient an anatomical, physiological, pathological or therapeutic suggestion should be avoided. These primary principles are to be implemented by using the following secondary principles: 3. In devising the INN of the first substance in a new pharmacological group, consideration should be given to the possibility of devising suitable INN for related substances, belonging to the new group. 379 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019 4. In devising INN for acids, one-word names are preferred; their salts should be named without modifying the acid name, e.g. “oxacillin” and “oxacillin sodium”, “ibufenac” and “ibufenac sodium”. 5. INN for substances which are used as salts should in general apply to the active base or the active acid. Names for different salts or esters of the same active substance should differ only in respect of the name of the inactive acid or the inactive base. For quaternary ammonium substances, the cation and anion should be named appropriately as separate components of a quaternary substance and not in the amine-salt style. 6. The use of an isolated letter or number should be avoided; hyphenated construction is also undesirable. 7. To facilitate the translation and pronunciation of INN, “f” should be used instead of “ph”, “t” instead of “th”, “e” instead of “ae” or “oe”, and “i” instead of “y”; the use of the letters “h” and “k” should be avoided. 8. Provided that the names suggested are in accordance with these principles, names proposed by the person discovering or first developing and marketing a pharmaceutical preparation, or names already officially in use in any country, should receive preferential consideration. 9. Group relationship in INN (see General principle 2) should if possible be shown by using a common stem. The following list contains examples of stems for groups of substances, particularly for new groups. There are many other stems in active use.2 Where a stem is shown without any hyphens it may be used anywhere in the name. Latin English -acum -ac anti-inflammatory agents, ibufenac derivatives -adolum -adol } analgesics -adol- -adol-} -astum -ast antiasthmatic, antiallergic substances not acting primarily as antihistaminics -astinum -astine antihistaminics -azepamum -azepam diazepam derivatives bol bol steroids, anabolic -cain- -cain- class I antiarrhythmics, procainamide and lidocaine derivatives -cainum -caine local anaesthetics cef- cef- antibiotics, cefalosporanic acid derivatives -cillinum -cillin antibiotics, 6-aminopenicillanic acid derivatives -conazolum -conazole systemic antifungal agents, miconazole derivatives cort cort corticosteroids, except prednisolone derivatives -coxibum -coxib selective cyclo-oxygenase inhibitors 1 In its Twentieth report (WHO Technical Report Series, No. 581, 1975), the WHO Expert committee on Nonproprietary Names for Pharmaceutical Substances reviewed the general principles for devising, and the procedures for selecting, INN in the light of developments in pharmaceutical compounds in recent years. The most significant change has been the extension to the naming of synthetic chemical substances of the practice previously used for substances originating in or derived from natural products. This practice involves the use of a characteristic “stem” indicative of a common property of the members of a group. The reason for, and the implications of, the change are fully discussed. The guiding principles were updated during the 13th consultation on nonproprietary names for pharmaceutical substances (Geneva, 27-29 April 1983) (PHARM S/NOM 928 13 May 1983, revised 18 August 1983). 2 A more extensive listing of stems is contained in the working document WHO/EMP/RHT/TSN/2018.1 which is regularly updated and can be requested from the INN Programme, WHO, Geneva. 380 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121 -entanum -entan endothelin receptor antagonists gab gab gabamimetic agents gado- gado- diagnostic agents, gadolinium derivatives -gatranum -gatran thrombin inhibitors, antithrombotic agents gest gest steroids, progestogens gli gli antihyperglycaemics io- io- iodine-containing contrast media -metacinum -metacin anti-inflammatory, indometacin derivatives -mycinum -mycin antibiotics, produced by Streptomyces strains -nidazolum -nidazole antiprotozoal substances, metronidazole derivatives -ololum -olol β-adrenoreceptor antagonists -oxacinum -oxacin antibacterial agents, nalidixic acid derivatives -platinum -platin antineoplastic agents, platinum derivatives -poetinum -poetin erythropoietin type blood factors -pril(at)um -pril(at) angiotensin-converting enzyme inhibitors -profenum -profen anti-inflammatory substances, ibuprofen derivatives prost prost prostaglandins -relinum -relin pituitary hormone release-stimulating peptides -sartanum -sartan angiotensin II receptor antagonists, antihypertensive (non-peptidic) -vaptanum -vaptan vasopressin receptor antagonists vin- / -vin- vin- / -vin- vinca-type alkaloids ANNEXE 1  PROCEDURE A SUIVRE EN VUE DU CHOIX DE DENOMINATIONS COMMUNES INTERNATIONALES RECOMMANDEES POUR LES SUBSTANCES PHARMACEUTIQUES1 L’Organisation mondiale de la Santé (également désignée ci-après sous l’appellation « OMS ») observe la procédure exposée ci-dessous pour l’attribution de dénominations communes internationales recommandées pour les substances pharmaceutiques, conformément à la résolution WHA3.11 de l’Assemblée mondiale de la Santé, et pour le remplacement de telles dénominations. Article 1 - Les propositions de dénominations communes internationales recommandées et les propositions de remplacement de telles dénominations sont soumises à l’OMS sur la formule prévue à cet effet. L’examen de telles propositions est soumis au paiement d’une taxe administrative destinée uniquement à couvrir les coûts correspondants assumés par le Secrétariat de l’OMS (« le Secrétariat »). Le montant de cette taxe est déterminé par le Secrétariat et peut être modifié de temps à autre. Article 2 - Ces propositions sont soumises par le Secrétariat aux experts désignés à cette fin parmi les personnalités inscrites au Tableau d’experts de la Pharmacopée internationale et des Préparations pharmaceutiques, ci-après désignés sous l’appellation « le Groupe d’experts des DCI » ; elles sont examinées par les experts conformément aux « Directives générales pour la formation de dénominations communes internationales pour les substances pharmaceutiques » reproduites ci-après2.La dénomination acceptée est la dénomination employée par la personne qui découvre ou qui, la première, fabrique et lance sur le marché une substance pharmaceutique, à moins que des raisons majeures n’obligent à s’écarter de cette règle. 1 Voir annexe 1 dans OMS, Série de Rapports techniques, N° 581, 1975. Le texte original a été adopté par le Conseil exécutif dans sa résolution EB15.R7 et amendé dans ses résolutions EB43.R9 et EB115.R4. 2 Voir annexe 2. 381 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019 Article 3 - Après l’examen prévu à l’article 2, le Secrétariat notifie qu’un projet de dénomination commune internationale est à l’étude. a) Cette notification est faite par une insertion dans WHO Drug Information1 et par l’envoi d’une lettre aux Etats Membres et aux commissions nationales et régionales de pharmacopée ou autres organismes désignés par les Etats Membres. i) Notification est également faite à la personne qui a soumis la proposition (« le demandeur initial ») et à d’autres personnes portant à la dénomination mise à l’étude un intérêt notoire. b) Cette notification contient les indications suivantes : i) dénomination mise à l’étude; ii) nom de l’auteur de la proposition tendant à attribuer une dénomination à la substance, si cette personne le demande ; iii) définition de la substance dont la dénomination est mise à l’étude ; iv) délai pendant lequel seront reçues les observations et les objections à l’égard de cette dénomination ; nom et adresse de la personne habilitée à recevoir ces observations et objections ; v) mention des pouvoirs en vertu desquels agit l’OMS et référence au présent règlement. c) En envoyant cette notification, le Secrétariat demande aux Etats Membres de prendre les mesures nécessaires pour prévenir l’acquisition de droits de propriété sur la dénomination proposée pendant la période au cours de laquelle cette dénomination est mise à l’étude par l’OMS. Article 4 - Des observations sur la dénomination proposée peuvent être adressées à l’OMS par toute personne, dans les quatre mois qui suivent la date de publication de la dénomination dans WHO Drug Information (voir l’article 3). Article 5 - Toute personne intéressée peut formuler une objection formelle contre la dénomination proposée dans les quatre mois qui suivent la date de publication de la dénomination dans WHO Drug Information (voir l’article 3). Cette objection doit s’accompagner des indications suivantes : i) nom de l’auteur de l’objection ; ii) intérêt qu’il ou elle porte à la dénomination en cause ; iii) raisons motivant l’objection contre la dénomination proposée. Article 6 - Lorsqu’une objection formelle est formulée en vertu de l’article 5, l’OMS peut soit soumettre la dénomination proposée à un nouvel examen, soit intervenir pour tenter d’obtenir le retrait de l’objection. Sans préjudice de l’examen par l’OMS d’une ou de plusieurs 1 Avant 1987, les listes de dénominations communes internationales étaient publiées dans la Chronique de l’Organisation mondiale de la Santé. 382 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121 appellations de remplacement, l’OMS n’adopte pas d’appellation comme dénomination commune internationale recommandée tant qu’une objection formelle présentée conformément à l’article 5 n’est pas levée. Article 7 - Lorsqu’il n’est formulé aucune objection en vertu de l’article 5, ou que toutes les objections présentées ont été levées, le Secrétariat fait une notification conformément aux dispositions du paragraphe a) de l’article 3, en indiquant que la dénomination a été choisie par l’OMS en tant que dénomination commune internationale recommandée. Article 8 - En communiquant aux Etats Membres, conformément à l’article 7, une dénomination commune internationale recommandée, le Secrétariat : a) demande que cette dénomination soit reconnue comme dénomination commune de la substance considérée ; et b) demande aux Etats Membres de prendre les mesures nécessaires pour prévenir l’acquisition de droits de propriété sur cette dénomination et interdire le dépôt de cette dénomination comme marque ou appellation commerciale. Article 9 - a) Dans le cas exceptionnel où une dénomination commune internationale déjà recommandée donne lieu à des erreurs de médication, de prescription ou de distribution ou en comporte un risque démontrable, en raison d’une similitude avec une autre appellation dans la pratique pharmaceutique et/ou de prescription, et où il apparaît que ces erreurs ou ces risques d’erreur ne peuvent être facilement évités par d’autres interventions que le remplacement éventuel d’une dénomination commune internationale déjà recommandée, ou dans le cas où une dénomination commune internationale déjà recommandée diffère sensiblement de la dénomination commune approuvée dans un nombre important d’Etats Membres, ou dans d’autres circonstances exceptionnelles qui justifient le remplacement d’une dénomination commune internationale recommandée, toute personne intéressée peut formuler une proposition dans ce sens. Cette proposition est présentée sur la formule prévue à cet effet et doit s’accompagner des indications suivantes : i) nom de l’auteur de la proposition ; ii) intérêt qu’il ou elle porte au remplacement proposé ; iii) raisons motivant la proposition ; et iv) description, faits à l’appui, des autres interventions entreprises pour tenter de régler le problème et exposé des raisons pour lesquelles ces interventions ont échoué. Les propositions peuvent comprendre une proposition de nouvelle dénomination commune internationale de remplacement, établie conformément aux Directives générales, compte tenu de la substance pharmaceutique pour laquelle la nouvelle dénomination commune internationale de remplacement est proposée. Le Secrétariat transmet une copie de la proposition pour examen, conformément à la procédure exposée plus loin au paragraphe b), au Groupe d’experts des DCI et au demandeur initial ou à son successeur (s’il s’agit d’une personne différente de celle qui a formulé la proposition de remplacement et pour autant que le demandeur initial ou son successeur soit connu ou puisse être retrouvé moyennant des efforts diligents, notamment des contacts avec les associations industrielles). De plus, le Secrétariat demande aux entités et personnes ci-après de formuler des observations sur la proposition : 383 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019 i) les Etats Membres et les commissions nationales et régionales de pharmacopée ou d’autres organismes désignés par les Etats Membres (en insérant une note à cet effet dans la lettre mentionnée à l’article 3.a), et ii) toutes autres personnes portant au remplacement proposé un intérêt notoire. La demande d’observations contient les indications suivantes : i) dénomination commune internationale recommandée pour laquelle un remplacement est proposé (et la dénomination de remplacement proposée, si elle est fournie) ; ii) nom de l’auteur de la proposition de remplacement (si cette personne le demande) ; iii) définition de la substance faisant l’objet du remplacement proposé et raisons avancées pour le remplacement ; iv) délai pendant lequel seront reçus les commentaires et nom et adresse de la personne habilitée à recevoir ces commentaires ; et v) mention des pouvoirs en vertu desquels agit l’OMS et référence au présent règlement. Des observations sur la proposition de remplacement peuvent être communiquées par toute personne à l’OMS dans les quatre mois qui suivent la date de la demande d’observations. b) Une fois échu le délai prévu ci-dessus pour la communication d’observations, le Secrétariat transmet les observations reçues au Groupe d’experts des DCI, au demandeur initial ou à son successeur et à l’auteur de la proposition de remplacement. Si, après avoir examiné la proposition de remplacement et les observations reçues, le Groupe d’experts des DCI, l’auteur de la proposition de remplacement et le demandeur initial ou son successeur reconnaissent tous qu’il est nécessaire de remplacer la dénomination commune internationale déjà recommandée, le Secrétariat soumet la proposition de remplacement au Groupe d’experts des DCI pour qu’il y donne suite. Nonobstant ce qui précède, le demandeur initial ou son successeur n’est pas habilité à refuser son accord à une proposition de remplacement au cas où il ne peut être démontré qu’il porte un intérêt durable à la dénomination commune internationale recommandée qu’il est proposé de remplacer. Dans le cas où une proposition de remplacement est soumise au Groupe d’experts des DCI pour qu’il y donne suite, le Groupe choisit une nouvelle dénomination commune internationale conformément aux Directives générales mentionnées à l’article 2 et selon la procédure décrite dans les articles 3 à 8 inclus. La notification faite par le Secrétariat en vertu de l’article 3 et de l’article 7, respectivement, y compris au demandeur initial ou à son successeur (si ce n’est pas la même personne que celle qui a proposé le remplacement et pour autant que le demandeur initial ou son successeur soit connu ou puisse être retrouvé moyennant des efforts diligents, notamment des contacts avec les associations industrielles), doit dans un tel cas indiquer que la nouvelle dénomination remplace une dénomination commune internationale déjà recommandée et que les Etats Membres peuvent souhaiter prendre des mesures transitoires pour les produits existants qui utilisent la dénomination commune internationale déjà recommandée sur leur étiquette conformément à la législation nationale. 384 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121 Si, après examen de la proposition de remplacement et des observations communiquées conformément à la procédure exposée plus haut, le Groupe d’experts des DCI, le demandeur initial ou son successeur et l’auteur de la proposition de remplacement ne s’accordent pas sur le fait qu’il y a des raisons impératives de remplacer une dénomination commune internationale déjà recommandée, cette dernière est conservée (étant entendu toujours que le demandeur initial ou son successeur n’est pas habilité à refuser son accord à une proposition de remplacement au cas où il ne peut être démontré qu’il porte un intérêt durable à la dénomination commune internationale recommandée qu’il est proposé de remplacer). Dans un tel cas, le Secrétariat informe l’auteur de la proposition de remplacement, ainsi que le demandeur initial ou son successeur (s’il s’agit d’une personne différente de celle qui a formulé la proposition de remplacement et pour autant que le demandeur initial ou son successeur soit connu ou puisse être retrouvé moyennant des efforts diligents, notamment des contacts avec les associations industrielles), les Etats Membres, les commissions nationales et régionales de pharmacopée, les autres organismes désignés par les Etats Membres et toutes autres personnes portant un intérêt notoire au remplacement proposé que, malgré une proposition de remplacement, il a été décidé de conserver la dénomination commune internationale déjà recommandée (avec une brève description de la ou des raisons pour lesquelles la proposition de remplacement n’a pas été jugée suffisamment impérative). ANNEXE 2 DIRECTIVES GENERALES POUR LA FORMATION DE DENOMINATIONS COMMUNES INTERNATIONALES APPLICABLES AUX SUBSTANCES PHARMACEUTIQUES1 1. Les dénominations communes internationales (DCI) devront se distinguer les unes des autres par leur consonance et leur orthographe. Elles ne devront pas être d’une longueur excessive, ni prêter à confusion avec des appellations déjà couramment employées. 2. La DCI de chaque substance devra, si possible, indiquer sa parenté pharmacologique. Les dénominations susceptibles d’évoquer pour les malades des considérations anatomiques, physiologiques, pathologiques ou thérapeutiques devront être évitées dans la mesure du possible. Outre ces deux principes fondamentaux, on respectera les principes secondaires suivants : 3. Lorsqu’on formera la DCI de la première substance d’un nouveau groupe pharmacologique, on tiendra compte de la possibilité de former ultérieurement d’autres DCI appropriées pour les substances apparentées du même groupe. 4. Pour former des DCI des acides, on utilisera de préférence un seul mot. Leurs sels devront être désignés par un terme qui ne modifie pas le nom de l’acide d’origine : par exemple «oxacilline» et «oxacilline sodique», «ibufénac» et «ibufénac sodique». 5. Les DCI pour les substances utilisées sous forme de sels devront en général s’appliquer à la base active (ou à l’acide actif). Les dénominations pour différents sels ou esters d’une même substance active ne différeront que par le nom de l’acide inactif (ou de la base inactive). 1 Dans son vingtième rapport (OMS, Série de Rapports techniques, N° 581, 1975), le Comité OMS d’experts des Dénominations communes pour les Substances pharmaceutiques a examiné les directives générales pour la formation des dénominations communes internationales et la procédure à suivre en vue de leur choix, compte tenu de l’évolution du secteur pharmaceutique au cours des dernières années. La modification la plus importante a été l’extension aux substances de synthèse de la pratique normalement suivie pour désigner les substances tirées ou dérivées de produits naturels. Cette pratique consiste à employer des syllabes communes ou groupes de syllabes communes (segments-clés) qui sont caractéristiques et indiquent une propriété commune aux membres du groupe des substances pour lequel ces segments-clés ont été retenus. Les raisons et les conséquences de cette modification ont fait l’objet de discussions approfondies. Les directives ont été mises à jour lors de la treizième consultation sur les dénominations communes pour les substances pharmaceutiques (Genève, 27-29 avril 1983) (PHARM S/NOM 928, 13 mai 1983, révision en date du 18 août 1983). 385 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019 En ce qui concerne les substances à base d’ammonium quaternaire, la dénomination s’appliquera de façon appropriée au cation et à l’anion en tant qu’éléments distincts d’une substance quaternaire. On évitera de choisir une désignation évoquant un sel aminé. 6. On évitera d’ajouter une lettre ou un chiffre isolé ; en outre, on renoncera de préférence au trait d’union. 7. Pour simplifier la traduction et la prononciation des DCI, la lettre « f » sera utilisée à la place de « ph », « t » à la place de « th », « e » à la place de « ae » ou « oe », et « i » à la place de « y » ; l’usage des lettres « h » et « k » sera aussi évité. 8. On retiendra de préférence, pour autant qu’elles respectent les principes énoncés ici, les dénominations proposées par les personnes qui ont découvert ou qui, les premières, ont fabriqué et lancé sur le marché les préparations pharmaceutiques considérées, ou les dénominations déjà officiellement adoptées par un pays. 9. La parenté entre substances d’un même groupe (voir Directive générale 2) sera si possible indiquée dans les DCI par l’emploi de segments-clés communs. La liste ci-après contient des exemples de segments-clés pour des groupes de substances, surtout pour des groupes récents. Il y a beaucoup d’autres segments-clés en utilisation active. 1 Les segments-clés indiqués sans trait d’union pourront être insérés n’importe où dans une dénomination. Latin Français -acum -ac substances anti-inflammatoires du groupe de l’ibufénac -adolum -adol } analgésiques -adol- -adol- } -astum -ast antiasthmatiques, antiallergiques n’agissant pas principalement en tant qu’antihistaminiques -astinum -astine antihistaminiques -azepamum -azépam substances du groupe du diazépam bol bol stéroïdes anabolisants -cain- -caïn- antiarythmiques de classe I, dérivés du procaïnamide et de la lidocaïne -cainum -caïne anesthésiques locaux cef- céf- antibiotiques, dérivés de l’acide céphalosporanique -cillinum -cilline antibiotiques, dérivés de l’acide 6-aminopénicillanique -conazolum -conazole agents antifongiques systémiques du groupe du miconazole cort cort corticostéroïdes, autres que les dérivés de la prednisolone -coxibum -coxib inhibiteurs sélectifs de la cyclo-oxygénase -entanum -entan antagonistes du récepteur de l’endothéline gab gab gabamimétiques gado- gado- agents diagnostiques, dérivés du gadolinium -gatranum -gatran antithrombines, antithrombotiques gest gest stéroïdes progestogènes gli gli antihyperglycémiants io- io- produits de contraste iodés -metacinum -métacine substances anti-inflammatoires du groupe de l’indométacine -mycinum -mycine antibiotiques produits par des souches de Streptomyces 1 Une liste plus complète de segments-clés est contenue dans le document de travail WHO/EMP/RHT/TSN/2018.1 qui est régulièrement mis à jour et qui peut être demandé auprès du programme des DCI, OMS, Genève. 386 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121 -nidazolum -nidazole substances antiprotozoaires du groupe du métronidazole -ololum -olol antagonistes des récepteurs β-adrénergiques -oxacinum -oxacine substances antibactériennes du groupe de l’acide nalidixique -platinum -platine antinéoplasiques, dérivés du platine -poetinum -poétine facteurs sanguins de type érythropoïétine -pril(at)um -pril(ate) inhibiteurs de l’enzyme de conversion de l’angiotensine -profenum -profène substances anti-inflammatoires du groupe de l’ibuprofène prost prost prostaglandines -relinum -réline peptides stimulant la libération d’hormones hypophysaires -sartanum -sartan antagonistes d’un récepteur de l’angiotensine II, antihypertenseurs (non peptidiques) -vaptanum -vaptan antagonistes du récepteur de la vasopressine vin- vin- } alcaloïdes du type vinca -vin- -vin- } ANEXO 1 PROCEDIMIENTO DE SELECCIÓN DE DENOMINACIONES COMUNES INTERNACIONALES RECOMENDADAS PARA SUSTANCIAS FARMACÉUTICAS1 La Organización Mundial de la Salud (OMS) seguirá el procedimiento que se expone a conti- nuación tanto para seleccionar denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas, de conformidad con lo dispuesto en la resolución WHA3.11, como para sustituir esas denominaciones. Artículo 1 - Las propuestas de denominaciones comunes internacionales recomendadas y las propuestas de sustitución de esas denominaciones se presentarán a la OMS en los formularios que se proporcionen a estos efectos. El estudio de estas propuestas estará sujeto al pago de una tasa destinada a sufragar los costos de administración que ello suponga para la Secretaría de la OMS («la Secretaría»). La Secretaría establecerá la cuantía de esa tasa y podrá ajustarla periódicamente. Artículo 2 - Estas propuestas serán sometidas por la Secretaría a los miembros del Cuadro de Expertos en Farmacopea Internacional y Preparaciones Farmacéuticas encargados de su estudio, en adelante designados como «el Grupo de Expertos en DCI», para que las examinen de conformidad con los «Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas», anexos a este procedimiento.2 A menos que haya poderosas razones en contra, la denominación aceptada será la empleada por la persona que haya descubierto o fabricado y comercializado por primera vez esa sustancia farmacéutica. Artículo 3 - Tras el examen al que se refiere el artículo 2, la Secretaría notificará que está en estudio un proyecto de denominación internacional. a) Esa notificación se hará mediante una publicación en Información Farmacéutica OMS3 y el envío de una carta a los Estados Miembros y a las comisiones nacionales y regionales de las farmacopeas u otros organismos designados por los Estados Miembros. 1 Véase el anexo 1 en OMS, Serie de Informes Técnicos, Nº 581, 1975. El texto vigente fue adoptado por el Consejo Ejecutivo en su resolución EB15.R7 y modificado en las resoluciónes EB43.R9 y EB115.R4.. 2 Véase el anexo 2. 3 Hasta 1987 las listas de DCI se publicaban en la Crónica de la Organización Mundial de la Salud. 387 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019 i) La notificación será enviada también a la persona que haya presentado la pro- puesta («el solicitante inicial») y a otras personas que tengan un interés especial en una denominación objeto de estudio. b) En esa notificación se incluirán los siguientes datos: i) la denominación sometida a estudio; ii) la identidad de la persona que ha presentado la propuesta de denominación de la sustancia, si lo pide esa persona; iii) la identidad de la sustancia cuya denominación está en estudio; iv) el plazo fijado para recibir observaciones y objeciones, así como el nombre y la dirección de la persona a quien deban dirigirse; y v) los poderes conferidos para el caso a la OMS y una referencia al presente procedimiento. c) Al enviar esa notificación, la Secretaría solicitará de los Estados Miembros la adopción de todas las medidas necesarias para impedir la adquisición de derechos de patente sobre la de- nominación propuesta, durante el periodo en que la OMS la tenga en estudio. Artículo 4 - Toda persona puede formular a la OMS observaciones sobre la denominación propuesta dentro de los cuatro meses siguientes a su publicación en Información Farmacéutica OMS, conforme a lo dispuesto en el artículo 3. Artículo 5 - Toda persona interesada puede presentar una objeción formal a una denominación propuesta dentro de los cuatro meses siguientes a su publicación en Información Farmacéutica OMS, conforme a lo dispuesto en el artículo 3. Esa objeción deberá acompañarse de los siguientes datos: i) la identidad de la persona que formula la objeción; ii) las causas que motivan su interés por la denominación; y iii) las causas que motivan su objeción a la denominación propuesta. Artículo 6 - Cuando se haya presentado una objeción formal en la forma prevista en el artículo 5, la OMS podrá reconsiderar el nombre propuesto o utilizar sus buenos oficios para intentar lograr que se retire la objeción. La OMS no seleccionará como denominación común internacional una denominación a la que se haya hecho una objeción formal, presentada según lo previsto en el artículo 5, que no haya sido retirada, todo ello sin perjuicio de que la Organización examine otra denominación o denominaciones sustitutivas. Artículo 7 - Cuando no se haya formulado ninguna objeción en la forma prevista en el artículo 5, o cuando todas las objeciones presentadas hayan sido retiradas, la Secretaría notificará, conforme a lo dispuesto en el párrafo a) del artículo 3, que la denominación ha sido seleccionada por la OMS como denominación común internacional recomendada. Artículo 8 - Al comunicar a los Estados Miembros una denominación común internacional, conforme a lo previsto en el artículo 7, la Secretaría: 388 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121 a) solicitará que esta denominación sea reconocida como denominación común para la sus- tancia de que se trate; y b) solicitará a los Estados Miembros que adopten todas las medidas necesarias para impedir la adquisición de derechos de patente sobre la denominación, y prohíban que sea registrada como marca de fábrica o como nombre comercial. Artículo 9 a) En el caso excepcional de que, debido a su semejanza con otra denominación utilizada en las prácticas farmacéuticas y/o de prescripción, una denominación común internacional recomendada anteriormente ocasione errores de medicación, prescripción o distribución, o suponga un riesgo manifiesto de que esto ocurra, y parezca que tales errores o potenciales errores no sean fácilmente subsanables con otras medidas que no sean la posible sustitución de esa denominación común internacional recomendada anteriormente; en el caso de que una denominación común internacional recomendada anteriormente difiera considerablemente de la denominación común aprobada en un número importante de Es- tados Miembros, o en otras circunstancias excepcionales que justifiquen el cambio de una denominación común internacional recomendada, cualquier persona interesada puede presentar propuestas en este sentido. Esas propuestas se presentarán en los formularios que se proporcionen a estos efectos e incluirán los siguientes datos: i) la identidad de la persona que presenta la propuesta; ii)las causas que motivan su interés en la sustitución propuesta; iii) las causas que motivan la propuesta; y iv) una descripción, acompañada de pruebas documentales, de las otras medidas que se hayan adoptado con el fin de resolver la situación y de los motivos por los cuales dichas medidas no han sido suficientes. Entre esas propuestas podrá figurar una relativa a una nueva denominación común internacional sustitutiva, formulada con arreglo a los Principios generales y que tenga en cuenta la sustancia farmacéutica para la que se proponga la nueva denominación común internacional sustitutiva. La Secretaría enviará al Grupo de Expertos en DCI y al solicitante inicial o a su sucesor (en el caso de que sea una persona diferente de la que ha presentado la propuesta de sustitución y siempre que el solicitante inicial o su sucesor sean conocidos o puedan ser encontrados mediante esfuerzos diligentes, como el contacto con las asociaciones industriales) una copia de la propuesta, para que sea examinada de conformidad con el procedimiento descrito en el párrafo b) infra. Además, la Secretaría solicitará observaciones sobre la propuesta: i) a los Estados Miembros y a las comisiones nacionales y regionales de las far- macopeas u otros organismos designados por los Estados Miembros (ello se hará in- cluyendo una notificación a tal efecto en la carta a la que se refiere el párrafo a) del artículo 3), y ii) a cualquier persona que tenga un interés especial en la sustitución propuesta. Al solicitar que se formulen estas observaciones se facilitarán los siguientes datos: i) la denominación común internacional recomendada que se propone sustituir (y la denominación sustitutiva propuesta, si se ha facilitado); 389 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019 ii) la identidad de la persona que ha presentado la propuesta de sustitución (si lo pide esa persona); iii) la identidad de la sustancia a la que se refiere la sustitución propuesta y las razones para presentar la propuesta de sustitución; iv) el plazo fijado para recibir observaciones, así como el nombre y la dirección de la persona a quien deban dirigirse; y v) los poderes conferidos para el caso a la OMS y una referencia al presente pro- cedimiento. Toda persona puede formular a la OMS observaciones sobre la sustitución propuesta dentro de los cuatro meses siguientes a la fecha en que se realizó la solicitud de observaciones. b) Una vez agotado el mencionado plazo para la formulación de observaciones, la Secretaría enviará todos los comentarios recibidos al Grupo de Expertos en DCI, al solicitante inicial o a su sucesor, y a la persona que haya presentado la propuesta de sustitución. Si después de examinar la propuesta de sustitución y las observaciones recibidas, el Grupo de Expertos en DCI, la persona que haya presentado la propuesta de sustitución y el solicitante inicial, o su sucesor, están de acuerdo en la necesidad de sustituir la denominación común internacional recomendada anteriormente, la Secretaría remitirá la propuesta de sustitución al Grupo de Expertos en DCI para que la tramite. No obstante lo anterior, el solicitante inicial o su sucesor no tendrán derecho a impedir el acuerdo sobre una propuesta de sustitución en el caso de que hayan dejado de tener un interés demostrable en la denominación común internacional cuya sustitución se propone. En caso de que la propuesta de sustitución sea presentada al Grupo de Expertos en DCI para que la tramite, este grupo seleccionará una nueva denominación común internacional de conformidad con los Principios generales a los que se refiere el artículo 2 y al procedimiento establecido en los artículos 3 a 8 inclusive. En ese caso, en las notificaciones que la Secretaría ha de enviar con arreglo a los artículos 3 y 7, respectivamente, incluida la notificación al solicitante inicial o a su sucesor (en el caso de que no sea la misma persona que propuso la sustitución y siempre que el solicitante inicial o su sucesor sean conocidos o puedan ser encontrados mediante esfuerzos diligentes, como el contacto con las asociaciones industriales), se indicará que la nueva denominación sustituye a una denominación común internacional recomendada anteriormente y que los Estados Miembros podrán, si lo estiman oportuno, adoptar disposiciones transitorias aplicables a los productos existentes en cuya etiqueta se utilice, con arreglo a la legislación nacional, la denominación común internacional recomendada anteriormente que se haya sustituido. En caso de que, después de haber estudiado la propuesta de sustitución y los comen- tarios recibidos de conformidad con el procedimiento descrito anteriormente, el Grupo de Expertos en DCI, el solicitante inicial o su sucesor y la persona que haya presentado la propuesta de sustitución no lleguen a un acuerdo sobre la existencia de razones poderosas para sustituir una denominación común internacional recomendada anteriormente, esta denominación se mantendrá (siempre en el entendimiento de que el solicitante inicial o su sucesor no tendrán derecho a impedir el acuerdo sobre una propuesta de sustitución en el caso de que hayan dejado de tener un interés demostrable en la denominación común in- ternacional cuya sustitución se propone). En ese caso, la Secretaría comunicará a la persona que haya propuesto la sustitución, así como al solicitante inicial o a su sucesor (en el caso de que no sea la misma persona que propuso la sustitución y siempre que el solicitante inicial o su sucesor sean conocidos o puedan ser encontrados mediante esfuerzos diligentes, como el contacto con las asociaciones industriales), a los Estados Miembros, a las comisiones 390 WHO Drug Information, Vol. 33, No. 2, 2019 Proposed INN: List 121 nacionales y regionales de las farmacopeas o a otros organismos designados por los Estados Miembros y a cualquier otra persona que tenga interés en la sustitución propuesta, que, pese a la presentación de una propuesta de sustitución, se ha decidido mantener la denominación común internacional recomendada anteriormente (con una descripción de la o las razones por las que se ha considerado que la propuesta de sustitución no estaba respaldada por razones suficientemente poderosas). ANEXO 2 PRINCIPIOS GENERALES DE ORIENTACIÓN PARA FORMAR DENOMINACIONES COMUNES INTERNACIONALES PARA SUSTANCIAS FARMACÉUTICAS1 1. Las denominaciones comunes internacionales (DCI) deberán diferenciarse tanto fonética como ortográficamente. No deberán ser incómodamente largas, ni dar lugar a confusión con denominaciones de uso común. 2. La DCI de una sustancia que pertenezca a un grupo de sustancias farmacológicamente emparentadas deberá mostrar apropiadamente este parentesco. Deberán evitarse las denominaciones que puedan tener connotaciones anatómicas, fisiológicas, patológicas o terapéuticas para el paciente. Estos principios primarios se pondrán en práctica utilizando los siguientes principios secundarios: 3. Al idear la DCI de la primera sustancia de un nuevo grupo farmacológico, deberá tenerse en cuenta la posibilidad de poder formar DCI convenientes para las sustancias emparentadas que se agreguen al nuevo grupo. 4. Al idear DCI para ácidos, se preferirán las de una sola palabra; sus sales deberán denominarse sin modificar el nombre del ácido: p. ej. «oxacilina» y «oxacilina sódica», «ibufenaco» y «ibufenaco sódico». 5. Las DCI para las sustancias que se usan en forma de sal deberán en general aplicarse a la base activa o al ácido activo. Las denominaciones para diferentes sales o esteres de la misma sustancia activa solamente deberán diferir en el nombre del ácido o de la base inactivos. En los compuestos de amonio cuaternario, el catión y el anión deberán denominarse adecuadamente por separado, como componentes independientes de una sustancia cuaternaria y no como sales de una amina. 6. Deberá evitarse el empleo de letras o números aislados; también es indeseable el empleo de guiones. 7. Para facilitar la traducción y la pronunciación, se emplearán de preferencia las letras «f» en lugar de «ph», «t» en lugar de «th», «e» en lugar de «ae» u «oe», e «i» en lugar de «y»; se deberá evitar el empleo de las letras «h» y «k». 8. Siempre que las denominaciones propuestas estén de acuerdo con estos principios, recibirán una consideración preferente las denominaciones propuestas por la persona que haya descubierto las sustancias, o que fabrique y comercialice por primera vez una sustancia farmacéutica, así como las denominaciones ya adoptadas oficialmente en cualquier país. 1 En su 20º informe (OMS, Serie de Informes Técnicos, Nº 581, 1975), el Comité de Expertos de la OMS en Denominaciones Comunes para las Sustancias Farmacéuticas revisó los Principios generales para formar denominaciones comunes internacionales (DCI), y su procedimiento de selección, a la luz de las novedades registradas en los últimos años en materia de compuestos farmacéuticos. El cambio más importante había consistido en hacer extensivo a la denominación de sustancias químicas sintéticas el método utilizado hasta entonces para las sustancias originadas en productos naturales o derivadas de éstos. Dicho método conlleva la utilización de una «partícula» característica que indica una propiedad común a los miembros de un grupo. En el citado informe se examinan en detalle las razones y consecuencias de este cambio. Los Principios generales de orientación se actualizaron durante la 13ª consulta sobre denominaciones comunes para sustancias farmacéuticas (Ginebra, 27 a 29 de abril de 1983) (PHARM S/NOM 928, 13 de mayo de 1983, revisado el 18 de agosto de 1983). 391 Proposed INN: List 121 WHO Drug Information, Vol. 33, No. 2, 2019 9. El parentesco entre sustancias del mismo grupo se pondrá de manifiesto en las DCI (véase el Principio 2) utilizando una partícula común. En la lista que figura a continuación se indican ejemplos de partículas para grupos de sustancias, en particular para grupos nuevos. Existen muchas otras partículas que se usan habitualmente.1 Cuando una partícula aparece sin guión alguno, puede utilizarse en cualquier lugar de la palabra. Latin Español -acum -aco antiinflamatorios derivados del ibufenaco -adolum -adol ) analgésicos -adol- -adol- ) -astum -ast antiasmáticos, sustancias antialérgicas cuya acción principal no es la antihistamínica -astinum -astina antihistamínicos -azepamum -azepam derivados del diazepam bol bol esteroides anabolizantes -cain- -caína- antiarrítmicos de clase I, derivados de procainamida y lidocaína -cainum -caína- anestésicos locales cef- cef- antibióticos, derivados del ácido cefalosporánico -cillinum -cilina antibióticos derivados del ácido 6-aminopenicilánico -conazolum -conazol antifúngicos sistémicos derivados del miconazol cort cort corticosteroides, excepto derivados de prednisolona -coxibum -coxib inhibidores selectivos de ciclooxigenasa -entanum -entán antagonistas del receptor de endotelina gab gab gabamiméticos gado- gado- agentes para diagnóstico derivados de gadolinio -gartranum -gatrán inhibidores de la trombina antitrombóticos gest gest esteroides progestágenos gli gli hipoglucemiantes,antihiperglucémicos io- io- medios de contraste iodados -metacinum -metacina antiinflamatorios derivados de indometacina -mycinum -micina antibióticos producidos por cepas de Streptomyces -nidazolum -nidazol antiprotozoarios derivados de metronidazol -ololum -olol antagonistas de receptores E-adrenérgicos -oxacinum -oxacino antibacterianos derivados del ácido nalidíxico -platinum -platino antineoplásicos derivados del platino -poetinum -poetina factores sanguíneos similares a la eritropoyetina -pril(at)um -pril(at) inhibidores de la enzima conversora de laangiotensina -profenum -profeno antiinflamatorios derivados del ibuprofeno prost prost prostaglandinas -relinum -relina péptidos estimulantes de la liberación de hormonas hipofisarias -sartanum -sartán antihipertensivos (no peptídicos) antagonistas del receptor de angiotensina II -vaptanum -vaptán antagonistas del receptor de vasopresina vin- vin- ) alcaloides de la vinca -vin- -vin- ) 1 En el documento de trabajo WHO/EMP/RHT/TSN/2018.1, que se actualiza periódicamente y puede solicitarse al Programa sobre Denominaciones Comunes Internacionales, OMS, Ginebra, figura una lista más amplia de partículas. 392
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel